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Abstract 
The PI3K family is central to numerous cellular processes in both health and 
disease. The class IA isoforms of PI3K control such outputs as proliferation, 
metabolism and survival through their well-characterised function as lipid 
kinases, with their signalling thought to predominantly mediated by the Akt/PKB 
protein kinase. However there exist other signalling routes, including from the 
lipid kinase activity through other effectors, but also through a protein kinase 
function of the class IA isoforms themselves. 
Mass spectrometry is a powerful tool which has been central to the recent 
advances in phosphoproteomic techniques. It is now possible to use mass-
spectrometry to probe the phosphoproteome of any number of systems in an 
unbiased and global manner. 
In this project, we aimed to advance our understanding of two aspects of class 
IA PI3K signalling which are relatively poorly understood. We used 
phosphoproteomic techniques which allowed us to provide answers to some old 
questions which have up to now proved elusive. 
First, we investigated the protein kinase activity of p110α. We used an in vitro 
protein kinase assay and coupled this to mass spectrometry techniques to 
identify direct substrates of p110α. We proposed two novel protein substrates 
and attempted to characterise them further, although we were hampered by 
lack of available biochemical tools. 
Second, we investigated the differential phosphoproteomes of the ubiquitously 
expressed class IA PI3K isoforms p110α and p110β in a panel of breast cancer 
cell lines. We used mass spectrometry-based phosphoproteomics and found 
significant differences in signalling between p110α and p110β in 4T1 cells, 
including differential regulation of previously described PI3K effectors, amongst 
them the Akt substrate PRAS40, and potential novel targets. Additionally, we 
found that some of these effects were conserved between cell lines. 
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1. Introduction 
1.1. Phosphoinositide 3-kinases (PI3Ks) 
The phosphoinositide 3-kinase (PI3K) family is made up of eight enzymes which 
are conserved across species and have key roles in intracellular signalling. 
PI3Ks primarily act as lipid kinases and phosphorylate the inositol ring of 
phosphatidylinositol (PI) and its derivatives. This phosphate addition occurs at 
the 3’ position, a reaction which leads to the production of a number of new lipid 
products – PI(3)P from PI, PI(3,4)P2 from PI(4)P, and PI(3,4,5)P3 (PIP3) from 
PI(4,5)P2. These second messengers then recruit effector proteins to cellular 
membranes and further influence multiple downstream pathways. PI3K activity 
contributes to a diverse range of cellular processes, including cell division, 
metabolism and intracellular vesicular trafficking, and while its signalling is 
crucial for healthy cells, it is also implicated in a number of disease processes, 
most notably in cancer where the PI3K pathway is one of the most frequently 
dysregulated pathways. 
1.1.1. PI3K classification 
The eight PI3K isoforms are subdivided into three classes, based on structural 
homology and substrate preference [1].  There are four class I PI3Ks which are 
heterodimers made up of a p110 catalytic subunit bound to a regulatory protein, 
three monomeric class II PI3Ks, and a sole class III member called vacuolar 
protein sorting (Vps) 34, which is found in complex with Vps15 (Fig. 1.1.). PI3Ks 
share a common core made up of a helical, catalytic, and C2 lipid-binding 
domain. The class I isoforms will be discussed in greatest detail in this and later 
chapters, as their signalling pathways are the primary focus of this project.  
The first signs of a PI3K activity were observed in the 1980s when an 
association between viral oncoproteins and a PI kinase was noticed, which was 
discovered by the Cantley group to phosphorylate PI at the 3’ position. Further 
work saw the generation of PIP3 from PIP2 following RTK or GPCR activation, 
and purification of a PI3K activity was found to correlate with proteins of 110 
kDa and 85 kDa. Cloning of the 85 kDa protein showed that it had SH2 domains 
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but no intrinsic kinase activity, and subsequent cloning of the p110 kDa protein 
formally established it as holding the kinase activity in a p110-p85 heterodimer. 
This cloning revealed homology with the yeast Vps34 which was later shown 
also to have a PI3K activity, and further genetic and biochemical work saw 
genes for multiple PI3K family members identified and split into three classes. 
1.1.1.1. Class I PI3Ks 
The four members of class I PI3Ks are subdivided further depending on which 
regulatory subunit they bind: the class IA isoforms (p110α, β, and δ) bind to a 
p85 subunit, while p110γ binds to either p87 or p101 [2].  
1.1.1.2. Class II PI3Ks 
There are three mammalian class II isoforms, PI3K-C2α, PI3K-C2β and PI3K–
C2γ. Class II PI3Ks are monomers and consist of the conserved PI3K core, as 
well as extensions at both termini; proline-rich regions at the N-terminus, and a 
lipid-binding PX domain plus an extra C2 domain at the C-terminus [1]. While 
the tissue distribution of PI3K-C2α and PI3K-C2β is broad, PI3K–C2γ is found 
only in a limited number of tissues such as the liver [3]. 
 
Figure 1.1. Classification of PI3Ks. Adapted from [1]. The seven PI3K isoforms display a large 
degree of structural homology. A) The four class I PI3K family members are heterodimers 
composed of a catalytic and regulatory subunit. B) The three class II members are monomers 
with N- and C-terminal extensions, while C) the sole class III PI3K is a heterodimer which is 
membrane-bound. 
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Class II PI3Ks are the least studied isoforms, and our current understanding of 
their signalling and physiological roles is limited. Studies suggest that activation 
is achieved by GPCRs, RTKs and GTPases, and at least in vitro, the class II 
PI3Ks can utilise PI, PI(4)P and PI(4,5)P2 as substrates [4], with PI thought to 
be the preferred substrate in vitro and in vivo (Fig. 1.2.) [5, 6]. The class II 
PI3Ks have been implicated in a number of processes including vesicle 
trafficking, cell migration and metabolism [1], but exactly how they bind to 
membrane receptors and exert control over such biological outputs is unclear. 
1.1.1.3. Class III PI3Ks 
The sole class III member is Vps34, which is evolutionarily conserved and 
ubiquitously expressed in mammals [1]. Similar to the class I isoforms, it exists 
as a constitutive heterodimer with its partner Vps15. The Vps15 subunit is 
myristoylated, which targets class III PI3K to intracellular membranes where its 
primary substrate PI is found [7]. In addition to Vps15, Vps34 forms higher order 
complexes with other proteins which are required for its cellular functions [7, 8]. 
Vps34 is localised to the endosomal compartment, and it has been implicated in 
various processes involving vesicle trafficking such as autophagy and 
endocytosis [8, 9].  
1.1.2. Class I PI3K structure 
In resting cells, the class I regulatory subunit maintains the catalytic p110 
subunit in a closed, inactive conformation [11]. Upon stimulation, the regulatory 
subunit is required to recruit the heterodimer to activated receptors [12, 13]. The 
regulatory subunit further acts to stabilise the p110 proteins which are unstable 
as monomers [14]. 
All four p110 proteins share the conserved PI3K core plus a Ras-binding 
domain, with the class IA members having an extra p85-binding domain which 
dictates the preference for p85 as a regulatory partner [15]. The p85 proteins 
are transcribed from multiple different genes: p85α, p55α and p50α are 
produced from PIK3R1, while p85β is transcribed from PIK3R2 and p55γ from 
PIK3R3. The p85 proteins have multiple domains including a proline-rich region, 
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and a p110-binding domain which is flanked by two SH2 domains which allow 
binding to phosphorylated tyrosine (pTyr) residues, such as those at activated 
receptors [1]. p85α and β also possess an extra proline-rich region, as well as 
Bcr homology (BH) and SH3 domains, which may allow extra signalling outputs 
[1]. The structure and contribution of p87 and p101 to p110γ signalling are 
unclear, but they are able to help to recruit p110γ to Ras and GPCRs. 
Class I PI3Ks catalyse the production of PIP3 from PI(4,5)P2 [16], which allows 
recruitment of proteins which contain lipid-binding domains, such as pleckstrin 
homology (PH) domains, to the plasma membrane [17]. Class I PI3Ks are 
present in all cell types, although the distribution of the different isoforms varies: 
p110α and β are ubiquitously expressed, while p110γ and δ are enriched in 
leukocytes [3]. Perhaps because of the ubiquitous tissue distribution of p110α 
and p110β, mice lacking these isoforms display embryonic lethality [18, 19], 
while p110γ and p110δ deficient mice are viable but have immune defects [20, 
21]. It is important to note that both the upstream and downstream signalling of 
PI3Ks can vary in different cell- and signal-specific contexts. 
 
Figure 1.2. PI3K lipid substrates and products. Adapted from [10]. Phosphoinositde species 
are produced by the interplay between PI3K isoforms and the phosphatases which oppose their 
action. Class I PI3Ks produce PIP3 from PI(4,5)P2, while the class II and class III isoforms are 
thought to prefer PI as a substrate. The dynamic production of these species influence 
signalling cascades via binding of effector proteins. 
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As well as this lipid kinase activity, PI3Ks also have protein kinase activity [22]. 
The best characterised substrates of this activity are the PI3Ks themselves; 
p110α phosphorylates p85α at the Ser608 residue [23], while the other isoforms 
autophosphorylate the p110 subunit [22]. For the class IA isoforms 
(auto)phosphorylation causes a reduction in their lipid kinase activity, and so 
has been proposed to be a potential mode of negative regulation. Exogenous 
substrates have also been identified, although little work has been done to 
uncover the potential roles of those phosphorylations. The protein kinase 
function of PI3Ks will be discussed in more detail below. 
While the majority of studied PI3K outputs are predominantly kinase-dependent, 
the class I PI3K members also have roles as scaffolding proteins, with both 
p110 and p85 proteins reported to have non-PI3K binding partners such as the 
small GTPase Rab5 and Cdc42 [24, 25, 26, 27]. This non-catalytic function is 
less well studied but supported by different phenotypes of knock-out and knock-
in strategies (discussed later), and few interactions of this nature have been 
reported. It is certainly true that although the lipid kinase activity of PI3K is the 
best characterised effector of its own functions, other processes (i.e. protein 
kinase activity, scaffolding) can contribute to the diverse cellular outputs found 
in the PI3K pathway. 
1.1.3. Signalling upstream of class I PI3K  
Class I PI3Ks were originally subdivided based on differences in the perceived 
view of activation by RTKs and GPCRs (which has since changed), and in 
regulatory subunits, (which still stands) (Fig. 1.3.). However, the real picture is 
much more complex than a simple separation into class IA and IB. While p110α 
and p110δ are mainly activated by recruitment of the p85/p110 complex to pTyr 
residues in receptor tyrosine kinases (RTK) or adaptor proteins, they can also 
be activated by Ras [28, 29]. The class IB p110γ is activated downstream of 
Ras and G protein coupled receptor (GPCR) Gβγ subunits [30], whereas there 
is evidence for activation of p110β by all three modes, and possibly also by 
families of other small GTPases such as Rab5 [24, 31]. 
The canonical method of class I activation is downstream of activated growth 
factor receptors [2]. For example, PDGF binds its receptor causing activation 
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and autophosphorylation of intracellular portions of the receptor. These pTyr 
residues are recognised and bound by the SH2 domains of a variety of proteins, 
including p85 isoforms, leading to recruitment of class IA PI3Ks to the plasma 
membrane where they catalyse the production of PIP3 from PI(4,5)P2. Indirect 
recruitment of class I heterodimers to RTKs can also occur via adaptor proteins 
such as Grb2 or the insulin receptor substrate (IRS) -1. While p110β and p110δ 
seem to require both p85 SH2 domains to be bound to pTyr, p110α may be fully 
activated by binding of only the N-terminal SH2 domain [32]. This less stringent  
requirement for activation, along with its ubiquitous tissue expression, may help 
explain the fact that p110α has been the only PI3K found mutated in cancer 
[33].  
The class IB PI3K p110γ is activated downstream of GPCRs [30]. Upon 
activation, the Gβγ subunit dissociates from Gα and recruits p110γ, although 
the exact mechanism of this switch is still unclear. Expression of the p110γ 
adaptors p87 and p101 varies between cell types, and the two have different 
properties with regards to affinity and activation with p110γ-p101 heterodimers 
being more sensitive to activation by Gβγ, and less reliant on Ras [34] (see 
below). GPCRs have also been shown to be upstream of p110β [35], which is 
also activated through direct interaction with the Gβγ subunit.  
 
Figure 1.3. Class I PI3K structure and signalling input. Adapted from [10]. The canonical 
view of PI3K signalling is of the class IA isoforms being regulated by RTKs and p110γ being 
downstream of GPCRs, with Ras able to influence all isoforms. The emerging picture has p110β 
also regulated by GPCRs, with evidence for a role of other small GTPases. 
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All class I isoforms possess a Ras binding domain (RBD) and Ras family 
members have long been thought to be activators of all four isoforms. However, 
recent evidence suggests that p110β is an exception and is instead activated 
downstream of other small GTPases [31]. There are multiple different Ras 
family members, and Ras/PI3K interactions probably vary in cell- and agonist-
specific contexts. It has been shown that the class IA isoforms are activated 
downstream of Ras but in an RTK dependent manner [36], as p85 can block 
stimulation by Ras. For p110γ, p101 and p87 display the opposite dependency 
on upstream agonists: p110γ-p87 is more sensitive to Ras, while p110γ-p101 is 
more sensitive to Gβγ [37]. 
While there is a high level of sequence homology between p110α and p110β, 
differences exist in the RBD, suggesting varying sensitivity to small GTPases 
[31]. As well as inputs from both RTKs and GPCRs, p110β has the potential to 
be activated by Rab and the Rho family of GTPases [31]. Rab5 is found in 
endosomes and binding to p110β occurs in clathrin-coated vesicles [24, 38], 
suggesting a role for p110β in endosome formation, although this link has not 
been fully explored. Ras was also thought to activate p110β but recent evidence 
has emerged that this interaction does not take place, and it is in fact the Rho 
superfamily which is upstream of p110β [31]. The association of PI3K with 
various families of small GTPases may need to be re-examined, as the 
complexity and contexts may be more intricate than currently stated.   
The complexity of upstream PI3K activation has yet to be fully understood – 
questions still remain as to the role of the different regulatory isoforms, and the 
extent of overlap between the different inputs. In different contexts with spatial 
and temporal considerations the input to and output from PI3Ks will vary, and it 
has been shown that there is a certain amount of functional redundancy 
between isoforms. Cells and tissues are not presented with a single input and 
so signalling studies which typically only monitor the effect of one agonist over-
simplify the real physiological range of stimuli.  
1.1.4. Signalling downstream of class I PI3K 
As dual specificity kinases, PI3Ks are able to phosphoryate both lipid species 
and proteins [1, 22].  
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1.1.4.1. Lipid kinase activity 
The lipid kinase activity of PI3Ks is the best characterized function of these 
kinases and is largely responsible for its physiological effects.  
Phosphoinositide species are recognised with varying specificity by effector 
proteins which contain lipid-binding domains (such as PH or PX domains) 
leading to membrane recruitment [16]. This change in localisation may in turn 
affect protein function, activity or binding partners. Despite the variety of 
upstream signalling to the class I isoforms, they all catalyse the acute 
production of PIP3 from PI(4,5)P2, a lipid species which is ubiquitous in cells 
[16]. PIP3 is short-lived and recognised by proteins with PH domains, including 
the best characterised PI3K effector, the serine/threonine kinase Akt/protein 
kinase B (PKB), whose activity is discussed in detail below. It has been 
estimated that phosphoinositides make up around 10% of total cellular lipids, 
with PI(4,5)P2 present at low levels (~2-30 μM) and PIP3 more than 25 times 
lower still [39]. As well as providing platforms for signalling cascades, the 
presence or absence of PI species can help to define cellular membranes; PIP3 
is enriched at the plasma membrane, while PI3P is present mainly on 
intracellular membranes [16]. 
Recruitment of effector proteins to the plasma membrane allows them to 
continue the signalling cascade. For example, Akt is phosphorylated and 
activated by the kinase PDK1 [40], both of which are responsive to PIP3 levels. 
Akt then goes on to phosphorylate a number of proteins leading to changes in 
diverse processes such as metabolism, survival and proliferation [41]. There are 
over 200 proteins which contain putative PH domains, although not all will be 
responsive to PIP3. These include other kinases, such as Bruton’s tyrosine 
kinase (BTK), as well as some GTPase activating proteins (GAPs) and guanine 
nucleotide exchange factors (GEFs), which are effectors of PI3K function [42]. 
1.1.4.2. Akt 
Akt is one of the best characterised effectors of PI3K activity. Akt was originally 
identified through its homology with previously known protein kinases, and is a 
member of the AGC family of kinases which includes PKA, PDK and serum-and 
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glucocorticoid-induced protein kinase (SGK) [41]. There are three isoforms of 
the kinase, Akt1, 2 and 3, which have differential tissue distribution and are 
encoded by separate genes. The isoforms all have a similar structure including 
three conserved domains: an N-terminal lipid binding PH domain which allows 
membrane binding, a catalytic kinase domain, and a C-terminal hydrophobic 
motif which is found in other members of the AGC family. Isoform-specific 
knock-out mice are viable with different phenotypes, evidence for non-
redundant functions of the isoforms. Akt1 is highly expressed in all tissue types, 
and genetic knock-out leads to a reduction in body weight [43]. Akt2 and Akt3 
have more restricted tissue distribution: Akt2 is highly expressed in insulin-
responsive tissues such as liver and adipose tissues and is implicated in the 
control of metabolism [44] while Akt3 has high expression in the brain [45]. 
Genetic knock-outs of Akt2 and Akt3 cause metabolic and brain defects 
respectively [44, 45]. 
Through its PH domain Akt binds to both PI(3,4)P2 and the PIP3 lipid product of 
class I PI3Ks, leading to relocalisation from the cytoplasm to the plasma 
membrane [41]. This translocation event anchors Akt to the membrane, brings it 
into contact with its upstream activating kinases, and causes a small increase in 
kinase activity by way of a conformational change, but its activity is dramatically 
increased, by around 1000 fold, by two phosphorylation events. First, Thr308 is 
phosphorylated by phosphoinositide-dependent protein kinase 1 (PDK1) [40], 
which is also recruited to the plasma membrane through its own PH domain. 
This increases the kinase activity of Akt by around 100 fold, with a further 10 
fold increase being achieved by phosphorylation of the Ser473 residue [46], an 
event catalysed by mTORC2 [47]. 
Full activation of the kinase requires phosphorylation of these two residues 
which are located in separate domains. The Thr308 residue of Akt1 is located in 
a region termed the activation or T-loop, a domain which is conserved among 
kinases; phosphorylation of residues in this area is required for substrate 
recognition, and also efficient transfer of the phosphate group from the ATP 
donor molecule. The Ser473 residue is found in a C-terminal hydrophobic motif, 
and phosphorylation of residues in this region are commonly seen in the 
activation of other AGC family members [48]. The phosphorylations are 
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removed by phosphatases: protein phosphatase 2A (PP2A) targets Thr308 and 
Ser473 [49, 50], while PH domain and Leucine rich repeat Protein Phosphatase 
(PHLPP) targets Ser473 [51]. However, these phosphorylations are not always 
a reliable readout of activity of upstream or downstream pathways, or of the 
activity of Akt. It has been shown that the activating phosphorylations may be 
present when the activity of Akt is reduced [52], and inhibition of Akt by ATP-
competitive compounds can bring about conformational changes which shield 
the phosphorylations from phosphatase attack [53], which is also seen upon 
ATP binding. 
 
 
 
 
 
 
 
Figure 1.4. Akt phosphorylates and controls diverse substrates and processes. Adapted 
from [10]. Akt is thought of as the primary effector of class I PI3K function. It binds the PIP3 lipid 
product at the plasma membrane and is targeted by two activating phosphorylations from PDK1 
and mTORC2. In turn it phosphorylates a range of substrates, affecting many central cellular 
processes. 
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Akt is a central node in multiple signalling pathways, and it connects growth 
factor signalling and PI3K activity to numerous cell processes, many of which 
have been implicated in oncogenesis. These pathways are not under the control 
of one single Akt substrate, and some substrates may influence more than one 
output; the multiple Akt targets may change in a signal and cell-specific context, 
allowing fine tuning of the response. To date, more than 100 Akt substrates 
have been identified, allowing Akt to control multiple and diverse cellular 
signalling pathways such as survival, metabolism and proliferation (Fig. 1.4.) 
[41]. Like many other kinases Akt has a peptide consensus motif, in this case 
RxRxxpS/pT, which it recognises and phosphorylates [54], although it is absent 
from some reported substrates. Phosphorylation by Akt often provides a 
docking site for 14-3-3 scaffolding proteins; binding of 14-3-3 isoforms to Akt 
substrates can cause sequestration and inactivation. An example of this is the 
phosphorylation of Foxo3a by Akt at two sites which leads to 14-3-3 binding and 
relocalisation from the nucleus to the cytoplasm, hence the Foxo3a transcription 
factor is unable to influence expression of genes important in processes such 
as apoptosis [55]. 
One of the best described effects of Akt activation is subsequent activation of 
the mechanistic target of rapamycin complex 1 (mTORC1). mTORC1 is itself a 
key controller of cell growth, proliferation and metabolism, and Akt contributes 
to its regulation by phosphorylating and inhibiting two mTORC1 negative 
regulators; TSC2 [56, 57, 58] and proline-rich Akt substrate of 40 kDa 
(PRAS40) [59, 60]. TSC2 acts in a complex with TSC1 as a GAP for Rheb, 
which is an upstream activator of mTORC1 when GTP bound. Phosphorylation 
of the mTORC1 inhibitor PRAS40 causes dissociation from the complex and 
14-3-3 binding [60]. mTORC1 is then active and exerts its control over 
autophagy, protein synthesis and cell growth [61] (discussed in more depth 
later).  
Cell survival mechanisms are also triggered by Akt activation, mainly through 
direct phosphorylation and inactivation of proapoptotic proteins, or indirectly 
through down regulation of their expression. Akt phosphorylates Bim and Bad 
[62] to inhibit their function through 14-3-3 binding and sequestration, and 
phosphorylation of Bax inhibits mitochondrial translocation and membrane 
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disruption [63]. Bcl-2 is inhibited through the phosphorylation of mouse double 
minute 2 homolog (MDM2) by Akt [64], while, through its direct negative 
regulation of the Foxo family of transcription factors, Akt can reduce the 
expression of proapoptotic factors [65]. Akt aids cell cycle progression through 
phosphorylation and inhibition of glycogen synthase kinase 3 (GSK3) [66]. 
GSK3 has a negative impact on the cell cycle through phosphorylation of 
transcription factors and other regulators such as Myc [67]  and cyclin D [68], 
and the inactivation of GSK3 by Akt releases its block on progression through 
checkpoints.  
As the primary Akt isoform in insulin-responsive tissues, Akt2 plays a key role in 
cellular metabolism. This includes direct phosphorylation of the glycolytic 6-
phosphofructo-2-kinase isoforms to activate them [69], or of GSK3 [66] or PGC-
1α [70] to inhibit them, which pushes the cell towards a more glycolytic profile 
[71], a phenotype which is frequently seen in tumours [72]. At the receptor level 
too, Akt promotes translocation of the glucose transporter Glut4 to the plasma 
membrane through its phosphorylation and inhibition of AS160 which prevents 
translocation through its Rab-GAP activity [73]. Akt also inhibits the 
phosphatase PTB1B which dephosphorylates the insulin receptor and targets it 
for degradation, thereby allowing an extension of signalling [74]. Through 
regulation of mTOR and HIF-1α amongst other proteins, Akt regulates 
transcription of metabolic enzymes such as the glucose transporter Glut1 [75]. 
Akt is primarily thought of in terms of the PI3K signalling pathway, but there is 
also a degree of involvement in other signalling axes. This crosstalk allows 
further fine-tuning of signalling, and means that Akt has a wider reach than a 
first look would suggest, as it communicates with (among others) mitogen-
activated protein kinase (MAPK) pathways [76, 77, 78]. 
1.1.4.3. mTOR 
mTOR is an atypical serine/threonine protein kinase, and through its enzymatic 
activity it regulates crucial signalling pathways. It is able to respond to 
environmental stimuli to integrate such inputs as growth factors and stress with 
metabolism and cell fate, a function which is vital for maintaining a balance 
between nutrient availability in the environment, and cellular growth. mTOR is 
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often thought of as a sensor, which allows the cell to switch between energy 
conservation and recycling during periods of starvation, and metabolic growth 
when nutrients and cellular building blocks are freely available. Its central 
position as such a regulator means that it has been implicated in metabolic 
diseases such as diabetes [79], and also as the cell’s energy factory in cancer 
[80]. 
mTOR is part of the PI3K-related protein kinase family, and it exists in two 
discrete complexes (mTORC1 and mTORC2) which are formed of multiple 
regulatory proteins (Fig. 1.5.), thus allowing the two complexes to exhibit non-
redundant functions [81]. Both complexes have mTOR, deptor [82], mLST8 [83] 
and the homodimer Tti1/Tel2 [84] in common, while regulatory-associated 
protein of mTOR (RAPTOR) [85, 86] and PRAS40 [60, 87] are only found in 
mTORC1, and rapamycin-insensitive companion of mTOR (RICTOR) [88], 
mSin1 [89] and protor1/2 [90] are only found in mTORC2. A further difference is 
in the response of the two complexes to rapamycin, the bacterium-derived 
macrolide from which mTOR takes its name. Rapamycin interacts with the small 
protein FKBP12, and when bound the two are able to inhibit mTORC1 [91]. The 
complex does not seem to directly inhibit mTORC2, however there is evidence 
that long-term rapamycin treatment can reduce mTORC2 signalling [92]. 
Activation of the mTOR complexes impacts PI3K signalling through feedback 
loops [93]. mTORC1 activates p70 ribosomal S6 kinase (S6K) which in turn 
phosphorylates IRS1 to inhibit it (Manning 2004, [94]. Conversely, mTORC2 is 
part of a positive feedback loop, in which Akt is further activated [47].  
The two mTOR complexes have been shown to be key regulators of growth and 
metabolism in cells, and control these and other processes by acting on a 
number of different targets [79]. Of the two complexes, mTORC1 is the better 
characterised, and positively regulates anabolic pathways including protein and 
lipid synthesis while negatively regulating catabolic activities such as 
autophagy. Since the processes it controls require large amounts of energy, 
regulation of mTORC1 is closely linked to the energy state of the cell. Being 
under the control of four different regulatory inputs (growth factors, nutrients, 
energy and stress) means that the signalling output of mTORC1 is tightly 
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controlled, and biosynthesis occurs only when environmental conditions are 
favourable.  
mTORC1 has been shown to localise to the surface of lysosomes where it is 
activated, which is a two stage process. First, stimulation by amino acids 
promote activation of Rag GTPases, which recruit mTORC1 to the lysosome 
where it localises with Rheb [95, 96]. Second, growth factors promote the 
phosphorylation and inhibition of the TSC1/2 complex, which relieves the 
inhibition of Rheb. The now-active Rheb GTPase is able to activate mTORC1 to 
initiate down-stream signalling cascades. Phosphorylation by mTORC1 can be 
activating or inhibitory to the target: in the case of protein synthesis, S6K1 is 
activated and 4E-BP1 releases an inhibitory interaction in order to positively 
regulate mRNA transcription and ribosome biogenesis, while phosphorylation 
inhibits ATG1 to negatively impact autophagy [79, 97]. 
 
 
 
 
 
 
Figure 1.5. mTOR exists in two complexes. Adapted from [81]. The protein mTOR forms two 
functionally distinct complexes due to the binding of different partners. Both complexes contain 
DEPTOR and mLST8, while mTORC1 also comprises RAPTOR and PRAS40, and mTORC2 is 
also formed from RICTOR, mSIN1 and PROTOR. 
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The signalling networks around mTORC2 are less well defined, but one 
important downstream target is Akt, where phosphorylation of Ser473 is 
required for full activation [47]. It is thought that out of the four regulatory 
pathways governing mTORC1, only growth factors (such as insulin) control 
mTORC2. It has been suggested that by varying the members of the complex 
through different splice variants, specificity in terms of sensitivity to upstream 
activators and downstream targets may be achieved. A requirement of 
ribosomes for mTORC2 signalling has also been proposed [98], and because 
mTORC1 regulates ribosome biogenesis, activity of the two complexes may be 
linked in this way. Few targets have been identified downstream of mTORC2, 
however it has been shown to phosphorylate and activate three members of the 
AGC kinase subfamily: Akt, SGK [99] and protein kinase C (PKC) [100, 101]. 
Through the activity of these substrates, mTORC2 is able to control processes 
such as metabolism, survival, growth and cytoskeletal polarity. 
1.1.4.4. Akt-independent pathways 
Akt is the best understood PI3K effector, and its prominence in the literature can 
give the impression that is it the sole transducer of PI3K function. However Akt 
is only one of many proteins downstream of class I PI3Ks, and a variety of other 
catalytically active or scaffolding proteins are increasingly being shown to play 
important roles. This is especially true in cancer, where the importance of Akt-
independent PI3K pathways have been identified [102].  
PDK1 is the kinase responsible for phosphorylation of Akt at Thr308 [40]. PDK1 
possesses a PH domain sensitive to both PI(4,5)P2 and PIP3 [48, 103], which 
may contribute to its wide cellular distribution profile; it is found in the cytosol 
and nucleus, as well as at the plasma membrane. It has constitutive activity due 
to its ability to transphosphorylate itself on Ser241 [104, 105]. A region in its 
catalytic domain allows it to interact with, phosphorylate, and activate a number 
of other AGC kinases, including serum and glucocorticoid regulated kinases 
(SGK) [106], S6K [106], p90 ribosomal S6 kinase (RSK) [107] and PKC [108] 
isoforms once these substrates display a facilitating change in conformation. 
This constitutive activity provides a means of signal transduction which is 
different from other kinases such as Akt, which require an activating event such 
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as phosphorylation. Such “substrate-directed” regulation allows PDK1 to control 
branches of different signalling pathways which have diverse signalling inputs 
and are largely independent of each other, such as PI3K and MAPK [109]. 
SGK isoforms are serine/threonine kinases which are closely related to Akt. 
There are three isoforms, of which SGK1 is the best studied [110]. SGK and Akt 
appear to have similar requirements in terms of activation and substrate 
consensus motifs, but differences do exist. In contrast to Akt, SGK isoforms lack 
a PH domain and are primarily cytosolic, although SGK3 has a PX domain by 
which it can be recruited to PI3P-containing membranes [111]. As is the case 
with other AGC kinases, phosphorylation at two sites is required for full 
activation [48]. PDK1 phosphorylates SGK1 in the T-loop at Thr256 [112] which 
is equivalent to Thr308 in AKT1. While mTORC2 is responsible for the second 
activating phosphorylation of Akt on Ser473, both mTORC1 and mTORC2 are 
able to phosphorylate the equivalent site in SGK1 (Ser422) [99, 113].  
Both SGK and Akt can recognise and phosphorylate residues within the 
consensus motif RxRxxS/T and share a number of substrates [48]. For 
example, in a similar manner to Akt, SGK1 phosphorylation of p27 leads to its 
accumulation in the cytoplasm where it is unable to inhibit of the cyclin-E/Cdk2 
complex [113], hence promoting cell cycle progression. In addition, 
phosphorylation of Foxo3a provides a 14-3-3 binding site which allows 
sequestration in the cytoplasm, hence inhibiting Foxo3a transcriptional activity, 
and subsequent cell cycle arrest and apoptosis.  Both Akt and SGK1 can 
phosphorylate Foxo3a at Thr32, while SGK1 has a preference of Ser315 over 
Akt’s preferred Ser253 site [114]. This shows overlapping but also 
complementary functions of the two kinases.  
A number of studies have shown that SGK has an important role to play 
downstream of PI3K in cancer. A panel of PIK3CA mutated cell lines displayed 
minimal Akt activation, and were dependent on SGK3 for viability [115]. A 
further study showed that Akt inhibitor resistance in breast cancer cell lines was 
due to increased expression of SGK1, and that either its knock-down or mTOR 
inhibition could reduce proliferation [116]. While Akt may be the primary PI3K 
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effector in healthy tissues, SGK has an important function in at least a subset of 
cancer cells. 
S6K also lacks a PH domain, and is activated through phosphorylation in its 
hydrophobic motif at Thr389 by mTORC2, which promotes a second activating 
phosphorylation by PDK1 of Thr229 [48]. Activation allows initiation of protein 
synthesis through direct phosphorylation and activation of S6. Multiple PKC 
isoforms can also be activated by PDK1, which control a variety of downstream 
cellular processes such as cell growth and transcription. The control of multiple 
(more than 20) other kinases allows PDK1 to exert control over a wide range of 
cell functions, and to integrate parallel signalling pathways from diverse inputs 
[48, 109]. 
Kinase-independent PI3K pathways exist, where small GTPases and their 
GEFs and GAPs have important functions. One such example is the link 
between the PI3K-Akt and MAPK pathways, which is still somewhat unclear. It 
has been shown that some trials of PI3K inhibitors have been unsuccessful in 
part because of feedback loops which allow MAPK activation. In a panel of 
breast cancer cell lines with PIK3CA mutations, PI3K inhibition brought about 
Akt inhibition, as well as inhibition of c-Raf/MEK/ERK through Rac-1 and its 
GEF P-Rex1. This led to induction of apoptosis through Bim, displaying a role 
for both Akt and MAPK pathways in transducing the PI3K survival signal [117]. 
1.1.4.5. Phosphatases 
While the proteins discussed above are responsible for transducing the PI3K 
signal, others are responsible for ending it. The primary antagonist of class I 
PI3Ks is phosphatase and tensin homologue (PTEN), a lipid phosphatase which 
removes the 3’ phosphate group of PIP3 to generate PI(4,5)P2, thereby 
terminating the PI3K-transduced signal [118, 119]. As a key regulator of a 
pathway implicated in many aspects of cancer development, it is not surprising 
that PTEN is second only to p53 in terms of its frequency of loss in cancer, 
where it is absent at the chromosome level, or expressed in truncated forms 
[120].  
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In a manner analogous to that of PI3Ks being both lipid and protein kinases, 
PTEN is able to act as both a lipid and a protein phosphatase [105, 120]. This 
dual action was explained when the crystal structure of PTEN was solved [121], 
which showed that the active site of the protein is sufficiently large to also 
accommodate phosphorylated serine, threonine and tyrosine. 
The protein SH2 domain-containing inositol-5’-phosphatase (SHIP) is also able 
to dephosphorylate PIP3, removing the 5’ phosphate to produce PI(3,4)P2 [119, 
122]. In this way, metabolism of PIP3 terminates the PI3K signal, but this step is 
also important in providing opportunities for further signalling by phosphatases 
and effector proteins which recognise the new lipid species [16].  
As well as direct dephosphorylation of the PI3K lipid substrate, phosphatases 
are also important to terminate signalling by dephosphorylating PI3K protein 
effectors. For example, the activating phosphorylations on Akt (Thr308 and 
Ser473) have both been shown to be removed by PP2A [49, 123], while 
PHLPP1 and 2 dephosphorylate Ser473 [51, 124], leading to a down-regulation 
in the kinase output. Further along this signalling pathway, other phosphatases 
will antagonise the activity of Akt, and by removing the phosphate group will 
reverse changes in activity or localisation. 
1.1.4.6. Protein kinase activity 
As well as their canonical lipid kinase activity, PI3Ks are able to phosphorylate 
proteins [22]. This activity has been reported for all three PI3K classes, but 
many questions still remain. While the lipid kinase activity of class I PI3Ks has 
been relatively well characterised, even though their protein kinase function has 
been known about for decades, it remains largely unexplored. 
Autophosphorylation is a potential means of self-regulation, and a number of 
other substrates have been identified for various isoforms (Fig. 1.6.), but 
whether or not the protein kinase activity has in vivo significance has not yet 
been established.  
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1.1.4.6.1. Class I PI3K autophosphorylation 
Indications that PI3Ks have dual specificity came soon after discovery. 
Sequence similarity of a newly described p110 protein to Vps34 indicated that 
the two were related, and presence of motifs found in PKA suggested a protein 
kinase activity [125]. Soon after, p85 was shown to be phosphorylated on 
Ser608 by p110 with a good stoichiometry in vitro, and this phosphorylation 
negatively regulated the PI3K lipid kinase activity [126, 127], a finding which has 
since been shown repeatedly. Barring an examination of the in vivo relevance of 
the activity of p110α and basic biochemical characteristics of other isoforms and 
novel substrates, very few significant advances have been made to our 
knowledge of the protein kinase activity of PI3Ks. Discovery of novel protein 
kinase substrates is challenging, and PI3K lipid kinase activity remains by far 
the better characterised output.  
Of the protein kinase activity of the class I PI3Ks, most of the work has focused 
on p110α. Due to its ubiquitous tissue expression, early reports which analysed 
“p110” were likely examining p110α. Creation of a mutant p110 to remove its 
phosphotransferase ability (R916P) allowed interrogation of the p110-p85 
relationship. The two proteins were still able to form a heterodimer but the 
mutation removed the phosphorylation of p85, thereby demonstrating that p110 
is the kinase responsible [127]. The same study however also stated that the 
protein kinase activity of p110 was reliant on the presence of Mn2+; the absence 
of this cofactor in cells has led others to query the in vivo relevance of the 
activity. More recently however, this dependency has been called into question. 
While making a comparison of the protein kinase activity of the class I proteins, 
it was observed that p110α and two of its mutants displayed robust 
phosphorylation of p85α in the presence of Mg2+ alone [128]. An in vivo role for 
protein kinase activity was shown with the p110α agonists insulin and PDGF 
both being able to increase the level of pSer608 in CHO-IR and 3T3 cells, an 
effect which is reversed by treatment with wortmannin [23]. Furthermore, 
injection of mice with insulin or okadaic acid also increased pSer608 levels in 
liver and muscle extracts respectively [23]. This clear phenotype in addition to in 
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vitro activity in the presence of Mg2+ alone strongly support the case for the 
protein kinase activity of p110α having a true signalling relevance. 
 
Because of its frequent mutation in cancer [129], the contribution of the protein 
kinase activity to the signalling output of p110α is clearly of interest. In a 
functional comparison of two common p110α mutants (E545K in the helical 
domain, and H1047R in the kinase domain), it was shown that compared to 
wild-type p110α, the oncogenic mutants are able to phosphorylate p85α to a 
much greater extent [130]. This was confirmed more recently, both in terms of 
autophosphorylation and targeting of an exogenous substrate [128], and in AML 
cell lines. However, creation of lipid kinase deficient mutants of p110α and 
p110γ showed that the protein kinase activity is not sufficient for in vitro 
transformation, although the possibility remains that the protein kinase activity 
may contribute in some way once foci or tumours form [131]. 
 
 
 
Figure 1.6. p110α is has both protein and lipid kinase activity. p110α directs its lipid kinase 
activity towards PI(4,5)P2 to produce PIP3, which leads to activation of Akt and downstream 
signalling. The protein kinase activity of p110α can be directed towards p85α, an event which 
has an inhibitory effect on the lipid kinase activity of p110α. Other p110α protein kinase 
substrates have been identified, such as IRS-1, HRas, and 4EBP1. 
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Although p110α phosphorylates p85α [23], the other three class I PI3Ks have 
been shown to autophosphorylate the C-terminus of the p110 subunit [132, 
133]. Using a catalytically inactive mutant of p110δ, it was shown that the p110 
subunit was the main target of p110δ protein kinase activity [132], in contrast to 
p110α. Sequencing and mutation studies showed that the target residue was 
Ser1039 on p110δ, and that its phosphorylation reduced lipid kinase activity 
[132]. Ser1039 phosphorylation was stimulated by T cell agonists and displayed 
a reasonable stoichiometry of phosphorylation of 0.5 mol phosphate/mol p110δ. 
Further, both lipid and protein kinase activities display equal sensitivity to the 
PI3K inhibitor LY294002. Taken together this evidence suggests that 
autophosphorylation may have a functional significance in vivo.  
The existence and relevance of p110β protein kinase activity is much less clear. 
One study observed no in vitro autophosphorylation of the p110β subunit while 
p85α was phosphorylated. However, in vivo phosphorylation of p85α was not 
significantly decreased in cells expressing a kinase-dead p110β compared to 
wild-type kinase. Further to this, using a phospho-specific antibody, Foukas et 
al found that Ser608 phosphorylation was not increased upon p110β and p85α 
co-expression [23, 130]. In addition, an independent study observed limited 
p85α phosphorylation in vitro but found much more phosphate was to be 
incorporated into the p110β subunit, and sequencing and mutation studies 
revealed Ser1070 to be the target [133]. This autophosphorylation however was 
not found to be stimulated by either pTyr or Gβγ, although phosphomimetic 
mutants did bring about a down-regulation in lipid kinase activity, thereby 
suggesting similarities but also differences among the class IA PI3Ks, but still 
leaving unanswered questions about a physiological role. 
In contrast to the protein kinase activity of the class IA isoforms, p110γ 
autophosphorylates in the presence of Mg2+ alone, and this autophosphorylation 
does not negatively regulate its lipid kinase activity [133]. Again, using 
sequencing and mutation studies the autophosphorylation site was mapped to 
Ser1101 in the C-terminus [43]. There are differing reports on the ability of Gβγ 
to stimulate autophosphorylation of p110γ, but it has been shown that lipid 
vesicles enhance the effect of Gβγ suggesting a requirement of orientation with 
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a cellular membrane [18]. This autophosphorylation has no effect on observed 
lipid kinase activity of p110γ, and so physiological relevance remains unclear. 
A recent study undertook a comparison of the class I proteins protein kinase 
activities bringing some clarity to this issue. Using in vitro kinase assays, they 
confirmed that p110α mainly phosphorylates p85α, while p110β p110γ and 
p110δ autophosphorylate the p110 subunit [128]. In addition and to a lesser 
extent, p110α demonstrated autophosphorylation activity while p110β could 
also phosphorylate p85α. 
1.1.4.6.2. Biochemical characteristics 
While multiple studies have demonstrated that p110 has protein kinase activity, 
questions remain: how it is regulated, what is the full complement of exogenous 
substrates, and most importantly, what is the physiological consequence of this 
activity? 
One elegant study showed that the lipid and protein kinase activities of class I 
PI3K can have separate physiological signalling output. The study exchanged 
the lipid binding domain of p110γ for one of several proteins to create p110γ 
mutants which retained protein kinase activity but had different lipid-binding 
specificities. In this way, it was shown that while the lipid kinase activity is 
required for Akt activation, the protein kinase activity activates the MAPK 
pathway [134]. Additionally, the lipid and protein kinase activities were found to 
occur in different subcellular localisation. The authors showed that membrane 
targeting (which mimicked recruitment to activated receptors) of p110γ resulted 
in Akt activation, while protein kinase mediated activation of MAPK occurred 
when p110γ was free in the cytosol. Building on this work, membrane binding 
was further shown to inhibit p110γ autophosphorylation, suggesting a more 
general inhibition of p110γ protein kinase activity. 
A subsequent study demonstrated that the two kinase activities of p110γ may 
be differentially controlled by varying concentrations of Gβγ subunits of 
heterodimeric G proteins. p110γ lipid kinase activity was found to increase with 
increasing Gβγ concentrations, while the opposite was true for phosphorylation 
of an uncharacterised site on MEK1, or for p110γ itself [135]. While a clear 
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reduction in MEK1 phosphorylation was observed with increasing Gβγ, a less 
drastic change was seen in autophosphorylation, with still around 70% of 
maximum activity seen even with the highest Gβγ concentrations. Nevertheless, 
the data do point to physiological scenarios where PI3K protein and lipid kinase 
activities can function separately to produce different outputs. As we learn more 
about the regulation of PI3Ks, it would be worthwhile to revisit these hypotheses 
to comprehensively assess the effect of different stimuli (e.g. RTKs, GPCRs, 
Ras and small GTPases) on the class I isoforms.  
1.1.4.6.3. Non-PI3K substrates 
While analysis of a known phosphorylation can be a difficult enough task, and 
identification and characterisation of novel targets is even more challenging, 
non-PI3K substrates have also been identified. Early on in the characterisation 
of PI3K protein kinase activity, IRS1 was identified as a substrate [136, 137, 
138]. Insulin-stimulation of adipocytes increased phosphorylation of p85α and 
IRS-1, which was sensitive to treatment with the pan-PI3K inhibitor wortmannin 
[136, 138]. Such tools helped to first display a role for PI3K as a protein kinase 
and suggested a functional purpose in the insulin response in which PI3K was 
already implicated, but were not enough to assign a specific responsible 
isoform. More recently, both p110α and p110δ were shown to phosphorylate the 
GM-CSF/IL-3 receptor, which led to increased survival of two leukaemia cell 
lines [139]. The authors showed a detachment of lipid and kinase activities 
depending on the concentration of receptor agonists, with lower cytokine 
concentrations positively regulating protein kinase function.  
When searching for new substrates of a kinase, a targeted approach such as 
looking to known pathways has clear benefits. However, identification of less 
obvious proteins is unlikely. Foukas et al used a targeted method to identify 
novel PI3K substrates, by looking for sites that had similar characteristics to p85 
pSer608: phosphorylation sites that were surrounded by acidic residues and 
were wortmannin-sensitive. This led to the identification of Ser111 of 4EBP1 as 
an in vitro substrate of p110α and p110γ [140]. However, comparison of this 
activity to that of ERK1 (an established 4EBP1 kinase) showed that the 
stoichiometry of phosphorylation was very low: 0.16 compared to 0.6 mol of 
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phosphate/mol 4EBP1 for p110γ and ERK1 respectively [140]. The same study 
also identified H-Ras as an in vitro target of p110α, and p110γ but not p110β. 
However, functional effects were not elucidated for either phosphorylation, and 
in vivo relevance remains unclear. 
In the context of class I protein kinase activity, physiological effects of non-PI3K 
targets have been described. The use of lipid kinase- or protein kinase-only 
p110γ allowed the identification of non-muscle tropomyosin as a substrate 
[141], both in a whole cell context and in an in vitro kinase assay, although use 
of a more specific inhibitor than wortmannin would have been beneficial. Use of 
cells derived from p110γ knock-out mice led to the finding that p110α can 
compensate to phosphorylate non-muscle tropomyosin, but when both isoforms 
are lost phosphorylation is vastly reduced. Knock-down of non-muscle 
tropomyosin, as well as serine-to-alanine mutation of the PI3K target site, both 
resulted in a clear phenotype of a block in the internalisation of β-adrenergic 
receptor. 
1.1.5. Tools for studying PI3K function 
Although the class I PI3Ks are structurally conserved which implies redundancy, 
other characteristics suggest independent functions [1]. Tissue distribution, 
upstream signalling input, and regulation by heterodimer partners all point to the 
isoforms having non-redundant roles. While there is redundancy in terms of 
signalling between isoforms in different cell types, pharmacological and animal 
models have elucidated isoform-specific roles in healthy and disease 
processes. In our and other laboratories, model systems have been developed 
which target the genes of the various PI3K isoforms allowing activation (such as 
are found in cancer) or inactivation of the kinase activity [142, 143]. These lines 
have been key in delineating signalling pathways, assigning isoform-specific 
functions, and providing models to mimic disease states and assess efficacy of 
pharmacological compounds. 
The first approach, termed “knock-out”, involves the deletion of a gene so that it 
is not expressed. This can be cell- or tissue-specific, or it may be that the 
protein is absent from the whole organism, and is achievable in a wide range of 
systems, from yeast to mice. 
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A second approach, termed “knock-in”, involves the introduction of a point 
mutation to the gene of interest, so that it is still fully expressed, but with altered 
function. This may also be in a specific or general context. Our laboratory has 
developed mice which have activating and inactivating mutations for a range of 
PI3K isoforms. For example, the introduction of the oncogenic H1047R mutation 
into the Pik3ca gene produces an activated p110α and can be used to model 
cancer initiation and progression. The reverse can be achieved with mutation of 
the DFG motif in the kinase domain which coordinates ATP binding; substitution 
of DFG with AFG produces a catalytically inactive kinase [144, 145]. The 
inactivating knock-in model has a number of advantages over the knock-out 
system. First and foremost, knock-out models can suffer from compensation 
from other isoforms. Because the targeted gene is still present (albeit in a 
modified form) in the knock-in system, problems of compensation by other 
isoforms are less likely to occur, and so the knock-in approach more accurately 
represents small molecule inhibition. Another important factor is that a point 
mutation is less disruptive than gene deletion in terms of off-target effects; it has 
been shown that even when one gene is targeted for specific deletion, genes at 
distant loci can be affected, thereby clouding any conclusions drawn from its 
use. Complementary pharmacological and animal studies have been central to 
developing our knowledge of the PI3K pathway. 
1.1.6. Isoform-specific functions of class IA PI3K 
Both p110α and p110β have overlapping functions in downstream processes 
such as survival, proliferation and metabolism. However, it has long been 
known that the two isoforms have different contributions from upstream 
activators (see chapter 1.1.3) and mouse models and pharmacological tools 
have provided insights into functional differences.  
Homozygous loss of p110α causes embryonic lethality in mice [18]. This is a 
kinase- dependent phenotype as knock-in of a kinase-dead p110α is also 
embryonic lethal [144]. Mice heterozygous for the knock-in allele are viable and 
fertile but have reduced insulin sensitivity [144]. That p110α is critically 
positioned downstream of the insulin receptor, while p110β plays only a minor 
(or no) part, was confirmed by use of pharmacological compounds [146]. A key 
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role for p110α in the control of angiogenesis has also been demonstrated: in a 
comparative study of the class IA isoforms, it was only p110α that was critical 
for endothelial cell migration and vascular remodelling, acting through the small 
GTPase RhoA [145].  
Mice homozygous for loss of p110β are also embryonic lethal [19], with 
heterozygous litters viable and fertile. Interestingly, mice which express low 
levels of kinase-dead p110β are also embryonic lethal, while those which 
express higher levels of the same gene survive to adulthood [147]. This 
suggests that the kinase activity of p110β is dispensable and may have a 
scaffolding function.  An early isoform-specific role for p110β in platelet function 
and thrombosis was demonstrated through inhibitor use. Binding and stability of 
integrin bonds were reduced upon p110β inhibition [148]. Conditional knock-out 
of p110β in platelets also showed that isoform to be responsible for normal 
signalling downstream of both RTKs and GPCRs, and aggregation of platelets 
was defective [149]. These studies demonstrate the potential of p110β as a 
therapeutic target in thrombosis. A role for p110β in endocytosis has also been 
suggested, as it is able to bind the endocytotic regulator Rab5 [24, 38]. This 
may be a kinase-independent function, as ablation of p110β causes defects in 
receptor internalisation, which can be rescued by expression of kinase-dead 
p110β [147, 150].  
p110α and p110β also appear to have differing contributions to cancer, which 
are discussed below. Briefly, p110α is the only PI3K found mutated in cancer 
[129], while p110β has been shown to be required for oncogenesis in certain 
PTEN-null prostate cancers [152].  
In the same way that p110α and p110β share a tissue distribution but can 
control different functions, the two isoforms enriched in haematopoietic cells are 
able to produce distinct biological outputs. In terms of disease, p110γ has been 
shown to be important for cardiac function and p110δ for immunity and the 
tumour microenvironment [153]. As discussed previously there are also 
differences in terms of substrates for the protein kinase activities of the isoforms 
[128]. 
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Figure 1.7. Class I PI3K isoforms display differential signalling in health and disease. Adapted from  [151]. The emerging picture of upstream and 
downstream class I PI3K signalling is more complex than originally thought. Class IA isoforms are activated by RTKs and Ras, and p110γ by GPCRs and 
Ras, while p110β may also receive additional input from GPCRs and small GTPases. Both p110α and p110β have ubiquitous tissue expression, while p110γ 
and p110δ are expressed mainly in haematopoietic cell lines. They also have different roles in normal cellular and disease signalling.    
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1.1.7. Disease 
Since the PI3K-Akt-mTOR axis is at the heart of pathways critical for cell 
growth, survival and metabolism, it follows that their signalling is often 
dysregulated in a number of diseases. PI3Ks are activated downstream of 
growth factors such as insulin, and are highly expressed in immune cells, and 
so it stands to reason that they play a role in pathologies such as diabetes and 
inflammatory diseases. Many of the aberrations that enable a cell to grow 
uncontrollably and transform are controlled by the PI3K/Akt/mTOR pathway, 
and so mutations here are often observed in cancer [154]. That these pathways 
and proteins are so active in disease has resulted in a large amount of interest 
from academia and industry as well as a push to develop modulators of nodes 
of these pathways, particularly in cancer [155]. Mutations which increase the 
activity of oncogenes (gain of function) or decrease the activity of tumour 
suppressor genes (loss of function) contribute to the formation and survival of 
tumours. Both types of mutation affect the PI3K pathway in different cancers 
and mutations can occur at multiple nodes [154]. These include activating 
mutations upstream of PI3K in RTKs and Ras, and downstream in Akt, as well 
as in the regulatory subunit p85α [156, 157], which cluster in and around the 
SH2 domains thereby allowing decreased inhibition of the class I PI3K catalytic 
isoforms [158]. The two most frequently observed PI3K pathway mutations are 
in the genes coding for p110α [129] and PTEN, and in fact these are two of the 
most commonly mutated genes in cancer. 
The only PI3K isoform to have been found mutated in cancer is p110α, with 
mutations clustering around two “hotspots” in the helical and kinase domains 
[129]. Both mutations increase kinase activity though through different 
mechanisms: mutations at E542K or E545K in the helical domain relieve p85’s 
inhibition of p110α by mimicking the binding of pTyr residues, while the H1047R 
kinase domain mutation mimics activation by Ras, and this mutant can still be 
further activated by pTyr [130, 159].  
Loss of the phosphatase PTEN provides another means of activating the PI3K 
pathway, and it has been associated with a reliance on p110β in the context of 
prostate cancer [152]. Loss of p110β but not p110α prevented tumour formation 
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in PTEN-null mice [150]. In other models of prostate cancer, inhibition or siRNA-
mediated knock-down of p110β negatively impacted growth and colony 
formation of PTEN-null cell lines [160] and tumour progression  [152]. While 
PTEN loss and PIK3CA mutations allow essentially the same biochemical 
output, it has been shown that they can coexist in tumours, and a recent study 
demonstrated that inhibition of p110α protected PTEN-null mice from thyroid 
cancer, as well as a number of other diseases [152].  
PI3Ks other than p110α are part of signalling pathways which are important for 
tumour initiation and maintenance, and it is perhaps surprising that p110α is the 
only PI3K to be mutated in cancer. A number of features of p110α structure and 
signalling may help to explain this, as well as its ability to contribute to many of 
the hallmarks of cancer. Though not due to mutation, a role in angiogenesis not 
shared by other isoforms means that p110α can provide a lifeline to tumours 
[145], which cannot grow past ~1mm3 without a blood supply. Second, p110α is 
ubiquitously expressed [15] meaning that it can contribute to a wide range of 
tumour types, whereas in theory p110δ could only contribute to haematological 
malignancies. This, however, does not explain the lack of common oncogenic 
mutations in p110β which also has a widespread tissue distribution. Structural 
examination of the class I PI3K isoforms has suggested differences in the 
inhibitory pressures which the regulatory subunit places on the p110 protein. 
While p110α binds the nSH2 and iSH2 domains of p85α, other class I isoforms 
have an extra inhibitory contact at the cSH2, hence making p110α more 
amenable to oncogenic mutation than the other class I PI3Ks [32]. This is also 
the case with upstream signalling: p110α is activated primarily by RTKs, in 
contrast to p110β and p110γ which have additional input from GPCRs [30, 35]. 
The importance of the class I PI3Ks to a range of cellular outputs means that 
their role in disease is not limited to cancer. For example, both p110α and 
p110β have been implicated in cardiovascular disease, and p110γ and p110δ 
are known to contribute to autoimmunity (Figure 1.7 lists more examples). One 
interesting and recently characterised phenotype is an overgrowth syndrome 
caused by somatic mutations in p110α; sequencing studies found an amino acid 
substitution at H1047 (to R or L), which caused  dramatic overgrowth of bone as 
well as fibrous and adipose tissues [161]. Interestingly, while H1047 is the same 
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residue mutated in many cancers, in these syndromes the mutation was found 
to induce benign mosaic hyperplasia instead of tumour formation. This provides 
an interesting aspect to the thoughts around whether or not p110α is important 
in tumour initiation and maintenance.  
An analogous mutation in the p110δ kinase domain has recently been 
characterised. A single amino acid substitution (E1021K) resulted in increased 
activation and membrane association of the isoform [162], which led to a range 
of clinical phenotypes including respiratory disease and splenomegaly. The 
mutant was able to be inhibited by the p110δ-specfic inhibitor IC87114. 
1.1.8. Pharmacological Intervention 
Because of the relevance of the PI3K-Akt-mTOR signalling pathway in a variety 
of disease states and clinical settings, an effort has been made to target various 
nodes with pharmacological compounds. Typically, it has been the case that the 
down-regulation of an enzyme is more easily achieved than up-regulation, and 
so more progress has been made in trying to inhibit kinase activity rather than 
increasing phosphatase activity.  
With 518 kinases present in the human genome [163], they play roles in most if 
not all signal transduction cascades. With this in mind, kinases have long been 
attractive targets for therapeutic intervention, and both specific and general 
inhibitors have been developed for use in the laboratory and through clinical 
trials. These inhibitors are generally small molecules which competitively target 
the ATP-binding site of the kinase [164]. Inhibitors targeting the active site can 
be type I or II ATP competitive (binding to the active or inactive kinase 
conformation respectively) or covalent, or may bind a region away from the 
active site (allosteric inhibitors).  
Because of the degree of conservation of the catalytic region within members of 
the kinase family, achieving specificity for different kinases and isoforms is 
challenging, and so next generation inhibitors may seek to exploit differences in 
the rest of the molecule to realise this desired specificity. It is also true that in a 
cancer setting, the selective pressure on the kinase to mutate which is caused 
by the drug, alongside the rapidly growing tumour promote the rapid outgrowth 
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of resistant cells. This resistance can occur due to mutations in the ATP-binding 
site, and often to a specific ‘gate-keeper’ residue which controls access to this 
site, but may also be due to increased activity of other parts of the signalling 
cascade, for example by mutation of receptors, or differential expression of 
other enzymes, such as by loss of phosphatases like PTEN. 
In spite of the large amount of effort devoted to seeking to block the PI3K 
pathway at various points and in various cancers, there has been a 
disappointing amount of success [155]. This is the case when therapy has been 
given to groups both with and without PI3K pathway mutations. Despite its 
central role in many pathways which tumour cells are dependent on, it would 
seem that inhibition of PI3K or its allies is not enough to produce large and long 
term beneficial effects in the clinic.  
In both the laboratory setting and the clinic, it is becoming increasingly clear that 
targeting more than one enzyme or signalling pathway is necessary for optimal 
therapeutic benefit. This is also true in terms of resistance to inhibitors, as it is 
harder for a cancer to become resistant to multiple therapies compared to one. 
However, the use of multiple inhibitors can complicate the readout of their 
effect, especially when feedback loops are considered. Through the build-up of 
knowledge of individual and integrated signalling pathways, as well as structural 
insights gained from crystallography, a more targeted approach is now being 
taken in terms of design of novel inhibitors. In the same way that drug design is 
informed by our knowledge of the target and related kinases, the decision on 
which patients receive these drugs is beginning to be directed by genetic factors 
and biomarker readout. 
The pan PI3K-isoform inhibitors wortmannin and LY294002 were first described 
in the early 1990s, and are still in use today to make general observations about 
PI3K activity. Both compounds were originally thought to be more specific than 
they in fact are, with off target effects including inhibition of mTOR meaning that 
conclusions drawn from their early use may have to be re-evaluated. 
Nevertheless, they were very useful for the initial characterisations of PI3K 
function.  
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More recently, specific and pan-isoform inhibitors have become available for 
class I PI3Ks, as well as for pan-Akt and mTORC1/2; these are listed in Table 
1.1. The most promising translational results have been with p110δ inhibitors: 
the first isoform-specific compound described was IC87114 which targets 
p110δ, and CAL101 is now in late stage clinical trials for use in haematological 
malignancies. Even though it is not actually mutated in cancer, it has been 
found that targeting p110δ can lead to clear positive outcomes in a clinical 
setting. Trials using the p110δ-selective inhibitor CAL-101 in patients with 
chronic lymphocytic leukaemia saw a large reduction in tumour burden, and the 
drug is well into phase III. The cause of the modulation has been suggested to 
be directly on the tumour cells by causing cell death, and also indirectly by 
inhibiting their retention in the microenvironment [165, 166]. 
As the only PI3K isoform to be found mutated in cancer p110α is an attractive 
target for inhibition and specific inhibitors have recently become available. 
Some of these compounds, including BYL-719, are now progressing through 
clinical trials. Another such compound, A66, has around 40 times more 
selectivity for p110α over the other class I isoforms, and is also potent against 
the E545K and H1047R mutants [167]. 
Alongside these encouraging results however, a number of findings suggest 
that PI3Ks may have a different role in cancer than previously thought. While 
the PI3K pathway is frequently found to be mutated in cancer, studies using 
specific or pan-isoform PI3K inhibitors have been less effective than anticipated 
at inducing cancer cell death, and it is also true that there is a lack of correlation 
between PIK3CA and PTEN mutation, and the ability of p110α-specific/pan-
class I PI3K inhibitors to reverse tumour growth. The failure of many anti-class I 
PI3K compounds in the clinical setting is due, at least in part, to the unwanted 
suppression of negative feedback loops, ultimately leading to increased not 
decreased signalling downstream of PI3K [93].  
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Table 1.1. Compounds available for inhibition of PI3K pathway 
components 
Compound Target Clinical Setting 
Wortmannin Pan-PI3K, mTOR  Anti-inflammatory, displayed in vivo 
anti-tumour effects, but also liver 
toxicity 
LY294002 Pan-PI3K, mTOR Displayed in vivo anti-tumour effects, 
but also dermal toxicity. 
GDC-0941 Pan-class I PI3K  Trials for solid tumours (including 
breast, ovarian, melanoma, 
pancreatic) 
BYL-719 p110α  Trials for solid tumours (including 
breast, cervical, endometrial, 
ovarian, head and neck) 
TGX221 p110β Thrombosis 
CAL-101 p110δ Trials for haematological cancers 
(including mantle cell lymphoma, 
chronic lymphocytic leukemia) 
IPI-145 p110δ/γ Trials for haematological cancers 
(chronic lymphocytic leukemia, small 
lymphocytic lymphoma) 
MK-2206 Akt Trials for solid tumours (including 
neuroendocrine) 
Rapamycin mTORC1 (mTORC2 
with long-term 
treatment) 
Approved for renal cancer, in trials 
for various other solid tumours, as 
well as ageing studies. 
AZD8055 mTORC1/2 Trials for solid tumours (gliomas, 
hepatocellular carcinoma) 
 
Inhibitors have also been generated for Akt [168], and the pan-isoform allosteric 
inhibitor MK-2206 is in phase II clinical trials for use in a number of carcinomas, 
both as a single agent and in combination with other drugs. While it is known 
that the different Akt isoforms display non-redundant roles, isoform-specific 
compounds are currently unavailable. 
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mTOR therapies began with the discovery of the macrolide rapamycin, and 
progressed when it was found that rapamycin acutely targets mTORC1 through 
FKBP12, although long term exposure can affect mTORC2. Rapamycin has 
immune-suppressive effects, and since its discovery various rapalogs have 
been developed and moved into clinical trials with varying success. Next-
generation compounds (some of which also target PI3K) are also in early phase 
trials for use in solid tumours, and inhibitors are available which are selective for 
one or both mTOR complexes. 
1.2. Proteomics 
Over the past few decades, the advances in sample processing, mass 
spectrometers and analytical techniques have allowed the large-scale 
identification and quantification of thousands of proteins and post-translational 
modifications in a single experiment. There are two general mass spectrometry 
methods for protein analysis: first is the ‘top down’ approach, in which whole 
proteins are examined intact, and the second is the ‘bottom up’ approach which 
looks at the peptides after digestion of a protein [169]. These techniques benefit 
from the unbiased manner in which proteins can be analysed, with no prior 
knowledge of the content of the sample required.  
While intact proteins can be analysed by mass spectrometry, it is more common 
for at least one digestion step to be used to produce peptides which are more 
amenable to LC-MS. Trypsin is typically the enzyme of choice, and works by 
cleavage of bonds C-terminal to lysine or arginine residues [170]; because of its 
high specificity, bioinformatic analysis is made simpler than if peptides with 
random termini were produced. This specificity is not always beneficial 
however, as some proteins may not be digested efficiently and some may be 
digested too well, causing fragments with m/z ratios which fall outside of the 
typical MS window of detection to be produced. The use of enzymes with 
different specificities can be used to combat this; for example, the combination 
of databases derived from samples treated with one or both of trypsin and Lys-
N typically allows greater coverage of the proteome compared to a database 
from the use of one enzyme alone [171]. 
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1.2.1. Post-translational modifications 
Signalling pathways are an essential means of coordinating and synchronising 
cellular processes with each other, and with the extracellular environment [172]. 
It has been found that the expression of a protein is not necessarily the best 
indicator of its signalling capacity, and a number of other factors affect activity. 
PTMs play a key role in regulating and integrating signalling pathways, as they 
can affect localisation and interactions of effector proteins, as well as protein 
stability. In addition they are a much more rapid method than alterations at the 
gene expression level. PTMs typically involve the addition of a chemical tag to 
the amino acid side chain of proteins, a change which can influence a variety of 
characteristics. Some PTMs are well characterised and understood: 
ubiquitination on specific lysine residues targets the protein for different 
processes (including degradation) [173], while phosphorylation of kinases in 
specific motifs typically confers higher activity [48]. Hundreds of PTMs have 
been identified including the above mentioned phosphorylation and 
ubiquitination, as well as acetylation, methylation and palmitoylation. The variety 
of modifications, the potential for dynamic addition and removal and the multiple 
functional effects that can occur, provides great scope for rapid and specific 
fine-tuning of signalling pathways, both inter- and intra-cellularly [172]. 
Phosphorylation is historically one of the most extensively studied PTMs and 
this is still the case today, in part due to the ease with which it can be monitored 
with the currently available tools; tools which continue to evolve and improve 
because of the extent of their use. 
As their correct function is required for correct signalling in healthy cells, it 
follows that aberrations in PTMs which control critical networks can be at the 
heart of disease processes. This is especially true for phosphorylation, where 
kinases and phosphatases are often mutated. The ability to delineate signalling 
networks, to assess functionality of PTMs, and to assign substrates to effector 
enzymes is increasingly important in our aim to understand and tackle diseases 
such as cancer. 
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1.2.1.1. Phosphoproteomics 
Phosphorylation is a reversible post-translational modification in which a 
phosphate group is covalently added to a serine, threonine or tyrosine residue 
[174]; some estimates suggest that more than half of proteins can be 
phosphorylated [175]. Phosphorylation of other amino acids can also occur, 
although these are less well studied. The process of phosphorylation is carried 
out by a group of proteins called kinases, of which there are over 500 in the 
human genome [163], and is antagonised by phosphatases, of which there are 
around 150. The addition of the negatively charged bulky phosphate group can 
cause a change in protein structure which may affect a protein’s activity or 
binding partners, and in this way phosphorylation is able to control the amount, 
activity and cellular location of the protein target [176]. It is therefore an 
important regulator of most, if not all, cellular pathways which can be regulated 
at each level, allowing the capacity for both positive and negative feedback, and 
input from different and diverse signalling networks [93].  
While the study of genes (genomics) and their transcription (transcriptomics) 
can provide valuable information about the state of a cellular or biological 
system, a major limitation is that they do not necessarily correlate with presence 
or activity of the cellular protein product. Therefore, it is important to look to 
other fields in order to study signalling outputs and cellular processes, and 
proteomics is increasingly being used to delineate and functionally analyse 
pathways. While some sites in the phosphoproteome will not impact function or 
be dynamically regulated, a significant number affect protein activity or 
localisation. This means that monitoring phosphorylation of a protein can give 
useful information on the signalling output of a particular system and so can be 
more relevant than genomic or transcriptomic data. However, when 
comparisons are being made of samples over long time points (>6 h), especially 
regarding PTMs, thought must be given to potential discrepancies in protein 
expression. Where appropriate, experiments should take information on the 
abundance of both proteins and PTMs, which would allow stoichiometry to be 
established.  
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1.2.1.2. Enrichment Techniques 
It is possible to identify and quantify many thousands of phosphorylation events 
from a single experiment using similar techniques employed for typical 
proteomic analysis. However, in order to gain significant insight into the 
phosphosites present in a sample, great care needs to be taken to conserve the 
modification, which is typically present at low abundance. This requires 
inhibition of phosphatases which would otherwise attack and dephosphorylate 
it, throughout sample processing until those enzymes are inactivated through 
denaturing or digestion. Phosphatases are thought to have faster reaction 
kinetics than kinases [177], adding to the importance of their inhibition. 
Identification and quantification of modified peptides is more challenging than 
when analysing their unmodified counterparts. This is because while unmodified 
proteins will have a number of peptide fragments produced upon digestion 
which can be used for analysis, only the peptide which is post-translationally 
tagged is of interest and used for characterisation in the case of modified 
proteins.  
Other problems also need to be addressed. Ionisation of the peptide and 
dissociation along its backbone are key steps required to allow identification, 
however there is evidence that phosphopeptides ionise less efficiently than their 
non-phosphorylated counterparts [178].  A further challenge arises when one 
considers that the phosphate group attached to the amino acid side chain is 
often the first bond to break under the pressure of the internalised energy from 
whichever collision method is employed [179]. This means that instead of 
allowing dissociation of the peptide backbone and better identification of the 
sample, the desired information on PTM and location is difficult to obtain. 
Different strategies for fragmentation avoid this problem, for example electron 
capture dissociation (ECD) and electron transfer dissociation (ETD) which 
achieve fragmentation through electron bombardment rather than through 
vibrational energy transfer [180, 181].  
As well as these problems due to the chemistry of phosphopeptides, issues with 
the technology used to identify them exist. Because of their relatively low 
abundance compared to their non-phosphorylated counterpart, phosphoproteins 
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and phosphopeptides are unlikely to be detected using standard non-targeted 
discovery MS techniques. This is due to the limitations of the mass 
spectrometer, which permit only a fraction of peptides from a complex sample 
mixture to be selected for fragmentation and analysis [182]. Because of this 
under-sampling, phosphopeptides should be enriched to facilitate detection and 
analysis; there are a number of techniques in use for this purpose, many based 
on affinity purification. 
Antibodies have been raised to a number of different phospho-motifs, both in 
specific and more general contexts. For example, antibodies exist to pSer473 of 
Akt, and also to pTyr motifs which will recognise a wide variety of proteins. 
These can be used in the same way as immobilised metal affinity 
chromatography (IMAC) to enrich for phosphoproteins, in much the same way 
as immunoprecipitation for whole proteins. While this may work well for IP and 
WB, commercially available antibodies specific for pSer, pThr and pTyr most 
probably lack the phosphoproteome coverage required for large-scale global 
analysis [183]. Different IMAC approaches may favour proteins with different 
numbers of phosphorylations but do not discriminate based on the amino acid 
residue to which the modification is attached. There are large differences in the 
proportion of pSer, pThr and pTyr found in nature, and differences in affinity of 
antibodies will dramatically impact enrichment. 
Exploitation of the chemical properties of the phosphate group can produce high 
enrichment yields. Because of the negative charge which the phosphate 
species incorporates into the modified protein, positively charged “baits” can be 
used to pull down phosphoproteins in a relatively specific manner. For example 
in IMAC, positively charged metal ions such as Fe3+ are bound to a solid 
support which will then bind any proteins with a large negative charge [184, 
[185]. One limitation of this method is that the positive ions also bind with high 
affinity to acidic proteins, and measures need to be taken to remove these 
proteins before mass spectrometry, where they may interfere with detection of 
the less abundant phosphoproteins of interest. Solutions include modification of 
acidic amino acid side chains to prevent them from binding the metal ion, and 
varying solvents and pH, although these do not always fully resolve the issue 
[186, 187, 188]. A further problem with IMAC-based enrichment is the 
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preference for binding peptides with more than one phosphate which can 
introduce a bias which should be borne in mind during analysis [189]. 
Titanium dioxide (TiO2) –based affinity chromatography is essentially a modified 
version of IMAC [190, 191]. Introduction of steps during sample processing 
have greatly reduced the presence of non-phosphorylated proteins after the 
purification round, for example use of acidic buffers and various combinations of 
washes after binding of proteins to the TiO2 [192, 193]. Due to its higher 
enrichment efficiency than IMAC, and by being more resilient to various buffers 
[177], TiO2 is now widely used. In contrast to IMAC methods which use 
transition metal ions as “bait”, TiO2-based enrichment favours identification of 
peptides with a single phosphorylation [193]; higher numbers of phosphates 
increase affinity of binding which makes elution of multiply-phosphorylated 
challenging. Peptides which are rich in acidic residues can bind non-specifically 
to TiO2 in a similar manner to conventional IMAC techniques, thereby reducing 
specificity of the methodology for phosphopeptides. Measures can however be 
taken to counter this, such as by the use of compounds which bind TiO2 in a 
manner intermediate to that of phosphopeptides and acidic peptides; thereby 
allowing binding of the former but competing with the binding of the latter.  
Different approaches have different benefits, and so there may be advantages 
to combining one or more methods. Separation steps such as hydrophilic 
interaction liquid chromatography (HILIC) or strong cation exchange (SCX) can 
also be used in concert along with IMAC methods to reduce sample complexity 
and hence improve enrichment, as a number of studies have shown [177]. 
As well as these affinity based methods, it is possible to chemically modify the 
phosphate bond in order to subsequently capture the peptide to which it is 
attached, which may be done with and without the loss of the phosphate ion 
itself. The peptide can be linked to biotin via reactions which expel the 
phosphate, and then this complex can be captured through biotin-avadin affinity 
[194]. Alternatively, by keeping the phosphate attached to the peptide and 
coupling it to iodoacetyl beads, peptides can be immobilised and subsequently 
eluted. Both of these strategies can suffer from chemical modification of non-
phosphate bonds, while the former method does not work for pTyr residues. 
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Vast improvements in proteome coverage have been made in recent years 
which are attributable to developments in handling techniques and analysers; 
these improvements will continue. Stimulation as well as spatial and temporal 
contexts must also be kept in mind, which may mean that a specific PTM is not 
present in a sample. Also, despite the best efforts to maximise proteome 
coverage and PTM identification, not all proteins or modifications actually 
present in a sample will be detected. The duty cycle of a mass spectrometer is 
a limiting factor, meaning that less abundant peptides are not selected for 
analysis, but it must be remembered that just because a peptide is not detected 
it may still be present in the sample. 
1.2.2. Instrumentation 
While small numbers of proteins can be detected and analysed by techniques 
such as western blotting, the analysis of many thousands of proteins needs a 
more sophisticated approach provided by mass spectrometry and its associated 
systems. Today’s tools allow detection of thousands of proteins in a single 
sample, and the increase over what was achievable even just a few years ago 
is due in no small part to improvements in instrumentation and analysers. Mass 
spectrometers all employ the same basic components and consist of a source 
which provides the ionised sample, an analyser which separates ions based on 
their mass-to-charge (m/z) ratio, and a detector which measures relative 
abundance. 
In order to be identified by the mass spectrometer, the sample must be 
introduced to it in gaseous form. Two different methods are used to achieve 
this: electrospray ionisation (ESI) which uses the sample in liquid phase [195], 
and matrix-assisted laser desorption/ionisation (MALDI) which uses the sample 
in the solid phase [196]. ESI is more commonly used, partly because it can be 
coupled more easily to the LC system and ionisation can take place on-line, 
although MALDI has added sensitivity and is more tolerant to the presence of 
contaminants such as salts or small amount of detergent [197]. ESI is based on 
coulombic repulsion, whereby the liquid sample is reduced to a spray of 
charged droplets after evaporation of the solvent by application of a high 
voltage, and the charge density reaches such a point that the charged ions are 
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produced in the gas phase. The same result is achieved using MALDI, but in 
this case a laser beam is used to both sublimate and ionise the sample.  
Once inside the mass spectrometer ions can be fragmented by their excitement 
and contact with inert gases [198], a process termed collision-induced 
dissociation (CID). Collision allows internalisation of the kinetic energy which 
then leads to peptide fragmentation. Ideally this occurs along the backbone of 
the peptide, but may instead bring about loss of the phosphate ion as discussed 
earlier [179, 199]. A further problem of CID is that low mass ions will not be 
fragmented, but this may be resolved by using higher energies. Instead of 
collision with inert gases, the peptide ions can be bombarded with electrons 
(ECD or ETC) to achieve the same goal [180, 181]. While these approaches 
can have high sensitivity, they are much less effective when analysing ions of 
low charge.  
A number of different methods may be used in analysers for sample detection. 
Time of flight (TOF) instruments rely on measurement of the time taken for an 
ion to reach the detector from the source, while other instruments manipulate 
electrical or magnetic fields to control how ions of different mass/charge ratio 
(m/z) move and behave. Instruments which use the latter technique may be 
referred to as ion traps, and include quadrupole and orbitrap analysers. How an 
ion oscillates in two or three dimensions when a specific field is applied relates 
to its m/z, and equations which relate the two aid detection and quantification. 
Orbitrap analysers have higher mass accuracy and resolution than other mass 
spectrometers while maintaining a wide dynamic range, which makes them the 
analyser of choice for many groups. 
While improvements have been made with instrumentation and methodology, 
there are still limitations of MS analysis. One significant challenge is the 
reproducibility in terms of identification of a specific peptide. Some estimates 
suggest that replicate analyses will only yield a 60-70% overlap of 
phosphopeptides [200]. 
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1.2.3. Quantification 
While protein/peptide identification alone was the object of early proteomic 
studies utilising mass spectrometry, quantification is now often a requirement 
especially when comparing across samples and conditions. There are two main 
approaches currently being employed to achieve either absolute or relative 
quantification; one involves the addition of differential labels to either the whole 
protein or digested peptide, while the other avoids this and so is referred to as 
‘label-free’ (Fig. 1.8.). 
1.2.3.1. Labelling methods 
There are various labelling techniques currently being employed in the field, 
usually involving the modification of the separate samples with tags which may 
be of the same or different mass (isobaric and isotopic respectively) [201]. 
These small differences can be resolved by the mass spectrometer, meaning 
that different samples can be pooled for concurrent identification and analysis. 
Labelling approaches mean that different conditions can be mixed early in the 
methodology and so samples are handled in the same way, thereby reducing 
the effect of any errors; the earlier that the samples are mixed, the greater the 
reduction in artificial differences between them. Strategies which allow high 
throughput identification and quantitation of proteins from multiple samples, 
such as the isobaric tags for relative and absolute quantitation (iTRAQ) method, 
are now widely used. 
Metabolic labelling approaches provide the earliest point at which a label can be 
introduced. One such method involves using amino acids made from heavy and 
light isotopes of carbon or nitrogen which are added to cell culture medium 
taken up by the growing cells, and hence incorporated at the translational level 
[202]. Different combinations of heavy and light isotopes can be used, so that a 
number of conditions may be analysed simultaneously using this stable isotope 
labelling by amino acids in cell culture (SILAC) method. After sample pooling, 
standard digestion and mass spectrometry processing procedures can then be 
applied. 
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Tags can also be introduced at later stages of sample processing by chemical 
derivation methods. The iTRAQ method introduces tags which are chemically 
identical, and uses their fragmentation into specific reporter ions to obtain 
quantification by measuring their relative intensities [203]. The iTRAQ method 
allows comparison of up to eight samples and the identification and quantitation 
of proteins and post-translational modifications, while the tandem mass tags 
(TMT) technique can compare up to six samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8. Approaches to quantification. A variety of techniques are used for the purpose of 
quantifying proteins and post-translational modifications. (A) The SILAC metabolic labelling 
method introduces amino acids with light or heavy isotopes, (B) methods like iTRAQ and ICAT 
add tags of different mass to the protein, whereas other methods are termed (C) label-free, and 
rely on comparisons of peptide intensity between samples. 
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Among the isotopic labelling techniques is the isotope-coded affinity tags (ICAT) 
method [204]. This involves the addition of a biotin affinity tag which aids 
purification of the sample, and either a heavy or light region which links this to a 
reactive group to allow incorporation into the protein sample. Isotopic labelling 
can also be achieved through modification of the carboxyl or amino groups, or 
the side chains within the peptide by addition of heavy or light tags based on 
incorporation of deuterium. This is the case with the ICAT method [204] which 
modifies cysteine residues in order to add the tag. Variations of the ICAT 
method include addition of fluorescent labels to aid quantification, and affinity 
tags to aid purification. A second approach incorporates light or heavy oxygen 
atoms from water during trypsinisation to create the mass difference [205], but 
this 16O or 18O incorporation means that only two samples can be analysed at 
the same time.  
Despite its inherent quantitative value, there exist a number of drawbacks of the 
labelling techniques. Due to the fact that there is a limit to the number of 
combinations of light/heavy isotopes which can be introduced to the samples, 
there is a limit to the number of samples which may be mixed and analysed 
together. A further problem is that the costly reagents required add extra 
expense to any experiments and so may prohibit some laboratories from 
applying it to their projects. Recently, a “SILAC-mouse” was reported [206], but 
this is expensive and technically challenging for widespread use.  
1.2.3.2. Label-free methods 
Label-free approaches permit the direct comparison of an unlimited number of 
samples and avoid additional sample processing steps required to add the 
metabolic or chemical tag, which can allow the introduction of error. Limitations 
of label-free methods, such as difficulty in confidently assigning spectra for peak 
identification and comparison, have been greatly reduced by advances in 
analysers and bioinformatics, and many approaches display high accuracy and 
precision. Two broad categories of label-free analysis exist; one based on the 
abundance of detected peptides (spectral counting), and the other based on the 
measurement of peak height or area. 
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The technique of spectral counting is based on the theory that in a given 
sample, more abundant proteins will produce more peptides when digested 
[207]. This means that the ionic intensities of these peptides will be greater, and 
therefore more likely to be selected for analysis in the mass spectrometer than 
the peptides produced from a less abundant protein. It has been shown that 
there is a correlation between this spectral count and overall protein 
concentration, but a number of other factors can complicate interpretation of 
results. In the same way that more abundant proteins provide more peptides 
upon digestion, larger proteins will be more highly represented than smaller 
proteins; optimisation and normalisation are therefore required to improve 
accuracy, which may need to be carried out for each sample or experiment 
type. This method has a requirement for reproducibility with regard to the 
selection and fragmentation of ions, and this is not always achievable with 
highly complex samples. The use of internal standards may aid accuracy and 
precision.  
Alternatively non-labelling methods may use a peptide’s peak height or area to 
quantify it, in this instance using peptide ion intensities for the inference of 
protein abundance and concentration rather than a specific label. An approach 
based on this technique has been developed and previously published by Pedro 
Cutillas’ group [191] and was employed for the work contained in this thesis. In 
this method, peptides are identified using the freely available MASCOT 
database, and quantified with an in-house program named Pescal. The 
extracted ion chromatograms (XIC) for peptides are used for correlation with 
peptide abundance. Internal standards (enolase) spiked into each sample are 
then used to align chromatograms from different samples so that peptide peaks 
can be matched and directly compared between MS runs. This overcomes 
problems caused by shifts in retention times that can occur across different 
sample runs and which can be large as well as non-linear.  
Non-labelling approaches suffer from the uneven distribution of errors 
introduced due to sample handling; labelled samples can be mixed at an early 
stage and so any such errors affect all samples equally, whereas this is not the 
case with non-labelled samples. Additionally the mass spectrometry and data 
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analyses can be more involved and more complex, and are more reliant on 
stability of elution and reproducibility of spectra due to the importance of 
alignment for quantification. Despite the weaknesses of non-labelling 
approaches, they may (at least in theory) be used to analyse an unlimited 
number of samples while avoiding costly and time-consuming addition of labels. 
These methods are especially useful when comparing clinical samples, of which 
there are often large numbers and so the use of a finite number of labels is 
limiting [208].  
While each enrichment or quantification method will have inherent advantages 
and disadvantages, choices must be made during experimental design. Many of 
these techniques can in fact be complementary, and in the same way that 
running the same sample multiple times can improve proteome or 
phosphoproteome coverage, this is also true of employing more than one 
approach for different stages of sample processing and analysis. Ideally, there 
would be scope for many different combinations of the above to be used to best 
maximise coverage, but in reality we are limited by time and financial 
constraints. 
1.2.4. Validation and characterisation of phosphosites 
While PTMs can now be identified and quantified with high degrees of 
confidence, their functional relevance is often not known. Analyses of some 
abundant and important (with regard to specific signalling pathways) 
phosphosites have been well characterised, such as phosphorylation of Ser473 
on Akt, but this is lacking for the vast majority of sites in the phosphoproteome. 
What phosphoproteomics must now seek to do is assign functional significance 
to the sites which it detects, which is a huge challenge. A phosphorylation is the 
result of interplay between (potentially multiple) kinases and phosphatases, but 
less dynamic phosphorylation of sites suggests that they are not as important 
as those which are acutely regulated upon different stimuli. It is not a trivial task 
to separate phosphorylations which play key roles in dynamic signal 
transduction from those which are “silent” but frequently identified in screens. It 
should however not be discounted that these phosphosites which appear to be 
silent do actually have a purpose, much in the same way that some stretches of 
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DNA and RNA once thought to be redundant are now being shown to have 
important functions. More realistic short-term goals of the field which can be met 
include the reduction of the time from obtaining a sample to quantifying its 
contents, and more widely applying these techniques in a clinical setting, both 
of which are achievable considering recent advances and ever-improving 
technology. 
Bearing in mind the points discussed previously, characterisation of 
phosphosites is an important aim. Of the many thousands of phosphopeptides 
identified and quantified in a typical MS screen, there will inevitably be some 
false positives and so proper validation is an important component of an 
experimental plan. This can be done in a number of different ways depending 
on the protein of interest, MS experimental design, as well as time and financial 
constraints.  
If no kinase is suspected as being responsible, consideration of the amino acid 
sequence around the phosphosite may reveal a motif particular to a kinase or 
family, from which further studies can be based. Once a specific kinase is 
hypothesized to be responsible for a phosphorylation event, in vitro kinase 
assays with purified kinase and radio-labelled phosphate may be performed to 
test this theory. Incorporation of radioactivity can be monitored to assess both 
the presence and strength of catalysis, and some quantitation is possible. The 
ability of a kinase to phosphorylate a substrate in vitro is often the first step in 
validation/characterization. However as kinases are often promiscuous in vitro, 
and this setting does not fully mimic characteristics such as localisation and 
binding partners, further work is necessary to confidently claim a relationship.  
Studies in which the phosphorylation is examined in vivo are the next step, and 
simple tools such as monitoring a possible shift on a western blot caused by the 
phosphorylation can be very helpful, in the context of different stimuli or 
inhibitors. If possible, antibodies can be raised against the sequence around the 
phosphorylated residue, although this may be costly and time-consuming. Use 
of inhibitors or siRNA specific to the kinase of interest can also be of use in vitro 
and in vivo, assuming that these exist. Mutation of the site to a non-
phosphorylatable residue (alanine) or to a phospho-mimetic one 
 59 
 
(aspartic/glutamic acid) may offer information about the function of the site. 
However it should be noted that phosphomimetic mutations do not always 
reproduce the effect of phosphorylation on the tertiary structure of the protein, 
and hence its function. If a protein of interest is not well characterised, relevant 
knowledge and tools may not be available, meaning that functional studies can 
be challenging. While further studies of MS data are always useful, it must be 
kept in mind that these screens are in themselves informative and powerful 
tools.  
1.3. Aims 
The three class IA PI3K catalytic isoforms display structural homology and 
preference for regulatory binding partners, though there exist differences in both 
upstream activation and downstream effects of these signalling nodes. The 
mechanisms around such differences have yet to be fully elucidated and while it 
is the case that the lipid kinase activity of class IA PI3K isoforms is relatively 
well-characterised, certain aspects of the signalling of these proteins is less 
clear.  
The aim of this research project was to explore these differences in signalling 
and had two main branches, focusing on the ubiquitously expressed class IA 
PI3K isoforms p110α and p110β. 
First, we aimed to discover novel targets of the protein kinase activity of p110α 
in a global and unbiased manner. Only a small number of protein substrates of 
p110α have been identified, and full characterisation of most of these has not 
been completed. Large scale analyses of the protein complement of p110α 
substrates are also lacking. Therefore, we designed a p110α protein kinase 
assay coupled to phosphoproteomic and mass spectrometry techniques with 
the goal of identifying a wider range of substrates than has previously been 
achieved, along with subsequent characterisation. 
Second, we compared and contrasted the phosphoproteomes associated with 
p110α and p110β. We used conditions of serum starvation and stimulation, with 
which differential phenotypes have been observed in our laboratory following 
selective isoform-inhibition. Using similar analytical techniques as when 
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addressing our first aim, we sought to identify individual and groups of 
phosphopeptides which might account for these differences in signalling, as well 
as the effectors which may be responsible for these differences. 
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2. Materials and Methods 
2.1. Antibodies 
Table 2.1 Antibody reagents 
Target Specification Manufacturer Product 
number 
WB conc. 
Anti-mouse 
secondary 
HRP 
conjugated 
GE Healthcare NA931 1:2500 
Anti-rabbit 
secondary 
HRP 
conjugated 
GE Healthcare NA934 1:2500 
p-NDRG1  
p-Ser330 
Rabbit pAb Cell Signalling 3506 1:1000 
p-PRAS40  
p-Thr246 
Rabbit pAb Cell Signalling 2640 1:1000 
p-S6  
p-Ser235/236 
Rabbit pAb Cell Signalling 2211 1:1000 
Vinculin Mouse mAb Sigma-Aldrich V9131 1:10000 
 
2.2. Other materials and reagents 
Table 2.2. Other materials and reagents 
Reagent Manufacturer Product number 
A66 Symansis SY-A66 
ATP Sigma-Aldrich 01930-5G 
[γ-32P] ATP Hartmann 
Analytic 
SRP-401 
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Protein assay dye reagent BioRad 500-0006 
Dulbecco’s Modified Eagle’s 
Medium (DMEM) 
Sigma-Aldrich D8062 
Foetal bovine serum (FBS) Invitrogen 16000-044 
Immobilon-P Milipore IPVH00010 
L-glutamine Invitrogen 25030-081 
Lambda protein phosphatase BioLabs P0753S 
OASIS HLB 1 cc cartridges Waters WAT094225 
p110α (recombinant) AstraZeneca Gift 
P81 phosphocellulose paper  Gift 
PD MiniTrap G-25 column GE Healthcare 28-9180-07 
Penicillin/Streptomycin PAA P11-010 
PepClean C18 spin columns  Thermo 
Scientific 
89870 
Phosphatase inhibitor cocktail Roche 88667 
Protease inhibitor cocktail Sigma-Aldrich P8340 
RPMI-1640 Sigma-Aldrich R5886 
TGX221 AstraZeneca Gift 
Titanosphere TiO2 beads (10 
micron) 
GL Sciences 5020-75010 
TPCK-Trypsin Thermo 
Scientific 
20230 
Trypsin-EDTA Sigma-Aldrich T4049 
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2.3. Cell culture 
All cell culture work was carried out in a laminar flow hood using standard sterile 
techniques. Cell lines were grown at 37°C with 5% CO2 using the corresponding 
media outlined in Table 2.3. 
2.3.1. Cell lines 
Table 2.3. Cell lines 
Cell line Cell type Species Growth Medium 
4T1 Breast Mouse RPMI supplemented with 
10% FBS, 1% Pen/Strep, 
1% L-glutamine 
MCF-7 Breast Human DMEM supplemented 
with 10% FBS, 1% 
Pen/Strep 
MDA-MB-231 Breast Human DMEM supplemented 
with 10% FBS, 1% 
Pen/Strep 
MDA-MB-453 Breast Human DMEM supplemented 
with 10% FBS, 1% 
Pen/Strep 
MEFs  Immortalised 
embryonic 
fibroblasts 
Mouse DMEM supplemented 
with 10% FBS, 1% 
Pen/Strep 
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2.3.2. Growth maintenance 
Cells were grown in a humidified incubator with 5% CO2, and kept at 37ºC. 
Growth media for each cell line is as described in Table 2.3. 
Cells were passaged or seeded for experiments when they reached 80-90% 
confluency. Using standard sterile conditions, cells were washed with PBS and 
detached using 0.05% trypsin-EDTA. Trypsin was inactivated by addition of an 
excess of growth media. Cells were then further diluted in growth media in a 
fresh tissue culture flask, or seeded at the required density in 6-well plates or 15 
cm dishes, depending on the use. 
2.3.3. Inhibitor treatments 
Table 2.4. Inhibitors and concentrations used 
Compound Target Concentration Source Chapter 
A66 [167] p110α 3 µM Symansis 3, 4 
TGX221 [148] p110β 100 nM AstraZeneca 4 
 
Table 2.5. IC50 of inhibitors towards class IA PI3K isoforms 
 IC50 of compounds towards class IA PI3K isoforms (nM) 
Compound p110α p110β p110δ p110γ 
A66 [167] 32 >12500 >1250 3480 
TGX221 [148] ~5000 5 100 >10000 
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2.4. Cell lysate preparation 
2.4.1. Cell lysis 
Table 2.6. Lysis buffer composition 
Lysis Buffer Composition Use 
40 mM Hepes (pH 7.5), 0.3% CHAPS, 120 mM NaCl, 
1mM EDTA, supplemented with protease inhibitor and 
phosphatase inhibitor cocktails 
Western blotting 
20 mM Tris-HCl pH 7.0 1% Triton X-100, supplemented 
with 15 mM DTT, 1 mM phenylmethylsulfonyl fluoride, 10 
μg/ml aprotinin, 10 μg/ml leupeptin,100 mM Na3VO, 1 
mM NaF, 1 mM -Glycerol phosphate, 2.5 mM 
Na2H2P2O7 
Phosphoproteomic 
assays 
 
Cells were lysed from tissue culture plates when 80-90% confluent. Plates were 
placed on ice, washed 2x with ice cold PBS supplemented with phosphatase 
inhibitors, and the corresponding lysis buffer was added. Cells were scraped 
into Eppendorf tubes and vortexed then incubated at 4°C for 30 min with 
rotation to allow full lysis of cells. Lysates were then centrifuged at 13,000 rpm 
for 10 min at 4°C, and the supernatant collected for determination of protein 
concentration and further processing.  
2.4.2. Determination of protein concentration 
Protein concentration was determined using protocols and reagents supplied by 
Bio-Rad, and listed in Table 2.2. 200 µl of Bio-Rad reagent was dispensed into 
the wells of a 96-well plate and either BSA protein standard to produce a 
calibration curve, or sample was added. All wells of the plate were then 
measured at absorbance of 595 nm on a TECAN plate reader. Absorbance of 
the known standards was used to create a calibration curve, from which protein 
concentration of the samples could be calculated.  
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2.5. Sodium dodecyl sulphate polyacrylamide gel 
electrophophoresis (SDS-PAGE) 
Lysed samples were diluted with 4x sample buffer (200 mM Tris-HCl pH 6.8, 
400 mM DTT, 8% SDS, Bromophenol Blue (0.0025%), 40% glycerol) and 
incubated for 5 min at 100ºC to denature proteins, then separated by SDS-
PAGE. 1.5 mm 8 – 12.5% acrylamide resolving gels (acrylamide as indicated, 
375 mM Tris pH 8.8, 0.1% SDS, 0.1 ammonium persulphate) were cast using 
BioRad apparatus. A layer of stacking gel (5% acrylamide, 375 mM Tris HCl pH 
8.8, 0.1% SDS, 0.1% ammonium persulphate) was poured above, containing 
wells for sample loading. Gels were placed into a tank containing running buffer 
(25 mM Tris HCl, 200 mM glycine, 0.1% SDS) protein ladder or samples were 
loaded into wells, and electrophoresis performed at 75 V for 20 min then at 125 
V until the dye front reached the bottom of the gel.  
2.5.1. Western Blotting 
Proteins separated by SDS-PAGE were transferred from the gel to a PVDF 
membrane activated with ethanol for 1 min. “Semi-dry” transfer was achieved by 
assembly into a Bio-Rad Trans-Blot Turbo Blot System cassette of the following 
which had been previously incubated in transfer buffer (25 mM Tris HCl, 200 
mM glycine, 0.1% SDS, 20% ethanol): 3 pieces Whatman paper, gel, PVDF 
membrane, 3 pieces Whatman paper. Transfer of proteins was performed at 25 
V for 40 min.  
After transfer, membranes were blocked by 30 min incubation with 5% BSA in 
TBS-T (150 mM NaCl, 50 mM Tris HCl pH 7.6, 0.1% Tween-20). Membranes 
were then incubated for 18 h with primary antibody prepared in 5% BSA 
(concentrations of antibodies are shown in Table 2.1). After incubation with 
primary antibody, membranes were washed for 6 x 5 min with 2.5% milk 
prepared in TBS-T. Membranes were incubated with secondary antibody diluted 
(as described in Table 2.1) in 2.5% milk prepared in TBS-T for 1 h at room 
temperature. Membranes were then washed 6 x 3 min in 2.5% milk prepared in 
TBS-T, followed by 2 x 3 min washes in TBS-T, followed by incubation for 2 min 
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in enhanced chemiluminescent (ECL) solution, after which time antibody 
binding was visualised by exposure to X-ray film. 
As required, membranes were stripped by 3x 5 min washes in distilled water 
then 20 s incubation in 8 M guanidine hydrochloride solution, followed by 3x 10 
min washes in distilled water and 3x 5 min washes in TBS-T. 
2.5.2. Staining 
Where necessary, gels were rehydrated in coomassie staining solution (50% 
methanol, 10% acetic acid, 0.025% Coomassie Brilliant Blue) for 1h and 
destained (30% methanol, 10% acetic acid) to visualise proteins. 
2.6. In vitro protein kinase assay 
2.6.1. With recombinant proteins 
PI3K protein kinase assays were performed in a final volume of 30 μL in a 
buffer containing 50 mM Tris-HCl pH 7.4, 1 mM EGTA, 1 mM DTT, 10 mM 
MgCl2, 10 mM MnCl2 and 100 uM ATP, plus 5 μCi [γ-
32P]-ATP per reaction 
condition. 1μg of protein kinase was incubated with the buffer for 20 minutes at 
25°C, and reactions were terminated by addition of 5x SDS-PAGE sample 
buffer and boiling for 5 minutes. Samples were separated by SDS-PAGE, and 
gels subsequently fixed with 10% acetic acid, 20% methanol for 30 minutes and 
dried down. Visualisation of phosphorylation was achieved with PhosphoImager 
and a Typhoon scanner.  
When recombinant peptides were included as substrates, 1 μg of each was 
added per reaction condition. When the inhibitor A66 was used, this was 
incubated with the kinase at the concentrations indicated for 30 minutes on ice 
before initiation of the kinase reaction.  
2.6.2. With peptides 
As described in Hastie et al.  [209]. PI3K protein kinase assays were performed 
in a final volume of 50 µL containing 50 mM Tris-HCl pH 7.4, 1 mM EGTA, 1 
mM DTT, 10 mM MgCl2, 10 mM MnCl2 and 100 uM ATP, plus 5 μCi [γ-
32P]-ATP 
per reaction condition. 1 µg each of recombinant p110α and peptide substrate 
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were incubated together in this buffer for 10 min at 30ºC. 40 µL of solution was 
spotted onto P81 phosphocellulose paper which was immediately immersed in 
75 mM phosphoric acid for 4x 5 min washes. The papers were briefly rinsed 
with acetone, left to air-dry, then bound radioactivity measured by Cerenkov 
counting using a 32P program.  
2.7. Preparation of samples for MS 
After cell lysis as described above (without inclusion of phosphatase inhibitors), 
size exclusion chromatography was performed on samples using PD MiniTrap 
G-25 to remove small molecules such as ATP. Proteins were eluted into 1 mL 
of equilibration buffer (40 mM Tris-HCl pH 7.0, 1 mM DTT, 0.1 mM EGTA, 0.1% 
Triton X-100). Samples were pooled and protein quantified. Total cell lysate was 
dephosphorylated through incubation with Lambda protein phosphatase for 1 h 
at 37ºC. Phosphatase activity was inhibited by addition of sodium fluoride (to a 
final concentration of 50 nM), sodium orthovanadate (to a final concentration of 
10 mM) and EDTA (to a final concentration of 50 mM), and proteases inhibitor 
cocktail was added at a 1:100 dilution. Aliquots equivalent to 500 µg were taken 
and made up to 800 µl in equilibration buffer.   
2.7.1. In vitro protein kinase assay for MS 
1ml of reaction buffer (60 mM Tris-HCl pH 7.5, 2 mM EGTA, 1 mM DTT, 20 mM 
MnCl2, 20 mM MnCl2) was added to the sample along with 200 μL of ATP (final 
concentrations of 0 μM, 50 μM, 100 μM). 2 μg of recombinant p110α was then 
added, and the reaction mixture was incubated for 5 min at 30°C. The reaction 
was terminated through addition of urea to a final concentration of 8M, buffered 
in 20 mM HEPES pH 8.0. 
2.7.2. In-solution digestion 
Samples were incubated with 4.1 mM DTT and 8.3 mM iodoacetamide for 15 
min each to achieve reduction and alkylation. Samples were then diluted 1 in 4 
with 20 mM HEPES, and incubated with immobilized TLCK-trypsin for 18 h at 
37°C with agitation. Tryptic digestion was inhibited by addition of trifluroacetic 
acid (TFA) at a final concentration of 1%. Samples were centrifuged at 2000 g 
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for 5 min at 5ºC and the supernatant removed to a fresh tube and beads 
discarded. 
2.7.3. Desalting 
Samples were then desalted and concentrated using OASIS HLB 1cc extraction 
cartridges. Cartridges were assembled into a vacuum manifold with a pressure 
<15 inHg and washed sequentially with 1 ml 100% acetonitrile (ACN), 1.5 ml 
1% ACN, 0.1 TFA. Peptide samples were then loaded and washed with 1 ml 
1% ACN, 0.1 TFA, and eluted in 0.5 ml 1 M glycolic acid (GA), 1% ACN, 0.1% 
TFA. 
2.7.4. Phosphopeptide enrichment 
Sample volumes were normalised to 1000 µL with 1M GA, 1% ACN, 0.1% TFA 
then incubated with 50 µL of re-suspended TiO2 beads for 5 min with rotation, 
centrifuged for 30 s at 2,000 rpm and TiO2 beads applied to spin columns 
previously equilibrated with 100% ACN. Beads were washed 2 x 1 M GA, 80% 
ACN, 5% TFA, 1 x 100 mM ammonium acetate, 25% ACN, 4 x 1% ACN, with 3 
min centrifugation at 1,500 rpm for each wash. Peptides were eluted with 4 x 50 
µL 5% NH4OH, 1% ACN, also with 3 min centrifugation at 1,500 rpm. Samples 
were snap-frozen and dried under a vacuum, and stored at -20ºC. Immediately 
before LC-MS/MS, samples were reconstituted in reconstitution buffer. 
2.8. Liquid chromatography mass spectrometry 
Analysis was carried out as detailed in [215]. Briefly, phosphopeptide pellets 
were dissolved in 13 µl of 0.1% TFA and run in a ThermoFisher LTQ-Orbitrap 
XL mass spectrometer (full scan survey spectra, m/z 375–1800, 30,000 
resolution at m/z 400) which was coupled to a NanoAcquity UPLC system from 
Waters. Separation of peptides was achieved by C18 reverse-phase column 
(inner diameter = 100 µm, length = 100 mm, particle size = 1.7 µm, pore size = 
300 Å). 4 µl of sample were loaded at a flow rate of 2 μL/min for 8 min followed 
by a gradient elution at 400 nL/min, during which the instrument operated with a 
back pressure of around 3,000 psi. Gradient elution was from 99% solution A 
(0.1% formic acid in LC-MS grade H2O), 1% solution B (0.1% formic acid in LC-
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MS grade acetonitrile) to 65% solution A, 35% B in 100 min, followed by a 10 
min wash using 15% solution A, 85% solution B, and an equilibration with 99% 
solution A, 1% solution B for 10 min. Data dependent analysis (DDA) was used 
in the LTQ-Orbitrap XL, whereby the five most abundant multiply charged ions 
present in the survey spectrum were selected, and CID used for fragmentation. 
MS analysis was carried out as in [215]. Briefly, Mascot Daemon was used to 
analyse the MS data generated. This software functions to automate the use of 
Mascot Distiller in order to smooth and centroid the MS/MS data, and also the 
Mascot search engine [210], which searches the processed files against the 
peptide sequence library in the Swiss Prot database (restricted to either human 
or mouse entries, depending on the cell line origin). The search parameters 
included: human/mouse taxonomy; digestion enzyme: trypsin, up to two missed 
cleavages permitted; fixed modification: carbamidomethyl (C); variable 
modifications: Pyro-glu (N-term), Oxidation (M), Phospho (STY). Datasets were 
searched with a mass tolerance of ±7 ppm and a fragment mass tolerance of 
0.6 Da. Hits were considered significant when returned with an expectation 
value < 0.05 as returned by Mascot. False discovery rates were ~2% as 
determined by decoy database searches. Identifications of peptide of interest 
and parent protein were returned with confidence scores representing 
probability. Mascot was used to assign site of phosphorylation, with Delta score 
returned to represent confidence through probability (Figure 2.1.).  
Mascot results were extracted to Microsoft Excel files using an in-house script. 
Identification of the correct position of phosphorylation for peptides with multiple 
potential was achieved using the delta score between the first and second hits 
as reported by Mascot. The in-house program Pescal [211] was used to 
automate the generation of extracted ion chromatograms (XIC) and to calculate 
the peak heights and areas.  
In experiments using DDA, the nature of undersampling and stochasticity of 
peak selection for fragmentation of ions means that MS/MS data were not 
obtained for all phosphopeptides across all runs. To overcome this issue, 
phosphopeptides identified by Mascot above a statistically significant threshold 
were placed in a database of peptides quantifiable by LC-MS. Pescal was used 
 71 
 
to quantify the intensities of the peptides present in the database across all the 
samples, using the m/z and retention time of the selected peptides to construct 
extracted ion chromatograms (XICs) for the first three isotopes of each ion. This 
applies restrictions on the molecular mass, retention time, charge, and isotope 
distribution, thereby permitting high confidence (false positive discovery rate ~ 
5%) identification of the LC-MS elution profiles corresponding to the studied 
phosphopeptides  (windows for XIC construction: m/z = 7 ppm, retention time = 
5), following which the peak height and areas of each individual XIC could then 
be determined. Internal peptide standards (enolase) were spiked into each 
sample to allow chromatographic alignment. The resulting quantitative data 
were parsed into Microsoft Excel files for further normalization and statistical 
analysis. Peptide intensities were normalised to the total chromatogram 
intensity, and expressed relative to the greatest intensity value across all 
samples. Data were statistically analysed in Microsoft Excel files. 
2.9. Bio-informatic analysis 
2.9.1. Peptide production 
Water solubility (vital for reconstitution of solid state manufactured peptides) 
and pH of peptides was predicted using Innovagen calculator 
(http://pepcalc.com/peptide-solubility-calculator.php). The amino acid sequence 
of residues surrounding candidate phosphorylation site of interest was used as 
input, and additional lysine residues were included to ensure binding of peptides 
to P81 phosphocellulose paper; a net positive charge at low pH indicates 
likelihood of peptide binding. 
2.9.2. Motif analysis 
The freely available online program motif-x [212] was used to interrogate the 
phosphopeptide sequences identified in MS screens for conserved motifs. 
When necessary, sequences were manually extended to five residues on either 
side of the phosphorylation site of interest. Selections were: MS/MS foreground 
format, extend from=IPI mouse proteome, central character=S/T/Y, width=11, 
occurrences=5, significance=0.0499, background=IPI mouse proteome.  
 72 
 
2.9.3. Sequence analysis  
The ClustalW2 tool (http://www.ebi.ac.uk/Tools/msa/clustalw2/) was used for 
the alignment of protein sequences and identification of conservation across 
species. 30 amino acids surrounding the phosphorylation site of interest were 
compared to the equivalent human, rat, and bull sequences, and ClustalW2 
returned qualitative data on conservation of residues.  
 
Figure 2.1. Illustration of peptide and phosphopeptide spectra. MS/MS fragmentation of the 
peptide EVFSSCSSEVVLSGDDEEYQR is shown with A) no modifications and  
B) phosphorylation of residue 13 (serine). Elimination/neutral loss of H3PO4 (97.9769 Da) is 
represented by y(residue)-98 for y ions which include the modified residue. 
 
Retention time: 41.66 min 
Retention time: 43.72 min 
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3. Investigation into the protein kinase activity of p110α 
3.1. Introduction and aim of study 
While the lipid kinase activity of the PI3K family has been studied extensively, 
relatively little is known about the protein kinase function which the PI3K 
isoforms also exhibit. As lipid kinases, PI3Ks have been shown to have 
important roles in a number of normal cellular and pathological processes 
including cancer. The protein kinase activity of class IA PI3Ks has been shown 
to be capable of down-regulating their own lipid kinase activity, suggesting a 
means of self-regulation and supporting the case for further study. 
All three classes of PI3K have been shown to display a protein kinase activity 
with the class I isoforms capable of autophosphorylation: in the case of p110α 
the regulatory subunit p85α is phosphorylated [126, 127], while the remaining 
class I isoforms phosphorylate the p110 subunit [132, 133]. For the class IA 
PI3K isoforms, this phosphorylation causes a down-regulation of their lipid 
kinase activity, and so is a potential method of autoregulation. In addition, a 
number of non-PI3K targets have been identified, and the possibility of the 
existence of undiscovered protein substrates remains.  
Mass spectrometry and proteomic techniques have advanced significantly over 
the past decade, and they are powerful tools capable of characterising 
intracellular signalling pathways. Many of these pathways rely heavily on protein 
phosphorylation as a means of transmitting and regulating the intensity and 
duration of the signal, and so phosphoproteomics is an area of increasing 
relevance. Techniques developed by Dr Cutillas and others allow for unbiased 
identification and quantitation of thousands of phosphosites from the starting 
point of a whole cell lysate [191, 211], making phosphoproteomics a powerful 
discovery tool, and suitable for delineating signalling pathways and uncovering 
novel kinase-substrate pairings.  
The aim of the work presented in this chapter was to uncover novel substrates 
of the protein kinase activity of p110α, using an in vitro kinase assay coupled to 
innovative mass spectrometry techniques available in our laboratory.  
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Figure 3.1. Summary of phosphoproteomic approach. A total cell lysate of MEF cells was 
dephosphorylated using exogenous lambda phosphatase and used as a substrate for an in vitro 
kinase assay with p110α. Samples were digested using trypsin, and phosphopeptides enriched 
by titanium dioxide affinity purification, and analysed by LC-MS/MS. Data analysis was carried 
out using a combination of in-house and freely available software programs. 
 
3.2. Optimisation of experimental conditions  
Since a number of studies have shown conflicting reports on the conditions 
necessary for robust p110α protein kinase activity, we first sought to optimise 
the conditions for an in vitro kinase assay. We performed a number of 
experiments with the aim of identifying the necessary cofactors, as well as 
inhibitor concentration and time point for a phosphoproteomic screen using 
recombinant p110α in an in vitro kinase assay. To assay p110α protein kinase 
activity, we carried out in vitro kinase assays with recombinant p110α/ p85α 
heterodimers using [γ-33P]-ATP as a phosphate donor, and monitored 
phosphorylation of p85α as a read-out of the protein kinase activity of p110α. 
Conflicting reports have been published as to the divalent cation preference of 
p110α in terms of its protein kinase activity [127, 128]. Therefore, we first 
sought to address which of Mg2+ or Mn2+ supports the strongest in vitro protein 
kinase activity of p110α. In vitro kinase assays were carried out as detailed in 
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Figure 3.2A, which shows a representative autoradiogram. As is clear, robust 
phosphorylation of the p85α subunit is observed with either cofactor. Use of 10 
mM Mg2+ produces slightly lower p85α phosphorylation than 10 mM Mn2+ alone, 
which is in turn similar to the use of both cofactors together. Therefore, we 
decided to use a concentration of 10 mM of each cofactor in future assays, 
including in the MS screen. 
Next, we sought to evaluate the kinetics of phosphorylation of p85α by p110α 
and to determine an optimal time point for the MS screen. We proceeded to 
carry out in vitro kinase assay time courses as described in Figure 3.2B, which 
shows a representative autoradiogram and quantification of three experiments. 
Phosphorylation of p85α is clearly seen at the shortest time point of 1 min and 
increases across the time points used. Based on these data, we decided to use 
for the MS screen a time of 5 min for the kinase assay, in order to allow p110α 
sufficient time to phosphorylate its substrates, while also minimising the 
inevitable background phosphorylation events catalysed by other kinases 
present in the cell lysate. 
A      B 
Kinase  -   +   +   +   +   +      Kinase           -    +    +   +   +   +   +   +   + 
[ATP] (µM)  +   -   +   +   +   +      [ATP] (µM)         +    -     +   +   +   +   +   +   + 
Mg2+   -    -   -    +   -    +             Time (min)          0   0    0    1   2   5  10 20 30 
Mn2+   -    -   -    -    +   +  
   p-p110α              
p-p85α     
 
Coomassie   
          
 
C 
Kinase  -   +   +   +   +   +   +   +   +  
[ATP] (µM)  +   -   +   +   +   +   +   +   +  
A66 (µM)  0   0    0  0.3  0.6  0.9  3   6   9 
 
p-p110α 
p-p85α 
 
 
Figure 3.2. p110α phosphorylates p85α in vitro. In vitro kinase assays were performed using 
recombinant p110/p85α heterdimers and [γ
32
P], with the stated conditions: kinase assays were 
carried out (A) for 20 min at 30°C in the presence or absence of 10 mM Mg
2+
;or 10 mM Mn
2+ 
; 
(B) at 30°C for the stated time with 10 mM Mg
2+
 and 10 mM Mg
2+
; (C) at 30°C for 5 min in the 
presence or absence A66 at 30°C with 10 mM Mg
2+
 and 10 mM Mg
2+
 with the indicated 
concentrations of A66. Proteins were separated by SDS-PAGE, and gels were fixed and dried 
then incorporation of [γ
32
P] visualised using a Typhoon scanner and PhosphoImager. ATP was 
included at a final concentration of 100 µM where indicated. 
p-p110α 
p-p85α 
 
Coomassie 
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Two controls are present in the MS screen. In one, the cell lysate is left 
untreated as a measure of the level of background phosphorylation present in 
the samples and in the other, inactive p110α is added. Therefore, we next 
sought to determine how best to achieve full deactivation of p110α. A66 is a 
highly selective inhibitor of wild-type and oncogenic p110α isoforms, with an 
IC50 around two orders of magnitude lower for p110α than other class IA PI3K 
isoforms, and extremely limited inhibition of other kinases. In order to determine 
the optimal concentration of A66 for full inhibition of the protein kinase activity of 
p110α, we performed in vitro kinase assays as described in Figure 3.2C, which 
shows a representative autoradiogram. A dose-dependent effect is observed, 
with the lowest concentration of A66 used eliciting a negative effect in terms of 
the phosphorylation of p85α. Maximum inhibition is achieved using A66 at a 
concentration of 3 µM, and so we decided to use this concentration to achieve 
inactivation of p110α in the MS screen, in line with the reported IC50 values 
(Chapter 2.3.3.). 
It should be noted that for all kinase assays described above, phosphorylation 
of p110α is also observed, though to a much smaller degree than the 
phosphorylation of p85α, and that observed profiles of the phosphorylation of 
p85α and p110α are similar. 
3.3. Use of a phosphoproteomic screen to analyse p110α protein 
kinase activity 
Having established optimum conditions for its protein kinase activity, we next 
moved on to identifying the phosphorylation events catalysed by p110α. The 
approach we used, in which an in vitro kinase assay was coupled to mass 
spectrometric analysis, is based on the work of the Cohen group (MRC Protein 
Phosphorylation and Ubiquitylation Unit, University of Dundee) [213], and 
further developed by the Cutillas laboratory (Integrative Cell Signalling and 
Proteomics, Barts Cancer Institute, Queen Mary University of London) [214].  
Briefly, 500 µg of a whole cell lysate was taken from MEFs, the proteins from 
which were dephosphorylated by addition of recombinant lambda phosphatase 
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and used as the substrate for an in vitro kinase assay using p110α. This assay 
was designed so as to provide qualitative and quantitative information about the  
phosphorylation events. First, three conditions were compared: cell lysate only 
(termed “cell lysate”) to which no recombinant p110α was added, cell lysate 
which was treated with recombinant wild-type p110α and 3 µM of the p110α-
specific inhibitor A66 (termed “p110α/A66”), and cell lysate which was treated 
with recombinant wild-type p110α (termed “p110α”). This enabled us to 
compare the data from p110α and both cell lysate and p110α/A66 conditions to 
ensure that we could discount background phosphorylation events not specific 
to the protein kinase activity of p110α. Second, each condition was subjected to 
three separate kinase assays with three different ATP concentrations (0 µM, 50 
µM and 100 µM), and it is expected that intensity of a valid kinase-dependent 
phosphorylation would increase with an increase in ATP concentration. Also 
relevant and a reason for the experimental design is inclusion of multiple ATP 
concentrations allows approximations of reaction kinetics to be made.  
After an in vitro kinase assay, proteins were denatured by reduction and 
alkylation, followed by digestion using trypsin, followed by enrichment of 
phosphopeptides based on TiO2 affinity. The samples were then subjected to 
LC-MS/MS using an Orbitrap-XL, and phosphopeptides were identified and 
quantified using in-house techniques [191, 211]. The experiment was performed 
so as to have three biological replicates; therefore there were 27 samples in 
total (3 ATP concentrations x 3 kinase conditions x 3 biological replicates). 
Targets were chosen for validation based on comparison of phosphopeptide 
levels in p110α samples with cell lysate and A66 samples, and also the kinetic 
profile of phosphorylation which was determined by analysis of intensity of 
phosphorylation at multiple ATP concentrations.  
The data from the MS analysis of the samples were used to interrogate the 
MASCOT protein database, and peptides which were returned with an 
expectation value of <0.05 were chosen for further analysis. This resulted in a 
group of 641 peptides which were quantified using the in-house program Pescal 
[215] (Appendix 1).  
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Figure 3.3. Quantitative analysis of response of phosphorylation events to in vitro p110α 
kinase assay. MEF cell lysate was dephosphorylated using exogenous lambda phosphatase 
and incubated with 0, 50, 100 µM ATP, in the presence or absence of recombinant p110α and 
its specific inhibitor A66 for 5 min at 30°C. Phosphorylated proteins were subjected to 
phosphoproteomic analysis (n=3). Quantification of 641 phosphopeptides identified was 
visualised as a heat map, where intensity of phosphorylation for a given phosphopeptide was 
expressed relative to the maximum intensity for that phosphopeptide. 
 
 
 
 
  Cell lysate      p110α/A66         p110α 
0 µM  50 µM 100 µM   0 µM 50 µM 100 µM   0 µM 50 µM 100 µM  
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3.3.1. Comparison of in vitro kinase assay conditions 
After averaging the values from the three replicates, we used a heat map to 
graphically represent patterns of phosphorylation of peptides across all samples 
(Fig. 3.3). Quantification of all 641 phosphopeptides identified in this experiment 
shows that the conditions broadly behave in a similar manner, with high 
intensity of some phosphorylation events present in the control samples. This 
includes in the cell lysate, p110α/A66, and 0 µM ATP p110α conditions. While 
some individual events do display a profile expected of true p110α targets, there 
is a greater number of phosphorylation events which are positively regulated in 
the p110α+ATP samples and also in one or both control samples. This 
suggests that the effect on the phosphoproteome of adding recombinant p110α 
is minor, and that the effects caused by the addition of recombinant p110α in 
this context are subtle, further implying that its protein kinase activity is not 
significant, at least when tested under the indicated conditions. 
Principle component analysis (PCA) can be used to assess the similarities 
between sets of conditions. We subjected the whole dataset to PCA, the results 
of which are shown in Figure 3.4A, which reveals an effect which reinforces the 
conclusion drawn above. Instead of a clear separation being observed between 
the cell lysate and A66, and p110α conditions, the data points showed a more 
indiscriminate grouping with none of the conditions clustering. This is also true 
of the 0 µM ATP samples for cell lysate, A66 and p110α conditions which would 
be expected to behave similarly, and also the replicates of a given condition. 
Both the cell lysate and A66 controls appear to be similar to the p110α variable 
in terms of PCA and the majority of peptides in the heat map. Had it been the 
case that in this context cell lysate displayed different characteristics to A66 and 
p110α, it could have been argued that full inhibition in the A66-treated samples 
had not been achieved. However, this is unlikely to be true, and it is more 
reasonable to consider p110α as being inhibited to a similar level to Figure 3.2. 
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Figure 3.4. PCA indicates little effect of addition of recombinant p110α. MEF cell lysate 
was dephosphorylated using exogenous lambda phosphatase and incubated with 0, 50, 100 µM 
ATP, in the presence or absence of p110α and its specific inhibitor A66 for 5 min at 30°C. 
Phosphorylated proteins were subjected to phosphoproteomic analysis, and three independent 
experiments were carried out (n=3). Green = cell lysate; red = p110α/A66; blue = p110α. 
Number = ATP concentration (µM). 
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3.3.2. Identification of potential substrates of p110α protein kinase 
activity  
We then took the average of the individual replicates so that a single value was 
obtained which was then used for comparison and subsequent analysis, and 
then proceeded to define arbitrary criteria to define p110α substrates. To ensure 
that phosphorylation increased with an increase in ATP concentration, we 
defined a cut-off of a Pearson correlation value of >0.6 for the p110α-treated 
samples. This resulted in a list of 254 phosphopeptides, whose quantitative data 
are graphically represented by way of a heat map in Figure 3.5. As is clearly 
seen, intensity of phosphorylation increases with ATP concentration for the 
p110α condition, however within this list are phosphopeptides whose 
phosphorylation is present at high levels in either or both of the control samples. 
Examples of such profiles are shown in Figure 3.6. It is important to note the 
variation in the levels of intensity of phosphorylation in the controls, with some 
phosphopeptides displaying higher intensity than in the p110α samples, even at 
the 0 µM ATP concentration 
Because of this level of background phosphorylation present in the controls, we 
included a second criterion for defining potential candidates. Phosphorylation 
events were considered to be due to addition of recombinant p110α if there was 
at least a two-fold increase from the 50 µM and 100 µM ATP concentrations in 
both the cell lysate and A66 samples, to the p110α condition.  
Two phosphopeptides were found to meet these criteria, and their profiles of 
phosphorylation are shown in Figure 3.7. Both phosphopeptides had two 
phosphorylation sites, all of which were previously undescribed. FBX7 (Ser283, 
Ser294) is the substrate recognition component of SCF E3 ubiquitin protein 
ligase complex, and GRIA1 (Ser873, Ser881) is a membrane-bound glutamate 
receptor, whose putative phosphorylation sites are in its cytoplasmic portion. 
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Figure 3.5. Quantitative analysis reveals phosphoproteomic response to an in vitro 
kinase assay using total cell lysate and recombinant p110α. MEF cell lysate was 
dephosphorylated using exogenous lambda phosphatase and incubated with 0, 50, 100 µM 
ATP, in the presence or absence of p110α and its specific inhibitor A66 for 5 min at 30°C. 
Phosphorylated proteins were subjected to phosphoproteomic analysis, and three independent 
experiments were carried out (n=3). Quantification of 254 phosphopeptides with a Pearson 
correlation >0.6 for the p110α-treated samples was visualised as a heat map, where intensity of 
phosphorylation for a given phosphopeptide was expressed relative to the maximum intensity 
for that phosphopeptide. 
 
 
 
 
  Cell lysate      p110α/A66         p110α 
0 µM  50 µM 100 µM   0 µM 50 µM 100 µM   0 µM 50 µM 100 µM  
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Figure 3.6. Examples of phosphorylation events identified in p110α in vitro kinase assay 
which display high background intensity in control samples. MEF cell lysate was 
dephosphorylated using exogenous lambda phosphatase and incubated with 0, 50, 100 µM 
ATP, in the presence or absence of p110α and its specific inhibitor A66 for 5 min at 30°C. 
Phosphorylated proteins were subjected to phosphoproteomic analysis. Mean (n=3) normalised 
phosphopeptide intensities for four candidate p110α substrates are shown. Many 
phosphorylation events which display an increase in intensity with an increase in ATP 
concentration for the p110α condition, such as A-D, are also observed to have high background 
phosphorylation in the control cell lysate and A66 samples. 
 
 
A                                                             B 
 
 
 
 
 
 
 
C                                                             D 
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Figure 3.7. Candidate p110α substrates identified using an in vitro p110 protein kinase 
assay. MEF cell lysate was dephosphorylated using exogenous lambda phosphatase and 
incubated with 0, 50, 100 µM ATP, in the presence or absence of p110α and its specific inhibitor 
A66 for 5 min at 30°C. Phosphorylated proteins were subjected to phosphoproteomic analysis. 
Mean (n=3) normalised phosphopeptide intensities for two candidate p110α substrates, as 
defined by arbitrary criteria, are shown, (A) FBX7_MOUSE and (B) GRIA1_MOUSE. 
 
 
 
 
 
 
 
 
 
 
 
 
A                                                                   B 
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3.3.3. Sequence analysis 
It has been noted that the site of phosphorylation on previously described 
p110α protein substrates, including Ser608 of p85α, is often within an acidic 
primary protein structure. While the small number of characterised p110α 
substrates means that describing a definitive consensus motif is challenging, no 
striking similarities have been elucidated. Software which allows comparison of 
the primary protein structure around a phosphosite is available, however these 
are typically most useful when large numbers of sites are being compared, and 
so in this context we chose to do this comparison manually.  
Sequence comparison between the two candidate proteins and previously 
described p110α substrates revealed no obvious similarities in terms of 
preference for a specific amino acid at a particular position relative to the 
phosphorylation site. However, three of the four phosphorylation sites (Ser294 
of FBX7 and both sites for GRIA1) have an acidic amino acid within two 
residues, though none are in a region as acidic as Ser608 of p85α (Fig. 3.8.). 
These acidic residues are also conserved between mouse and human 
sequences for glutamate receptor 1. 
The degree of overall sequence conservation around these residues should 
also be noted. Ser608 of p85α lies in a region of extremely high conservation, 
and all residues from 529 to the C-terminus are conserved between the mouse, 
human, rat and bovine sequences. For FBX7, Ser283 is conserved between the 
mouse, human and bovine sequences, and Ser294 between the mouse and rat 
sequences. Identical residues make up 33% of the amino acid sequence 271-
300, with a further 33% displaying some conservation (Fig. 3.8.). There is a 
higher level of sequence homology in the C-terminal of GRIA1 between the 
mouse, human, rat and bovine proteins. Between residues 861-890, 90% of the 
amino acids are identical, including both candidate phosphorylation sites. Well-
conserved sequences or phosphorylation sites are indicative of an important or 
conserved function, and it is more likely that functional phosphorylation events 
are conserved between species. 
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PIK3R1_Mouse  591  QKKLNEWLGNENTEDQYSLVEDDEDLPHHD 620 
PIK3R1_Human  591  QKKLNEWLGNENTEDQYSLVEDDEDLPHHD 620 
PIK3R1_Rat  591  QKKLNEWLGNENTEDQYSLVDDDEDLPHHD 620 
PIK3R1_Bull   591  QKKLNEWLGNENTEDQYSLVEDDEDLPHHD 620 
               ****************************** 
 
 
FBX7_Mouse  271  IKNVKSVQLQPGSYVAAGVEPGESAAKVYKD- 300 
FBX7_Human  271  IRSVKRLQLLPESFICK-EKLGENVANIYKD- 300 
FBX7_Rat   271  IKNVKSVQLKPGAYVRR-AEPGESAAKVYKD- 300 
FBX7_Bull       271  -RSVKRLQLLPESFICK-EESGENVAMIYKDL 300 
                :.** :** * :::    : **..* :** 
 
 
GRIA1_Mouse  861  RNSGAGASGGSGSGENGRVVSQDFPKSMQSI 891    
GRIA1_Human  861  RNSGAGASSG-GSGENGRVVSHDFPKSMQSI 890 
GRIA1_Rat       841  RNSGAGASGGGGSGENGRVVSQDFPKSMQSI 871 
GRIA1_Bull      792  RNSGAGASGA-GSGENGRVVSHDFPKSMQSI 821 
               ********.. **********:********* 
  
 
Figure 3.8. Sequence alignment of known and candidate p110α substrates. The amino acid sequences of previously described and candidate p110α 
substrates show varying degrees of conservation between species. An area of 30 amino acids around the phosphosites of interest from human and mouse 
sequences were analysed and annotated using the freely available ClustalW2 program. Key: Single letter amino acids code; "*“=identical; ":“=conserved 
substitution; "."=semi-conserved substitution. S indicates phosphosite.  
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3.3.4. Quantification of reaction kinetics 
The in vitro p110α kinase assays for the MS screen were performed with three 
ATP concentrations, and therefore correlation of the ATP concentration and 
abundance of a given phosphorylation event can be used to quantify the affinity 
of the kinase for that particular phosphorylation site. Using the principles of 
Michaelis-Menten kinetics, it is possible to deduce dynamics of the kinase-
substrate interaction in the same way as one would for other enzyme-substrate 
reactions. However, these experimental conditions may not follow those set out 
for a typical Michaelis-Menten reaction, for instance the substrates in the in vitro 
kinase assay may not be in excess over kinase. The experimental setup was 
one which allowed some approximation of reaction kinetics, but which was 
mindful of practical considerations such as time and cost. Therefore the number 
of ATP concentrations included is a compromise and does not allow for a 
perfect characterisation of kinetics, but gives a quantitative estimate.  
In order to better characterise the phosphorylation events chosen for validation, 
we used the data for intensity of phosphorylation to generate quantitative data 
for reaction kinetics for each phosphosite to grade the potential substrates. In 
Michaelis-Menten kinetics, Km is the substrate concentration at which the 
reaction rate is half of the maximum (Fig. 3.9.). We defined KATP (the p110α-
ATP affinity for a given phosphorylation event) as the ATP concentration 
required to reach half the maximum rate of reaction (Fig. 3.9.), and used this to 
calculate KATP for both candidates identified as potential p110α substrates, 
based on our criteria (Fig. 3.7). These are shown in Table 3.2. The data suggest 
that the p110α-GRIA1 interaction has a higher affinity for ATP than the p110α-
FBX7 interaction, however it is assumed that for each protein candidate, the two 
phosphorylation events have equal kinetics. 
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Figure 3.9. Principles of Km and estimation of KATP. The principles of Michaelis-Menten 
kinetics allow quantification of affinity of reaction (Km) from knowledge of substrate 
concentration and maximum rate of reaction (Vmax). Substitution of phosphopeptide intensity for 
reaction rate allows us to estimate affinity of a kinase-ATP interaction for a given substrate, 
hence KATP is an estimation of Km. 
Reaction rate = phosphopeptide intensity; Km = KATP 
 
 
 
Table 3.2. Affinity of phosphorylation for candidate p110α substrates 
Protein Phosphosite KATP (µM) 
FBX7_MOUSE pSer283 + pSer294 36.07 
GRIA1_MOUSE pSer873 + pSer881 27.63 
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3.4. Validation of targets identified in phosphoproteomic screen 
After selection of candidates which, based on our criteria, had the potential to 
be substrates for the protein kinase activity of p110α, we next moved on to 
attempt to validate these links. The easiest way to provide further evidence for a 
kinase-substrate relationship is to use in vitro kinase assays in which the 
association can be directly probed without possible contaminating factors (such 
as other kinases) which may be present in the original MS screen. Incubation of 
recombinant kinase and substrate with [γ-32P]-ATP allows incorporation of the 
radiolabelled phosphate, which can then be visualised. 
Neither candidate was commercially available as recombinant protein for use as 
a substrate in an in vitro kinase assay. Therefore, we decided to use as a 
substrate peptide fragments of each phosphosite and the amino acid sequence 
directly adjacent to it. Engineering of peptide fragments also allows the 
substitution of a non-phosphorylatable amino acid for the phosphorylated serine 
residue for use as a negative control. The peptides were designed so as to be 
able to bind P81 phosphocellulose paper, a requirement for one of our chosen 
methods of validation (see below). Therefore, basic lysine residues were 
incorporated into the N-termini of peptides to facilitate binding. The sequences 
of the peptide fragments are shown in Table 3.3.  
We employed two different approaches for validation via in vitro kinase assays 
using the peptide fragments, both involving presentation of the substrate to the 
kinase in an appropriate buffer with [γ-32P]-ATP. While the first method involves 
use of SDS-PAGE and subsequent detection of incorporated 32P by 
autoradiography, phosphorylated peptide fragments must be immobilised onto 
P81 phosphocellulose paper prior to measurement of incorporated radioactivity 
for the latter [209]. This approach has not previously been shown to work for a 
peptide based on the sequence around Ser608 of p85α, but given the 
biochemical tools it was one of the few options open to us for our attempted 
validation. 
First, we performed in vitro kinase assays using the peptides in Table 3.3 as 
substrates, and separated components of the assays by SDS-PAGE. Gels were 
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dried and incorporated 32P was used as a measure of phosphorylation, and 
visualised by exposure to a PhosphoImager screen scanned on a Typhoon 
scanner. A challenge with this method is that the small molecular weight of the 
peptides used means that they migrate at a similar rate and to a similar position 
as the 
 
Table 3.3. Sequences of peptides synthesised for validation of p110α in 
vitro kinase assay 
Protein Phosphosite Sequence 
p85α pSer608 KKKTEDQYSLVEDD 
p85α pSer608 KKKTEDQYALVEDD 
FBX7_MOUSE pSer283 + 
pSer294 
KKQLQPGSYVAAGVEPGESAAK 
FBX7_MOUSE pSer283 + 
pSer294 
KKQLQPGAYVAAGVEPGESAAK 
FBX7_MOUSE pSer283 + 
pSer294 
KKQLQPGSYVAAGVEPGEAAAK 
FBX7_MOUSE pSer283 + 
pSer294 
KKQLQPGAYVAAGVEPGEAAAK 
GRIA1_MOUSE pSer873 + 
pSer881 
KKGSGSGENGRVVSQDFPK 
GRIA1_MOUSE pSer873 + 
pSer881 
KKGSGAGENGRVVSQDFPK 
GRIA1_MOUSE pSer873 + 
pSer881 
KKGSGSGENGRVVAQDFPK 
GRIA1_MOUSE pSer873 + 
pSer881 
KKGSGAGENGRVVAQDFPK 
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unincorporated 32P-ATP. This means that any signal from 32P incorporated into 
peptides during the kinase assay may be masked by the free 32P-ATP. 
Therefore, the unincorporated 32P-ATP must be run off the edge of the SDS-
PAGE gel, or else the very edge of the gel cut off, but in a way so as to leave 
the peptides from which to detect a signal. 
Despite performing the assay three times and attempting to optimise the 
removal of the free 32P-ATP, we were unable to do so in a way as to detect a 
signal suggesting phosphorylation of the peptide substrates over the 
background of free 32P-ATP (data not shown). Therefore, we proceeded to 
attempt to validate the interaction by a different method. We performed the 
same in vitro kinase assays, but used phosphocellulose paper to immobilise the 
peptides after the reaction. Unbound 32P-ATP was washed away, and 
incorporated 32P again used as a measure of phosphorylation and quantified. 
The experiment was performed with four replicates, and the values were 
averaged and shown in Figure 3.10. 
We included a peptide based on the sequence around Ser608 of p85 as a 
control, and observed an increase in incorporated 32P-ATP (shown as cpm) 
relative to the ATP and kinase only control, which reduced to background levels 
when the p85 Ser608Ala mutant was used, indicating specificity of 
phosphorylation of that residue. However the absolute level of 32P-ATP 
incorporation was low, relative to control. We again observed increased 32P-
ATP incorporation for FBX7 relative to control, with decreases when using 
either of the Ser283Ala or Ser294Ala mutants and a further decrease with the 
double mutant, though again the absolute changes relative to control were 
small. For GRIA1, the levels of 32P-ATP incorporation for all four peptides was 
below the ATP and kinase only control. The values observed are lower than 
would be expected for a strong kinase with a valid substrate. Because of the 
low cpm seen even for the previously characterised Ser608 residue, it may be 
argued that either this assay or the peptides designed are not suitable for our 
goal of validation. 
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Figure 3.10. p110α is a weak protein kinase towards peptide substrates. An in vitro protein 
kinase assay was performed with p110α and peptide substrates as shown. Recombinant p110α 
was incubated with or without ATP and peptide substrates for 10 min at 30°C, peptides were 
bound to P81 phosphocellulose paper and washed, then incorporated radiolabeled phosphate 
was measured by scintillation counting. Four replicates were performed, and the mean count 
per minute are displayed. 
*p<0.05 **p<0.005 
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3.5. Discussion 
PI3K isoforms have been well-characterised as lipid kinases and exert control 
over many important cellular processes through this catalytic activity [1, 41]. 
PI3Ks also exhibit a protein kinase function which has been less 
comprehensively studied [23]. All class I PI3K isoforms have been described as 
being able to autophosphorylate and some non-PI3K substrates have been 
identified, although comprehensive analyses are lacking [23, 132, 133, 140].  
p110α is the best characterised PI3K in terms of protein kinase activity, and it 
can phosphorylate the Ser608 residue of its regulatory partner p85α [23]. It has 
been reported that this phosphorylation event brings about a reduction in the 
lipid kinase activity, and so is a means of regulation [23]. The ubiquitously 
expressed p110α is central to a number of vital cellular processes and is the 
only PI3K isoform found mutated in cancer [1, 129]. 
We therefore decided to investigate PI3K protein kinase activity further, 
focusing on the p110α isoform. Using a quantitative phosphoproteomic 
approach, we employed a strategy to search in an unbiased and global manner 
for novel substrates of p110α protein kinase activity, which we then sought to 
validate candidate proteins by independent means.  
3.5.1. Optimisation of the in vitro p110α protein kinase model 
We used a method based on work from the Cohen laboratory (MRC Protein 
Phosphorylation and Ubiquitylation Unit, University of Dundee) [213] and further 
developed by the Cutillas laboratory (Integrative Cell Signalling and Proteomics, 
Barts Cancer Institute, Queen Mary University of London) [214], which has 
previously been used to examine the signalling pathways downstream of Akt. A 
total cell lysate is hereby used as the substrate for an in vitro kinase assay 
using a purified/recombinant protein kinase, and the resulting phosphopeptides 
are analysed using mass spectrometry. While there are relatively few data in 
the literature regarding the activation of PI3K protein kinase activity, some long-
held beliefs have recently been challenged. For instance in terms of p110α, it 
was thought that phosphorylation of Ser608 of p85α brought about a reduction 
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in p110α lipid kinase activity [23, 126, 127], but a recent study found this not to 
be the case [217]. 
We optimised the conditions for our in vitro kinase assay by using an in vitro 
protein kinase assay in which radiolabelling of p85α was used as a readout of 
p110α protein kinase activity. Protein kinases require a metal ion cofactor to 
allow catalytic activity; often this is in the form of Mg2+, but p110α has been 
reported to be inactive in the presence of Mg2+ and to instead require Mn2+ 
[127]. In terms of p110α activity as measured by phosphorylation of p85α we 
found there to be little difference between using either Mg2+ or Mn2+, with robust 
phosphorylation observed for either cofactor. However use of both cofactors 
together brought about the highest level of p110α activity.  
An important consideration is the length of time for the assay itself. Due to a 
whole cell lysate being used as a substrate for the kinase assay, there will 
inevitably be active endogenous protein kinases present, as well as protein 
phosphatases. These will both increase the background level of 
phosphorylation through reactions not specific to addition of exogenous p110α 
kinase and potentially reduce the signal. Therefore, a time point is required 
which allows robust p110α protein kinase activity while minimising this 
background contamination. We observed robust p85α phosphorylation at the 
shortest time point examined (1 min) which continued to increase with time, and 
so chose 5 minutes as the length of time for all future assays. 
3.5.2. A phosphoproteomic screen to analyse p110α protein kinase 
activity 
Following optimisation of conditions for p110 protein kinase activity, we used 
these specifications for an MS-coupled in vitro kinase assay. We used these 
conditions and presented recombinant p110α with a total cell lysate of mouse 
embryonic fibroblasts (MEFs) in the presence or absence of the p110α-specific 
inhibitor A66. We coupled the kinase assay to an enrichment process for 
phosphopeptides based on TiO2 affinity purification and analysis using label-
free quantification which allows the comparison of an unlimited number of 
samples [191, [211]. 
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3.5.2.1. General characterisation of phosphoproteomic screen  
We identified and quantified 641 phosphopeptides, and used heat maps and 
PCA to visualise the data. This approach suggested that there were only minor 
differences between the cell lysate only, p110α/A66, and p110α samples. While 
there were phosphopeptides which appeared to display an increase in intensity 
with increasing ATP concentration in the p110α condition, these were in the 
minority and large groups of such phosphopeptides were not obvious. It is also 
the case that large differences were not observed between the conditions when 
visualised by a heat map, and this may explain the lack of a clear separation 
when all 641 phosphopeptides were used as the input in a PCA.  
Similar experiments in our laboratory using more well-characterised protein 
kinases such as Akt have yielded larger datasets comprising thousands of 
proteins [218]. The output from our screen was significantly smaller, with 641 
phosphopeptides identified and quantified. This observation has three 
implications.  
The first is that the small number of phosphopeptides identified and quantified in 
this screen is evidence that the dephosphorylation step of the methodology 
worked well. If this was not the case, a greater number of phosphopeptides 
would have been found across the samples. Due to the method employed, all 
material from the in vitro kinase assay was processed and analysed by LC-
MS/MS, and so none was available to be used for analysis of relative levels of 
total phosphorylation by, for example, immunoblotting. However, there are 
arguments against this conclusion (discussed below). 
Secondly, this suggests that the protein kinase activity of p110α is relatively 
limited in the context of this experiment. This may be considered to be in 
keeping with the literature, in that very few p110α protein substrates have been 
identified. A potential way around this could be to increase the amount of 
exogenous p110α in the assay, or to increase the length of time for which the 
assay was performed. While the earlier radiometric in vitro kinase assay 
controls showed good p110α activity in a simple reaction mixture, this is likely to 
be diluted due to the cell lysate in the MS-based assay. However making either 
or both of these changes would probably lead to more non-specific 
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phosphorylation events being produced, thus increasing the background 
through which to detect real substrates.  
Finally, it is likely that the majority of phosphopeptides generated during the in 
vitro kinase assays and present in the samples were identified. The 
phenomenon of under-sampling is frequently a problem in MS studies which 
yield large (many thousands) of hits, due to the limited duty cycle of mass 
spectrometers. However due to the relatively small number of peptides 
identified in this study and the duty cycle of the Orbitrap, it is unlikely that 
identification of a large number of phosphopeptides was missed.  
Another important point to note is the high level of background phosphorylation 
observed in the 0 µM ATP condition of the cell lysate. The substrate for the in 
vitro kinase assays is a dephosphorylated cell lysate, from which small 
molecules such as ATP have been removed. It is possible that either the steps 
involving dephosphorylation or exclusion of small molecules were incompletely 
performed, leading to background phosphorylation events observed. However, 
there is also variation across the conditions at the 0 µM ATP concentrations. 
This was also observed during previous experiments in our laboratory 
employing a similar method, with variability and background phosphorylation 
seen [218]. It may be the case that removal of ATP from the cell lysate has not 
been completely achieved, and so it would be of interest to include extra steps 
in future experiments to make sure that this aim is met.  
We included an extra control in our experimental design, and used kinase with 
its specific inhibitor. This was so that candidates taken for validation would be 
as robust as possible. However it may be the case that this extra control means 
that comparisons of intensity of phosphorylation across samples in the search 
for true novel substrates are confounded due to the variability present in the 
system. It may be of benefit to perform additional similar experiments of a 
different, perhaps more simple, design and compare these datasets to identify 
robust candidates suitable for validation. For instance, changing the amount of 
recombinant kinase instead of ATP concentration as done alongside the Akt in 
vitro kinase assay discussed above [218], or using as a substrate cell lysate, 
the proteins of which have been enzymatically digested, as described by Xue et 
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al.  [219]. The latter approach should have the added benefit of also reducing 
background as kinases present in the sample would be digested and hence 
inactive. These strategies would however increase time, cost and complexity, 
and in the latter case peptides may not be as good a substrate as full length 
proteins.  
We note that previously identified p110α substrates, including Ser608 of p85α, 
were not identified in our MS screen. Because of the incomplete 
characterisation of these substrates in the literature, it is not known which 
conditions produce robust phosphorylation, for example cell stimulation, other 
priming phosphorylation events, or binding to an adaptor. Therefore we do not 
know whether or not the conditions required to achieve these specific (or indeed 
wider) phosphorylation events were replicated in this assay. Pilot experiments 
were carried out using a similar experimental design, and phosphorylation of 
Ser608 was observed, though not across all experiments. This suggests that 
the assay is capable of bringing about phosphorylation and identification of 
Ser608 and in theory other valid substrates, though not with a 100% success 
rate. 
It is not a trivial task to design an experiment which assays the endogenous 
protein kinase activity of p110α while excluding the effects of its lipid kinase 
activity. Were we to analyse the protein kinase activity in intact cells with 
stimulation using, for instance, insulin, this stimulation would also activate 
signalling cascades downstream of the lipid kinase arm, and separating 
phosphorylation events due to the two activities would be impossible. However 
the use of conditions which optimally induce p110α protein kinase in vitro and in 
vivo, would of course be the ideal scenario.  
Work in other laboratories has reported the creation of p110γ mutants in which 
the lipid and protein kinase activities have been separated. Through the 
swapping of binding domains, Wymann et al. [134] produced proteins which 
were deficient for lipid kinase activity, but with protein kinase activity intact. It 
would in theory be possible to introduce these mutants (or similar versions for 
p110α) into cells in which the endogenous protein has been knocked out, and 
attempt to identify novel substrates in this way. However issues exist around the 
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ability of these mutants to retain some capacity for lipid phosphorylation, though 
it may be reduced or directed towards a different substrate. These mutants 
have the potential to be a useful tool in the context of our experiments, but it 
would be challenging to assign phosphorylation events directly to p110α, or 
even to conclusively separate them from the lipid kinase activity. 
3.5.2.2. Selection of candidate phosphorylation events for validation 
as p110α substrates 
It was necessary to define a set of arbitrary criteria in order to narrow the 
hundreds of phosphorylation events identified and quantified in our screen down 
to likely candidates for true p110α substrates. The inclusion of multiple ATP 
concentrations for each condition allows a basic understanding of the reaction 
kinetics to be inferred. Therefore we used this to set one criterion as a 
correlation of intensity of phosphorylation with ATP concentration in the p110α 
condition, and set a Pearson correlation of >0.6. 254 phosphopeptides 
exceeded this threshold, however many had background phosphorylation in one 
or both of the control (cell lysate or p110α/A66) conditions. For that reason, we 
used a second criterion which was a requirement of at least a two-fold increase 
in intensity of phosphorylation from both control 50 µM and 100 µM ATP 
conditions to the same concentrations in the p110α condition. When both 
criteria were applied, two phosphopeptides remained, each with two 
phosphorylation events identified, none of which had been previously identified: 
FBX7 (Ser283, Ser294) and GRIA1 (Ser873, Ser881). It is interesting to note 
that peptides with two phosphorylation events have been identified for both 
proteins. In this context, it is not possible to thus far separate the 
characterisation of the two phosphorylation events, especially in the absence of 
previously described features.  
FBX7 codes for the substrate recognition element of the ubiquitin ligase 
machinery, which targets proteins for proteasomal degredation by tagging them 
with ubiquitin. GRIA1 codes for the protein glutamate receptor 1, a serpentine 
receptor located at the plasma membrane. The identified phosphorylation sites 
in GRIA1 lie within the cytoplasmic portion of the protein, meaning that p110α 
could access them.  
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Because none of these phosphorylation events have previously been 
characterised, it is not possible to speculate in great depth over the effect of the 
potential p110α action. Both proteins function as part of signalling cascades: 
Phosphorylation of receptor-associated proteins by p110α has been described 
with IRS1, and it may be the case that p110α acts in a similar manner towards 
GRIA1.  
It is important to note the variety of phosphorylation profiles observed for the 
events which we do not assign as being p110α-dependent. Phosphorylation 
events in the dataset with high or low intensity exist for all combinations of 
conditions (e.g. low in cell lysate, high in p110α/A66, low in p110α; high in cell 
lysate, low in p110α/A66, low in p110α etc). Given that each ATP concentration 
for each condition had as its starting material the same cell lysate, this 
variability is interesting especially when considering control and 0 µM ATP 
samples, though perhaps not entirely unexpected. As discussed previously, 
experiments within our laboratory using a similar design with Akt also saw 
variability between replicates and conditions [218]. While the protein substrates 
and kinases present in each reaction condition should be largely the same, it is 
not true that the same reactions will occur or products be formed; this would be 
expected in closed system, but variability is anticipated in a biological context. It 
is clear that this complex mixture of substrates and products makes analysis 
more challenging. 
While optimising conditions, radiometric in vitro kinase assays using 
phosphorylation of p85α as a readout of p110α protein kinase activity showed 
activity to be high in a simple reaction mixture (i.e. recombinant p110α/p85 
only; in the absence of cell lysate). However due to the unavoidable dilution 
effect of generating a cell lysate this activity is likely to be diluted somewhat in 
the in vitro kinase assays used prior to the MS screens, and it could be argued 
that there is a suggestion implicit in the literature that having few characterised 
substrates of p110α protein kinase activity means that it is a weak kinase.  
Additionally, it is certainly true that the same residue of a particular protein may 
be targeted for phosphorylation by more than one kinase, and it is realistic that 
any p110α substrates have additional kinases that phosphorylate them. If it is 
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accepted that in such a complex reaction mixture the products 
(phosphoproteins) will not be identical across the conditions, then this could 
therefore lead to any true substrates of p110α being masked by their 
phosphorylation by more active kinases still present in the total cell lysate 
substrate, even with the amount of exogenous p110α used.  
3.5.2.3. Biochemical characteristics of candidate phosphorylation 
events 
For many well-characterised protein kinases, there exist consensus motifs 
which are present in their substrates at the primary sequence level, and 
recognised by the kinase which then phosphorylates the target [220]. For 
example, Akt phosphorylates residues within the RxRxxpS/pT motif, though not 
all substrates conform to this sequence [54]. Had a larger number of 
phosphorylation events been found to be potential p110α substrates, it would 
have been informative to use bio-informatic analysis tools such as motif-x to 
interrogate these sequences in p110 substrates in search of sequence 
similarities around the phosphosite pointing to a conserved motif. This approach 
works best with a larger dataset, and as we only took two substrates for 
validation, we decided to compare the sequences around the candidate 
phosphorylation events to the sequences of previously described p110α 
substrates manually, as well as examining conservation across species. Even 
this approach can be informative; a measure of how little work has been done 
regarding the protein kinase activity of p110α is the limited characterisation of 
its substrates, even those discovered decades ago. This includes IRS1, where 
the phosphosite targeted by p110α has not yet been mapped. 
We first looked at the degree of conservation around the Ser608 residue of 
p85α between mouse and human sequences, and found 100% conservation 
between amino acids 591-620. Of the two phosphorylation sites for each 
protein, FBX7 has Ser283 conserved between mouse and human proteins, 
while GRIA1 has both candidate phosphosites conserved. We then analysed 
the wider sequences of our candidates and found 33% conservation between 
mouse, human, rat and bovine sequences in the residues around the 
phosphosites of FBX7, and 90% conservation for GRIA1. This degree of 
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sequence conservation for GRIA1 is evidence for a conserved function for that 
area of the protein, one which may include one or both phosphorylation events. 
The MS assay was designed to include different concentrations of ATP for each 
condition (cell lysate, p110α/A66, p110α) so as to be able provide quantitative 
data on reaction kinetics. These data can then be used to infer qualitative 
information for the kinase-substrate pairing, including its validity and strength of 
interaction compared to other previously characterised pairings or others found 
in the MS screen. A shortcoming of this approach applied to our experiments is 
the limited number of ATP concentrations that we have used: while it is 
preferable to have as many as possible over as large a range as possible, 
practical considerations such as cost and time need to be taken into account. 
We therefore decided to use three separate ATP concentrations for each 
condition, which allowed us to reasonably consider a phosphorylation event in 
terms of the relationship between the control and p110α conditions, but could 
only give an approximation of reaction kinetics. 
Data on reaction kinetics can provide valuable information on the strength of an 
enzyme-substrate pairing, which can be used to infer physiological relevance. 
The principles of Michaelis-Menten kinetics can be applied to a kinase-substrate 
interaction to produce the quantitative data mentioned above. It is important to 
note that these principles were set out for an idealised interaction, and not all of 
the clauses will be met. For instance, the substrate concentrations may not be 
saturating, and the curves of phosphorylation intensity may not show a plateau 
were more ATP concentrations to be included. Additionally, an assumption was 
made that the two phosphorylation events on each protein had equal kinetics 
which is unlikely to be the case in reality. We redefined the components of the 
Michaelis-Menten model so that Km becomes an estimation of the affinity of a 
substrate for ATP (KATP). Using these approximations, we found that the affinity 
for ATP was higher for the p110α-GRIA1 interaction (KATP = 27.63 µM) than for 
the p110α-FBX7 interaction (KATP = 36.07 µM). Affinity in these terms has not 
been defined for previously characterised p110α substrates, and so it is not 
possible to make a direct comparison here. However, this approach has been 
used in our laboratory previously in an attempt to identify novel Akt substrates. 
This work resulted in identification of phosphorylation events which could be 
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grouped; events with relatively high affinity for ATP included those with KATP of 
lower than 10 µM, those with relatively low affinity for ATP had KATP calculated 
to be above 10 µM. This comparison gave further credence to the suggestion 
that the protein kinase activity of p110α is more limited than better characterised 
kinases. In combination with the sequence analysis of the two candidate 
proteins, it could be argued that GRIA1 is the stronger candidate, as its 
sequence homology and affinity of interaction are higher than for FBX7. 
That we observed the effect of the protein kinase activity of p110α as being 
relatively small in this experimental context is perhaps unsurprising for a 
number of reasons. Firstly, given the small number of described substrates 
previously published in the literature, it could be argued that a large 
physiological role for the p110α protein kinase activity is unlikely to have been 
hitherto overlooked. It is disappointing to note the absence of previously 
described substrates of p110α in the MS screen, though the phosphorylation of 
Ser608 on p85α was observed in pilot experiments. This may be due to the 
experimental setup, specifically that a dephosphorylation step removed any 
previously present phosphorylations from the lysate to produce as low a 
background as possible, which was followed by an in vitro model with an 
absence of any cell stimulation/p110 activation. Therefore, it may be that the 
protein kinase activity of p110α is dependent on the correct but unknown 
context of stimuli, scaffold, or membrane, which was not reproduced faithfully 
enough in these experiments. 
3.5.3. Validation of targets identified in p110 in vitro kinase 
phosphoproteomic screen 
The most straightforward method for validating a kinase-substrate interaction is 
by carrying out in vitro kinase assays, presenting the recombinant protein 
substrate to the kinase in a simple reaction mixture including ATP and a 
suitable buffer. Inclusion of ATP labelled with a radioisotope of phosphorus 
allows incorporation of ATP to be visualised, following separation of reaction 
components by SDS-PAGE and exposure of the resultant gel to X-ray film. 
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We wished to validate both candidate interactions by this method, but due to the 
relatively poor level of characterisation of both proteins and all phosphorylation 
events, the desired biochemical tools were not available, and neither was 
commercially available as a full length recombinant protein. We therefore 
decided to produce peptides which included the phosphosites of interest, as 
well as a number of amino acids on either side. Protein kinases generally use 
only a small number of amino acids directly adjacent to a phosphorylation site to 
aid recognition, so we reasoned that these short peptide fragments would be 
suitable for in vitro kinase assays. A variation on the method outlined above 
involves the immobilisation of the peptide onto phosphocellulose paper 
following the kinase reaction, and quantification of the radiolabelled ATP 
incorporated into the peptide [209]. Binding of the peptide to the 
phosphocellulose paper is aided by the addition of basic amino acids to a 
peptide terminus, and so we chose to add lysine residues to each peptide we 
produced. All peptides which we had synthesised were predicted by freely 
available online bio-informatic tools to be water soluble. 
As well as using peptides which replicate the protein sequence around the 
phosphosites of interest, we decided to also test peptides with serine-to-alanine 
substitutions for each phosphosite, as well as dual substitutions for each 
candidate protein. In this way it is possible to glean more qualitative and 
quantitative data, and have more confidence in a true kinase-substrate 
interaction, as well as separating the characterisation of the individual 
phosphorylation events.  
We first attempted to use an in vitro kinase assay followed by 1D SDS-PAGE to 
validate the candidate substrates. Due to the small size of the peptides 
(~2kDa), we anticipated that they would migrate to a similar position on a gel as 
the unincorporated radiolabeled ATP. This would mean that upon exposure to 
X-ray film, any free radiolabelled ATP would be indistinguishable from bands 
due to radiolabelled ATP incorporated into the peptides during the kinase 
assay. Therefore we endeavoured to overcome this by using Tricine gels to 
enable maximum separation of low molecular weight substances. Unfortunately, 
we were unable to achieve sufficient resolution of peptides and free 
radiolabelled ATP to counter this problem, and our multiple attempts resulted in 
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visualisation of a large area of exposure, with free radiolabeled ATP masking 
any possible signal from incorporated ATP. 
We then proceeded to validate in vitro phosphorylation of peptides using an 
alternative method. We again performed in vitro kinase assays, followed by 
peptide immobilisation onto phosphocellulose paper, a process aided by the 
incorporation of basic lysine residues in the peptides, and scintillation counting 
[209]. These experiments revealed only low incorporation of radiolabelled ATP 
into any of the peptides, including the p85α sequence which included Ser608, 
one of our controls. The overall increase from the kinase+ATP control to the 
non-mutated peptides was small, however comparing each peptide (p85α, 
FBX7, and GRIA1) with their single and double serine-to-alanine mutants, there 
was a trend towards a decrease in incorporation of radiolabelled ATP.  
We included peptides with the sequence around the Ser608 residue of p85α as 
controls, hoping to see radiolabelled ATP incorporate in the non-mutated which 
was not observed in the serine-alanine mutant. This trend was observed, but 
with very small differences, and with counts which were only slightly higher than 
the kinase+ATP control. The phosphorylation of Ser608 by p110α has been 
observed by us while using similar conditions (Fig. 3.2) and so we would expect 
that phosphorylation could be achieved in this assay. That we did not detect 
robust incorporation of radiolabelled ATP suggests either that the partial p85α 
peptide is not a good in vitro substrate for p110α and so incorporation does not 
occur, or that the p85α peptide has not bound well to the phosphocellulose 
paper and so incorporation occurs but is not observed. While designing the 
peptides for this assay, we included basic lysine residues so that the required 
immobilisation of the peptide onto phosphocellulose paper would occur, and 
used freely available prediction tools to assess pH and thereby inform sequence 
design. In using partial peptides rather than full length recombinant proteins 
there is a risk that the substrate will not optimally interact with the kinase 
because of some missing secondary or tertiary structure. These factors would 
suggest that it is likely that the peptides did indeed bind the phosphocellulose 
paper, but that they were not a suitable substrate for the kinase. Another 
possibility is that in this assay, the phosphorylation of full length recombinant 
p85α by p110α which we have previously shown to be strong (Fig. 3.2) and 
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residual binding to the phosphocellulose paper is sufficient to mask the weak 
phosphorylation of the candidate peptides. 
The lack of high levels of incorporation of radiolabelled ATP in the p85α Ser608 
peptide that served as a positive control of p110α protein kinase activity, 
suggests the need for an alternative positive control. It is possible that the 
protein kinase of p110 only occurs when the full-length p85 substrate is in 
close proximity with p110 by virtue of forming a heterodimeric protein complex 
with high affinity between p110 and p85. While the protein kinase activity of 
p110α has not been well-characterised, it would be possible to use a better-
studied kinase such as Akt or S6 kinase II which have been shown to 
phosphorylate synthetic peptides (Aktide and kemptide respectively) [221, 222]. 
Inclusion of such a control would at least allow verification of the assay as a 
whole, but the activity of such a robust protein kinase may not be directly 
comparable to the activity of the weaker p110α protein kinase. 
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4. Investigation into differential p110α and p110β signalling in 
the mouse 4T1 breast cancer cell line model 
4.1. Introduction and aim of study 
Of the four class I PI3K isoforms, only p110α and p110β are ubiquitously 
expressed. PI3Ks control many important cellular functions, and p110α and 
p110β share a number of outputs including in the regulation of cell survival, 
proliferation and migration, but also have differential functions as detailed 
below. We therefore explored potential difference in global protein kinase 
pathways downstream of these PI3K isoforms.  
Activation of class I PI3Ks is through recruitment to activated receptors and 
small GTPases. Traditionally, class IA PI3Ks were thought to be downstream of 
RTKs, and the class IB p110γ downstream of GPCRs, with all four class I PI3Ks 
responsive to input from Ras or other small GTPases. While p110α has RTKs 
and Ras as upstream activators, the relative contribution of agonists appears to 
be more complex for p110β. RTKs, GPCRs and small GTPases other than Ras 
(i.e. Rac and cdc42) are now known to all activate p110β. 
Binding of the class I PI3K homodimer to membrane-bound receptors brings the 
complex to the plasma membrane, where the p110 subunit catalyses the 
production of PIP3 from PI(4,5)P2. This 3-phosphoinositide lipid is recognised by 
a subset of proteins through their lipid-binding domains, including Akt. These 
proteins may also be kinases, act as molecular scaffolds, or transduce the 
signal in some other way. This binding event causes translocation to the plasma 
membrane where signalling cascades can be initiated or affected. Akt is the 
best characterised PI3K effector, but there are other proteins which have been 
shown to have a growing importance such as the related AGC kinase, SGK.  
Differences in both upstream activation of and downstream signalling from 
p110α and p110β are becoming increasingly apparent. The two PI3K isoforms 
control different biological outputs: p110α but not p110β regulates 
developmental and tumour angiogenesis and insulin signalling/glucose 
metabolism [144, 145]. Although p110α is the only PI3K found mutated in 
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cancer, there is a growing body of evidence that non-mutated p110β plays a 
role in PTEN-null cancers such as prostate cancer. 
Unpublished work from our laboratory by Dr Salma Taboubi has shown that 
inhibition of p110α or p110β in the murine BALB/c 4T1 breast tumour cell line 
results in differential effects on a number of phenotypes. The 4T1 cell line 
expresses wild-type PIK3CA and PTEN, and is deficient for TP53. Dr Taboubi 
found that in vitro proliferation and invasion, as well as levels of in vivo 
metastasis were enhanced upon inhibition of p110β but unaltered following 
inhibition of p110α. The initial attempts of Dr Taboubi to characterise the 
signalling of these cells by western blotting in terms of levels of phosphorylation 
of Akt and its downstream targets found no obvious causes for the phenotypic 
outputs. The specific inhibitors A66 and TGX211 were used to inhibit the p110α 
and p110β isoforms respectively [167, 148]. While both isoforms are 
ubiquitously expressed and signal through similar effectors such as Akt, they 
control different processes (see Chapter 1.1.6.). Although Akt is likely the main 
effector of the two isoforms and certainly the best characterised, the specific 
signalling pathways for the differential phenotypes have not been fully 
elucidated and were what we aimed to characterise. While the efficacy and 
specificity of our inhibitors for the PI3K isoforms under investigation has been 
determined previously in in vitro assays [167, 148], the possibility exists that off-
target effects on other kinases may occur, and so work to validate findings is 
key. The 4T1 cell line is frequently used in our laboratory in other experiments 
[153] and was therefore an interesting model system to further characterise, in 
terms of the specific phenotypes observed but also more generally. 
We decided to characterise biological differences by probing the 
phosphoproteome upon selective inactivation of p110α or p110β. The aim of the 
work presented in this chapter was to compare phosphorylation events 
downstream of p110α and p110β in 4T1 cells in a global and unbiased manner, 
using label-free quantitative mass spectrometry. The experimental design (Fig. 
4.1) replicates the conditions under which Dr Taboubi observed differential 
phenotypes following inactivation of p110 and p110β. 
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4.2. Phosphoproteomic investigation of signalling downstream of 
p110α and p110β 
Exponentially growing 4T1 cells were starved for 18 h in media which lacked 
serum, followed by pre-treatment with DMSO or drug as indicated for 2 h, also 
in media without serum. Cells were then left unstimulated (subsequently 
referred to as “Starved”), or stimulated with 0.5% serum which contained either 
DMSO (“DMSO”), the p110α-specific inhibitor A66 (“A66”) or the p110β-specific 
inhibitor TGX221 (“TGX221”), at 3 µM and 100 nM respectively (Fig. 4.1). Three 
biological replicates were performed with two technical replicates analysed for 
each condition.  
 
Figure 4.1. Summary of phosphoproteomic approach. 4T1 cells were starved for 18 h in 0% 
serum, followed by a 2 h incubation with or without inhibitor. Cells were then left untreated or 
stimulated with 0.5% serum with or without inhibitor for 30 min, and subjected to 
phosphoproteomic analysis. Samples were lysed, digested using trypsin, and phosphopeptides 
enriched by titanium dioxide affinity then analysed by LC-MS/MS. Data analysis was carried out 
using in-house and freely available programs. Three biological replicates were performed for 
each condition, each of which was analysed in duplicate (n=6). 
 
 
Cell lysates were harvested and analysed using methodology published 
previously by the Cutillas laboratory [191]. Briefly, 500 µg of total protein was 
isolated and denatured, reduced and alkylated. Proteins were then subjected to 
overnight trypsin digestion, phosphopeptides were enriched by TiO2 affinity 
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chromatography, after which they were analysed by LC-MS/MS using an 
Orbitrap-XL and identified and quantified by in-house techniques.  
The data from the MS analysis of the samples were used to interrogate the 
MASCOT protein database, and peptides which were returned with an 
expectation value of <0.05 were chosen for further analysis. The in-house 
program Pescal (developed by Dr Cutillas) was then used to quantify this 
database of 2121 peptides across all 24 samples (Appendix 2). 
Quantification of intensity of phosphorylation across the samples was visualised 
in the form of a heat map (Fig. 4.2). The data show groups of phosphopeptides 
which are positively or negatively regulated upon inhibition of one or both PI3K 
isoforms.  
Interestingly, whereas almost half of the phosphopeptides increased in intensity 
upon serum-stimulation relative to the starved control, a slightly larger number 
of phosphopeptides showed the reverse pattern, with phosphorylation being 
higher in starved cells. 
Of interest, a number of phosphorylation events which have previously been 
shown to be downstream of class I PI3Ks are found in the dataset, giving us 
confidence in the output as a whole. These include phosphorylations on AKTS1 
(PRAS40; pThr257) and RS6 (40S ribosomal S6; pSer236). Interestingly, these 
phosphopeptides display different profiles in terms of relative change of 
intensity upon inhibition of p110α or p110β. Indeed, intensity of AKTS1-Thr257 
is reduced to 13% of control following inhibition of p110α and 79% of control 
following p110β inhibition, and intensity of RS6-Ser236 reduced to 43% of 
control after inhibition of p110α, and 118% of control after inhibition of p110β 
(discussed in more detail later).  
This analysis showed that although there are clear differences in the way that 
individual phosphopeptides change, the inclusion of all peptides from the 
dataset masks these variables and so these differences are not sufficiently 
large to enable the conditions to separate out. 
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Figure 4.2. Quantitative analysis reveals phosphoproteomic response to an in vitro 
kinase assay. 4T1 cells were starved for 18 h in 0% serum, followed by a 2 h incubation with or 
without inhibitor. Cells were then left untreated or stimulated with 0.5% serum with or without 
inhibitor for 30 min, and subjected to phosphoproteomic analysis (n=6). Quantification of 2121 
phosphopeptides identified was visualised as a heat map, where intensity of phosphorylation for 
a given phosphopeptide was expressed relative to the maximum intensity for that 
phosphopeptide.  
 
 
 
 
 Starved       DMSO         A66        TGX221 
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To assess the differences between the conditions on a large scale, we 
performed principle component analysis (PCA) on the entire dataset (Fig. 4.3A). 
 
 
 
 
Figure 4.3. PCA shows similar profiles following PI3K isoform inhibition. 4T1 cells were 
starved for 18 h in 0% serum, followed by a 2 h incubation with or without inhibitor. Cells were 
then left untreated or stimulated with 0.5% serum with or without inhibitor for 30 min, and 
subjected to phosphoproteomic analysis (n=6). PCA was performed using all identified and 
quantified phosphopeptides. Purple = starved; green = DMSO; red = A66, blue = TGX221. 
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The aim of the experiment was to compare the phosphorylation events 
downstream of p110α and p110β, hence sites of phosphorylation which are 
either mutually or differentially regulated were of specific interest to us. These 
include phosphorylation events which either increased or decreased upon PI3K 
isoform-inhibition. Those which decrease upon PI3K isoform-inhibition are likely 
to be under direct control of effector protein kinases downstream of either 
p110α or p110β, and those which increase upon PI3K isoform-inhibition may be 
part of a feedback loop. We decided to focus our analysis mainly on 
phosphorylation events which are negatively regulated upon PI3K isoform-
inhibition, as these are more likely to be amenable to future investigation. 
A summary of the data is shown in Table 4.1. Inhibition of either p110α or 
p110β elicits a response of a similar magnitude, with around 10% of 
phosphorylation events in the dataset reduced by more than twofold, and 
around one third of these being significantly altered as determined by a 
Student’s t-test. Within these categories will be phosphorylation events which 
are regulated by one or both PI3K isoforms. We next proceeded to define some 
(arbitrary) criteria which would allow us to categorise phosphorylation events to 
aid further analysis. 
Table 4.1. Phosphorylation events identified as regulated by p110α or 
p110β. 
DMSO vs >2x Decrease P<0.05 >2x Increase P<0.05 
A66 180 54 148 28 
TGX221 195 59 108 9 
 
A phosphorylation event was considered to be regulated by both PI3K isoforms 
when, upon inhibition, there was at least a twofold change in its intensity when 
comparing the impact of inhibition of each PI3K isoform to the DMSO control 
(Fig. 4.4).  
A phosphorylation event was considered to be regulated by only one PI3K 
isoform when (1) there was at least a twofold change in its intensity when 
comparing inhibition of that PI3K isoform to the DMSO control, and (2) the fold 
 113 
 
change of intensity upon inhibition of the other PI3K isoform compared to the 
DMSO control was less than 1.5-fold (Fig. 4.4).  
Unless otherwise stated, comparisons are made between the intensity of a 
phosphopeptide in an inhibitor-treated sample (A66 or TGX221) relative to the 
DMSO control condition.  
These criteria were applied to the whole dataset (2121 peptides), and the 
summary of the categories is shown in Table 4.2. As may be expected, a large 
proportion of phosphopeptides lie outside of the boundaries for fold change of 
intensity which we defined, and so are not stated to be under the control of one 
or both PI3K isoforms. By our criteria, 150 phosphorylation events are under the 
control of both p110α and p110β, 106 phosphorylation events are under 
selective control of p110α, and 93 phosphorylation events are under selective 
control of p110β. These values include those phosphorylation events which 
decrease and also those which increase upon PI3K isoform-inhibition and are 
summarised in Table 4.2. 
 
Figure 4.4. Criteria for categorising targets. 4T1 cells were starved for 18 h in 0% serum, 
followed by a 2 h incubation with or without inhibitor. Cells were then left untreated or stimulated 
with 0.5% serum with or without inhibitor for 30 min, and subjected to phosphoproteomic 
analysis (n=6). (A) Phosphopeptides were defined as being regulated by both p110 and p110β 
when there was ≥ 2x reduction in phosphopeptide intensity after inhibition of each PI3K isoform 
compared to DMSO control (p<0.05 in each case). (B) Phosphopeptides were defined as being 
regulated by either p110 or p110β only when there was ≥ 2x reduction in phosphopeptide 
intensity after inhibition of that PI3K isoform compared to DMSO control (p<0.05), and a < 1.5x 
reduction in phosphopeptide intensity after inhibition of the other PI3K isoform compared to 
DMSO control. 
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4.2.1. Results of phosphoproteomic screen 
Both p110α and p110β are ubiquitously expressed, can control similar 
processes, and share a number of downstream effectors such as Akt. 
Surprisingly, when we applied our criteria we found that there were fewer 
mutually regulated phosphorylation events than events regulated by either 
p110α or p110β. It is likely that the emerging complexity of signalling upstream 
of class I PI3K contributes to this PI3K isoform-selective downstream signalling. 
For example the interplay and contribution from different RTKs, GPCRs, Ras 
and other small GTPases feeding into class I PI3Ks has yet to be fully 
described, and they are likely to promote different signalling networks. 
4.2.1.1. Categorisation of phosphorylation events 
Of the 150 phosphorylation events found to be regulated by both p110 and 
p110β, 67 were positively regulated, and intensity of phosphorylation of 12 of 
these reduced significantly as determined by a Student’s t-test using a threshold 
of p<0.05. A heat map was used to visually represent these quantitative data, 
and shows negative regulation of phosphorylation upon inhibition of either 
p110α or p110β (Fig. 4.5A). 
 
Table 4.2. Phosphorylation events identified as mutually or differentially 
regulated. 
Regulated by >2x Decrease P<0.05 Group 
p110α and p110β 67 12 A 
p110α 66 17 B 
p110β 76 9 C 
 
 
Again based on the criteria outlined above, 106 phosphorylation events were 
found to be regulated by p110α alone. Intensity of 66 of these phosphorylation 
events reduced, and 17 of these were significantly altered as determined by a 
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Student’s t-test using a threshold of p<0.05. A heat map was used to visually 
represent the quantitative data, and shows negative regulation of 
phosphorylation upon inhibition of p110α but not p110β (Fig. 4.5B). 
In a similar manner, 93 phosphorylation events were found to be regulated by 
p110β alone, 76 of which reduced upon p110β inhibition. Of these, intensity of 9 
phosphorylation events reduced significantly as determined by a Student’s t-test 
using a threshold of p<0.05. A heat map was used to visually represent the 
quantitative data, and shows negative regulation of phosphorylation upon 
inhibition of p110β but not p110α (Fig. 4.5C). 
Interestingly, while intensity of phosphorylation for mutually or p110α-regulated 
substrates appears to increase following serum starvation (from the Starved to 
DMSO controls), the reverse pattern is seen in the p110β-regulated category. 
Intensity of phosphorylation is often relatively high in the serum-starved control, 
and reduces after stimulation. Examples of phosphopeptides from each 
category are shown in Figure 4.6. 
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Figure 4.5. Examples of phosphorylation events identified following inhibition of p110α 
or p110β PI3K. 4T1 cells were starved for 18 h in 0% serum, followed by a 2 h incubation with 
or without inhibitor. Cells were then left untreated or stimulated with 0.5% serum with or without 
inhibitor for 30 min, and subjected to phosphoproteomic analysis (n=6). Mean normalised 
phosphopeptide intensity are represented as a heat map for events described as regulated by 
(A) p110α and p110β, (B) p110α only, (C) p110β are shown, where intensity of phosphorylation 
for a given phosphopeptide was expressed relative to the maximum intensity for that 
phosphopeptide 
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Figure 4.6. Examples of phosphorylation events identified following inhibition of p110α 
or p110β PI3K. 4T1 cells were starved for 18 h in 0% serum, followed by a 2 h incubation with 
or without inhibitor. Cells were then left untreated or stimulated with 0.5% serum with or without 
inhibitor for 30 min, and subjected to phosphoproteomic analysis (n=6). Mean normalised 
phosphopeptide intensity for examples of events described as regulated by (A) p110α and 
p110β, (B) p110α only, (C) p110β are shown, where intensity of phosphorylation for a given 
phosphopeptide was expressed relative to the maximum intensity for that phosphopeptide. 
Error bars represent one standard deviation from the mean. *p<0.05 **p<0.005 
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Figure 4.7. Phosphorylation events downstream of PI3K/Akt are under the control of 
p110α but not p110β. 4T1 cells were starved for 18 h in 0% serum, followed by a 2 h 
incubation with or without inhibitor. Cells were then left untreated or stimulated with 0.5% serum 
with or without inhibitor for 30 min, and subjected to phosphoproteomic analysis (n=6). Mean 
normalised phosphopeptide intensity for examples of events previously described as being 
regulated by PI3K/Akt are shown where intensity of phosphorylation for a given phosphopeptide 
was expressed relative to the maximum intensity for that phosphopeptide. Error bars represent 
one standard deviation from the mean. *p<0.05 **p<0.005 
 
As previously mentioned, the Akt substrates AKTS1 (pThr247) and 40S 
ribosomal protein S6 (pSer236) were both identified in this MS screen as being 
negatively regulated upon PI3K inhibition (Fig. 4.7). Because Akt is a 
downstream effector of PI3K, this observation serves to increase confidence in 
the dataset as a whole. Interestingly, these two phosphoproteins display similar 
profiles in terms of the relative intensity of phosphorylation, which suggests 
ns 
** 
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 * 
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different roles of p110α and p110β. Serum-stimulation brings about an increase 
in phosphorylation relative to the starved control. Inhibition of p110α causes a 
reduction in phosphorylation to a level lower than the starved control. However, 
this is not repeated upon inhibition of p110β. Instead, only a minor reduction in 
phosphorylation of AKTS1 is seen, and a slight increase is observed for 
phosphorylation of ribosomal protein S6. This observation suggests that in this 
context, p110α and p110β have different absolute contributions to cellular 
signalling through Akt.  
This p110α-specific dataset also includes pSer330 of NDRG1. This 
phosphorylation event has previously been described as being a direct target of 
SGK  [216], a kinase which has been shown to signal downstream of PI3K 
[112]. This phosphorylation event will be discussed in more detail later. 
 
4.2.2. Motif analysis 
Phosphorylation of a protein is the result of the interplay between a kinase and 
a phosphatase. Many kinases have been described to have specific motifs 
which they preferentially phosphorylate, for example the motif RxRxxS/T is 
present in a number of Akt substrates. Therefore we reasoned that Akt, which is 
known to be a prominent PI3K effector, or one or more other kinases may be 
responsible for phosphorylating a large number of the proteins identified in our 
MS screen.  
Identified phosphorylation events which conform to the previously described Akt 
motif [54] are listed in Table 4.3. These proteins represent around one third 
(13/38) of the phosphorylation events identified as being significantly down-
regulated by PI3K isoform inhibition in the screen, suggesting a rather 
substantial possible involvement of non-Akt-directed pathways in this 
experimental context. Only one phosphorylation event from the p110β-regulated 
category is seen to have an Akt motif. It is important to bear in mind that many 
of the identified phosphorylation events will be one or several layers below the 
first PI3K effector, be it Akt or other kinases such as SGK.  
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One of these phosphorylation events is pSer330 of NDRG1. Interestingly, the 
kinase SGK1 which has previously been described as being responsible for this 
phosphorylation has similar substrate specificity to Akt.  
Table 4.3. Phosphorylation events identified which conform to the Akt 
consensus motif. 
Accession 
Number 
Phosphosite Sequence (* 
indicates phosphosite) 
Full/Partial 
Akt motif 
Group 
AKTS1_MOUSE Akt1s1 p-T247 RPRLNT*SDFQ Full B 
CE170_MOUSE Cep170 p-S829 LVRQGS*FTID Partial A 
CHSP1_MOUSE Carhsp1 p-S53 RTRTFS*ATVR Full A 
DNJC5_MOUSE Dnajc5 p-S10 RQRSLS*TSGES Full A 
HDGR2_MOUSE Hdgfrp2 p-S450 RTRKRS*EGLS Full B 
MELK_MOUSE Melk p-S497 ERRCRS*MDVD Partial B 
NDRG1_MOUSE Ndrg1 p-T328  
p-S330 
LMRSRT*AS*GS Partial/Full B 
PALLD_MOUSE Palld p-S901 TARIAS*DEEI Partial B 
PPIG_MOUSE Ppig p-S411  
p-S413 
DHRHMS*ES*PN
RK 
Partial/No C 
RS6_MOUSE Rps6 p-S236  
p-S240 
RRRLSS*LRAS* Full/No B 
SGTA_MOUSE Sgta p-S303  
p-S307 
IRSQVVRS*RTPS
*ASH 
No/Full B 
SRRM1_MOUSE Srrm1 p-T633  
p-S635 
KRRT*AS*PPPP No/Partial B 
SRSF2_MOUSE Srsf2 p-S206  
p-S208 p-S212 
KSRSRS*KS*PPK
S*PEEE 
Partial/No/ 
No 
A 
 
We used the freely available web-based program motif-x [212] in order to 
identify common motifs within the dataset. Identifying motifs from small datasets 
is challenging unless the motif is extremely well-represented. Therefore, we 
decided to increase the number of sequences from which we aimed to detect 
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motifs, and included phosphopeptides which fell within our categories although 
did not meet the required significance of p<0.05 (Table 4.2). Consensus motifs 
are typically made up of a small number of amino acids adjacent to the 
phosphosite, and so using the UniProt database, we extended the sequences of 
our identified phosphopeptides to account for tryptic cleavages and avoid 
missing motifs. The top ranking motifs are shown in Tables 4.4-6 and Fig. 4.8. 
While no one motif is obviously enriched in the dataset, a full or partial Akt motif 
(RxRxxS/T) is prominent within the phosphorylation events of each category 
(Table 4.7). Two other features of the motifs also stand out: a proline residue in 
the +1 position, and acidic residues prominent at various positions both N- and 
C-terminal to the phosphorylation site. Proline-directed kinases are in the 
minority among the protein kinase family but include cyclin-dependent protein 
kinases (CDKs), mitogen-activated protein kinases (MAPKs) and the Akt 
effector GSK-3. Acidic residues have been shown to be important for 
recognition of substrates by casein kinase 2 and polo-like kinase 1. These 
motifs appear to show different profiles within the categories. All three are well 
represented in the mutually regulated phosphorylation events, while acidic and 
SP motifs are most prominent in p110α- and p110β-regulated phosphorylation 
events, respectively (Table 4.7). 
That an Akt consensus motif is found in a minority of the interrogated 
sequences, and that no one other motif is dominant suggests that multiple other 
kinases or families are involved in transducing the PI3K signal in this context. It 
should be noted that because of the nature of tryptic digestion, some sequence 
information will be lost, therefore some motifs will be under-represented by this 
method of analysis. 
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Table 4.4. Motifs enriched in phosphorylation events categorised as being 
mutually regulated by p110α and p110β 
# Motif Matches (/67) Fold Increase 
1. xxxDxS*PEPxx  3 1476.25 
2. xxRxxS*PxxSx  3 74.08 
3. xxxxxS*PTxxx 4 14.45 
4. xxxxxS*xDExD  3 178.80 
5. RxRxxS*xxxxx 6 17.86 
6. ExxxxS*DxDxx  4 262.73 
7. xxxExS*Pxxxx 3 15.47 
8. xxxxxS*DxExx 5 23.97 
9. xxxxxS*Pxxxx 11 3.88 
10. xxRRxS*xxxxx 4 27.64 
11. xxDxxS*xxSxx 3 21.21 
12. xxxxxS*xEExx  4 21.76 
13. xxxxxS*xxxPx 6 4.18 
14. xxxxxS*xESxx  3 38.58 
15. xxxxxS*Sxxxx 6 3.85 
16. xxxxxS*Fxxxx 3 9.08 
 
Fold increase = increase in observations of motif while searching this group of 
sequences versus a group of randomly generated sequences. 
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Table 4.5. Motifs enriched in phosphorylation events categorised as being 
regulated by p110α only 
# Motif Matches (/66) Fold Increase 
1. xxxxxS*DEExx  6 164.81 
2. xNxxxS*Pxxxx  3 22.78 
3. xxRxxS*Pxxxx  4 15.18 
4. xxxQxS*xxExx  4 23.33 
5. xxSxxS*Pxxxx  5 12.57 
6. xxxxxS*xxEDx 4 20.59 
7. RxRxxS*xxxxx  5 23.75 
8. xxxxxS*PxRxx  3 25.45 
9. xxxxxS*xxEEE  3 85.52 
10. xxxQxS*xxDxx  3 45.43 
11. xxxxxS*xDxxx  5 3.85 
12. xxxxxS*xxxxS  6 2.59 
13. xxxxxS*xxxEx  4 3.72 
14. xxxxAS*xxxxx  4 4.40 
 
Fold increase = increase in observations of motif while searching this group of 
sequences versus a group of randomly generated sequences. 
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Table 4.6. Motifs enriched in phosphorylation events categorised as being 
regulated by p110β only 
# Motif Matches (/76) Fold Increase 
1. AxAxxS*PxKxx  3 2522.27 
2. xxKAxS*PSxxx  3 1618.34 
3. xxxxxS*PxxxR  6 22.16 
4. xxSxxS*PxKxx  3 179.37 
5. xxxxxS*PxxxK  4 22.58 
6. xxxxxS*PxxxT  4 19.59 
7. xxxxxS*PxRxx  3 20.76 
8. xxRRxS*xxxxx  4 20.19 
9. xxxxxS*PTxxx  3 25.37 
10. RxxxxS*xPxxx  4 31.10 
11. xxxxxS*PxxxL  3 17.26 
12. xxxxDS*DxDxx  3 278.48 
13. xxxxxS*ExxxD  3 40.60 
14. xxxRxS*xxxxx  5 4.81 
15. xxxxxS*xxxDx  4 5.49 
16. xxRxxS*xxxxx  3 4.38 
17. xxxxxS*xExxx  3 5.34 
 
 
Table 4.7. Motifs enriched in phosphorylation events across categories 
Motif Mutual (/67) p110α (/66) p110β (/76) 
RxxS* 13 9 7 
S*P 24 15 32 
Acidic 28 29 13 
 
Fold increase = increase in observations of motif while searching this group of 
sequences versus a group of randomly generated sequences. 
 125 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8. Specific motifs are enriched upon PI3K isoform inhibition. 4T1 cells were 
starved for 18 h in 0% serum, followed by a 2 h incubation with or without inhibitor. Cells were 
then left untreated or stimulated with 0.5% serum with or without inhibitor for 30 min, and 
subjected to phosphoproteomic analysis (n=6). Sequences of phosphopeptides found to exhibit 
a >2-fold reduction upon PI3K isoform-inhibition were interrogated using the motif-x website. 
Top ranking consensus sites as returned by motif-x are displayed for (A) mutually regulated 
phosphorylation events and events regulated by (B) p110α or (C) p110β only. 
A                                                    B                                                    C  
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4.2.3. Pathway analysis 
The PI3K pathway is known to exert control over a number of cellular functions 
such as survival and proliferation, and does so through well-defined networks. 
We therefore decided to look for known connections between the identified 
proteins, including between the phosphorylation events and PI3Ks. While it is 
sensible to ordinarily take only robust candidates forward for validation, when 
attempting to elucidate connections within a network it may be preferable to use 
less stringent parameters. This is endorsed by our finding of 40S ribosomal 
protein S6 (pSer236) being regulated by p110α alone, but at p=0.07 falling short 
of reaching significance although the change was a greater than 2-fold 
reduction. Therefore we decided to seek connections in the groups of 
phosphopeptides which we classified as described above (Fig. 4.4), but this 
time not taking significance into account.  
We used the freely available online tool STRING to produce maps which plot 
previously described connections between the proteins identified in our MS 
screen, with proteins lacking connections omitted. Figures 4.9.A-C show the 
proteins categorised as being mutually regulated, or regulated by p110α or 
p110β alone, respectively. For each group of proteins, distinct nodes exist 
where connections are made between effectors of transcription (1) and 
translation (2), as well as DNA binding proteins (3). Other smaller nodes also 
exist for each group, relating to cell adhesion (4). It is interesting to note that 
even though the three groups which we defined (phosphorylation events 
regulated in common and exclusively) contain different phosphorylation events, 
the proteins within them represent similar pathways (e.g. transcription and 
translation). This is noteworthy that PI3Ks may act through different targets for 
the same ends, and possibly points towards redundant signalling.  
The experiment was primarily designed to explore the signalling downstream of 
p110α and p110β, which could potentially be used to help to explain the 
differences in observed phenotypes such as proliferation, invasion and 
metastasis. However, we could not discriminate obvious differences in terms of 
pathways represented which could explain the observed differences in 
phenotypes following PI3K isoform-selective inhibition observed by Dr Taboubi. 
 127 
 
 
Figure 4.9. Analysis of pathways regulated by PI3K isoforms. 4T1 cells were 
starved for 18 h in 0% serum, followed by a 2 h incubation with or without inhibitor. 
Cells were then left untreated or stimulated with 0.5% serum with or without inhibitor for 
30 min, and subjected to phosphoproteomic analysis (n=6). The online tool STRING 
was used to map networks mapped of phosphorylation events described as being 
regulated by (A) p110α and p110β, (B) p110α only, (C) p110β only. Previously 
described interactions (lines) between proteins (circles) from each category are 
depicted, and proteins without connections omitted. 
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depicted, and proteins without connections omitted. 
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Figure 4.9. Analysis of pathways regulated by PI3K isoforms. 4T1 cells were 
starved for 18 h in 0% serum, followed by a 2 h incubation with or without inhibitor. 
Cells were then left untreated or stimulated with 0.5% serum with or without inhibitor for 
30 min, and subjected to phosphoproteomic analysis (n=6). The online tool STRING 
was used to map networks mapped of phosphorylation events described as being 
regulated by (A) p110α and p110β, (B) p110α only, (C) p110β only. Previously 
described interactions (lines) between proteins (circles) from each category are 
depicted, and proteins without connections omitted. 
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4.3. Validation 
While large-scale MS screens are of themselves informative, it is prudent to 
follow up on some aspects so as to have greater confidence in the data 
generated. Therefore, we chose a number of targets identified in the MS screen 
for validation by independent methods. These targets were chosen based on a 
number of criteria, including an established link to the PI3K pathway, 
involvement in other well-characterised pathways, and, importantly, availability 
of biochemical tools for analysis. We focused our attention on phosphorylation 
events which were negatively regulated upon PI3K isoform-inhibition, as these 
are likely to be directly downstream of PI3K, rather than phosphorylation events 
which were positively regulated and possibly part of a feedback loop. 
Using these criteria, we chose the targets listed in Table 4.4. This list includes 
pSer236 of 40S ribosomal protein S6 which is a direct target of Akt and found to 
be negatively regulated in the MS screen upon inhibition of p110α, although it 
did not meet our set cut-off threshold for significance. Also chosen is pSer330 of 
NDRG1 which is a direct target of SGK1, a kinase which has shown to be able 
to transduce the PI3K signal, and pThr247 of AKTS1 which is a direct target of 
Akt. Figure 4.7 shows the relative mean intensity of phosphorylation within the 
MS screen of the proteins taken for validation.  
 
Table 4.4. Phosphoproteins identified in MS screen and chosen for 
validation 
Accession 
Number 
Protein Phosphosite Significance 
Negatively regulated upon inhibition 
RS6_MOUSE 40S ribosomal protein 
S6 
p-Ser236 Akt substrate 
NDRG1_MOUSE NDRG1 p-Ser330 SGK1 
substrate 
AKTS1_MOUSE Proline-rich AKT1 
substrate 1 
p-Thr247 Akt substrate 
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The proteins listed in Table 4.4 all have commercially available antibodies 
targeted to the phosphorylation event identified in the MS screen, which was a 
limiting factor in choosing candidates for validation. It would have been 
preferable for more phosphorylation events to be studied, and for these to cover 
all categories, but unfortunately this was not possible due to a lack of available 
biochemical tools such as protein- and phosphosite-specific antibodies.  
Our next step was to probe by western blot the relative levels of 
phosphorylation of the candidates. 4T1 cells were treated in the same way as in 
the MS screen, and then subjected to western blot analysis, representative blots 
are shown in Figure 4.10. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10. Validation of phosphorylation events categorised as being regulated by 
p110α but not p110β. 4T1 cells were starved for 18 h in 0% serum, followed by a 2 h 
incubation without or with inhibitor. Cells were then left untreated (S) or stimulated with 0.5% 
serum without (D) or with inhibitor (A=A66, T=TGX221) for 30 min, and subjected to WB 
analysis with antibodies to the indicated proteins. Representative blots are shown. Vinculin was 
used as a loading control. 
 
  Serum Starved  
           0.5% FBS 
 DMSO  DMSO   A66   TGX221 Inhibitor 
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The results show that for the phosphorylation events under investigation which 
decrease upon PI3K isoform-inhibition, the same pattern is observed by 
western blot as in the MS screen. Each of the phosphorylation sites of 40S 
ribosomal protein S6, NDRG1, and AKTS1 are observed to strongly reduce 
upon inhibition of p110α, but not p110β. This confirms a PI3K isoform-specific 
role for p110α in the regulation of these proteins, which likely extends to others. 
4.4. Comparison with other cell lines 
After observing differences in the signalling of p110α and p110β in 4T1 cells, 
we decided to test other breast cancer cell lines to test whether or not these 
findings would be specific to 4T1 cells. We chose a panel of breast cancer cell 
lines which had previously shown similar phenotypes to 4T1 cells upon class I 
PI3K inhibition (Dr Taboubi – unpublished). These cell lines are listed in Table 
4.5, along with genotypes related to the PI3K pathway and some other genes 
important in breast cancer cell biology.  
 
Table 4.5. Breast cancer cell lines chosen for comparison with 4T1 
Cell line PIK3CA  PTEN p53 ERBB2 Oestrogen 
Receptor 
4T1 WT Positive Negative   
MCF-7 E545K Positive Positive Negative Positive 
MDA-MB-
231 
WT Positive Negative Negative Negative 
MDA-MB-
453 
H1047R Positive Negative Positive Negative 
 
 
Each cell line was treated in the same way as the 4T1 cells prior to the MS 
screen (Fig. 4.1) and validation studies (Fig. 4.10), and subjected to analysis by 
western blot. We probed for the same proteins and phosphorylation events as in 
Fig. 4.10, and representative blots are shown in Fig. 4.11 (and summarised in 
Table 4.6.). 
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It is clear that the overall 4T1 phosphorylation signature of the three proteins 
tested is not replicated in any of the three other cell lines examined. Indeed 
while as in 4T1 cells phosphorylation of NDRG1 is greatly reduced upon p110α 
inhibition in both MCF7 and MDA-MB-231 cell lines, this is not the case with 
phosphorylation of PRAS40 any other cell line studied. Additionally, the 
reduction of phosphorylation of RS6 following inhibition of p110α seen in 4T1 
cells is not replicated any of the three cell lines. In fact the signalling profile of 
these three cell lines is more similar to each other than 4T1 cells. Of the cell 
lines we assessed, regulation of phosphorylation of AKTS1-Thr247 and RS6-
Ser236 is specific to p110α only in 4T1 cells, while regulation of NDRG1-Ser330 
is dependent on p110α in 4T1, MCF7 and MDA-MB-231 cells. 
 
Table 4.6. PI3K isoform-inhibition on phosphorylation events compared to 
4T1 cell line 
Cell line 4T1  MCF-7 MDA-MB-231 MDA-MB-453 
Compound 
Phosphosite 
A66 TGX221 A66 TGX221 A66 TGX221 A66 TGX221 
pNDRG1  –    – – – 
pPRAS40  – – – – – – – 
pS6  – – – – – – – 
(  ) = decrease, (–) = no change in phosphorylation relative to DMSO control
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Figure 4.11. Differences in signalling downstream of class IA PI3K isoforms in a panel of breast cancer cell lines. Cells were starved for 18 h in 0% 
serum, followed by a 2 h incubation with or without inhibitor. Cells were then left untreated or stimulated with 0.5% serum with or without inhibitor for 30 min, 
and subjected to WB analysis with the antibodies described. Representative blots are shown for the (A) MCF7 cell line, (B) MDA-MB-231 cell line and (C) 
MDA-MB-453 cell line. Vinculin was used as a loading control. 
 
     (A)                                                                                (B)                                                                         (C)  
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The genetic background of the panel of cell lines varies and is shown in Table 
4.5. In terms of PI3K-related signalling, all cells lines are positive for PTEN, 4T1 
and MDA-MB-231 have wild-type p110α, while the remaining two cell lines have 
oncogenic p110α mutants. The signature of each cell line is different and does 
not appear to correlate with PI3K pathway mutational status, and it is likely that 
other aberrations in these cell lines contribute to the observed signalling output. 
4.5. Discussion 
Alongside our examination of less well-studied aspects of p110α signalling, we 
wanted to compare its wider downstream signalling profile (of lipid and protein 
kinase activity) to that of the other ubiquitously expressed class I PI3K, p110β. 
While both PI3K isoforms are expressed across cell types, there is a growing 
body of evidence showing differential upstream regulation, and downstream 
signalling [24, 28, 31, 38]. p110α appears to be mainly activated by RTKs and 
Ras, while p110β has input from GPCRs and Rho GTPases. These differences 
in upstream signalling may go some way to account for the differences in 
cellular processes controlled by the two PI3K isoforms. This extends to 
differences in phenotypes observed within our laboratory after PI3K isoform 
inhibition in a 4T1 murine breast cancer cell model (unpublished data from our 
laboratory). 
Following activation of class IA PI3Ks, phosphorylation signalling cascades are 
initiated which involve transduction through effector kinases such as Akt. Other 
AGC kinases are also involved in relay of the PI3K signal, but these networks 
are less well-characterised than the Akt signalling node. 
Therefore, we decided to use a quantitative phosphoproteomic approach to 
interrogate the signalling pathways downstream of p110α and p110β in an 
unbiased and global manner using mass spectrometry and more traditional 
biochemical tools for validation of identified phosphorylation events. 
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4.5.1. Phosphoproteomic investigation of signalling downstream of 
p110α and p110β 
Building on previous experiments performed in our laboratory which observed 
different cell biological phenotypes upon p110α or p110β inhibition in 4T1 cells, 
we designed a strategy which would allow us to characterise the signalling 
pathways downstream of those class IA PI3K. We used the same conditions 
with which differential phenotypes were observed in 4T1 cells, and so compared 
serum-starved cells with cells which were stimulated with 0.5% serum, with or 
without inhibition of either p110α or p110β. Isoform inhibition was achieved with 
the specific inhibitors A66 (for p110α) and TGX221 (for p110β), reducing 
signalling from these isoforms and through the well-characterised PI3K effector 
Akt and other proteins. In this way, we hoped to match signalling profiles in 
terms of phosphorylation events with previously observed differential phenotypic 
outputs. Off-target effects of inhibitors on other kinases may occur and should 
be kept in mind when interpreting data, with validation by additional methods 
preferred. 
While there are imperfections in this model, we decided to use it because of its 
relation to the cancer context, and its interesting and differential biology upon 
p110α and p110β inhibition. Flaws will always exist in any cell line model, 
especially around questions as to the physiological relevance of the system 
being assessed. In this case, we were seeking to answer questions raised by 
specific observations from previous work, and so it was necessary to use the 
same system. The 4T1 cell line is of murine mammary gland in origin, and 
closely resembles human breast cancer progression in terms of growth and 
spontaneous metastatic spread to a number of sites, and so for these reasons 
is a model relevant to oncology, and also basic biology. 
The specificity of interaction for both A66 and TGX221 has been determined 
previously [167, 148], and both compounds have been shown to have highest 
efficacy against p110α and p110β respectively, out of the panels of kinases 
assayed. It is the case that efficacy and specificity of inhibition of these isoforms 
is analysed in the context of in vitro methodology and criteria defined in the 
pharmacological (often cell-free) assays, and other considerations must be 
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taken into account when analysing data from more complex systems such as 
ours. The use of a more intricate system such as our 4T1 cell model allows for 
the possibility of a wider range of interactions between the pharmacological 
compounds and the proteins, lipids, metabolites etc. that are present in the cell 
mixture. This in turn suggests that the inhibitors used may have characteristics 
(such as IC50) which are different to those analysed or derived while using 
simpler models, and so the possibility exists that concentrations which were 
used were not the optimal ones for the isoforms under study. 
It is also true that with a much greater number of kinases present in the 4T1 cell 
system compared to some pharmacological assays which have only a single 
kinase, off-target effects of the inhibitor may occur. There are more than 500 
kinases coded in the human genome, and it is possible that A66 and TGX221 
display some efficacy regarding the inhibition of some of these enzymes, and so 
it may be that regulation of some phosphorylation sites was in fact due to 
kinases other than p110α and p110β. It is also true that one specific 
phosphosite may have more than one parent kinase. These points should be 
kept in mind when interpreting data, and there is always a need for follow up 
work and subsequent validation. We therefore used complementary techniques 
to confirm some of our findings, and western blotting was able to strengthen the 
conclusions we reached; western blotting has among its advantages speed, 
ease and cost. Another option for validation is the knock-down of a protein of 
interest using siRNA targeted to the transcript product of a specific gene. This 
technique would be useful in confirming the specificity of the inhibitors and so 
similar results obtained while using inhibitors or siRNA would add weight to a 
specific claim. However no system or technique is without its disadvantages, 
and the use of siRNA might also elicit off-target effects in terms of knocking-
down other proteins which play some part in a specific pathway. Therefore 
caution must always be exercised when analysing data and drawing 
conclusions. 
Whereas in Chapter 3 we used a number of different concentrations of ATP so 
as to have an idea of reaction kinetics and identify dose-response relationships, 
in this investigation we decided to use a single concentration of each inhibitor. 
We reasoned that having a large number of replicates informs the validity of the 
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inhibition of a given phosphorylation event, but equally additional inhibitor 
concentrations would also be of benefit. The use of only one concentration 
means that we must be aware of false positives, but generally these should be 
able to be accounted for by analysing the replicates, and of course validation is 
always preferred. Were we to carry out this investigation again, the inclusion of 
an additional inhibitor concentration and use of three replicates would mean that 
the same resources may be distributed more effectively, although the success 
which we achieved with our validation studies does in part vindicate our 
approach. 
Using this model, we treated cells and subjected samples to processing in such 
a way as to maximise identification and quantification of phosphorylation 
events. We performed the experiment triplicate, and analysed each replicate 
twice by LC-MS, thereby having six replicates for each of the four conditions. In 
a similar manner to the experiments in Chapter 3, we used TiO2-based 
enrichment of phosphopeptides, and analysed them using label-free methods 
[191, 211]. Following LC-MS, we again used the freely available online Mascot 
tool to identify peptides present in our samples. The program PESCAL, 
developed in-house, was then used to quantify these phosphopeptides across 
all samples. 
4.5.1.1. General characterisation of phosphoproteomic data 
A total of 2121 phosphopeptides were identified and quantified, and we used 
heat maps and PCA to visualise the quantitative data generated. Heatmaps 
showed that different profiles of intensity of phosphorylation were observed, 
with some phosphorylation events showing similarities, and some differences, 
when comparing p110α- and p110β-inhibited samples.  
Following quantification, we defined arbitrary criteria to categorise 
phosphorylation events as mutually or differentially regulated. We defined 
events at being mutually regulated when there was a two-fold change in 
intensity (p<0.05) upon inhibition of each isoform versus DMSO control. As 
even small changes in the relative phosphorylation of a protein can induce an 
effect on, for example, localisation or activity of that protein, it may be argued 
that by placing a lower limit of a two-fold change is too stringent, but we chose 
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this criterion along with requiring a significance of p<0.05 to increase our 
chances of finding phosphorylation events which truly fitted into each category. 
We defined differentially regulated phosphorylation events as those with a two-
fold change in intensity (p<0.05) upon inhibition of one isoform compared to 
DMSO control, with an upper limit of a 1.5 fold-change in intensity upon 
inhibition of the other isoform compared to DMSO control. The upper limit of a 
fold change of 1.5 for an event following inhibition of “the second isoform” was 
set so as to categorise events which had a clear difference in intensity for 
inhibition of the two isoforms. A consequence of these criteria is that 
phosphorylation events which would, under less stringent criteria and perhaps 
physiologically, be considered to be in a different category instead fall into the 
“no difference” category. It may be the case that this approach limits false 
positives, but increases false negatives. However we wanted to be able to 
choose strong candidates to take forward for validation, and the success of the 
validation vindicates this approach. 
While phosphorylation events which decrease upon isoform-inhibition are likely 
under the direct positive control of a kinase, phosphorylation events which 
increase upon PI3K isoform-inhibition may be part of a feedback loop. 
Phosphopeptides in either category were of interest to us, although we thought 
it likely that the former may be easier to characterise. 
It is interesting to note the different profiles of intensity of phosphorylation which 
are observed between the categories. While phosphorylation events which are 
negatively regulated by both p110α and p110β, and those which are negatively 
regulated by only p110α show an intensity which increases from the starved to 
DMSO condition, the majority of those which are defined as being regulated by 
p110β only have an intensity which is already high in the starved condition and 
decreases to the DMSO control. This suggests a separation of the types of 
signalling which the two PI3K isoforms are involved in.  
A scenario can be considered in which p110α is the PI3K isoform primarily 
responsible for the acute response to stimuli such as those found in the fetal 
bovine serum used in this experiment, and p110β is the isoform responsible for 
low level continual tonic signalling necessary to sustain a cell. The experimental 
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design used serum starvation to remove stimulating factors and reduce the 
majority of signalling pathways down to a baseline level. Pathways responsive 
to stimuli like growth factors would therefore be at a low level and elevated upon 
addition of serum, and these contain the phosphorylation events which tend to 
be regulated by p110α alone or with p110β. Pathways necessary for tonic 
signalling would be high in the starved condition relative to the DMSO condition, 
and these tend to be regulated by p110β only. 
4.5.1.2. Biochemical consideration of motifs and kinases  
In contrast to the work carried out in Chapter 3, here we were not exclusively 
interested in substrates of PI3K protein kinase activity. These experiments 
focused on the inhibition of p110α and p110β and the effect on downstream 
signalling pathways, the majority of which are likely to be initiated by the lipid 
kinase function, and which will include multiple effector kinases. As outlined 
previously, kinases often phosphorylate residues in the context of a specific 
amino acid motif, such as Akt which targets the RxRxxpS/pT motif, or SGK 
which phosphorylates amino acids in a similar context [48]. We therefore 
decided to interrogate our database of phosphopeptides for the presence of 
common motifs. We first did this in a targeted manner, and looked for the Akt 
consensus motif amongst the sequences. The Akt motif was found in 13/38 
phosphorylation events we defined as being positively regulated by PI3K 
(phosphorylation decreased upon PI3K inhibition). It is important to remember 
that these phosphorylation events will be part of a signalling cascade, and so 
may not be phosphorylated by the primary effector of PI3K signalling, i.e. some 
will be targeted by kinases further downstream. It is interesting to note that only 
one of these phosphorylation events was from the p110β-regulated category.  
We then searched for common motifs within the dataset, the size of which we 
increased by including peptides which met our criteria for fold change, but had a 
significance of p>0.05. It could be argued that our stringent criteria mean that 
phosphorylation events will be missed from the relevant groups, but that those 
present in these groups are strong candidates and more likely to be 
successfully validated. For the question of motifs, it is reasonable to apply less 
stringent criteria because the success of the approach relies on larger numbers 
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of sequences being analysed and picking up patterns, and so in expanding the 
dataset by removing the p value requirement we increase our chances of 
finding relevant commonalities.  
We were able to pick out a number of common features from our increased sets 
of peptide sequences. At least a partial Akt motif (RxxS*) was again observed 
for a relatively higher proportion of phosphopeptides in the mutual or p110α-
only categories compared to the p110β-only category, however this was still 
only for a minority of phosphorylation events (mutual=13/67; p110α=9/66; 
p110β=7/76). Two other motifs were represented more widely in all categories: 
the S*P motif (common=24/67; p110α=15/66; p110β=32/76), and a motif 
characterised by prominence of acidic residues around the phosphosite 
(mutual=28/67; p110α=29/66; p110β=13/76). 
It has been reported the majority of serine/threonine kinases disfavour a protein 
substrate which contains a proline residue immediately to the C terminus of the 
phosphorylated residue, but that over a quarter of identified phosphorylation 
sites are S*P or T*P  [174]. The values which we observe are therefore roughly 
in keeping with other global studies. This motif has a higher relative 
representation for p110β-regulated than p110α-regulated phosphorylation 
events, while the opposite is true of acidic motifs. Proline-directed kinases 
include cyclin-dependent kinase-2 and casein kinase II; the latter displays a 
preference for acidic motifs [223]. It may be that these kinases or others are 
more heavily involved in transduction of p110α or p110β than previously 
appreciated.  
These findings may reflect a difference in the effector kinases downstream of 
p110α and p110β: it could be that p110α is more reliant on Akt (or SGK), while 
p110β has a different range of effectors. It is known that the upstream input to 
these kinases is different in terms of RTKs, GPCRs and small GTPases, and it 
is feasible that this somehow translates to differences downstream.  
4.5.1.3. Interpretation of data in a biological pathways context 
Another approach in looking for common features in datasets is to analyse 
connections between identified proteins. Therefore we mapped the interactions 
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for the proteins (rather than phosphorylation events themselves) within the 
same datasets used for our motif analysis by using the bio-informatic program 
STRING, which visually represents previously described interactions between 
proteins. We observed nodes which were present in all three categories 
(mutually regulated events, and those regulated only by p110α or p110β). 
These nodes, though made up of different phosphoproteins, represented 
transcription- and translation-related processes. These two hubs were the best 
represented in each dataset, with proteins involved in cell adhesion also forming 
nodes. The remainder of the components were diverse and unconnected.  
Transcription and translation are central to protein synthesis, and are vital 
cellular processes. It is well established that the PI3K-Akt-mTOR pathway is a 
significant driver in protein synthesis [79], and so it is not surprising that proteins 
regulated by each category have these nodes. It may be reasoned from our 
earlier conclusions that p110α could be producing this effect through Akt, while 
p110β may well be using an alternative pathway. 
It is not entirely unexpected that other nodes did not appear through the 
observation of more direct interactions. The assay we designed is one which 
characterises phosphorylation events, but phosphorylation events do not need 
to occur at each step of a signalling pathway. For instance a phosphorylation 
event X may occur, and Protein Y which binds this new phosphosite can be 
regulated spatially and temporally without itself being phosphorylated. Therefore 
while Protein Y is in fact regulated by our assay, it would not show in our 
screen. This diverse set of phosphorylation events, and pathways which they 
regulate, are therefore likely representative of the transduction of the PI3K 
signal from p110α or p110β.  
Unfortunately, we have not been able to relate the observed differences 
between p110α and p110β in terms of signalling pathways to the differential 
phenotypes seen by Dr Taboubi. We chose to explore PI3K signalling upon 
acute activation at early time points and for short periods, and it may be that 
longer time points or different stimuli are necessary to exactly replicate the 
conditions used by Dr Taboubi. 
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We note that we identified a similar proportion of phosphorylation events whose 
intensity was decreased, as those whose intensity increased. It may seem 
counterintuitive that inhibition of a kinase or signalling pathway results in an 
increase in a phosphorylation event, but the complexity of signalling networks 
which contain feedback loops and other regulatory elements helps to explain 
this [93]. The PI3K pathway is a prime example of such feedback events: 
mTORC1 exerts a negative influence over the pathway through a feedback 
loop, and studies which targeted it for inhibition in cancer models found 
hyperphosphorylation of Akt [224, 225]. It is therefore likely that many of the 
phosphorylation events which increase in intensity upon PI3K isoform-inhibition 
result from such feedback loops which impact on phosphorylation status 
through direct modulation of other kinases, mechanisms which prevent protein 
degradation, the activity of phosphatases or access to their phosphorylated 
substrate.  
4.5.2. Validation of phosphorylation events regulated in an isoform-
specific manner  
We identified a number of phosphorylation events which defined as mutually or 
differentially regulated in 4T1 cells by p110α and p110β, and decided to validate 
these by independent means. Western blotting has long been used to analyse 
abundance of proteins and post-translational modifications, and is a relatively 
fast, accurate, and inexpensive method using antibodies raised against a 
specific target. We therefore chose to use it to validate our phosphorylation 
sites of interest. Unfortunately not all candidates had suitable reagents for 
analysis by western blotting, which limited our potential choices in terms of 
targets picked for subsequent analysis. It would have been preferable to 
validate more targets across more categories (specifically to include mutually 
regulated and p110β-regulated phosphorylation events) than we were able to, 
especially in light of the success achieved with the phosphorylation events 
analysed. 
Based on the reagents available, we took three candidate phosphosites for 
validation: two of which are known components of the PI3K pathway, and a third 
which could also be a part of that network. These were RS6 and AKTS1, both 
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previously described direct targets of Akt, and NDRG1 which has been shown 
to be phosphorylated by SGK1. We used the same conditions and inhibitor 
treatments as described previously, however in this case we coupled the 
method to SDS-PAGE and western blot rather than LC-MS/MS. After probing 
for phosphorylation of each of these proteins, we observed the same patterns of 
phosphorylation for each candidate as in the MS screen, and the relative ratios 
of intensity of phosphorylation were also similar between the conditions. That is 
to say that phosphorylation of both all proteins is reduced much more strongly 
upon p110α inhibition compared to p110β, although there is some variability 
between the MS and western blot data. This is to be expected because of the 
differing sensitivities of the two techniques, but it is encouraging that the same 
general outcomes are observed.  
Direct phosphorylation of both RS6 and AKTS1 by Akt positively regulates 
protein synthesis. RS6 is a component of ribosomes, organelles which are 
responsible for translation. Its phosphorylation at Ser236 has been shown to be 
directed by Akt [87, 226], an event which activates the protein and hence 
promotes protein synthesis. AKTS1, also known as PRAS40, is a negative 
regulator of mTOR [60, 87]. The mTOR pathway positively regulates protein 
synthesis amongst other pathways, and phosphorylation of Thr247 on AKTS1 
by Akt promotes its binding to 14-3-3 and hence sequestration away from 
mTOR, thereby allowing activation of the mTOR pathway and protein synthesis 
[59, 60]. 
NDRG1 is a tumour suppressor involved in cell growth and differentiation. 
Ser330 of NDRG1 has previously been shown to be a direct target of SGK1, 
and phosphorylation primes NDRG1 for subsequent phosphorylation by GSK3 
[216].  
That inhibition of p110α has a greater effect on the phosphorylation of 
previously described Akt and SGK1 substrates than inhibition of p110β, and that 
it also appears to regulate more phosphorylation events with Akt/SGK1 motifs, 
are interesting findings. While it is known that p110α and p110β have 
differential signalling inputs, they both produce PIP3 and explanations for non-
redundant processes are not complete. The evidence which we put forward for 
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p110α relying more on Akt to transduce its signal could go some way to 
explaining the differences in the phenotypic outputs of the two isoforms. 
4.5.3. Cross species comparison of phosphorylation events 
regulated in an isoform-specific manner 
After validating in a 4T1 cell model a number of phosphorylation events from 
our MS screen by western blot, we proceeded to investigate the 
phosphorylation status of these events in a panel of other breast cancer cell 
models. These cell lines were used originally in experiments by Dr Taboubi 
which revealed differential phenotypes upon inhibition of p110α or p110β, and 
differ in the mutational status of several common oncogenes, including PIK3CA. 
We treated the panel of cell lines in the same way as during the validation of 
candidate phosphorylation events in the 4T1 cell line, and probed for the same 
phosphosites.  
Compared to 4T1 cells, we observed different signatures in terms of 
phosphorylation events analysed in the three human cell lines studied. While 
some significant similarities were observed with 4T1 cells, there were also clear 
differences, for instance phosphorylation of NDRG1 was significantly decreased 
upon inhibition of p110α but not p110β in MCF7 and MDA-MB-231 cells, while 
little difference was seen following inhibition of either isoform in MDA-MB-453 
cells. Indeed all other changes upon isoform-inhibition are much less striking 
than this effect on NDRG1, and it is clear that the phosphorylation of PRAS40 
and S6 is less dependent on p110α in these three cell lines than in 4T1 cells. It 
would be interesting to compare the effects of Akt inhibition on these 
phosphorylation events in light of these cell line-specificities, to determine 
whether or not they are Akt-dependent in 4T1 cells and if this dependence 
remains in other cell lines but is directed by something other than p110α. The 
variation observed between the cell lines may be in part accounted by the 
differences in species of origin, in that 4T1 cells are murine and the remaining 
three are derived from human breast tissue. However it is also interesting to 
note the differences in phosphorylation signatures observed between the 
human cell lines themselves. 
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It is challenging to account for these observations in terms of the genetics of the 
PI3K pathway; all four cell lines are positive for PTEN, and MCF7, MDA-MB-
231 and MDA-MB-453 have p110α that is oncogenic (E545K), wild-type, and 
oncogenic (H1047R) respectively, and the differences in phosphorylation 
signature to not display a clear pattern. It is likely that the variations are due to 
the interplay between these and other key signalling proteins, such as those 
listed in Table 4.5, though it would be necessary to characterise the pathways 
further to explore this hypothesis.  
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5. Discussion 
The PI3K pathway is central to both normal cellular and disease signalling. Its 
control over crucial cellular functions such as metabolism, growth and survival 
mean that a better understanding of this signalling pathway can contribute to 
our understanding of the cell in both health and disease. This project sought to 
investigate aspects of the PI3K pathway which are incompletely understood. 
Modern proteomic techniques provide opportunities to address questions which 
have until now proven difficult to answer by more traditional methods. They 
allow interrogation of the phosphoproteome of a given pathway, process or 
condition on a global scale. In an unbiased manner, these novel techniques 
allow the characterisation of both new and previously described relationships, 
as well as elucidation of quantitative data for thousands of phosphopeptides. 
We therefore used mass spectrometry-based phosphoproteomics to explore 
signalling pathways downstream of class I PI3K isoforms. 
The protein kinase activity of p110α was first reported over a decade ago, yet a 
comprehensive and unbiased assessment of its potential substrates has been 
lacking. We have used novel and unbiased quantitative phosphoproteomic 
techniques to globally examine targets of p110α protein kinase activity, and 
identified two potential novel substrates (Chapter 3).  
Another poorly understood aspect of PI3K signalling is the difference between 
downstream signalling of the p110α and p110β isoforms of PI3K. We applied a 
similar unbiased and quantitative approach to examine the phosphoproteomes 
of mouse 4T1 breast cancer cells after inhibition of either p110α or p110β. We 
found evidence of phosphopeptides which were mutually or exclusively 
controlled by p110α or p110β and were able to validate these findings by 
independent means. Furthermore, we showed that the control of these 
phosphorylation events varies between cell types (Chapter 4). 
5.1. Investigation into the protein kinase activity of p110α 
The work described in Chapter 3 aimed to identify novel substrates of the 
protein kinase activity of p110α using an unbiased quantitative MS-based 
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phosphoproteomic approach, after which we sought to validate candidate 
proteins by independent means.  
We performed in vitro kinase assays using radiolabelled ATP to monitor 
phosphorylation of p85α as a readout of p110α protein kinase activity. This 
allowed us to define the optimum conditions for robust p110α protein kinase 
activity for use in our MS-based screen. We observed robust p85α 
phosphorylation from our shortest time-point (1 min) in the presence of one or 
both of the cofactors Mg2+ and Mn2+.  
Employing a MEF cell lysate as a substrate for in vitro protein kinase assays 
with recombinant p110α/p85α protein, we used a time-point of 5 min to ensure 
good p110α protein kinase activity but also to also minimise non-specific 
phosphorylation events due to other protein kinases present In the sample. We 
included both Mg2+ and Mn2+ as cofactors, and were able to identify and 
quantify the resulting 641 phosphopeptides. This is a relatively low number 
when compared to previous experiments in our laboratory using Akt kinase, and 
suggests that the protein kinase activity of p110α is low, which could be inferred 
from the sparse number of published substrates in the literature. We were also 
unable to identify previously described p110α protein kinase substrates, though 
p85α was observed in pilot studies. Despite observing robust activation of 
p110α protein kinase activity in our radiometric in vitro kinase assays, the 
different conditions which were used when using a MEF cell lysate as a 
substrate may mean that the optimal conditions were not met. It would be of use 
to explore this future (discussed later). 
PCA and heatmaps based on all 641 phosphopeptides also suggested that the 
effect of the protein kinase activity of p110α in this context was minor, and that 
only a few phosphorylation events were modulated in the samples using 
recombinant p110α. Phosphorylation of a large number of peptides was also 
seen in the control samples (cell lysate without p110α kinase, or p110α and its 
specific inhibitor A66). This is interesting and unexpected. It could be argued 
that the high levels of phosphorylation present in the control samples is due to 
incomplete dephosphorylation before the in vitro kinase assay. However there is 
variability between the two sets of control samples and the recombinant p110α-
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treated samples, and since the substrate for all assays was the same MEF cell 
lysates, the same patterns of phosphorylation would be expected to be seen. It 
would be of benefit to have some of this starting material to reanalyse, but all 
was used for the initial MS assay. Since this is not the case the variability is not 
accounted for, though it should be acknowledged that incomplete 
dephosphorylation may play a part. Equally, kinases which are present in the 
cell lysate and which are more active or more potent than p110α may contribute 
to the high background phosphorylation. Though the same MEF cell lysate is 
used as a substrate, a different mixture of kinase-substrate interactions will 
occur in each sample, leading to the different observed phosphorylation events. 
It is likely that this, along with incomplete dephosphorylation, plays a role in the 
high and variable background phosphorylation. 
Following identification and quantification of these phosphopeptides, we next 
proceeded to define criteria to categorise proteins as potential p110α 
substrates. We reasoned that a true kinase-substrate interaction would see 
intensity of phosphorylation increase with ATP concentration in our assays. 
Therefore we defined criteria concerning this correlation to exclude 
phosphorylation events which did not see this positive trend of ATP 
concentration with phosphopeptide intensity in the p110α-treated samples. This 
relatively low stringency measure alongside manual verification of the profiles of 
candidates to ensure that the control samples did not see significant peptide 
phosphorylation, resulted in only two phosphopeptides being chosen as suitable 
for validation as p110α substrates, in agreement with the above proposition that 
our system observed weak p110α protein kinase activity. The candidate 
proteins were GRIA1, a membrane receptor; and FBX7, a protein involved in 
ubiquitylation.  
Following the classification of phosphosites, we moved on to use the available 
data of intensity of phosphorylation at a given ATP concentration to profile the 
two candidates based on reaction kinetics and efficiency of phosphorylation. We 
estimated affinity of the kinase-substrate interaction by using the three ATP 
concentration points present for each sample set (cell lysate only; recombinant 
p110α+A66; recombinant p110α), and we found p110α-GRIA1 to be the 
stronger partnership. In addition to this, we analysed the sequence homology of 
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the amino acid residues around the phosphosites of interest. A functional 
phosphosite will often be conserved across species, and we reasoned that 
sequence analysis might provide information as to the relevance of the site, with 
areas of primary protein structure which are superfluous to function being less 
likely to be evolutionarily conserved. By way of reference, the Ser608 residue of 
p85α which is phosphorylated by p110α has 100% conservation for the 30 
residue fragment surrounding it for the species which we looked at (mouse, 
human, rat, bull). We found the phosphorylations under analysis for GRIA1 to 
have strong (90%) homology across four analysed species, while 33% of 
residues were conserved for FBX7. 
We then proceeded to attempt to validate our two candidate proteins as p110α 
substrates by independent means. Ideally validation would take the form of in 
vitro kinase assays using recombinant p110α and [γ-32P]-ATP, and the protein 
of interest. Unfortunately neither candidate was available as a recombinant 
protein, and so we instead produced peptide fragments which included the 
phosphosites of interest for use as substrates in these kinase assays. Following 
incubation of p110α, peptide substrate and [γ-32P]-ATP, we then utilised SDS-
PAGE to separate, visualise and quantify peptides and phosphorylation. 
However due to the small molecular weight of the peptides and their migration 
close to the [γ-32P]-ATP used in the assay, this approach proved unsuccessful, 
as any phosphorylation present was masked by the large signal from the free 
[γ-32P]-ATP. Therefore we attempted validation using an alternative means, 
and employed scintillation counting which uses in vitro kinase assays performed 
in a similar manner, though is able to capture [γ-32P]-ATP bound to the 
peptides and discard unbound [γ-32P]-ATP, thereby theoretically allowing a 
“cleaner” quantification. Here, we observed incorporation of radiolabelled ATP 
into our peptides of interest as well as control p85α peptides, and the levels of 
incorporation decreased when using serine-to-alanine mutants, suggesting that 
our candidates may in fact be substrates of p110α. The relative levels of 
incorporation were however low, in keeping with the theory that p110α is a 
relatively weak protein kinase. 
In conclusion, we provided evidence for novel substrates of the protein kinase 
activity of p110α. However, we also suggest that this activity may be limited a) 
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in the context of this experiment due to investigation of the basal state and lack 
of stimulation, or b) more generally in a physiological setting. 
5.2. Investigation into differential p110α and p110β signalling in 
the mouse 4T1 breast cancer cell line model 
The work described in Chapter 4 aimed to compare the phosphoproteomes 
regulated by the p110α and p110β class IA isoforms of PI3K. With the goal of 
gaining insight in the remarkable differences in cell biological phenotypes 
observed upon inhibition of these PI3K isoforms in the 4T1 murine breast 
cancer cell line, we compared downstream signalling of p110α and p110β in an 
unbiased manner using MS-based phosphoproteomics. We used the same 
experimental design which produced differential phenotypes following isoform 
inhibition, and so limited ourselves in this respect. 
Comparing serum-starved cells with those which had been starved and 
stimulated, and those which had additionally been treated with inhibitors of 
p110α or p110β allowed us to identify mutually and differentially regulated 
phosphopeptides. We used the specific inhibitors A66 and TGX221 to inhibit 
p110α and p110β respectively, and analysed the signalling profiles in terms of 
phosphorylation events downstream of these isoforms. These inhibitors have 
been shown to be specific for the relevant isoforms through in vitro testing of 
panels of kinases, though the possibility exists that they exhibit off-target 
inhibition of other kinases in the more complex cell model which we employed. 
Therefore we moved to validate a number of our results and were successful, 
though these caveats must be kept in mind for the wider dataset. As mentioned 
previously, we followed an experimental design which had previously shown 
interesting results and so chose only one concentration for each inhibitor though 
it is possible that the same resources could have been distributed differently, for 
example by having two concentrations per inhibitor and three rather than six 
replicates.  
We defined arbitrary criteria to help us categories phosphopeptides as being 
downstream of either p110α, p110β, or both. It is desirable to have criteria 
which minimise false negatives and positives, and this is difficult to completely 
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achieve without modelling or attempts at validation. Using the criteria which we 
defined, we made the following main observations: 
(1) more phosphorylation events are differentially than mutually controlled. This 
is surprising given the similarities in upstream signalling and cellular processes 
controlled by the two PI3K isoforms. It is also interesting to note that 
phosphorylation of the previously characterised Akt substrates AKTS1 and 
ribosomal protein S6 appear to be under the control of p110α but not p110β, 
and that the phosphorylation events share a functional output and serve to 
promote protein synthesis. 
(2) many phosphorylation sites were found to be increased upon PI3K inhibition. 
It is possible that this is a consequence of the induction of feedback loops that 
turn off the initial pathways, a phenomenon frequently observed in the PI3K 
pathway. 
It was also interesting to note that phosphorylation sites which we defined as 
being positively regulated by both p110α and p110β, or by p110α alone, usually 
had low intensity of phosphorylation in the serum-starved state, high intensity in 
the serum+DMSO control, and low intensity after isoform inhibition. However 
those phosphopeptides which we defined as being positively regulated by 
p110β only usually displayed high intensity of phosphorylation in the serum-
starved basal state. This could be related to the suggestion that p110α is 
responsible for acute signalling and the response to stimuli, while p110β is 
involved in tonic signalling. 
Following categorisation, moved on to analyse the groups of phosphorylation 
sites. Due to the importance of sequence motifs for substrate recognition by 
kinases, we interrogated the primary sequences around our phosphorylation 
sites of interest for any signs of consensus. In a targeted analysis, we found the 
Akt motif in a third of all peptides which we defined as being positively regulated 
by our PI3K isoforms, though the majority of these came from phosphorylation 
events regulated by both p110α and p110β, or by p110α alone. This suggests a 
reliance of p110α on Akt for mediation of its signalling, whereas p110β perhaps 
relies on other signal transducers. 
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We then looked in an unbiased way for any motifs in the peptides within our 
categories, and found motifs associated with proline residues adjacent to the 
phosphosite, and phosphosites rich in acidic residues nearby. These types of 
motifs have been shown to be recognised by cyclin-dependent kinase 2 and 
casein kinase II respectively, and it may be that these kinases are important in 
PI3K signalling in this context.  
We next attempted to uncover links between the proteins in our categories in 
terms of function and mutual processes. Though the categories contain different 
phosphosites and proteins, similar processes were found each time, namely 
transcription, translation, and cell adhesion. It is unsurprising that these nodes 
were found as the importance of the PI3K-Akt-mTOR pathway here is well-
established.  
We then proceeded to take some candidate phosphorylation events for 
validation by independent methods. Western blotting has long been used as a 
relatively simple way of analysing protein expression and post-translational 
modifications, and it is frequently the first choice in terms of follow up for such 
studies. Unfortunately we were limited in terms of the number of candidates 
which we could validate due to a lack of antibodies to either the proteins or 
phosphosites of interest, and it would have been preferable to validate more 
candidates and across more categories. It could be the case that subsequent 
studies could use mass spectrometry as a tool to look for the phosphorylation of 
a specific protein in a targeted way, and hence a wider range of candidates 
could be assayed. 
Of the proteins which displayed a dependence on p110α in the MS screen, we 
used western blotting to successfully confirm the p110α-specific role in 
regulation of phosphorylation of the 40S ribosomal protein S6 (pSer256), 
AKTS1 (pThr257), and NDRG1 (pSer330) in 4T1 cells. The first two 
phosphorylation events are known to be under the control of PI3K, and promote 
protein synthesis. The validation of these substrates and the suggestion of 
p110α rather than p110β displaying a preference for Akt is in line with our motif 
analyses which imply a similar result. It may be that differential use of Akt is a 
means of non-redundant p110α/p110β signalling. 
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Having made novel observations in 4T1 cells, we next analysed the extent and 
profile of phosphorylation of the same panel of proteins in other breast cancer 
cell lines with different genetic backgrounds. We found that each cell line 
differed in terms of the dependence on p110 or p110β of phosphorylation of 
the proteins assessed, for reasons that are as yet unclear. This is remarkable, 
and points towards cell line-specific regulation of p110 and p110β signal 
transduction pathways. 
Unfortunately, we were unable to ascribe the original observations of Dr 
Taboubi of differential phenotypes following inhibition of p110α or p110β to 
specific phosphorylation events or defined pathways. While this is somewhat 
disappointing we have still explored the differences in downstream signalling of 
the two PI3K isoforms, and uncovered specific and general aspects of 
differential signalling, indicating a greater complexity of the PI3K pathway than 
previously appreciated.  
In summary, we have provided evidence of differential regulation of signalling 
pathways downstream of p110α and p110β. 
5.3. Implications of study and future directions 
Our objectives focused on two main parts: to characterise the protein kinase 
activity of the PI3K isoform p110, and to compare and contrast the signalling 
pathways downstream of p110 and p110β. 
Addressing the first point, our strategy of coupling an in vitro kinase assay to 
MS-based phosphoproteomic methods identified and quantified hundreds of 
phosphorylation events but it turned out to be challenging to ascribe these to 
selective activity of the kinase under study, namely p110 PI3K. Due to the 
relatively poor characterisation of p110α as a protein kinase, little is known 
about the upstream input that may be required to stimulate the activity of this 
kinase. This means that planning an experiment such as the one carried in 
Chapter 3 is not a trivial task, and there will always be an unknown element 
relating to whether or not the p110α protein kinase has been sufficiently 
activated. While it is likely that the conditions chosen for our in vitro kinase 
assay are the optimum for our scenario and this is supported by the data, it may 
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well be the case that there are additional requirements in order to observe 
phosphorylation of physiologically relevant substrates. For instance, stimuli 
such as growth factors may be necessary, or an association with membranes or 
scaffolds which induce or enhance the protein kinase activity of p110α, and 
further examination of optimal conditions could be carried out. 
It may however be possible to redesign the assay with different controls or 
comparisons, with the aim of making true p110α substrates more obvious within 
a dataset. The levels of background within the control samples should be as low 
as possible to help valid substrates stand out. This could be better achieved by 
adding steps with the aim of completely removing ATP, such as extra 
fractionation or purification of the cell extract, such as further size exclusion. 
Additionally, dephosphorylation of the cell lysate may benefit from the use of 
additional phosphatases or longer time points. 
Two controls are present in our MS-based assay: cell lysate only, and cell 
lysate plus recombinant p110α and its specific inhibitor A66. We used 
recombinant kinase-dead p110α in pilot experiments, but this was unavailable 
at the time the MS-based assay was performed. We instead used A66, but this 
is an added variable in our system. Were kinase-dead p110α available, it would 
be interesting to use it in future experiments. It can be challenging to achieve an 
experimental setup which optimally assays kinase activity, especially so with a 
protein kinase as poorly characterised as p110α. Improvements could be made 
learning from the experiments described here: an experimental redesign could 
also compare the full or scaled down version of the current assay, with a related 
variation such as one which altered the amount of recombinant kinase added 
rather than ATP concentration, or one which used enzymatically digested 
proteins as a substrate, such as described by Xue et al. [219]. In this setting, a 
redesign would mean that the two experiments complement and act as a 
validation for each other, but would also increase time taken and cost.  
We have provided evidence for novel substrates of the protein kinase activity of 
p110α – GRIA1 and FBX7. Estimation of reaction kinetics and analysis of the 
degree sequence conservation suggested GRIA1 to be a stronger candidate, or 
a stronger p110α substrate. While our options have been limited in terms of 
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validation of these substrates and attempts at validation hampered, it would still 
be of use to continue these efforts and examine the kinase-substrate 
relationship further. Attempts at validation with SDS-PAGE proved inconclusive, 
and the findings of in vitro assays with peptides do not rule out a valid 
interaction. 
Having the substrates available as recombinant proteins would be extremely 
valuable. Initial validation is more relevant when using full length recombinant 
proteins because protein secondary and tertiary structures can impact on a 
kinase-substrate interaction, and further investigation of the relationship is also 
aided. Though time and cost will be factors, it would be hugely beneficial to 
future experiments to produce these either commercially or in-house through 
e.g. bacterial or yeast protein expression systems. In vitro kinase assays using 
recombinant full length protein substrate in place of peptides would provide 
more evidence for a relationship, and these tools could be used alongside A66 
to analyse biochemical characteristics such as reaction stoichiometry and 
kinetics. Additionally, comparison of the extent of phosphorylation of these 
substrates using wild-type p110α or the E545K/H1047R oncogenic mutants as 
the kinase would also be interesting and informative. Looking much further 
ahead, raising specific antibodies to the proteins and phosphorylation sites of 
interest would be a useful exercise so that in vivo studies could be carried out 
which would enable questions around physiological relevance and upstream 
stimuli to be probed. 
As suggested previously, our results are in keeping with what may be inferred 
from the literature, in that the protein kinase activity of p110α is likely to be 
limited in a physiological setting. While the existence of p110α protein kinase 
activity has been previously established, it may be that this is dependent on a 
narrow set of as yet determined criteria and stimuli. 
To address our second aim, we used a 4T1 mouse breast cancer cell line 
model to compare the phosphoproteomes of p110α- or p110β-inhibited 
conditions, and found evidence of mutual and differential signalling.  
Based on motif analyses, as expected we found that Akt appears to play a role 
in a number of phosphorylation events downstream of both p110α and p110β, 
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but in neither case is it responsible for the majority of phosphorylations. We 
suggest that this is due to 1) some of these events being carried out at levels 
below the primary effector kinase of PI3K function and 2) other kinases such as 
SGK1 playing a role alongside Akt in transducing the PI3K signal. It would 
therefore be interesting to characterise these pathways more completely. Initial 
work has been done to validate some identified phosphorylation events, but lack 
of biochemical tools has meant that this was limited – in future it would be 
attractive to revisit these results. Were specific antibodies to the proteins and 
phosphorylation sites identified within our screen available, these would be 
valuable tools in validating our results more widely, and across more of our 
defined categories. The success of the validation which we carried out is a 
strong justification for continuing these efforts if the necessary tools become 
available. We focused our analysis on phosphorylation events which were 
positively regulated by PI3Ks, and it would also be worthwhile to investigate 
further phosphorylation events which are negatively regulated by PI3Ks, though 
extensive characterisation of these would likely be harder. 
The validation and analyses which we conducted stemmed from our initial 
approach of interrogating signalling pathways downstream of p110α and p110β 
in an untargeted manner. These analyses suggested that p110α signals 
through Akt more than p110β does, and so it would be interesting to revisit this 
area in a more objective manner. Akt-specific inhibitors exist, such as the 
compound MK-2206, and could be used in conjunction with PI3K isoform-
specific inhibitors to further dissect these pathways. 
Additionally, while we have identified and validated previously described Akt 
substrates as being differentially regulated by p110α and p110β, there remain 
many other Akt substrates which could be specifically assayed in a similar 
manner to those described in this chapter. For example phosphorylation of 
GSK3, Bad and TSC2 among others could be analysed, to examine whether or 
not specific pathways downstream of Akt are differentially regulated. 
Phosphorylation of proteins such as TSC2 and AKTS1 could be interrogated in 
parallel to look at the extent of functional redundancy in the system, as 
phosphorylation of either negatively impacts on the ability of the protein to 
inhibit mTOR.  
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Exploration of these networks in terms of effector kinases active downstream of 
p110α and p110β would also be a valuable prospect in order to better 
understand the extent to which Akt, SGK1 and other kinases transduce the 
signalling of individual PI3K isoforms, a task which would have additional 
benefits in a clinical setting with PI3K and Akt inhibitors in trials for various 
diseases.  
We were unable to assign specific phosphorylation events to the differential 
observed phenotypes which led to this study, but it would still be of benefit to 
continue efforts in this area. We chose a relatively short time point for inhibition 
of p110α or p110β which included serum starvation and a short stimulation, but 
this could be altered to mimic the longer time points at which the different 
phenotypes were seen. Such further experiments could obviously complement 
the current study, and it would be interesting to look at the phosphorylation of 
events identified in these experiments in such a context. 
An attractive future direction would be to analyse the differences in signalling of 
both p110α and p110β through Akt and other effector kinases, alongside p110δ 
and/or p110γ in an immunological background. Additionally, while we focused 
our attention on the 4T1 cell line specifically and on breast cancer cells in 
general, there are obvious questions as to whether or not these patterns of 
phosphorylation and phenotypes would be seen in other cell types. Our results 
have demonstrated the general principle that signalling downstream of p110α 
and p110β is likely to be more different than perhaps originally appreciated, and 
given specific examples of this divergence.  
5.4. Concluding remarks 
While the importance of the PI3K pathway in both normal and pathological 
cellular processes is well established, there remain a number of features of 
signalling which remain underexplored and unclear. We chose to specifically 
target two of these lesser-known aspects of PI3K pathway and characterise 
them further: namely the protein kinase activity of p110α, and the differences 
between the downstream signalling of the two ubiquitous class IA PI3K isoforms 
p110α and p110β. 
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To achieve our aims, we used mass spectrometry-based phosphoproteomics 
and employed these powerful tools to address fundamental questions in a way 
which has not previously been possible. We have proposed novel protein 
substrates of p110, and uncovered differences between signalling of p110α 
and p110β in terms of specific substrates and on a larger scale than perhaps 
previously appreciated. These experiments build on previous knowledge, and 
provide opportunities for further exploration. 
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Appendix 1 
Summary of phosphorylation events identified following in vitro p110α protein 
kinase assay (Chapter 3). 
 Relative mean phosphopeptide intensity 
Cell lysate, ATP] p110α /A66, ATP] p110α, ATP] 
Accession number Phosphopeptide identification 0 µM 50 µM  100 µM  0 µM 50 µM 100 µM 0 µM 50 µM 100 µM 
A2MP_MOUSE A2mp p-Y1018 (z= 3) 88.7 87.2 65.1 82.9 73.8 74.3 100.0 81.3 82.8 
AAA1_MOUSE AAA1 p-S5 p-S9 (z= 3) + Oxi 98.3 72.5 74.0 46.1 76.8 94.4 54.5 52.4 100.0 
ABCA2_MOUSE Abca2 p-T1173 p-S1177 (z= 3) 100.0 33.4 52.5 95.9 55.0 87.5 64.1 57.6 68.7 
ABCBA_MOUSE ABCBA p-S494 (z= 4) 100.0 7.3 64.2 76.3 48.7 47.6 21.2 13.2 71.8 
ABCD3_MOUSE Abcd3 p-T222 p-T245 (z= 3) + Oxi 69.8 72.6 93.5 92.0 63.5 100.0 83.6 64.2 62.8 
ABHGA_MOUSE Abhd16a p-S91 p-Y99 p-T102 (z= 5) 100.0 32.1 45.4 57.5 46.2 37.8 6.7 0.0 75.5 
ABI1_MOUSE Abi1 p-S183 (z= 2) 89.5 66.2 71.8 90.3 100.0 82.0 88.4 89.3 82.9 
ABI1_MOUSE Abi1 p-S183 (z= 3) 74.2 75.9 78.5 100.0 67.9 62.6 71.2 73.9 78.0 
ACADV_MOUSE Acadvl p-T348 (z= 3) + Oxi 87.0 73.2 54.9 100.0 62.5 37.5 65.3 21.9 65.7 
ACSF4_MOUSE Aasdh p-S1053 (z= 4) 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
ACTT3_MOUSE Actrt3 p-S2 p-Y4 (z= 3) + Oxi 14.8 31.7 66.6 23.3 19.5 43.3 55.4 100.0 36.8 
ADA17_MOUSE Adam17 p-S322 p-S330 (z= 4) + Oxi 59.3 71.3 82.2 100.0 54.9 66.4 67.8 41.9 65.2 
ADCY4_MOUSE Adcy4 p-T833 p-T835 (z= 4) 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
ADCY6_MOUSE Adcy6 p-T1029 p-T1054 (z= 5) + 
Oxi 
100.0 28.2 19.1 26.1 21.8 84.2 17.8 5.8 83.8 
ADCY7_MOUSE Adcy7 p-T176 p-T195 p-S207 (z= 5) 
+ Oxi 
100.0 71.7 76.3 84.7 50.7 77.3 26.9 17.9 52.4 
ADCY9_MOUSE ADCY9 p-S394 p-T404 (z= 3) 100.0 73.8 54.2 45.4 66.4 72.1 42.5 48.8 74.1 
ADCYA_MOUSE Adcy10 p-T161 (z= 4) 17.7 41.5 49.5 49.5 100.0 44.9 20.1 31.6 6.6 
AFAD_MOUSE Mllt4 p-S1182 (z= 3) 100.0 18.1 15.2 20.8 25.3 64.3 20.9 23.7 17.3 
AFF3_MOUSE Aff3 p-T585 p-T598 (z= 4) 100.0 85.3 78.6 77.9 74.1 64.6 35.2 44.5 57.4 
AKT3_MOUSE Akt3 p-S238 (z= 5) + Oxi 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
AL3A1_MOUSE Aldh3a1 p-S383 p-T387 p-T396 (z= 
4) + Oxi 
9.9 0.0 3.0 83.7 69.9 54.3 100.0 43.6 78.2 
ALDH2_MOUSE Aldh2 p-Y499 (z= 3) + Oxi 78.7 54.5 70.2 67.0 66.0 100.0 98.1 74.4 62.2 
ALEX_MOUSE Gnas p-T590 p-S591 (z= 4) 79.8 52.2 84.0 100.0 63.1 67.8 55.5 60.8 57.7 
AMER3_MOUSE Fam123c p-S141 (z= 3) 57.2 48.9 31.3 56.8 45.1 100.0 26.4 23.3 30.1 
AMGO1_MOUSE Amigo1 p-S480 p-T488 (z= 3) + Oxi 81.7 74.9 77.5 73.8 25.1 100.0 31.0 46.9 0.0 
ANK1_MOUSE Ank1 p-S1473 p-S1482 (z= 3) + Oxi 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
AP5B1_MOUSE Ap5b1 p-S19 p-S21 (z= 3) 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
APMAP_MOUSE Apmap p-T189 p-T205 (z= 4) + Oxi 96.3 100.0 81.3 88.5 82.2 81.9 64.2 62.3 72.0 
ARG33_MOUSE Arhgef33 p-T145 p-S148 p-S152 (z= 
7) + Oxi 
31.2 32.2 100.0 81.0 29.0 23.6 12.6 0.0 94.5 
ARGL1_MOUSE Arglu1 p-S75 (z= 2) 76.1 50.5 59.8 41.0 94.1 91.1 97.7 100.0 74.8 
ARHG6_MOUSE Arhgef6 p-S487 (z= 3) 62.9 68.4 94.1 75.8 79.1 65.4 100.0 75.2 75.8 
ARHL1_MOUSE Adprhl1 p-Y19 (z= 3) + Oxi 27.2 54.9 66.9 100.0 67.4 31.3 75.4 15.8 56.0 
ARX_MOUSE Arx p-S142 (z= 3) 87.6 47.4 83.3 100.0 48.8 99.3 72.6 62.6 39.8 
ASH2L_MOUSE Ash2l p-S270 p-S287 (z= 3) 63.4 65.7 76.4 93.6 75.6 96.3 100.0 61.2 62.7 
ASPD_MOUSE Aspdh p-S173 (z= 5) + Oxi 60.5 53.0 94.6 100.0 55.7 34.4 59.7 23.6 61.5 
ASXL2_MOUSE Asxl2 p-S590 (z= 3) 85.6 100.0 67.7 79.5 69.1 64.1 75.3 75.3 87.1 
AT2A1_MOUSE Atp2a1 p-T729 p-S731 p-S741 (z= 
3) 
32.2 54.5 39.3 32.3 68.6 100.0 47.2 61.5 60.3 
ATG4D_MOUSE Atg4d p-T312 (z= 3) 4.9 77.0 92.2 100.0 43.7 21.1 69.4 89.5 83.8 
ATPG_MOUSE Atp5c1 p-T122 (z= 4) 70.3 100.0 69.8 86.0 72.9 37.1 26.5 76.1 10.0 
BCOR_MOUSE Bcor p-S453 (z= 3) 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
BCORL_MOUSE Bcorl1 p-S657 (z= 4) 100.0 42.4 59.6 57.4 37.5 36.8 29.3 11.5 56.8 
BCR_MOUSE Bcr p-S113 (z= 4) 88.8 60.3 70.0 66.3 50.4 100.0 72.1 76.6 59.6 
BCR_MOUSE Bcr p-S122 (z= 3) 42.5 35.6 52.2 45.5 85.9 100.0 76.7 82.2 83.8 
BCR_MOUSE Bcr p-S124 (z= 4) 92.7 22.8 77.1 100.0 64.6 96.4 28.9 52.2 90.3 
BEGIN_MOUSE Begain p-S307 (z= 3) 80.6 0.0 11.5 35.5 20.2 67.7 37.8 24.6 100.0 
BICD2_MOUSE Bicd2 p-T393 (z= 3) 100.0 46.5 53.3 68.5 50.3 56.0 42.4 29.7 73.9 
BICR1_MOUSE Ccdc64 p-S390 p-S417 (z= 6) 66.7 100.0 68.9 88.8 0.0 0.0 64.2 65.3 0.0 
BIG1_MOUSE Arfgef1 p-T1130 (z= 3) 100.0 78.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
BPHL_MOUSE BPHL p-S139 p-Y155 (z= 4) 100.0 54.1 30.7 38.6 7.0 62.3 0.9 0.0 54.7 
BSSP4_MOUSE Prss22 p-S4 p-T34 p-S38 (z= 7) + 
Oxi 
23.4 100.0 26.4 25.5 4.9 9.7 0.0 0.0 30.6 
C1QL3_MOUSE C1ql3 p-Y35 p-T38 p-S42 p-T43 (z= 
4) 
76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
C209B_MOUSE Cd209b p-Y27 p-S28 p-S31 p-S32 
(z= 4) + Oxi 
76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
CAC1H_MOUSE Cacna1h p-S2326 (z= 6) + Oxi 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
CAH3_MOUSE CAH3 p-S85 (z= 2) + Oxi 89.7 68.5 47.2 61.0 59.4 60.9 100.0 50.5 77.9 
CAHD1_MOUSE Cachd1 p-T351 (z= 3) + Oxi 44.4 81.3 59.8 100.0 52.0 3.7 27.1 15.5 37.2 
CAN10_MOUSE CAN10 p-T494 p-S498 (z= 4) 98.9 100.0 86.9 75.2 78.0 78.0 41.9 44.5 74.9 
CAP1_MOUSE Cap1 p-T77 (z= 4) + Oxi 93.8 96.1 95.7 100.0 74.9 67.7 82.8 78.7 79.5 
CAPG_MOUSE Capg p-S131 (z= 3) 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
CARF_MOUSE Cdkn2aip p-S355 p-T356 p-S362 
(z= 3) 
11.0 39.8 39.2 45.4 75.5 38.6 47.2 73.8 100.0 
CASC3_MOUSE Casc3 p-S27 (z= 2) 73.4 59.8 46.2 51.2 89.7 89.1 78.3 100.0 87.0 
CBL_MOUSE Cbl p-S9 (z= 3) + Oxi 100.0 43.3 65.2 57.8 54.6 50.6 35.2 28.6 87.9 
CBPA3_MOUSE Cpa3 p-T302 p-S305 p-Y306 (z= 4) 
+ Oxi 
82.9 100.0 88.6 62.0 71.0 82.2 51.7 51.5 59.8 
CBS_MOUSE Cbs p-T138 p-Y160 (z= 4) + Oxi 0.1 100.0 80.8 69.5 0.1 0.1 0.1 0.1 0.1 
CBX6_MOUSE CBX6 p-T194 (z= 4) 91.7 100.0 57.2 89.8 63.0 31.7 61.2 71.4 75.5 
CC103_MOUSE Ccdc103 p-T203 (z= 5) + Oxi 17.3 100.0 54.1 16.7 11.9 15.2 0.0 0.0 48.6 
CC105_MOUSE Ccdc105 p-T374 (z= 2) + Oxi 72.0 80.5 69.2 25.9 99.0 78.0 100.0 58.4 68.3 
CC105_MOUSE Ccdc105 p-Y372 (z= 3) + Oxi 82.0 88.3 84.1 80.9 69.4 69.9 100.0 48.7 52.6 
CCD18_MOUSE CCD18 p-Y8 p-S19 p-S26 (z= 3) + 
Oxi 
53.3 100.0 78.8 60.9 53.3 86.9 46.3 53.5 54.9 
CCNC_MOUSE Ccnc p-Y76 p-S77 p-S95 (z= 4) + 
Oxi 
91.3 100.0 39.7 33.9 25.8 59.4 14.9 16.5 45.4 
CD021_MOUSE Cntnap1 p-S649 p-S663 (z= 3) 51.0 100.0 97.3 91.4 71.7 58.6 81.0 72.4 72.8 
CD158_MOUSE Ccdc158 p-S1054 p-T1057 (z= 4) 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
CD158_MOUSE Ccdc158 p-S219 p-T230 (z= 4) 69.0 54.0 79.6 100.0 0.0 46.0 52.4 33.8 0.0 
CD19_MOUSE Cd19 p-S477 p-S482 p-Y493 p-
Y501 (z= 5) + Oxi 
100.0 16.4 47.5 0.0 16.4 23.4 58.3 18.1 56.9 
CD2AP_MOUSE Cd2ap p-S434 p-T439 (z= 3) 63.3 85.8 100.0 93.8 88.9 92.1 60.9 99.4 41.5 
CD80_MOUSE Cd80 p-S146 (z= 4) 71.6 87.1 92.8 100.0 64.2 69.8 51.4 67.3 55.2 
CDK1_MOUSE Cdk1 p-Y15 (z= 2) 57.6 57.8 55.1 71.4 78.1 86.8 68.7 100.0 77.4 
CDK13_MOUSE Cdk13 p-S343 (z= 2) 0.0 27.9 41.1 45.6 100.0 64.1 58.1 67.3 55.3 
CDK18_MOUSE CDK18 p-T134 (z= 2) 57.6 57.8 55.1 71.4 78.1 86.8 68.7 100.0 77.4 
CDT1_MOUSE Cdt1 p-S328 (z= 4) + Oxi 57.2 48.0 21.0 0.0 0.0 10.9 44.5 68.2 100.0 
CDV3_MOUSE Cdv3 p-S214 (z= 3) 0.0 52.9 74.1 0.0 74.5 72.7 0.0 71.9 100.0 
CDV3_MOUSE Cdv3 p-Y213 (z= 3) 0.0 52.9 74.1 0.0 74.5 72.7 0.0 71.9 100.0 
CE034_MOUSE Tmem130 p-S154 p-S160 (z= 3) 100.0 9.6 25.5 47.2 84.9 34.7 6.7 9.4 27.3 
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CEA16_MOUSE Ceacam16 p-T327 p-T330 (z= 4) + 
Oxi 
98.2 8.3 23.5 31.5 51.4 70.7 3.5 0.0 100.0 
CEA18_MOUSE Ceacam18 p-S156 (z= 3) 100.0 51.3 0.0 0.0 52.7 71.9 63.1 56.1 60.1 
CELR3_MOUSE Celsr3 p-T1784 p-T1787 (z= 3) + 
Oxi 
68.6 100.0 77.5 66.8 34.0 61.1 7.4 5.7 97.0 
CENPB_MOUSE Cenpb p-T117 (z= 3) 20.4 32.6 100.0 41.3 7.4 29.2 72.0 65.0 90.0 
CEP85_MOUSE CEP85 p-S84 p-T87 p-T90 (z= 4) 74.0 63.8 57.7 52.7 51.9 23.5 100.0 45.1 72.7 
CF132_MOUSE Fgf17 p-S1098 (z= 4) + Oxi 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
CF132_MOUSE M21D2 p-T799 (z= 3) 100.0 74.5 53.9 79.8 56.8 72.4 54.1 35.8 54.6 
CHIP_MOUSE Stub1 p-S20 (z= 2) 63.1 57.0 67.5 55.5 100.0 86.4 79.2 97.4 95.6 
CHIP_MOUSE Stub1 p-S20 (z= 3) 82.1 72.5 75.8 100.0 83.3 66.6 60.9 61.2 79.9 
CHIP_MOUSE Stub1 p-S20 (z= 3) 69.5 80.7 96.2 100.0 64.7 82.1 79.2 96.1 76.6 
CHSP1_MOUSE Carhsp1 p-S33 (z= 2) 0.0 0.0 24.5 40.5 14.6 13.6 42.4 100.0 61.4 
CI172_MOUSE CI172 p-S571 p-S572 (z= 3) 71.7 59.8 70.3 71.5 77.6 78.0 100.0 48.0 69.9 
CJ088_MOUSE Myzap p-S174 (z= 4) 44.5 51.9 100.0 65.2 49.3 71.2 25.9 98.9 26.9 
CKP2L_MOUSE Ckap2l p-S225 p-T232 (z= 4) 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
CLC1B_MOUSE Clec1b p-S39 p-S40 p-Y60 (z= 4) + 
Oxi 
100.0 76.8 83.8 57.9 78.8 24.3 0.0 0.0 49.8 
CLCKA_MOUSE Clcnka p-T322 p-S323 p-Y327 p-
Y340 (z= 4) + Oxi 
80.1 70.3 66.1 61.9 68.1 33.8 100.0 54.3 81.2 
CLCN6_MOUSE Clcn6 p-T538 p-T568 (z= 4) + Oxi 100.0 27.0 0.0 25.6 0.0 60.6 0.0 0.0 0.0 
CLH_MOUSE Cltc p-S77 (z= 4) + Oxi 0.1 0.1 0.1 0.1 0.1 100.0 0.1 0.1 0.1 
CLUA1_MOUSE Cluap1 p-S308 p-S326 p-S334 (z= 
7) + Oxi 
99.0 0.1 0.1 77.8 100.0 0.1 0.1 0.1 0.1 
CM033_MOUSE CM033 p-S243 (z= 4) 100.0 46.5 46.7 33.1 6.9 13.7 0.0 17.0 16.8 
CMAH_MOUSE Cmah p-T398 p-T415 p-S417 (z= 3) 100.0 70.7 32.4 43.8 70.3 79.4 32.7 21.5 60.8 
CMLO5_MOUSE Cml5 p-Y198 p-T209 (z= 4) 100.0 65.2 73.9 53.1 61.3 77.1 26.6 19.8 14.2 
CN079_MOUSE Usp37 p-S284 (z= 2) 53.2 37.6 51.6 77.2 43.4 100.0 24.1 23.7 33.3 
CNDP2_MOUSE Cndp2 p-Y311 p-S324 (z= 4) 92.0 75.7 82.3 93.4 69.5 100.0 74.5 23.8 36.1 
CNN1_MOUSE Cnn1 p-Y261 (z= 2) 0.0 85.4 92.8 0.0 100.0 65.6 0.0 67.5 84.4 
CNN3_MOUSE Cnn3 p-Y261 (z= 2) 0.0 67.9 100.0 0.0 81.1 63.1 0.0 48.1 69.4 
CNO6L_MOUSE Cnot6l p-T129 p-S138 (z= 4) + Oxi 100.0 87.5 44.3 42.1 77.8 96.8 20.8 17.6 70.7 
CNTLN_MOUSE Cntln p-T624 p-T642 (z= 4) + Oxi 71.5 73.1 52.8 29.1 100.0 85.3 30.4 48.1 18.4 
CNTN2_MOUSE Cntn2 p-T80 p-S88 (z= 3) + Oxi 73.9 86.8 100.0 93.0 67.9 82.4 57.1 52.6 64.1 
CO4A2_MOUSE Col4a2 p-S1480 p-S1482 (z= 5) + 
Oxi 
6.0 0.0 0.0 0.0 12.0 100.0 0.0 0.0 0.0 
CO4A3_MOUSE Col4a3 p-T1348 (z= 5) + Oxi 100.0 0.0 0.0 0.0 0.0 51.1 0.0 0.0 0.0 
CO6A5_MOUSE Col6a5 p-T1235 p-S1251 p-Y1252 
(z= 5) 
100.0 86.1 81.4 82.7 91.3 89.7 46.7 85.0 88.3 
COBL_MOUSE Cobl p-S314 (z= 3) 62.1 80.6 100.0 90.8 87.6 91.3 55.1 95.0 38.4 
COFA1_MOUSE Col15a1 p-S1333 p-T1337 (z= 3) 78.2 84.2 90.1 100.0 67.7 74.1 98.5 62.0 60.3 
COG4_MOUSE Cog4 p-S468 p-S469 (z= 2) + Oxi 71.0 72.4 82.6 31.4 100.0 52.6 51.2 55.1 62.7 
COG4_MOUSE Cog4 p-S468 p-S469 (z= 3) + Oxi 83.7 100.0 80.6 89.1 75.5 43.9 57.6 63.0 63.8 
COKA1_MOUSE Col20a1 p-S809 p-S821 (z= 3) + Oxi 72.6 84.8 76.8 100.0 44.8 71.5 71.5 54.0 41.2 
COMT_MOUSE Comt p-S261 (z= 2) 54.0 84.7 81.3 91.5 74.5 69.7 84.4 100.0 87.9 
COOA1_MOUSE Col24a1 p-S1513 p-T1528 p-S1531 
(z= 7) + Oxi 
0.0 100.0 58.0 19.5 31.9 65.6 0.0 0.0 25.2 
COPG1_MOUSE COPG1 p-T135 (z= 4) + Oxi 60.9 65.1 66.6 100.0 76.6 64.1 55.5 61.7 71.8 
CP110_MOUSE Ccp110 p-S306 p-S309 (z= 5) + Oxi 0.0 57.4 100.0 53.1 34.5 0.0 0.0 0.0 0.0 
CRK_MOUSE Crk p-Y221 (z= 4) 93.0 32.3 54.8 50.0 35.2 100.0 36.0 22.6 67.2 
CRK_MOUSE Crk p-Y221 (z= 5) 50.8 22.4 49.2 23.7 63.2 100.0 43.6 49.4 33.6 
CRKL_MOUSE Crkl p-S197 (z= 3) 69.7 52.0 84.9 65.5 47.0 27.5 62.5 100.0 89.2 
CRKL_MOUSE Crkl p-T212 (z= 5) 20.4 61.2 69.4 100.0 57.5 37.5 58.7 57.9 73.1 
CRKL_MOUSE Crkl p-Y198 (z= 4) 60.6 61.6 83.1 97.6 77.5 48.9 83.1 67.7 100.0 
CS069_MOUSE Gm7092 p-S15 (z= 3) 50.1 50.3 100.0 50.0 33.9 16.6 93.7 19.9 51.2 
CTF8A_MOUSE Chtf8 p-T305 p-T309 (z= 4) 31.0 100.0 0.0 35.3 47.7 5.5 75.2 34.4 37.6 
CTNA1_MOUSE Ctnna1 p-S641 (z= 2) 55.1 54.8 53.4 30.1 62.6 68.0 55.9 100.0 68.9 
CTND2_MOUSE Ctnnd2 p-S1094 (z= 4) + Oxi 27.2 26.5 53.3 34.2 26.8 19.9 100.0 48.4 57.4 
CTR4_MOUSE Slc7a4 p-T548 (z= 3) + Oxi 80.0 100.0 21.5 18.8 21.7 40.1 12.2 8.2 15.5 
CTRO_MOUSE Cit p-S826 (z= 5) 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
CTRO_MOUSE Cit p-T1582 p-S1586 (z= 3) 75.4 83.8 67.3 100.0 77.1 82.0 71.7 65.0 43.2 
CYHR1_MOUSE Cyhr1 p-S168 p-S171 (z= 3) 100.0 31.1 20.9 33.2 31.6 45.3 34.6 32.3 12.3 
CYTSA_MOUSE Specc1l p-S33 p-S50 (z= 4) 68.8 57.1 71.0 100.0 0.0 60.3 0.0 42.0 42.6 
DBPA_MOUSE Csda p-S328 (z= 2) 0.0 12.2 19.5 0.0 76.7 78.6 0.0 64.9 100.0 
DBPA_MOUSE Csda p-S328 (z= 3) 0.0 40.0 58.5 0.0 97.4 62.2 0.0 91.8 100.0 
DCLK1_MOUSE Dclk1 p-S352 (z= 2) 0.0 27.2 38.1 0.0 100.0 92.4 0.0 72.8 59.9 
DDR1_MOUSE Ddr1 p-T3 p-T17 (z= 3) + Oxi 79.3 85.4 80.7 92.3 80.4 100.0 97.9 95.6 87.8 
DDX3Y_MOUSE Ddx3y p-S227 (z= 5) + Oxi 55.8 43.0 88.5 76.8 55.6 55.4 100.0 37.5 79.0 
DDX42_MOUSE Ddx42 p-T724 p-S725 p-S726 (z= 5) 
+ Oxi 
76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
DEND_MOUSE DEND p-S309 p-S318 p-S327 (z= 4) 90.2 71.4 74.4 100.0 65.6 79.6 94.6 52.2 63.1 
DEPD5_MOUSE DEPD5 p-S779 p-S780 p-S781 (z= 
3) + Oxi 
100.0 9.5 18.1 10.3 6.3 48.4 0.0 0.0 28.0 
DESP_MOUSE Dsp p-Y28 p-T31 p-Y32 p-S33 (z= 
3) + Oxi 
100.0 41.9 36.5 28.0 16.3 67.8 8.8 9.1 40.6 
DHI1_MOUSE Hsd11b1 p-T40 p-S55 (z= 3) 60.5 17.6 38.8 100.0 82.8 17.4 19.7 25.4 32.1 
DI3L1_MOUSE Dis3l p-T568 p-S569 p-Y570 (z= 4) 
+ Oxi 
70.8 0.0 28.7 19.8 100.0 0.0 25.6 41.8 79.3 
DIEXF_MOUSE Die f p-S350 (z= 3) 100.0 76.5 60.4 62.4 69.6 72.0 67.7 57.4 69.5 
DISP1_MOUSE Disp1 p-S18 p-T19 p-S20 (z= 7) + 
Oxi 
0.0 0.0 0.0 0.0 0.0 100.0 0.0 0.0 85.0 
DJC15_MOUSE DJC15 p-T8 (z= 3) + Oxi 82.0 100.0 77.3 64.0 59.9 72.6 89.9 84.6 71.8 
DKKL1_MOUSE Dkkl1 p-T167 (z= 3) 54.9 84.8 61.2 95.4 100.0 43.2 67.9 47.1 84.6 
DLGP2_MOUSE Dlgap2 p-S574 p-S584 p-T594 (z= 
5) 
16.0 42.2 26.3 100.0 33.8 6.6 4.1 0.0 30.5 
DMRT1_MOUSE Dmrt1 p-Y31 (z= 3) + Oxi 88.1 92.0 61.1 83.0 59.6 59.5 100.0 88.6 44.5 
DMWD_MOUSE Dmwd p-S645 p-S647 p-S653 (z= 3) 43.5 11.0 0.0 18.5 0.0 100.0 24.8 0.0 36.0 
DMXL2_MOUSE Dmxl2 p-S483 p-T488 (z= 3) + Oxi 100.0 48.1 42.9 17.2 55.6 35.7 25.3 34.2 49.0 
DNLI1_MOUSE Lig1 p-S49 (z= 2) 79.0 53.7 74.0 68.7 100.0 94.2 75.9 90.1 93.8 
DOCK1_MOUSE Dock1 p-T721 (z= 3) 45.5 56.7 56.2 45.0 60.9 63.3 50.6 100.0 70.3 
DOCK9_MOUSE Dock9 p-T1587 (z= 3) + Oxi 42.9 46.9 57.7 55.3 42.0 40.1 100.0 36.6 51.4 
DPOLZ_MOUSE Rev3l p-S1777 p-S1778 (z= 2) 63.2 84.4 88.1 100.0 67.7 81.7 82.5 78.7 80.4 
DPYL3_MOUSE Dpysl3 p-T524 (z= 3) 86.0 81.9 69.2 100.0 54.0 85.0 67.4 87.1 70.8 
DRD3_MOUSE Drd3 p-S331 (z= 3) + Oxi 95.7 74.9 69.4 82.8 100.0 72.3 87.9 99.2 68.7 
DSG1B_MOUSE DSG1B p-S979 p-S984 p-T1022 (z= 
4) + Oxi 
76.0 52.8 71.0 100.0 55.0 62.6 52.9 48.4 38.6 
DTNB_MOUSE Dtnb p-S131 (z= 3) + Oxi 100.0 51.9 66.8 66.9 46.3 56.3 38.6 29.7 82.0 
DUS7_MOUSE Dusp7 p-T49 p-T50 (z= 5) + Oxi 100.0 27.3 28.0 28.3 66.6 10.3 23.1 29.4 38.2 
E41L1_MOUSE Epb41l1 p-S407 (z= 3) 26.6 21.9 38.2 33.4 18.2 13.7 100.0 28.3 52.1 
EAA1_MOUSE Slc1a3 p-Y80 p-S82 p-S116 (z= 4) + 
Oxi 
100.0 4.5 31.2 27.5 0.0 19.2 11.0 9.6 0.0 
EAA3_MOUSE Slc1a1 p-S73 p-S74 (z= 5) + Oxi 56.1 49.8 42.5 61.7 49.8 35.0 2.4 0.0 100.0 
ECM29_MOUSE ECM29 p-T900 (z= 3) 76.5 70.3 65.2 80.5 82.1 100.0 76.1 83.2 70.4 
EDRF1_MOUSE Edrf1 p-S26 (z= 4) 100.0 26.8 0.0 0.0 0.0 0.0 0.0 0.0 26.6 
EF1D_MOUSE Eef1d p-S162 (z= 3) 0.0 52.4 100.0 0.0 91.6 59.9 0.0 58.0 96.9 
EIF3B_MOUSE Eif3b p-S120 (z= 3) 100.0 37.4 61.8 80.4 51.6 91.1 68.5 52.7 77.6 
EMAL6_MOUSE Eml6 p-T1462 p-T1473 p-S1479 (z= 
4) 
80.7 77.5 100.0 63.5 67.0 72.3 87.2 37.9 57.5 
EME1_MOUSE Eme1 p-S397 (z= 3) + Oxi 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
EMIL1_MOUSE EMIL1 p-S723 (z= 4) 92.5 31.5 28.4 100.0 69.9 30.6 14.9 0.0 25.7 
EPHX4_MOUSE Ephx4 p-S284 p-T294 (z= 6) + Oxi 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
ERAP1_MOUSE Erap1 p-T512 p-T514 (z= 4) 100.0 61.9 87.0 68.6 67.6 44.1 41.0 9.7 12.6 
ERG28_MOUSE ORF11 p-S16 p-S26 (z= 3) + Oxi 100.0 74.9 58.0 48.2 69.1 74.9 47.3 48.0 76.6 
ERLEC_MOUSE Erlec1 p-Y189 p-T197 p-S200 p-
Y213 (z= 4) + Oxi 
92.8 85.9 76.7 100.0 81.7 58.3 93.0 71.7 64.9 
ERR1_MOUSE Esrra p-S72 p-S73 p-Y91 (z= 4) 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
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EVI2A_MOUSE Evi2a p-S84 p-T85 p-S86 (z= 3) 81.4 64.7 66.8 100.0 87.9 69.9 57.0 50.8 38.1 
F1142_MOUSE F1142 p-S2 (z= 4) 72.4 70.8 79.4 100.0 82.6 63.3 52.7 57.6 67.1 
F178A_MOUSE Fam178a p-S21 (z= 3) 71.7 59.8 70.3 71.5 77.6 78.0 100.0 48.0 69.9 
F178A_MOUSE Fam178a p-S591 (z= 4) 42.4 67.8 63.1 100.0 13.4 82.8 26.6 12.6 32.7 
F187A_MOUSE Fam187a p-S150 (z= 4) 30.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 100.0 
F190A_MOUSE Fam190a p-S6 (z= 2) + Oxi 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
FA40A_MOUSE Fam40a p-S335 (z= 2) 38.9 47.7 42.6 45.0 75.2 75.8 71.1 100.0 56.0 
FA63B_MOUSE Fam63b p-Y280 (z= 5) + Oxi 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
FA83D_MOUSE Fam83d p-S411 p-T417 p-T419 (z= 
4) + Oxi 
83.5 75.5 63.4 85.0 64.0 42.9 100.0 71.0 52.1 
FA86A_MOUSE Fam86a p-S320 p-T330 p-S331 (z= 
3) 
53.4 45.6 68.6 75.3 52.2 100.0 67.4 51.0 66.2 
FAS_MOUSE Fasn p-S1879 p-Y1880 (z= 3) 76.6 79.6 100.0 89.1 73.0 41.5 34.0 71.5 55.6 
FAT2_MOUSE Fat2 p-Y529 (z= 3) 50.6 27.8 24.7 0.0 53.1 0.0 0.0 100.0 0.0 
FBLI1_MOUSE Fblim1 p-S193 (z= 3) 32.1 31.6 32.1 60.0 100.0 60.0 21.3 24.4 12.0 
FBLL1_MOUSE FBLL1 p-S268 p-S275 (z= 3) 83.7 100.0 80.6 87.9 75.5 43.9 57.6 63.0 63.8 
FBSP1_MOUSE Fbxo45 p-S33 p-S41 (z= 4) 100.0 50.8 59.6 51.7 61.6 59.6 32.6 9.3 21.2 
FBX16_MOUSE Fbxo16 p-T166 (z= 4) + Oxi 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
FBX7_MOUSE Fbxo7 p-S283 p-S294 (z= 4) 30.2 29.8 32.2 32.4 5.6 4.5 0.0 69.3 100.0 
FBXL5_MOUSE Fbxl5 p-S331 p-T334 p-S340 (z= 4) 100.0 62.9 73.3 79.4 51.0 51.6 32.1 15.7 62.6 
FCSD2_MOUSE FCSD2 p-Y524 p-S545 (z= 4) 100.0 75.9 53.0 49.1 51.8 52.8 11.7 35.7 24.5 
FEM1B_MOUSE FEM1B p-S40 (z= 2) 64.3 62.0 61.3 71.1 60.6 39.5 100.0 57.9 60.7 
FEM1B_MOUSE Fem1b p-Y34 (z= 2) 64.3 62.0 61.3 71.1 60.6 39.5 100.0 57.9 61.0 
FKB1A_MOUSE Fkbp1a p-S9 (z= 2) 74.7 63.6 76.0 98.8 96.9 55.7 100.0 98.6 91.0 
FLIP1_MOUSE Filip1 p-T1180 (z= 4) + Oxi 100.0 65.1 63.5 58.2 60.6 68.0 0.0 14.3 10.6 
FLNA_MOUSE Flna p-S1084 (z= 2) 65.4 51.7 55.6 98.0 90.0 100.0 75.1 84.1 88.4 
FLNA_MOUSE Flna p-S2128 (z= 2) 49.3 32.2 32.7 28.9 75.0 100.0 62.3 76.4 56.7 
FLNA_MOUSE Flna p-S2128 (z= 3) 66.1 36.5 56.0 61.7 51.7 100.0 70.3 60.3 42.3 
FLNA_MOUSE Flna p-S2180 (z= 2) 57.8 35.9 0.0 41.9 45.2 66.9 77.8 96.0 100.0 
FLNA_MOUSE Flna p-S2327 (z= 3) 67.1 37.1 37.4 45.1 49.5 100.0 58.8 62.2 61.9 
FLNB_MOUSE Flnb p-S2130 (z= 3) 100.0 43.2 50.7 64.2 70.4 74.0 98.0 54.6 66.5 
FLNB_MOUSE Flnb p-S2137 (z= 4) 100.0 0.0 35.5 74.6 0.0 49.5 57.1 36.1 25.4 
FLNC_MOUSE Flnc p-S2234 (z= 2) 0.0 0.0 16.6 0.0 77.9 24.8 0.0 84.0 100.0 
FLT3_MOUSE Flt3 p-S980 (z= 4) 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
FLVC2_MOUSE Flvcr2 p-T315 (z= 4) 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
FMN1_MOUSE Fmn1 p-T91 (z= 2) 39.5 27.4 40.3 45.8 20.1 27.4 100.0 22.1 26.6 
FMO5_MOUSE Fmo5 p-S508 p-T515 (z= 3) + Oxi 0.1 100.0 60.3 82.6 0.1 0.1 0.1 0.1 77.5 
FND3A_MOUSE Fndc3a p-T911 p-Y913 (z= 4) 38.7 100.0 77.6 50.8 23.8 29.1 40.1 0.0 41.1 
FOXP2_MOUSE Foxp2 p-S25 (z= 4) + Oxi 90.1 71.4 74.4 100.0 65.6 79.6 94.6 52.2 63.1 
FOXP2_MOUSE FOXP2 p-T7 (z= 3) + Oxi 51.1 50.3 58.7 42.8 63.3 100.0 82.3 53.3 81.4 
FRAS1_MOUSE Fras1 p-Y3442 p-Y3443 p-S3465 p-
S3468 (z= 5) 
63.9 67.7 58.8 61.9 51.5 27.7 100.0 55.7 74.6 
FREM2_MOUSE Frem2 p-S197 p-S218 (z= 4) 100.0 83.8 49.2 51.1 43.3 53.2 21.6 32.2 38.4 
FSIP2_MOUSE Fsip2 p-S4863 p-S4866 p-Y4878 
(z= 6) + Oxi 
92.2 100.0 0.0 47.7 62.3 74.5 0.0 34.0 82.3 
FSIP2_MOUSE Fsip2 p-Y3219 p-S3220 p-T3222 p-
S3223 (z= 4) + Oxi 
77.8 59.4 77.1 85.9 100.0 74.0 96.2 73.3 91.6 
FUMH_MOUSE FUMH p-T282 (z= 3) + Oxi 78.4 39.6 44.5 100.0 34.3 42.5 47.6 10.6 31.3 
GBB4_MOUSE Gnb4 p-T34 p-T47 (z= 3) 100.0 56.5 79.7 62.6 52.2 30.1 64.8 35.9 50.2 
GBRB3_MOUSE Gabrb3 p-Y168 p-Y182 p-T201 (z= 
4) 
83.5 75.0 63.4 85.0 64.0 42.9 100.0 71.0 52.3 
GBX1_MOUSE Gbx1 p-S59 p-S88 (z= 3) + Oxi 18.1 0.0 29.1 22.9 63.4 90.7 0.0 32.5 100.0 
GCNT3_MOUSE Gcnt3 p-Y297 p-S301 (z= 4) + Oxi 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 100.0 
GDF5_MOUSE GDF5 p-S128 p-S129 p-S136 (z= 3) 100.0 73.8 54.2 45.4 66.4 72.1 42.5 48.8 74.1 
GFRA3_MOUSE Gfra3 p-Y179 (z= 3) 41.6 0.0 0.0 0.0 0.0 100.0 0.0 0.0 0.0 
GIT1_MOUSE Git1 p-S419 p-S422 p-Y435 (z= 7) + 
Oxi 
20.3 0.0 30.0 30.7 100.0 0.0 0.0 0.0 69.4 
GLGB_MOUSE Gbe1 p-T220 (z= 2) 48.5 58.3 49.8 37.7 56.4 45.3 100.0 82.7 57.2 
GMPR1_MOUSE Gmpr p-T44 p-S46 p-T57 (z= 4) 67.2 32.7 91.8 100.0 63.4 66.5 83.9 39.1 46.2 
GNTK_MOUSE Idnk p-S13 p-S18 p-T19 (z= 3) 30.0 100.0 52.7 83.3 0.0 40.9 0.0 0.0 56.9 
GON4L_MOUSE Gon4l p-S1412 p-S1414 (z= 4) + 
Oxi 
100.0 36.3 24.9 0.0 0.0 0.0 0.0 0.0 0.0 
GP128_MOUSE Gpr128 p-S243 (z= 6) 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
GPAT1_MOUSE Gpam p-Y494 (z= 6) + Oxi 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
GPC5B_MOUSE Gprc5b p-T11 p-S25 p-S28 (z= 5) 94.6 96.1 70.5 100.0 58.9 35.9 37.6 34.8 35.8 
GPR82_MOUSE Gpr82 p-S300 (z= 3) 100.0 43.9 45.3 36.9 36.2 64.9 24.4 22.0 33.8 
GPR88_MOUSE Gpr88 p-S39 p-T46 p-S57 (z= 5) + 
Oxi 
52.5 12.2 37.4 34.9 54.9 94.0 45.8 48.4 100.0 
GRB10_MOUSE Grb10 p-S503 p-S508 (z= 4) + Oxi 76.2 71.5 72.9 100.0 78.2 66.1 53.2 69.1 80.4 
GREB1_MOUSE GREB1 p-S293 p-S295 p-S309 (z= 
3) 
77.4 100.0 83.9 0.0 62.7 79.7 91.6 78.9 9.9 
GRIA1_MOUSE Gria1 p-S873 p-S881 (z= 3) 9.5 23.4 24.2 16.0 23.0 14.4 9.9 100.0 74.4 
GRIN1_MOUSE Gprin1 p-T493 p-S519 (z= 3) 21.7 60.3 60.9 71.1 64.5 59.9 37.6 58.5 100.0 
GRIN1_MOUSE Gprin1 p-T569 (z= 4) 91.9 100.0 73.4 88.3 0.0 0.0 0.0 0.0 0.0 
GSDA3_MOUSE Gsdma3 p-T324 p-Y344 (z= 6) + Oxi 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
GSDC2_MOUSE Gsdmc2 p-S195 (z= 3) 33.4 77.8 32.6 34.4 88.1 90.2 21.5 11.6 100.0 
GSK3A_MOUSE Gsk3a p-Y279 (z= 2) 75.2 45.4 66.6 74.1 100.0 98.0 84.8 83.0 82.2 
GTR7_MOUSE Slc2a7 p-S15 (z= 3) + Oxi 61.5 67.1 69.1 100.0 55.2 75.7 82.1 68.6 33.0 
GTR8_MOUSE Slc2a8 p-S99 p-T109 (z= 5) + Oxi 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
H12_MOUSE Hist1h1c p-S36 (z= 2) 36.1 44.1 49.8 64.1 77.8 38.5 82.7 65.1 100.0 
H12_MOUSE Hist1h1c p-S36 (z= 3) 39.4 19.1 37.1 63.5 82.3 37.1 43.3 59.4 100.0 
HELQ_MOUSE Helq p-T1007 p-S1012 (z= 3) + Oxi 57.0 12.1 36.2 100.0 66.5 10.9 18.3 9.2 33.7 
HES1_MOUSE Hes1 p-S12 p-T17 p-S20 (z= 3) + 
Oxi 
81.6 85.8 92.8 97.9 74.6 100.0 91.0 47.0 45.8 
HIRA_MOUSE Hira p-S79 (z= 4) + Oxi 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
HMCS2_MOUSE Hmgcs2 p-Y387 p-S392 p-S395 p-
S398 (z= 3) + Oxi 
100.0 85.6 46.1 42.2 98.7 60.8 87.3 70.1 68.9 
HNRPK_MOUSE Hnrnpk p-S214 (z= 3) 47.1 73.2 53.1 83.8 94.7 89.6 100.0 96.1 94.4 
HUWE1_MOUSE Huwe1 p-Y4234 (z= 4) 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
HXA10_MOUSE HXA10 p-S328 (z= 4) 100.0 68.8 58.8 85.0 57.6 57.1 59.4 47.1 55.2 
I2BP2_MOUSE Irf2bp2 p-S443 (z= 2) 74.4 75.4 91.0 100.0 65.4 69.1 82.1 62.4 57.4 
I2BP2_MOUSE Irf2bp2 p-S443 (z= 2) + Oxi 44.2 61.8 57.2 71.8 64.7 78.3 35.5 96.4 100.0 
IDHC_MOUSE Idh1 p-Y272 p-S278 p-S280 p-S287 
(z= 7) + Oxi 
0.0 0.0 0.0 99.1 0.0 0.0 0.0 0.0 100.0 
IF2B1_MOUSE Igf2bp1 p-S181 (z= 2) 63.0 60.0 68.0 77.2 67.7 88.9 69.8 100.0 74.9 
IF2B1_MOUSE Igf2bp1 p-S181 (z= 2) 49.0 50.3 72.2 68.7 52.1 97.5 63.0 100.0 64.7 
IF2B1_MOUSE Igf2bp1 p-S181 (z= 3) 65.2 100.0 93.6 66.6 76.7 66.9 84.0 61.4 87.9 
IF2M_MOUSE Mtif2 p-S180 (z= 3) 94.5 100.0 91.8 87.4 74.2 74.6 77.0 71.7 85.7 
IF4B_MOUSE Eif4b p-S504 (z= 2) 28.2 54.6 33.3 46.6 34.8 65.4 28.4 100.0 42.8 
IF4B_MOUSE Eif4b p-S504 (z= 4) 71.7 66.5 76.9 100.0 72.9 93.3 68.0 64.8 28.6 
IF4B_MOUSE Eif4b p-T506 (z= 3) 89.9 68.0 74.3 100.0 94.3 78.3 81.7 57.0 97.2 
IFI4_MOUSE Ifi204 p-S94 p-T106 p-T108 (z= 3) 53.2 100.0 54.6 55.1 88.5 82.2 59.4 50.6 52.7 
INCE_MOUSE Incenp p-T121 p-T124 p-S135 (z= 4) 49.1 68.1 97.4 57.3 15.4 100.0 35.6 37.7 72.5 
INF2_MOUSE Inf2 p-S327 (z= 3) 56.6 59.9 48.1 100.0 60.8 0.0 59.5 35.8 57.6 
INMT_MOUSE Inmt p-S213 p-Y216 (z= 2) 23.7 16.8 49.4 45.4 49.0 7.0 41.9 100.0 6.6 
INO1_MOUSE Isyna1 p-S331 (z= 4) + Oxi 100.0 50.2 39.5 55.9 37.5 34.9 15.7 0.0 40.8 
INP4B_MOUSE Inpp4b p-S425 (z= 4) 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
IPO4_MOUSE Ipo4 p-S973 (z= 3) 40.8 9.8 31.7 27.2 15.9 31.6 100.0 50.5 55.0 
IQCD_MOUSE Iqcd p-T24 p-T34 p-S40 (z= 4) 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
IRF2_MOUSE Irf2 p-Y272 p-T282 (z= 4) 0.1 100.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
JARD2_MOUSE Jarid2 p-S368 p-S376 (z= 4) 100.0 77.6 65.5 72.4 65.9 68.0 49.5 50.8 67.2 
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K0494_MOUSE K0494 p-T220 p-T221 p-S228 (z= 3) 
+ Oxi 
64.7 83.3 93.3 78.7 71.3 55.5 100.0 56.7 51.1 
K1468_MOUSE K1468 p-S243 (z= 3) 12.7 32.0 30.0 26.2 100.0 38.4 16.7 24.3 4.6 
K1958_MOUSE Dmkn p-T502 (z= 4) 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
K22E_MOUSE Krt2 p-S596 p-Y600 p-S620 p-S622 
(z= 6) 
0.0 100.0 91.8 20.9 20.7 40.7 0.0 0.0 22.1 
K22E_MOUSE Krt2 p-S596 p-Y600 p-Y614 p-S622 
(z= 5) 
0.0 100.0 73.5 16.0 9.5 22.8 0.0 0.0 21.7 
K22O_MOUSE Krt76 p-S559 p-S562 p-T564 (z= 6) 
+ Oxi 
0.1 88.6 0.1 0.1 0.1 0.1 0.1 0.1 100.0 
KAP2_MOUSE Prkar2a p-T101 (z= 3) 47.8 12.0 13.3 22.1 12.7 100.0 39.5 43.8 28.8 
KAPCA_MOUSE Prkaca p-S66 p-Y70 (z= 4) 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
KCD16_MOUSE KCD16 p-T208 (z= 4) 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
KCNQ5_MOUSE Kcnq5 p-S20 (z= 3) + Oxi 0.0 36.8 28.5 0.0 0.0 100.0 0.0 16.3 0.0 
KDM3A_MOUSE Kdm3a p-S994 (z= 4) 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
KDM4B_MOUSE Kdm4b p-S1027 p-S1029 (z= 4) 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
KDM5B_MOUSE Kdm5b p-T1138 (z= 4) + Oxi 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
KDM5B_MOUSE Kdm5b p-T203 (z= 2) 11.2 2.1 29.0 14.1 0.0 8.8 100.0 8.6 12.2 
KI26B_MOUSE Kif26b p-S1495 (z= 3) 35.9 48.0 47.6 66.1 68.0 34.0 54.1 93.5 100.0 
KIF7_MOUSE Kif7 p-S398 (z= 4) 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
KLC4_MOUSE Klc4 p-T465 p-T466 (z= 3) 58.2 81.2 73.1 92.7 78.2 47.9 100.0 81.5 79.3 
KNTC1_MOUSE Kntc1 p-T1304 p-S1308 (z= 3) 100.0 30.2 94.6 0.0 9.3 17.1 12.6 21.8 6.5 
KPCG_MOUSE Prkcg p-S192 (z= 4) + Oxi 13.3 100.0 72.4 41.4 0.0 4.6 0.0 0.0 15.1 
KRT83_MOUSE Krt83 p-T485 p-S489 (z= 3) 73.9 61.9 64.0 100.0 88.0 96.3 72.4 91.7 77.5 
LAMC3_MOUSE Lamc3 p-S4 p-S8 p-T12 (z= 3) + Oxi 0.0 100.0 0.0 0.0 0.0 0.0 0.0 60.6 0.0 
LC7L2_MOUSE Luc7l2 p-S2 p-T17 (z= 5) + Oxi 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
LIN41_MOUSE Trim71 p-S21 p-S42 (z= 3) 8.7 57.9 40.4 22.9 100.0 88.5 34.4 90.6 59.7 
LRBA_MOUSE Lrba p-T1955 p-S1974 (z= 4) 100.0 70.2 77.6 79.9 47.0 43.9 37.1 21.0 55.8 
LRC30_MOUSE LRC30 p-S113 p-S117 p-S136 (z= 
4) + Oxi 
93.0 22.9 78.1 100.0 65.6 99.1 31.8 52.4 90.6 
LRP6_MOUSE Lrp6 p-S1450 p-S1455 p-S1456 (z= 
4) + Oxi 
0.0 100.0 45.8 29.1 37.7 46.3 0.0 0.0 0.0 
LRRC7_MOUSE Lrrc7 p-S1428 (z= 3) 100.0 76.5 60.4 62.4 69.6 72.0 67.7 57.4 69.5 
LRRK1_MOUSE Lrrk1 p-T102 (z= 4) 47.1 100.0 74.9 49.4 38.2 29.8 42.7 31.0 46.8 
M4K1_MOUSE M4K1 p-S270 (z= 4) + Oxi 0.1 100.0 0.1 0.1 0.1 0.1 0.1 0.1 70.2 
MA7D1_MOUSE Map7d1 p-S401 (z= 2) 80.0 9.7 62.0 68.6 84.0 96.6 92.7 100.0 66.0 
MA7D1_MOUSE Map7d1 p-S401 (z= 2) 47.0 9.6 19.1 53.0 100.0 62.7 44.3 65.6 40.3 
MA7D2_MOUSE Map7d2 p-S235 (z= 4) 97.2 97.6 100.0 94.6 83.4 68.6 87.7 79.2 86.1 
MA7D2_MOUSE Map7d2 p-S4 (z= 3) + Oxi 50.5 100.0 72.9 76.2 55.6 30.0 66.4 68.1 51.3 
MACD1_MOUSE Macrod1 p-S248 (z= 5) 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
MAGI3_MOUSE Magi3 p-S1300 p-S1307 p-S1311 
(z= 4) 
0.1 0.1 100.0 0.1 0.1 0.1 0.1 0.1 0.1 
MAP2_MOUSE Map2 p-S333 (z= 3) 54.1 58.5 75.7 100.0 70.2 64.5 81.7 83.2 89.8 
MAP4_MOUSE Map4 p-S667 (z= 3) 76.5 70.3 65.2 80.5 82.1 100.0 76.1 83.2 70.4 
MAP4_MOUSE Map4 p-S667 (z= 3) 76.7 71.0 70.6 78.0 76.1 100.0 69.3 82.9 67.9 
MAP4_MOUSE Map4 p-S667 (z= 4) 55.9 72.7 76.2 93.5 69.8 100.0 72.5 74.9 58.6 
MAP6_MOUSE MAP6 p-S261 (z= 3) 85.5 98.2 100.0 89.8 70.9 90.4 62.2 80.0 68.4 
MARK3_MOUSE Mark3 p-T78 (z= 3) 24.1 26.2 56.5 40.6 7.3 16.5 100.0 10.6 27.3 
MBL2_MOUSE Mbl2 p-S137 (z= 2) 70.0 100.0 94.3 94.0 68.2 50.1 43.2 37.4 29.1 
MBOA5_MOUSE Lpcat3 p-S226 p-T227 (z= 4) + Oxi 92.5 66.3 82.4 100.0 56.7 59.7 64.2 47.4 36.8 
MBP_MOUSE Mbp p-S245 (z= 2) + Oxi 71.9 50.3 45.0 100.0 48.8 57.7 9.5 41.1 82.0 
MCAF2_MOUSE MCAF2 p-S32 p-T33 p-T41 (z= 3) 100.0 54.9 69.4 90.9 62.1 87.1 78.9 44.1 55.2 
MCH_MOUSE Pmch p-T5 p-S7 p-Y9 (z= 6) + Oxi 0.0 100.0 16.3 17.5 0.0 0.0 0.0 0.0 0.0 
MDR3_MOUSE Abcb4 p-T495 (z= 2) 68.3 64.3 100.0 50.8 93.7 29.0 62.8 22.9 10.7 
MED1_MOUSE Med1 p-S1149 p-T1151 (z= 2) + Oxi 69.8 68.5 69.6 59.7 76.0 79.1 100.0 53.9 62.7 
MED25_MOUSE Med25 p-S516 p-S517 (z= 3) + Oxi 75.7 79.9 79.7 74.0 39.9 43.2 100.0 52.8 70.0 
MED4_MOUSE Med4 p-S25 (z= 3) + Oxi 62.4 64.4 60.7 100.0 67.7 54.1 88.1 66.5 55.4 
MESD1_MOUSE Mesdc1 p-T10 (z= 3) + Oxi 21.0 37.7 43.4 43.5 23.6 48.0 44.5 100.0 35.6 
METH_MOUSE Mtr p-T1192 p-S1194 (z= 3) + Oxi 7.6 18.1 15.5 4.7 21.6 100.0 8.6 26.2 14.2 
MEX3B_MOUSE Mex3b p-S320 p-S321 p-Y332 (z= 
6) 
57.7 40.3 43.6 45.5 38.3 38.2 17.8 8.0 100.0 
MFGM_MOUSE Mfge8 p-S149 (z= 5) + Oxi 100.0 66.0 0.0 63.7 64.2 0.0 0.0 46.1 46.8 
MGAT3_MOUSE Mgat3 p-S522 p-S527 (z= 4) 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
MICLK_MOUSE MICLK p-S276 p-S281 (z= 3) 12.7 32.0 29.8 25.9 100.0 38.4 16.5 24.3 4.6 
MIER1_MOUSE Mier1 p-T234 (z= 3) 90.8 67.6 91.5 85.5 100.0 34.2 85.4 24.5 29.8 
MINK1_MOUSE Mink1 p-S903 (z= 3) 100.0 54.9 65.3 76.4 64.9 60.7 57.1 46.7 44.2 
MIPEP_MOUSE Mipep p-T177 (z= 4) 100.0 75.6 40.0 45.5 43.3 22.3 59.3 37.3 61.3 
MLF2_MOUSE Mlf2 p-S237 (z= 2) 86.8 81.9 86.2 97.5 78.0 87.1 98.5 100.0 89.0 
MLL3_MOUSE Mll3 p-S3108 (z= 4) + Oxi 82.5 61.7 59.7 100.0 64.1 73.3 60.7 23.5 38.9 
MLL3_MOUSE Mll3 p-Y1165 p-S1178 p-S1182 (z= 
3) 
83.1 100.0 85.2 71.9 80.7 88.1 78.1 81.3 58.6 
MOGT2_MOUSE Mogat2 p-S157 (z= 2) 100.0 20.9 26.4 61.2 60.4 70.6 85.1 18.1 43.1 
MOGT2_MOUSE Mogat2 p-Y154 p-S157 (z= 2) 100.0 36.6 54.4 86.8 85.6 96.0 77.3 78.3 75.0 
MOGT2_MOUSE Mogat2 p-Y154 p-S157 (z= 3) 100.0 38.4 52.7 76.5 40.7 61.9 48.2 50.3 55.2 
MON2_MOUSE MON2 p-T329 (z= 3) 100.0 69.4 58.1 87.6 88.3 85.1 80.4 69.0 93.8 
MRC1_MOUSE Mrc1 p-S1385 p-S1386 p-T1393 (z= 
4) + Oxi 
25.9 29.1 100.0 66.9 15.5 0.0 61.2 16.8 45.5 
MRF_MOUSE MRF p-T964 (z= 4) 97.9 100.0 65.4 89.6 64.2 32.1 65.7 58.4 67.3 
MTCH1_MOUSE Mtch1 p-S4 (z= 3) 18.9 22.0 75.9 55.9 84.8 52.7 92.2 44.3 100.0 
MTOR_MOUSE Mtor p-T484 p-S487 (z= 4) 100.0 79.9 64.1 76.5 67.7 67.4 50.5 51.4 68.1 
MTUS2_MOUSE Mtus2 p-T370 p-S373 p-S379 (z= 6) 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
MUM1_MOUSE Mum1 p-S581 p-T585 p-Y603 (z= 7) 
+ Oxi 
29.4 46.8 94.3 100.0 25.3 43.1 0.0 0.0 91.1 
MYCB2_MOUSE Mycbp2 p-S3694 p-S3699 p-S3702 
(z= 6) + Oxi 
76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
MYCT_MOUSE Slc2a13 p-T311 (z= 3) 47.3 100.0 60.9 76.1 58.2 8.4 51.5 64.3 44.8 
MYH9_MOUSE Myh9 p-S1943 (z= 2) 0.0 0.0 53.0 0.0 80.3 100.0 0.0 80.6 79.0 
MYH9_MOUSE Myh9 p-S1943 (z= 3) 9.3 35.8 67.3 11.6 57.9 100.0 6.3 46.4 92.2 
MYL1_MOUSE Myl1 p-T140 (z= 3) + Oxi 100.0 61.9 79.6 63.1 53.9 56.1 6.1 26.5 54.2 
MYLK_MOUSE Mylk p-S263 (z= 2) 27.4 94.0 75.9 89.5 63.1 41.2 80.8 34.1 100.0 
MYO10_MOUSE Myo10 p-S1761 (z= 3) 27.1 42.8 59.3 100.0 37.5 61.5 44.0 65.3 12.8 
MYO1H_MOUSE Myo1h p-T356 p-S364 p-S365 (z= 
3) 
41.1 38.7 100.0 53.7 16.0 53.4 86.6 68.6 83.2 
MYOF_MOUSE Myof p-T231 (z= 3) 72.8 51.3 45.4 70.4 52.8 100.0 14.4 18.9 77.8 
NAA16_MOUSE Naa16 p-T759 p-S760 (z= 3) 63.4 65.7 76.4 93.6 75.6 96.3 100.0 61.2 62.7 
NACAM_MOUSE Naca p-T1535 p-S1559 (z= 4) 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
NAGAB_MOUSE Naga p-T134 (z= 3) + Oxi 100.0 66.6 79.1 76.0 57.8 92.5 55.3 17.6 34.3 
NAR2A_MOUSE Art2a p-S259 (z= 3) 56.1 79.2 75.0 100.0 86.5 55.2 94.7 58.5 58.7 
NCOR1_MOUSE Ncor1 p-S1993 p-Y2008 (z= 3) + 
Oxi 
100.0 97.7 85.8 89.7 87.8 88.2 78.1 19.0 28.7 
NDKA_MOUSE Nme1 p-S120 (z= 2) 0.0 0.0 73.5 0.0 28.5 100.0 0.0 25.1 0.0 
NDKB_MOUSE Nme2 p-S120 (z= 2) 0.0 10.6 53.3 0.0 44.4 100.0 0.0 34.9 53.1 
NDKB_MOUSE Nme2 p-T94 (z= 3) 41.3 52.0 94.4 100.0 64.4 39.0 84.0 50.5 41.7 
NDUA4_MOUSE Ndufa4 p-T27 (z= 3) + Oxi 52.3 70.0 83.5 59.1 74.4 56.1 84.0 83.7 100.0 
NDUAB_MOUSE Ndufa11 p-T74 p-S77 (z= 4) + Oxi 0.0 42.9 41.4 52.1 100.0 0.0 13.7 48.4 86.6 
NEK3_MOUSE Nek3 p-T477 (z= 3) 100.0 5.7 0.0 54.6 12.8 0.0 75.7 13.8 16.7 
NEUA_MOUSE Cmas p-S11 p-S20 (z= 4) + Oxi 100.0 77.6 65.5 72.4 65.9 68.0 49.5 50.8 67.2 
NF1_MOUSE Nf1 p-S1142 p-T1147 p-Y1171 (z= 
4) + Oxi 
71.6 50.0 56.8 100.0 43.7 44.9 33.7 31.4 26.8 
NF2IP_MOUSE Nfatc2ip p-S81 (z= 3) 39.2 68.4 64.8 19.1 57.4 100.0 15.6 75.0 73.5 
NIPBL_MOUSE Nipbl p-S1301 p-T1307 p-T1308 (z= 
3) + Oxi 
72.3 64.2 73.1 85.9 66.1 82.5 100.0 53.4 78.5 
NMS_MOUSE Nms p-T81 (z= 4) + Oxi 100.0 82.9 93.1 85.0 37.3 80.9 48.8 41.9 52.6 
NPA1P_MOUSE Urb1 p-T25 (z= 3) 100.0 73.7 0.0 11.0 87.9 16.5 0.0 42.9 0.0 
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NPAS2_MOUSE Npas2 p-S607 p-S611 (z= 3) 67.4 58.0 66.9 100.0 64.0 33.5 77.9 47.0 57.4 
NPM_MOUSE Npm1 p-S70 (z= 4) 46.3 0.0 78.3 64.5 51.4 86.3 38.4 27.2 100.0 
NPM_MOUSE Npm1 p-S70 (z= 4) + Oxi 34.0 30.9 28.9 27.3 82.6 75.8 67.2 100.0 84.9 
NR2E3_MOUSE Nr2e3 p-S3 p-T4 (z= 3) 6.2 29.5 19.8 21.2 31.5 19.3 7.9 100.0 20.7 
NSD1_MOUSE Nsd1 p-T2255 p-S2262 (z= 3) 100.0 84.1 76.9 93.3 78.5 57.7 89.6 76.3 82.4 
NSE2_MOUSE Nsmce2 p-S6 (z= 5) 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
NSF1C_MOUSE Nsfl1c p-S165 (z= 2) 0.0 65.3 70.9 0.0 77.7 84.2 0.0 87.9 100.0 
NSF1C_MOUSE Nsfl1c p-Y167 (z= 2) 0.0 65.3 70.9 0.0 77.7 84.2 0.0 87.9 100.0 
NTAN1_MOUSE Ntan1 p-S252 p-S256 (z= 3) 50.4 77.8 47.4 76.0 53.2 31.1 100.0 30.1 69.8 
NTKL_MOUSE Scyl1 p-T275 (z= 3) 35.7 50.8 100.0 78.4 45.7 21.9 32.7 42.9 44.8 
NU2M_MOUSE Mtnd2 p-S245 p-T258 (z= 4) + Oxi 99.6 53.1 37.0 41.9 6.1 100.0 0.5 0.0 64.9 
OPHN1_MOUSE Ophn1 p-T699 (z= 3) 100.0 43.9 43.1 65.5 50.1 40.2 36.5 13.2 44.8 
OPHN1_MOUSE Ophn1 p-T780 (z= 2) 32.0 57.4 53.4 50.3 64.6 100.0 91.5 32.2 49.5 
OSTF1_MOUSE Ostf1 p-T47 (z= 4) + Oxi 87.1 100.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
OTOF_MOUSE Otof p-Y1214 p-S1224 (z= 4) 76.2 73.5 81.2 100.0 80.5 61.0 59.6 62.3 67.8 
PACR_MOUSE Adcyap1r1 p-S465 p-S475 (z= 4) 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
PAK6_MOUSE Pak6 p-T213 (z= 3) 100.0 54.3 57.5 14.0 0.0 24.4 0.0 0.0 34.4 
PAR3L_MOUSE Pard3b p-S350 p-S352 (z= 3) 100.0 11.1 17.9 21.5 0.6 1.3 17.3 0.0 1.1 
PAX4_MOUSE Pax4 p-S120 p-S122 p-S123 (z= 4) 71.7 77.4 52.8 34.3 100.0 81.3 30.4 48.1 18.4 
PCBP3_MOUSE PCBP3 p-T346 p-S351 p-Y355 (z= 
4) + Oxi 
100.0 84.9 78.9 89.0 93.3 42.8 70.9 70.2 52.0 
PCX1_MOUSE Pcnx p-S1836 p-S1837 (z= 3) 19.2 59.5 43.2 13.1 80.8 87.5 67.8 100.0 44.7 
PCX2_MOUSE Pcnxl2 p-S1831 (z= 3) 76.7 44.0 53.2 81.8 85.4 86.4 100.0 50.6 69.8 
PCX2_MOUSE Pcnxl2 p-T809 (z= 3) 100.0 48.0 42.4 46.7 54.5 26.5 34.0 23.6 41.8 
PCY1A_MOUSE Pcyt1a p-S203 (z= 4) + Oxi 0.1 100.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
PDE4C_MOUSE Pde4c p-T500 (z= 3) + Oxi 57.3 53.0 25.6 63.4 30.2 28.3 100.0 21.5 34.1 
PDGFC_MOUSE Pdgfc p-T51 (z= 3) 0.0 0.0 0.0 0.0 0.0 42.7 0.0 0.0 100.0 
PDLI5_MOUSE Pdlim5 p-S228 (z= 2) 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
PDLI5_MOUSE Pdlim5 p-S228 (z= 3) 0.0 0.0 0.0 0.0 89.2 55.0 0.0 50.5 100.0 
PEG3_MOUSE Peg3 p-S303 p-S309 p-S311 (z= 7) 
+ Oxi 
0.0 100.0 67.9 22.7 0.0 17.4 0.0 0.0 51.2 
PF21A_MOUSE Phf21a p-T424 p-T426 p-S427 (z= 
3) 
43.4 7.7 24.1 42.6 41.5 25.8 15.0 14.6 100.0 
PHC2_MOUSE Phc2 p-S828 (z= 4) + Oxi 55.7 80.6 77.3 100.0 41.4 34.5 67.5 62.3 57.0 
PIAS1_MOUSE Pias1 p-S428 p-S437 p-S438 (z= 6) 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
PIGV_MOUSE Pigv p-S192 (z= 4) 100.0 29.1 69.8 79.7 38.1 42.0 22.1 17.4 49.5 
PITM2_MOUSE Pitpnm2 p-S820 p-S823 (z= 3) 64.5 47.8 58.3 0.0 35.4 29.2 100.0 47.9 96.7 
PKHG5_MOUSE PKHG5 p-S255 p-S259 (z= 4) 99.1 66.3 73.8 100.0 61.1 52.0 61.5 50.2 41.9 
PLAP_MOUSE Plaa p-T481 p-S482 (z= 3) 40.8 73.3 81.5 98.7 76.6 100.0 41.8 59.3 37.3 
PLCG1_MOUSE Plcg1 p-T33 p-T36 (z= 5) + Oxi 100.0 17.5 39.9 37.8 39.7 62.6 41.8 31.2 72.0 
PLD2_MOUSE Pld2 p-Y75 p-S79 p-T83 p-T85 (z= 
6) 
76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
PLIN1_MOUSE Plin1 p-T370 (z= 4) 100.0 80.7 54.1 56.0 71.6 81.7 27.1 22.1 66.5 
PLPL1_MOUSE PLPL1 p-S433 p-T435 p-S446 (z= 
3) 
52.1 75.3 56.9 57.7 89.0 68.8 77.4 100.0 98.8 
POC5_MOUSE Poc5 p-S501 (z= 3) + Oxi 50.7 66.4 69.4 100.0 57.9 33.4 80.4 45.4 71.8 
POL2_MOUSE Pol p-T3 p-S27 (z= 4) + Oxi 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
POLK_MOUSE Polk p-S309 p-S323 (z= 3) + Oxi 23.5 35.9 34.2 60.3 56.4 36.3 36.3 100.0 32.8 
PON3_MOUSE Pon3 p-S220 (z= 4) 69.6 39.0 71.6 0.0 75.8 100.0 26.0 11.9 50.8 
PP14C_MOUSE Ppp1r14c p-S2 p-T5 p-S25 (z= 4) 35.1 8.5 6.5 100.0 43.5 7.9 19.2 12.0 15.2 
PPAC2_MOUSE Ppapdc2 p-S31 (z= 3) 43.4 86.4 74.0 78.8 93.7 33.2 92.0 95.4 100.0 
PPIC_MOUSE Ppic p-T116 (z= 3) 35.7 57.1 51.8 36.5 59.7 87.0 58.1 94.3 100.0 
PPR3F_MOUSE Ppp1r3f p-S201 p-S229 p-S232 (z= 
4) + Oxi 
94.1 100.0 53.6 84.2 73.8 28.8 97.3 65.3 56.6 
PPRC1_MOUSE Pprc1 p-S440 p-S442 (z= 3) 48.8 0.0 0.0 53.0 0.0 100.0 32.6 20.7 0.0 
PR8A8_MOUSE Prl8a8 p-S103 p-T106 (z= 3) 54.2 81.9 52.2 41.9 90.0 68.0 55.0 78.3 100.0 
PREP_MOUSE Pitrm1 p-T912 p-S921 (z= 4) 45.0 87.5 87.5 76.5 58.8 80.6 76.5 100.0 55.8 
PRGC1_MOUSE PRGC1 p-S312 p-S318 (z= 3) 82.0 100.0 74.7 85.4 65.8 38.4 81.5 49.4 42.3 
PROM2_MOUSE Prom2 p-T803 (z= 2) 66.5 81.4 77.7 53.3 64.9 63.7 100.0 66.2 39.8 
PRRT3_MOUSE Prrt3 p-S760 (z= 4) 100.0 65.9 23.8 29.5 71.0 32.5 39.7 66.6 92.0 
PSA_MOUSE Npepps p-Y301 (z= 4) 42.7 26.3 77.6 65.6 28.0 100.0 59.6 11.4 27.7 
PTBP2_MOUSE Ptbp2 p-S26 (z= 4) + Oxi 50.5 0.0 0.0 0.0 0.0 100.0 0.0 0.0 0.0 
PTBP3_MOUSE PTBP3 p-S445 p-T447 p-S451 (z= 
4) 
54.2 100.0 74.6 71.2 47.3 59.5 45.9 47.2 52.1 
PTGR1_MOUSE Ptgr1 p-S77 p-S97 p-T103 (z= 3) 98.3 66.8 36.0 58.2 85.7 29.9 100.0 77.0 57.5 
PTN3_MOUSE Ptpn3 p-S394 p-Y405 p-S421 (z= 3) 71.0 59.9 60.0 46.7 76.1 100.0 86.9 70.9 65.5 
PTPRK_MOUSE Ptprk p-T365 p-T381 (z= 3) 76.7 100.0 81.3 78.7 68.1 60.5 70.4 73.1 89.7 
PTPRS_MOUSE Ptprs p-Y205 p-S218 (z= 4) 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
R51A1_MOUSE Rad51ap1 p-S309 p-S311 (z= 3) 70.9 71.1 57.2 86.5 75.9 66.5 100.0 40.9 50.4 
RADIL_MOUSE Radil p-T728 (z= 3) 100.0 80.5 57.3 80.4 33.3 58.1 21.9 24.3 48.3 
RAI1_MOUSE Rai1 p-S1093 p-S1102 p-S1104 (z= 
6) + Oxi 
11.6 100.0 35.2 20.9 22.7 14.1 3.5 0.0 72.5 
RANB3_MOUSE Ranbp3 p-S40 (z= 3) 52.6 58.8 76.3 54.0 92.1 86.6 41.9 65.7 100.0 
RANB3_MOUSE Ranbp3 p-S40 (z= 3) 0.0 57.8 74.7 0.0 69.2 100.0 40.6 93.2 75.4 
RANB3_MOUSE Ranbp3 p-S40 (z= 4) 54.8 69.0 82.2 65.8 73.7 70.5 31.4 62.2 100.0 
RASF4_MOUSE RASF4 p-T200 p-T205 (z= 5) + Oxi 52.9 39.1 94.2 69.4 57.0 48.0 100.0 29.4 74.1 
RAVR1_MOUSE Raver1 p-S676 (z= 3) + Oxi 22.3 100.0 23.5 72.8 37.0 23.0 15.0 32.3 16.9 
RBBP5_MOUSE Rbbp5 p-S130 p-T136 (z= 3) + Oxi 74.1 74.0 85.5 100.0 87.0 47.2 89.1 35.7 43.3 
RBM40_MOUSE Rnpc3 p-S306 p-S314 (z= 4) + Oxi 84.1 100.0 68.2 41.2 69.4 48.5 19.3 25.8 38.0 
RC3H1_MOUSE Rc3h1 p-S315 (z= 5) + Oxi 100.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
RDH13_MOUSE Rdh13 p-S221 p-T224 (z= 4) 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
RED1_MOUSE Adarb1 p-S291 p-S306 (z= 4) 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
RERE_MOUSE Rere p-S1105 (z= 3) 65.4 47.7 74.5 91.0 73.4 100.0 69.7 50.8 49.6 
RGP1_MOUSE Rgp1 p-T139 (z= 3) 72.7 100.0 63.1 71.0 39.7 54.8 32.6 39.2 33.6 
RGRF2_MOUSE Rasgrf2 p-T1150 p-Y1152 (z= 4) + 
Oxi 
76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
RGS19_MOUSE Rgs19 p-S159 (z= 4) 29.4 100.0 70.4 67.5 58.0 60.9 62.5 45.2 56.7 
RGS3_MOUSE Rgs3 p-S699 (z= 3) 69.1 0.0 13.0 42.7 0.0 0.0 83.9 100.0 58.7 
RHBL1_MOUSE Rhbdl1 p-S220 p-T237 (z= 3) + Oxi 52.2 43.5 70.9 86.7 65.8 22.1 100.0 55.3 72.4 
RHBL2_MOUSE Rhbdl2 p-S242 p-S245 p-Y261 (z= 
4) 
58.4 66.5 47.9 48.1 49.1 23.1 100.0 70.1 45.1 
RHG35_MOUSE Arhgap35 p-S1085 (z= 4) + Oxi 30.4 49.7 55.7 36.0 41.4 58.0 50.9 100.0 84.8 
RHGBA_MOUSE Arhgap11a p-T908 (z= 3) 47.6 50.7 60.7 100.0 64.1 27.9 56.0 42.7 66.9 
RIMB3_MOUSE Rimbp3 p-T1402 p-S1404 p-Y1408 
(z= 7) 
27.4 100.0 96.8 72.2 0.0 31.5 0.0 0.0 98.4 
RIPK1_MOUSE Ripk1 p-S181 p-T183 (z= 2) 34.4 6.8 34.5 54.6 37.4 100.0 6.9 8.1 35.1 
RLA1_MOUSE Rplp1 p-S104 (z= 2) 11.0 62.3 100.0 6.9 91.6 76.7 16.0 77.2 96.9 
RLA1_MOUSE Rplp1 p-S104 (z= 2) + Oxi 2.4 55.3 69.5 0.0 83.5 50.4 12.1 100.0 91.0 
RLA2_MOUSE Rplp2 p-S105 (z= 2) 1.0 36.2 81.0 0.0 57.6 68.1 0.0 53.7 100.0 
RLA2_MOUSE Rplp2 p-S105 (z= 2) + Oxi 0.0 48.4 52.0 0.0 57.4 55.6 0.0 82.4 100.0 
RM36_MOUSE Mrpl36 p-S8 p-S12 p-S21 (z= 4) 39.8 89.7 95.8 90.6 76.3 88.3 66.4 100.0 25.9 
RMD3_MOUSE Fam82a2 p-S57 (z= 3) 55.1 25.5 24.6 34.3 29.0 26.3 100.0 20.7 32.8 
RN139_MOUSE Rnf139 p-Y449 p-Y450 p-Y462 (z= 
4) 
0.0 50.7 100.0 24.7 18.5 0.0 10.6 10.1 0.0 
RN169_MOUSE Rnf169 p-T8 (z= 3) 38.3 83.9 59.6 55.9 80.2 12.9 100.0 82.9 65.7 
RNF12_MOUSE Rlim p-T404 p-Y414 p-S417 p-S419 
(z= 6) + Oxi 
23.7 74.4 39.5 52.4 15.7 49.6 18.9 0.0 100.0 
ROA2_MOUSE Hnrnpa2b1 p-S324 p-S344 (z= 4) + 
Oxi 
0.1 0.2 0.1 100.0 0.1 0.1 0.1 0.1 0.1 
ROA3_MOUSE Hnrnpa3 p-S356 p-S367 p-Y374 (z= 
4) 
76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
ROS1_MOUSE Ros1 p-S1099 p-S1101 p-S1108 (z= 
5) + Oxi 
0.0 0.1 80.2 100.0 56.7 0.0 0.1 0.1 99.7 
RPA1_MOUSE Polr1a p-S450 (z= 3) 39.3 72.3 65.2 46.0 71.2 86.8 82.5 100.0 57.9 
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RPN2_MOUSE Rpn2 p-T489 (z= 3) 30.8 79.6 100.0 65.8 0.0 43.1 0.0 0.0 63.0 
RPP29_MOUSE Pop4 p-T122 (z= 7) 12.6 74.3 35.5 0.0 100.0 87.5 0.0 33.7 0.0 
RT22_MOUSE Mrps22 p-T106 (z= 5) + Oxi 0.0 100.0 60.2 0.0 0.0 0.0 0.0 0.0 95.3 
RTN4_MOUSE Rtn4 p-T171 (z= 3) 0.0 49.1 54.1 0.0 100.0 89.5 0.0 76.4 86.0 
RUSC1_MOUSE Rusc1 p-S829 p-S832 (z= 3) 83.7 62.4 59.3 44.2 54.9 100.0 22.0 26.6 75.1 
RXFP2_MOUSE Rxfp2 p-S265 (z= 4) 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
RXFP2_MOUSE Rxfp2 p-S706 p-T712 (z= 4) 0.1 0.1 100.0 0.1 0.1 0.1 0.1 0.1 0.1 
RYR1_MOUSE Ryr1 p-S3056 (z= 4) 49.4 51.6 57.4 43.2 69.3 59.3 50.5 60.3 100.0 
S12A7_MOUSE Slc12a7 p-S775 p-T790 (z= 5) + Oxi 75.5 100.0 0.0 0.0 65.0 0.0 0.0 57.0 0.0 
S1PR5_MOUSE S1pr5 p-T91 p-S96 p-T100 (z= 4) + 
Oxi 
24.6 21.2 36.3 100.0 37.3 6.6 67.0 22.3 0.0 
S35D3_MOUSE Slc35d3 p-Y36 p-T48 p-S49 p-S50 
(z= 4) 
100.0 0.0 0.0 8.1 0.0 72.6 13.5 0.0 47.9 
S39A5_MOUSE S39A5 p-T273 p-S276 p-T302 (z= 4) 
+ Oxi 
62.6 61.9 88.2 97.5 79.4 52.3 87.2 71.6 100.0 
S39AC_MOUSE Slc39a12 p-S346 (z= 3) + Oxi 80.1 100.0 58.3 94.7 100.0 47.5 92.6 85.6 89.9 
SAHH3_MOUSE Ahcyl2 p-T155 (z= 3) 27.7 52.2 55.3 47.2 50.5 33.4 42.9 100.0 88.9 
SAMD8_MOUSE Samd8 p-T143 p-S153 p-S155 (z= 
6) + Oxi 
40.3 38.2 70.7 69.2 38.1 22.5 100.0 36.2 39.5 
SARM1_MOUSE Sarm1 p-S574 (z= 3) 55.5 36.7 46.1 100.0 45.3 36.7 96.5 49.1 25.4 
SBK1_MOUSE Sbk1 p-T101 p-S103 p-S105 (z= 2) 59.2 69.8 86.8 65.9 77.6 56.6 100.0 63.2 57.5 
SC61B_MOUSE Sec61b p-S7 (z= 3) 100.0 71.1 64.7 100.0 47.3 63.3 49.1 67.4 51.4 
SCRT1_MOUSE Scrt1 p-S138 p-S166 (z= 3) 59.5 73.1 57.7 40.7 100.0 99.4 76.2 77.6 66.1 
SF01_MOUSE Sf1 p-S82 (z= 2) 57.9 49.1 65.7 88.0 86.9 85.6 68.8 80.6 100.0 
SF01_MOUSE Sf1 p-S82 (z= 2) 43.3 51.3 59.0 87.1 86.3 100.0 63.7 98.6 79.3 
SF01_MOUSE Sf1 p-S82 (z= 3) 61.9 69.8 73.8 90.2 75.7 100.0 74.3 95.5 78.5 
SFI1_MOUSE Sfi1 p-T414 p-S416 (z= 3) 100.0 0.0 0.0 0.0 0.0 0.0 0.0 56.1 0.0 
SFPQ_MOUSE Sfpq p-T468 (z= 3) 25.6 51.0 36.5 32.2 47.5 57.9 52.8 100.0 54.7 
SFR1_MOUSE Sfr1 p-S115 (z= 3) 99.9 62.5 74.9 100.0 96.6 94.8 73.9 68.3 71.6 
SFR1_MOUSE Sfr1 p-S67 (z= 2) 80.1 82.8 78.9 89.6 95.5 95.3 99.2 100.0 92.8 
SFR1_MOUSE Sfr1 p-S67 (z= 3) 68.7 84.6 81.2 100.0 65.6 76.4 70.5 74.2 64.1 
SGCE_MOUSE Sgce p-T315 p-S325 (z= 5) 100.0 83.1 68.5 82.1 64.0 71.5 43.3 39.9 63.5 
SHPRH_MOUSE Shprh p-T504 (z= 4) 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
SHSA7_MOUSE Shisa7 p-S248 p-S249 p-S250 (z= 
4) + Oxi 
42.8 75.3 89.3 100.0 52.0 78.2 38.1 50.0 31.0 
SIA8E_MOUSE St8sia5 p-Y236 p-T238 (z= 4) 100.0 62.9 73.3 79.4 51.0 51.6 32.1 15.7 62.8 
SIN3B_MOUSE Sin3b p-S261 p-S270 (z= 4) 0.0 0.0 0.0 0.0 0.0 0.0 100.0 0.0 0.0 
SKIT6_MOUSE Skint6 p-S524 p-S525 (z= 4) + Oxi 72.2 56.8 77.1 100.0 50.9 60.7 78.3 32.9 39.7 
SLIT3_MOUSE Slit3 p-S1273 p-T1286 p-S1289 (z= 
3) 
0.0 11.0 100.0 29.3 1.5 27.0 61.1 57.7 81.3 
SMK2A_MOUSE Smok2a p-T354 p-S358 p-T362 (z= 
3) 
100.0 25.3 51.4 46.5 43.3 51.4 58.4 8.8 26.0 
SN_MOUSE Siglec1 p-T1515 p-T1519 (z= 3) 72.9 100.0 92.8 85.6 78.4 57.6 93.6 84.0 65.0 
SNX13_MOUSE SNX13 p-Y115 p-Y120 p-S128 (z= 
3) 
65.7 100.0 84.5 61.3 66.0 83.6 49.0 56.2 65.1 
SO1A5_MOUSE Slco1a5 p-S525 (z= 3) + Oxi 100.0 32.4 15.9 37.4 30.0 18.9 4.6 0.0 26.3 
SODM_MOUSE Sod2 p-T136 p-S145 (z= 3) 39.3 72.3 65.2 46.0 71.2 86.8 82.5 100.0 57.9 
SPB12_MOUSE Serpinb12 p-S360 (z= 3) 36.5 44.2 100.0 68.0 15.6 17.7 23.4 6.5 5.4 
SPCS2_MOUSE Spcs2 p-S4 p-S6 p-S11 (z= 5) 52.8 63.6 100.0 30.5 35.3 47.6 21.9 25.1 34.0 
SPG20_MOUSE Spg20 p-S537 p-S548 p-T555 (z= 3) 71.1 71.2 71.2 40.8 90.7 100.0 95.5 77.1 61.7 
SPRE1_MOUSE Spred1 p-T7 p-S8 p-S13 (z= 4) + 
Oxi 
54.8 69.0 82.2 63.0 73.7 70.7 30.2 62.2 100.0 
SPY2_MOUSE Spry2 p-S111 p-T112 (z= 3) 100.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
SRB4D_MOUSE Srcrb4d p-S184 (z= 3) + Oxi 84.1 95.6 93.4 95.7 89.0 46.9 100.0 83.2 74.2 
SRF_MOUSE SRF p-S99 p-T136 (z= 4) + Oxi 100.0 57.8 74.1 79.3 50.6 52.5 31.4 15.2 60.3 
SRRM1_MOUSE Srrm1 p-S391 (z= 2) 64.8 49.0 50.4 65.3 80.5 100.0 84.3 81.5 46.8 
SRRM1_MOUSE Srrm1 p-S400 (z= 3) 32.8 13.3 39.2 78.7 100.0 72.5 88.4 93.5 34.8 
SRRM1_MOUSE Srrm1 p-S574 (z= 2) 48.2 46.0 49.6 58.3 89.9 100.0 70.3 76.1 67.4 
SRRM1_MOUSE Srrm1 p-S574 (z= 3) 73.0 86.8 79.7 87.9 75.1 100.0 87.9 98.0 68.5 
SRRM1_MOUSE Srrm1 p-S574 (z= 3) 52.5 59.0 59.7 69.2 71.2 100.0 73.7 76.1 54.7 
SRRM1_MOUSE Srrm1 p-S602 (z= 2) 61.4 48.4 46.8 50.2 50.9 100.0 50.0 70.5 98.1 
SRRM1_MOUSE Srrm1 p-S602 (z= 2) 3.5 0.0 44.8 56.4 50.3 51.0 64.2 100.0 89.2 
SRRM1_MOUSE Srrm1 p-S781 (z= 2) 86.4 66.1 60.8 66.1 71.1 100.0 84.4 93.7 79.4 
SRRM1_MOUSE Srrm1 p-S810 (z= 3) 51.1 50.8 47.4 56.6 78.2 100.0 91.7 42.8 0.0 
SRRM1_MOUSE Srrm1 p-T736 (z= 2) 74.5 48.4 57.3 70.5 97.1 100.0 80.6 94.6 97.7 
SRRM2_MOUSE Srrm2 p-S1068 (z= 2) 52.9 75.2 73.3 33.6 45.8 94.1 52.2 93.3 100.0 
SRRM2_MOUSE Srrm2 p-S1572 (z= 3) 100.0 51.7 87.4 85.5 64.3 99.7 75.7 82.3 100.0 
SRRM2_MOUSE Srrm2 p-S1608 (z= 3) 74.3 36.4 40.7 62.1 56.5 100.0 47.7 48.2 51.6 
SRRM2_MOUSE Srrm2 p-S1650 (z= 2) 100.0 57.1 53.8 66.9 44.7 98.8 69.1 75.6 54.9 
SRRM2_MOUSE Srrm2 p-S1669 (z= 2) 0.0 0.0 40.5 41.2 0.0 6.5 21.7 100.0 95.6 
SRRM2_MOUSE Srrm2 p-S1683 (z= 2) 60.6 51.1 67.0 70.9 79.8 100.0 76.5 96.9 63.4 
SRRM2_MOUSE Srrm2 p-S1683 (z= 3) 77.6 42.0 56.8 75.1 56.3 100.0 57.3 41.1 50.1 
SRRM2_MOUSE Srrm2 p-S1998 (z= 2) 74.8 37.2 60.1 80.8 82.7 100.0 88.8 78.0 73.3 
SRRM2_MOUSE Srrm2 p-S2535 (z= 2) 54.8 58.0 73.5 77.8 87.5 100.0 93.0 85.3 39.8 
SRRM2_MOUSE Srrm2 p-S778 (z= 2) 100.0 72.0 54.3 0.0 0.0 0.0 88.4 0.0 0.0 
SRRM2_MOUSE Srrm2 p-S945 (z= 3) + Oxi 39.5 53.3 47.2 66.3 50.8 96.5 29.2 95.9 100.0 
SRRM2_MOUSE Srrm2 p-S946 (z= 2) 100.0 58.6 71.1 79.5 45.6 53.4 66.3 32.9 67.4 
SRRM2_MOUSE Srrm2 p-S946 (z= 2) + Oxi 41.4 46.4 37.2 12.2 45.0 63.1 23.8 83.7 100.0 
SRRM2_MOUSE Srrm2 p-T1574 (z= 2) 18.4 19.7 30.8 38.4 100.0 80.7 44.3 76.7 100.0 
SRRM2_MOUSE Srrm2 p-T1654 (z= 2) 53.6 19.9 48.1 39.5 43.4 78.5 52.6 65.0 100.0 
SRRM2_MOUSE Srrm2 p-T2096 p-S2099 (z= 4) + 
Oxi 
0.1 80.5 100.0 0.1 0.1 0.1 0.1 0.1 78.2 
SRRM2_MOUSE Srrm2 p-T955 (z= 3) 95.5 75.7 77.0 100.0 54.5 52.4 70.3 44.2 61.6 
SRSF2_MOUSE Srsf2 p-S208 (z= 2) 64.8 45.7 58.4 69.2 93.5 100.0 70.3 75.6 82.4 
SRSF2_MOUSE Srsf2 p-S208 (z= 3) 95.1 65.6 80.1 100.0 53.1 96.0 68.3 66.5 83.6 
SRSF2_MOUSE Srsf2 p-S26 (z= 3) 100.0 39.5 31.3 76.8 26.4 96.6 58.1 57.1 36.5 
SRSF2_MOUSE Srsf2 p-T22 (z= 2) 59.2 20.6 18.9 35.1 47.9 100.0 48.8 60.3 52.1 
SSFA2_MOUSE Ssfa2 p-T742 (z= 4) 65.2 58.5 100.0 71.0 93.8 96.5 32.4 51.3 89.8 
ST32C_MOUSE Stk32c p-S353 (z= 4) + Oxi 0.0 100.0 0.0 0.0 57.7 0.0 0.0 0.0 0.0 
STAR9_MOUSE Stard9 p-T360 p-S362 p-T366 (z= 4) 
+ Oxi 
72.6 81.5 84.0 80.6 71.8 87.8 100.0 58.1 67.7 
STON2_MOUSE Ston2 p-S342 (z= 3) 88.4 65.8 100.0 54.6 51.8 77.8 89.7 28.1 55.8 
STON2_MOUSE Ston2 p-S759 p-S762 p-S766 (z= 4) 
+ Oxi 
76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
STRN3_MOUSE STRN3 p-S389 p-S395 p-S397 (z= 
3) + Oxi 
92.4 80.4 54.9 54.8 77.0 47.9 100.0 74.8 55.9 
STS_MOUSE Sts p-S99 p-T113 (z= 3) + Oxi 64.2 100.0 50.9 46.7 94.5 78.4 74.0 74.0 68.0 
STT3B_MOUSE Stt3b p-T519 (z= 4) 47.0 63.7 57.4 77.1 100.0 0.0 0.0 24.6 54.1 
SYAP1_MOUSE Syap1 p-S226 p-S239 (z= 3) 0.0 100.0 17.7 0.0 0.0 7.2 0.0 0.0 0.0 
SYFM_MOUSE Fars2 p-S33 p-S34 p-S49 (z= 3) 82.0 94.2 80.7 100.0 62.6 57.0 65.1 39.9 56.1 
SYLC_MOUSE Lars p-Y266 p-T267 (z= 3) 100.0 44.9 49.9 57.6 37.8 68.0 31.8 22.2 38.3 
SYNE2_MOUSE Syne2 p-S2300 p-T2310 (z= 4) 74.1 87.6 70.6 100.0 87.0 44.6 85.6 40.8 73.5 
SYNP2_MOUSE Synpo2 p-T525 (z= 4) + Oxi 28.0 61.3 32.4 0.0 0.0 0.0 0.0 0.0 100.0 
SYVC_MOUSE Vars p-S7 p-S15 (z= 4) 84.8 100.0 75.4 84.4 75.8 58.2 54.9 46.3 55.6 
T2FA_MOUSE T2FA p-S431 p-S433 (z= 3) 54.9 71.6 65.6 11.5 99.3 100.0 6.5 45.3 82.4 
T30A1_MOUSE Ttc30a1 p-T230 (z= 3) + Oxi 33.8 100.0 57.7 97.8 99.0 28.4 45.6 39.1 75.6 
TAF1C_MOUSE TAF1C p-T20 (z= 3) + Oxi 40.6 69.4 48.5 38.4 99.0 88.4 67.9 100.0 86.2 
TAF3_MOUSE Taf3 p-T384 p-T387 p-S391 (z= 3) 67.4 100.0 79.4 78.7 65.8 63.7 73.0 67.2 56.5 
TBC8B_MOUSE Tbc1d8b p-Y34 p-T43 p-S52 p-S56 
(z= 4) 
76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
TBD_MOUSE Tubd1 p-S397 (z= 3) 53.7 100.0 51.4 72.1 89.8 70.8 36.3 20.7 49.6 
TBD2B_MOUSE Tbc1d2b p-T171 (z= 2) 55.3 46.1 63.8 100.0 85.4 17.2 75.4 53.3 77.1 
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TC1D3_MOUSE Tcte3 p-T15 p-S18 (z= 3) 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
TCEA1_MOUSE Tcea1 p-T241 (z= 2) 80.2 90.9 82.1 100.0 75.0 62.0 89.3 78.7 73.1 
TCPG_MOUSE Cct3 p-S45 (z= 3) + Oxi 26.7 51.9 45.5 34.1 51.4 57.5 53.3 100.0 56.5 
TCPG_MOUSE Cct3 p-S45 (z= 3) + Oxi 69.7 76.2 75.6 74.8 69.8 83.7 100.0 67.7 62.8 
TDT_MOUSE Dntt p-S200 p-S207 (z= 4) 45.0 87.5 87.5 76.5 58.8 80.6 76.5 100.0 55.8 
TET2_MOUSE Tet2 p-Y1095 p-T1096 (z= 2) 15.4 0.0 0.0 0.0 0.0 100.0 0.0 0.0 0.0 
TEX14_MOUSE Tex14 p-S310 (z= 4) + Oxi 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
TEX14_MOUSE Tex14 p-T1248 (z= 4) 85.9 86.2 65.6 89.8 100.0 80.5 19.8 69.1 62.3 
TGT_MOUSE Qtrt1 p-S235 (z= 3) 74.9 70.2 73.9 80.8 88.9 78.4 92.4 87.6 100.0 
THOP1_MOUSE Thop1 p-S655 (z= 3) + Oxi 85.0 100.0 89.0 98.8 77.0 43.7 66.6 47.3 69.2 
THY1_MOUSE Thy1 p-S6 p-S12 p-S17 (z= 4) + Oxi 53.4 0.1 75.8 100.0 0.1 0.1 0.1 0.1 0.1 
TISD_MOUSE Zfp36l2 p-T9 p-S18 (z= 3) + Oxi 100.0 60.5 67.4 76.3 61.7 29.8 64.5 16.3 23.0 
TITIN_MOUSE Ttn p-S566 (z= 3) 100.0 37.2 58.7 64.8 61.7 60.1 38.6 30.8 76.2 
TITIN_MOUSE Ttn p-T16223 p-S16238 (z= 4) 73.7 62.8 73.2 81.4 56.7 19.8 100.0 68.7 28.9 
TITIN_MOUSE Ttn p-T32932 (z= 2) 74.0 94.8 92.9 99.5 75.5 93.8 79.8 100.0 81.3 
TITIN_MOUSE Ttn p-Y25882 (z= 3) 71.2 100.0 80.2 65.0 71.3 74.4 47.3 98.2 30.9 
TLN1_MOUSE Tln1 p-S1328 (z= 2) 71.9 75.2 66.1 74.6 78.7 97.9 80.0 100.0 63.6 
TLR3_MOUSE Tlr3 p-S315 p-S318 p-S323 (z= 4) 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
TLR9_MOUSE Tlr9 p-S710 p-S711 p-S713 (z= 3) 3.8 100.0 24.8 9.3 14.2 19.9 26.0 27.6 3.5 
TM135_MOUSE Tmem135 p-S232 (z= 4) + Oxi 100.0 75.2 88.8 76.0 71.9 89.5 41.3 32.5 91.3 
TM158_MOUSE Tmem158 p-T246 (z= 4) 0.1 100.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
TM158_MOUSE Tmem158 p-T246 (z= 5) 100.0 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.1 
TM245_MOUSE Tmem245 p-S12 (z= 2) 66.8 0.0 67.1 0.0 67.0 100.0 71.8 76.9 0.0 
TM63C_MOUSE Tmem63c p-S679 p-S682 (z= 4) 29.2 21.8 91.9 65.3 66.4 34.5 100.0 25.5 63.3 
TMM74_MOUSE Tmem74 p-S180 p-S195 (z= 5) 24.9 100.0 79.1 28.3 40.7 28.7 0.0 0.0 87.0 
TMM9B_MOUSE Tmem9b p-S14 (z= 4) + Oxi 0.0 34.9 75.5 0.0 100.0 67.5 0.0 44.4 0.0 
TP4A1_MOUSE Ptp4a1 p-T13 (z= 3) 44.1 61.2 100.0 51.7 0.0 19.1 91.1 0.0 0.0 
TPC2L_MOUSE Trappc2l p-T74 p-S76 (z= 4) + Oxi 89.8 62.4 71.0 100.0 81.7 70.3 47.7 65.6 62.4 
TRA2A_MOUSE Tra2a p-S261 (z= 2) 33.8 20.2 58.0 79.8 77.4 92.7 44.8 62.5 100.0 
TRA2A_MOUSE Tra2a p-T200 p-T202 p-T211 (z= 3) 79.5 100.0 93.5 90.0 69.6 62.6 74.3 60.9 78.7 
TRA2A_MOUSE Tra2a p-T211 p-S213 (z= 3) + Oxi 14.6 0.0 100.0 0.0 0.0 6.8 0.0 0.0 8.4 
TRI32_MOUSE Trim32 p-T301 p-S307 (z= 4) + Oxi 100.0 38.9 21.4 0.0 0.0 0.0 0.0 0.0 45.0 
TRUA_MOUSE Pus1 p-T141 p-S153 (z= 4) 0.0 26.6 0.0 24.7 0.0 100.0 0.0 0.0 18.5 
TS1R2_MOUSE Tas1r2 p-T480 p-Y481 p-S483 p-
Y488 (z= 6) + Oxi 
0.0 25.7 72.5 100.0 14.8 19.0 0.0 0.0 48.1 
TSC2_MOUSE Tsc2 p-S687 (z= 2) 53.5 93.9 88.3 77.3 100.0 16.5 80.8 79.7 56.4 
TSSC4_MOUSE Tssc4 p-S64 (z= 3) 11.7 8.1 100.0 40.4 7.5 61.8 50.0 15.6 77.3 
TTC38_MOUSE Ttc38 p-T59 p-T77 (z= 4) + Oxi 52.4 83.6 100.0 73.7 35.4 61.7 22.8 11.5 78.6 
TTL10_MOUSE Ttll10 p-S637 p-S640 (z= 3) + Oxi 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
TTLL8_MOUSE Ttll8 p-S664 (z= 4) + Oxi 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
TYRP1_MOUSE Tyrp1 p-T199 p-T203 (z= 4) 47.7 100.0 51.1 0.0 0.0 0.0 0.0 67.9 47.7 
U119A_MOUSE Unc119 p-S12 p-S24 p-T28 (z= 3) 49.1 63.0 51.9 54.3 62.5 46.2 39.7 92.7 100.0 
UBE3C_MOUSE Ube3c p-S135 p-T139 (z= 3) 100.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
UBP14_MOUSE Usp14 p-S222 p-T226 (z= 3) 73.4 56.7 39.6 71.3 65.2 64.0 100.0 39.2 48.2 
UBP2_MOUSE Usp2 p-S92 p-S94 p-Y115 (z= 7) + 
Oxi 
2.9 19.4 66.3 13.6 4.0 6.5 2.2 5.7 100.0 
UBP3_MOUSE Usp3 p-T491 p-T493 (z= 3) 100.0 66.0 75.9 86.1 48.3 54.5 62.3 16.3 23.5 
UBP37_MOUSE Usp37 p-S298 (z= 2) 0.0 0.0 0.0 0.0 0.0 100.0 0.0 0.0 0.0 
UH1BL_MOUSE Uhrf1bp1l p-S443 (z= 4) 69.5 70.7 97.5 47.1 78.5 92.9 34.5 50.6 100.0 
UHRF2_MOUSE Uhrf2 p-T509 (z= 2) 54.9 77.0 65.6 100.0 62.0 22.8 68.5 69.6 55.7 
USH2A_MOUSE Ush2A p-S3872 p-S3873 p-T3883 
(z= 4) + Oxi 
70.6 63.5 77.7 79.7 100.0 70.9 90.3 70.5 85.8 
VCIP1_MOUSE Vcpip1 p-T1072 p-S1075 p-S1076 
(z= 4) 
0.0 100.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 
VINC_MOUSE Vcl p-S290 (z= 3) 28.3 16.8 21.5 61.8 41.1 70.0 100.0 38.1 36.5 
VINC_MOUSE Vcl p-S346 (z= 2) 45.4 55.0 59.2 100.0 62.9 88.9 89.7 92.1 70.4 
VINC_MOUSE Vcl p-S346 (z= 2) 60.8 0.0 28.8 42.8 89.2 100.0 39.9 68.5 45.3 
VINC_MOUSE Vcl p-S787 p-S795 (z= 3) 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
VITRN_MOUSE VITRN p-S267 (z= 3) 23.7 24.6 37.5 25.6 8.4 13.4 100.0 18.3 24.9 
WBP11_MOUSE Wbp11 p-S600 (z= 3) 40.2 63.3 45.8 54.4 47.4 69.7 35.0 35.8 100.0 
WDR11_MOUSE WDR11 p-S606 p-S620 p-S625 (z= 
4) 
100.0 90.0 66.2 75.6 51.7 28.6 31.3 32.7 33.4 
WDR24_MOUSE Wdr24 p-T450 p-S458 p-S463 (z= 3) 
+ Oxi 
74.8 72.3 63.2 55.2 68.4 100.0 68.2 64.6 82.5 
WDR33_MOUSE Wdr33 p-S1212 (z= 3) 0.0 0.0 0.0 0.0 0.0 100.0 0.0 0.0 0.0 
WDR78_MOUSE Wdr78 p-T58 (z= 5) + Oxi 15.9 100.0 94.9 65.4 3.3 38.3 0.0 0.0 68.2 
WNK2_MOUSE Wnk2 p-T279 p-T282 (z= 3) + Oxi 76.2 100.0 92.2 95.8 83.3 76.6 91.4 93.4 96.3 
WNT2_MOUSE Wnt2 p-S49 (z= 4) 84.8 94.8 76.8 50.1 85.9 96.5 100.0 63.2 60.4 
YBOX1_MOUSE Ybx1 p-S2 p-S3 p-T41 (z= 4) + Oxi 67.1 67.0 48.7 55.3 52.4 27.7 100.0 68.3 46.9 
YBOX1_MOUSE Ybx1 p-S2 p-S3 p-T7 (z= 3) + Oxi 69.2 75.3 39.1 20.1 61.7 27.7 100.0 77.3 45.7 
YIF1A_MOUSE Yif1a p-T251 (z= 3) 89.8 74.6 77.7 100.0 89.9 66.5 52.9 52.3 65.4 
YIPF6_MOUSE Yipf6 p-S196 p-T201 (z= 4) + Oxi 0.0 5.7 5.1 4.1 0.0 100.0 0.0 0.0 4.6 
ZFHX4_MOUSE Zfhx4 p-T417 p-T420 (z= 4) 59.2 73.3 86.8 72.5 90.0 60.4 100.0 65.2 63.0 
ZN503_MOUSE Znf503 p-S140 p-S141 (z= 4) 72.8 0.0 0.0 0.0 0.0 100.0 0.0 0.0 0.0 
ZNFX1_MOUSE Znfx1 p-S1877 p-T1895 (z= 6) + Oxi 0.1 0.1 79.9 100.0 0.1 0.1 0.1 0.1 0.1 
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Appendix 2 
Summary of phosphorylation events identified in phosphoproteomic screen for 
proteins differentially regulated by p110α and p110β (Chapter 4). 
  Relative mean phosphopeptide intensity of condition: 
Accession Number Phosphopeptide identification Starved DMSO A66 TGX221 
1433E_MOUSE Ywhae p-S213 (z= 2) 61.2 100.0 80.8 84.8 
3BP1_MOUSE Sh3bp1 p-S553 (z= 3) 55.0 100.0 91.8 94.6 
3BP5L_MOUSE Sh3bp5l p-S377 (z= 2) 72.3 84.8 100.0 47.9 
4ET_MOUSE Eif4enif1 p-S563 (z= 2) 91.7 90.7 100.0 85.0 
4ET_MOUSE Eif4enif1 p-S949 (z= 2) 100.0 56.7 58.1 97.8 
A7L3B_MOUSE Atxn7l3b p-S92 (z= 3) 81.8 85.0 100.0 78.1 
AAK1_MOUSE Aak1 p-S635 (z= 2) 69.7 100.0 45.3 59.6 
AAK1_MOUSE Aak1 p-S674 (z= 2) 100.0 58.9 98.5 58.0 
AAK1_MOUSE Aak1 p-T618 p-S622 (z= 2) 100.0 80.2 62.6 81.4 
AATF_MOUSE Aatf p-S283 p-S287 p-S288 (z= 3) 85.7 81.4 100.0 99.0 
AB1IP_MOUSE Apbb1ip p-S507 (z= 2) 85.0 100.0 52.8 43.1 
AB1IP_MOUSE Apbb1ip p-S507 (z= 3) 100.0 97.8 69.0 87.2 
ABCAD_MOUSE Abca13 p-S4703 p-T4710 (z= 4) 100.0 77.0 87.5 85.3 
ABCF1_MOUSE Abcf1 p-S107 (z= 2) 93.7 90.7 99.8 100.0 
ABCF1_MOUSE Abcf1 p-S138 (z= 2) 95.9 87.1 100.0 84.1 
ABCF1_MOUSE Abcf1 p-S138 (z= 3) 82.0 67.4 88.1 100.0 
ABI1_MOUSE Abi1 p-S183 (z= 2) 72.4 100.0 55.7 14.6 
ABI1_MOUSE Abi1 p-S183 (z= 3) 100.0 92.4 65.8 51.2 
ABI1_MOUSE Abi1 p-S225 (z= 2) 100.0 57.1 77.9 55.6 
ABL1_MOUSE Abl1 p-S838 p-S840 p-T844 (z= 3) + Oxi 92.2 50.6 47.5 100.0 
ABL2_MOUSE Abl2 p-S632 (z= 2) 100.0 93.3 87.9 79.1 
ABLM1_MOUSE Ablim1 p-S475 (z= 2) 87.0 100.0 77.1 89.4 
ABLM1_MOUSE Ablim1 p-S789 (z= 2) 100.0 80.3 85.5 83.7 
ACACA_MOUSE Acaca p-S79 (z= 2) 45.0 56.3 56.7 100.0 
ACINU_MOUSE Acin1 p-S1003 (z= 2) 89.1 57.7 82.0 100.0 
ACINU_MOUSE Acin1 p-S216 (z= 3) 91.7 100.0 98.6 65.4 
ACINU_MOUSE Acin1 p-S477 p-S491 (z= 2) 100.0 37.6 55.2 61.2 
ACINU_MOUSE Acin1 p-S477 p-S491 (z= 3) 100.0 36.7 62.7 57.8 
ACINU_MOUSE Acin1 p-S479 (z= 2) 74.5 100.0 54.4 66.3 
ACINU_MOUSE Acin1 p-S710 (z= 4) 51.7 100.0 71.8 33.4 
ACLY_MOUSE Acly p-S455 (z= 2) 54.3 78.7 75.6 100.0 
ACSM1_MOUSE Acsm1 p-T226 p-Y228 (z= 3) + Oxi 100.0 68.2 82.1 87.0 
ACY3_MOUSE Acy3 p-S7 (z= 2) 81.7 32.5 100.0 57.4 
ADCY8_MOUSE Adcy8 p-Y1147 (z= 3) 63.2 4.3 100.0 32.3 
ADDA_MOUSE Add1 p-S465 (z= 2) 23.9 100.0 50.0 45.4 
ADNP_MOUSE Adnp p-S679 p-S681 (z= 3) 75.0 96.5 94.6 100.0 
AF1L2_MOUSE Afap1l2 p-T674 (z= 2) 39.1 0.0 9.2 100.0 
AFAD_MOUSE Mllt4 p-S1107 (z= 3) 67.3 100.0 45.7 35.5 
AFAD_MOUSE Mllt4 p-S1173 p-S1182 (z= 3) 100.0 83.8 73.4 81.6 
AFAD_MOUSE Mllt4 p-S1795 (z= 2) 64.7 87.0 65.0 100.0 
AFAP1_MOUSE Afap1 p-S669 (z= 2) 88.5 100.0 74.3 76.9 
AFAP1_MOUSE Afap1 p-T342 p-S343 (z= 3) 98.1 100.0 76.6 61.8 
AFTIN_MOUSE Aftph p-S151 (z= 2) 100.0 85.4 85.9 91.7 
AGAP2_MOUSE Agap2 p-S224 p-S226 p-T227 (z= 3) 47.8 63.2 97.8 100.0 
AGFG1_MOUSE AGFG1 p-S179 p-S181 (z= 4) 100.0 58.5 61.4 63.5 
AGFG1_MOUSE Agfg1 p-S181 (z= 2) 73.6 0.0 100.0 0.0 
AGFG1_MOUSE Agfg1 p-T177 p-S181 (z= 3) 100.0 56.0 61.0 62.6 
AJUBA_MOUSE Ajuba p-S132 p-S133 p-S146 (z= 4) 92.4 79.4 79.2 100.0 
AKAP2_MOUSE Akap2 p-S163 (z= 4) 100.0 70.6 87.5 75.4 
AKAP2_MOUSE Akap2 p-S740 (z= 2) 76.6 93.0 100.0 84.7 
AKAP2_MOUSE Akap2 p-S799 (z= 4) 99.9 100.0 93.8 93.8 
AKAP8_MOUSE Akap8 p-S320 p-S325 (z= 2) 50.7 59.1 100.0 77.2 
AKC1H_MOUSE Akr1c18 p-Y259 (z= 3) 100.0 94.7 81.5 88.8 
AKIR2_MOUSE Akirin2 p-S21 (z= 2) 89.0 90.6 100.0 83.8 
AKT1_MOUSE Akt1 p-S122 (z= 3) 67.0 68.4 82.1 100.0 
AKTS1_MOUSE Akt1s1 p-S184 (z= 2) 41.8 38.3 55.1 100.0 
AKTS1_MOUSE Akt1s1 p-S204 p-S213 (z= 2) 56.9 94.9 70.2 100.0 
AKTS1_MOUSE Akt1s1 p-S213 (z= 2) 99.3 46.3 100.0 98.3 
AKTS1_MOUSE Akt1s1 p-T247 (z= 2) 37.2 100.0 13.4 65.6 
AMGO1_MOUSE AMGO1 p-S407 p-S412 (z= 4) + Oxi 56.7 72.8 86.6 100.0 
AMOT_MOUSE Amot p-T785 (z= 3) + Oxi 89.9 58.3 92.2 100.0 
AMPD2_MOUSE Ampd2 p-S87 (z= 2) 100.0 76.8 60.4 94.3 
AMRA1_MOUSE Ambra1 p-T1195 (z= 3) 29.3 97.1 21.9 100.0 
AN32B_MOUSE Anp32b p-T265 (z= 2) 100.0 56.6 60.5 35.3 
ANLN_MOUSE Anln p-S180 (z= 2) 63.1 100.0 54.1 39.5 
ANLN_MOUSE Anln p-S293 (z= 2) 100.0 89.3 95.5 97.0 
ANLN_MOUSE Anln p-S318 (z= 3) 100.0 91.4 89.5 67.1 
ANLN_MOUSE Anln p-S557 (z= 2) 55.7 67.6 54.6 100.0 
ANLN_MOUSE Anln p-S637 (z= 2) 82.5 100.0 52.8 81.8 
ANLN_MOUSE Anln p-T316 (z= 2) 100.0 93.7 99.7 67.1 
ANLN_MOUSE Anln p-T359 (z= 2) 82.5 100.0 32.5 6.0 
ANLN_MOUSE Anln p-T505 (z= 3) 77.7 100.0 74.1 91.3 
ANM3_MOUSE Prmt3 p-S22 p-S24 (z= 3) 93.3 94.4 100.0 80.6 
ANR17_MOUSE Ankrd17 p-S2401 (z= 3) 77.8 100.0 73.9 64.3 
ANR52_MOUSE Ankrd52 p-Y349 p-T357 p-T360 p-T365 (z= 4) + Oxi 82.9 100.0 67.1 86.8 
ANR55_MOUSE Ankrd55 p-T5 p-S9 p-S11 (z= 3) + Oxi 76.2 97.0 100.0 83.9 
AP3D1_MOUSE Ap3d1 p-S755 p-S760 (z= 2) 58.4 100.0 88.0 66.2 
AP3D1_MOUSE Ap3d1 p-S760 (z= 2) 100.0 92.1 87.5 70.1 
AP3D1_MOUSE Ap3d1 p-S784 (z= 3) 81.8 95.6 100.0 72.9 
API5_MOUSE Api5 p-S462 (z= 2) 98.7 100.0 39.4 49.3 
API5_MOUSE Api5 p-S464 (z= 2) 54.6 76.1 100.0 24.6 
ARAF_MOUSE Araf p-S580 (z= 2) 100.0 74.9 79.4 68.4 
ARBK1_MOUSE Adrbk1 p-S670 (z= 2) 56.4 100.0 70.9 75.1 
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ARGL1_MOUSE Arglu1 p-S75 (z= 2) 42.9 10.1 100.0 11.6 
ARGL1_MOUSE Arglu1 p-S75 (z= 2) 100.0 73.9 76.0 71.1 
ARGL1_MOUSE Arglu1 p-S75 (z= 3) 100.0 81.9 88.9 86.4 
ARH_MOUSE Ldlrap1 p-S198 (z= 2) 87.9 100.0 83.0 89.2 
ARHG1_MOUSE Arhgef1 p-S905 (z= 3) 57.8 100.0 63.3 70.6 
ARHG2_MOUSE Arhgef2 p-S151 (z= 3) 100.0 88.3 89.9 71.3 
ARHG2_MOUSE Arhgef2 p-S174 (z= 2) 92.5 81.5 82.2 100.0 
ARHG2_MOUSE Arhgef2 p-S885 (z= 2) 49.3 26.9 100.0 63.6 
ARHG7_MOUSE Arhgef7 p-S497 (z= 2) + Oxi 100.0 80.7 69.8 72.2 
ARHG7_MOUSE Arhgef7 p-S673 (z= 2) 69.1 97.2 100.0 84.5 
ARHGH_MOUSE Arhgef17 p-S906 (z= 2) 100.0 92.5 54.5 39.2 
ARI1A_MOUSE Arid1a p-S697 (z= 2) 68.1 100.0 74.5 74.5 
ARIP4_MOUSE Rad54l2 p-S1141 (z= 3) + Oxi 36.0 72.1 19.4 100.0 
ASAP2_MOUSE Asap2 p-S704 (z= 2) 80.0 100.0 94.3 65.5 
ASHWN_MOUSE Lyg1 p-S189 p-T197 (z= 3) 87.8 97.0 81.7 100.0 
ASPC1_MOUSE Aspscr1 p-S199 (z= 3) 79.2 77.2 100.0 70.0 
ASPC1_MOUSE Aspscr1 p-S285 (z= 3) 83.3 100.0 89.4 98.9 
ATRX_MOUSE Atrx p-S1223 p-S1224 (z= 3) 71.7 83.5 100.0 82.9 
ATRX_MOUSE Atrx p-S1290 (z= 2) 78.3 100.0 68.6 86.7 
ATRX_MOUSE Atrx p-S312 (z= 2) 100.0 88.5 71.8 77.8 
ATRX_MOUSE Atrx p-S315 (z= 3) 100.0 95.7 81.2 93.5 
ATRX_MOUSE Atrx p-S590 (z= 2) 57.7 92.9 77.3 100.0 
ATRX_MOUSE Atrx p-S590 (z= 3) 100.0 99.0 89.1 93.7 
ATRX_MOUSE Atrx p-S717 p-S719 (z= 3) 80.2 100.0 65.7 94.8 
ATRX_MOUSE Atrx p-S92 (z= 2) 64.3 100.0 60.5 78.1 
ATRX_MOUSE Atrx p-S92 (z= 3) 100.0 66.6 83.3 67.9 
ATX2_MOUSE Atxn2 p-T710 (z= 2) 100.0 76.7 49.3 50.9 
ATX2L_MOUSE Atxn2l p-S109 (z= 2) 75.9 91.9 95.8 100.0 
ATX2L_MOUSE Atxn2l p-S339 (z= 2) 80.0 100.0 72.7 75.7 
ATX2L_MOUSE Atxn2l p-S562 (z= 2) 100.0 76.3 87.6 89.6 
ATX2L_MOUSE Atxn2l p-S597 (z= 2) 74.6 91.5 95.4 100.0 
ATX2L_MOUSE Atxn2l p-S597 (z= 2) + Oxi 92.2 100.0 70.2 86.6 
ATX2L_MOUSE Atxn2l p-S681 p-S687 (z= 2) 100.0 2.9 46.4 57.1 
ATX2L_MOUSE Atxn2l p-S687 (z= 2) 93.9 100.0 94.7 18.7 
ATX2L_MOUSE Atxn2l p-T505 (z= 2) 81.0 100.0 66.1 88.5 
ATX2L_MOUSE Atxn2l p-T635 (z= 4) 17.2 90.1 56.8 100.0 
BAG3_MOUSE Bag3 p-S270 p-S274 (z= 3) 84.5 58.9 100.0 78.4 
BAG3_MOUSE Bag3 p-S289 p-S297 (z= 3) 100.0 88.5 72.5 67.9 
BAG6_MOUSE Bag6 p-S995 (z= 2) 45.9 100.0 53.7 93.2 
BAG6_MOUSE Bag6 p-S995 (z= 3) 94.5 100.0 81.6 76.7 
BAIP2_MOUSE Baiap2 p-S367 (z= 2) 80.0 100.0 68.0 70.9 
BAIP2_MOUSE Baiap2 p-S453 (z= 3) 100.0 37.1 33.5 20.9 
BAP18_MOUSE Bap18 p-S96 (z= 2) 95.0 97.3 94.3 100.0 
BAZ1A_MOUSE Baz1a p-T732 (z= 3) 100.0 90.4 59.4 74.3 
BAZ1B_MOUSE Baz1b p-S1464 (z= 3) 100.0 67.9 42.5 49.3 
BCAS1_MOUSE Bcas1 p-S544 (z= 2) 100.0 67.8 88.5 99.4 
BCLF1_MOUSE Bclaf1 p-S177 (z= 2) 66.4 100.0 95.4 70.2 
BCLF1_MOUSE Bclaf1 p-S177 (z= 2) 97.6 89.8 100.0 58.8 
BCLF1_MOUSE Bclaf1 p-S177 (z= 3) 69.7 100.0 90.4 78.9 
BCLF1_MOUSE Bclaf1 p-S177 (z= 3) 98.0 100.0 99.7 70.2 
BCLF1_MOUSE Bclaf1 p-S221 (z= 2) 55.8 78.1 100.0 66.1 
BCLF1_MOUSE Bclaf1 p-S284 p-S289 (z= 3) 67.3 100.0 90.7 70.7 
BCLF1_MOUSE Bclaf1 p-S284 p-S296 (z= 2) 66.0 100.0 94.3 79.6 
BCLF1_MOUSE Bclaf1 p-S383 (z= 3) 70.9 95.6 82.5 100.0 
BCLF1_MOUSE Bclaf1 p-S494 (z= 2) 99.4 100.0 95.7 66.3 
BCLF1_MOUSE Bclaf1 p-S510 (z= 2) 100.0 82.2 44.3 36.8 
BCLF1_MOUSE Bclaf1 p-S510 (z= 2) 87.0 83.9 100.0 92.5 
BCLF1_MOUSE Bclaf1 p-S510 (z= 3) 100.0 89.7 78.4 79.7 
BCLF1_MOUSE Bclaf1 p-S529 (z= 2) 100.0 58.3 63.9 50.9 
BCLF1_MOUSE Bclaf1 p-S646 (z= 2) 80.6 100.0 73.8 64.1 
BCLF1_MOUSE Bclaf1 p-S656 (z= 2) 91.5 99.0 94.9 100.0 
BCLF1_MOUSE Bclaf1 p-S658 (z= 2) 100.0 81.0 83.4 79.9 
BCR_MOUSE Bcr p-S113 (z= 4) 88.4 100.0 70.5 45.2 
BICD2_MOUSE Bicd2 p-S578 (z= 2) 100.0 92.8 99.4 83.4 
BICD2_MOUSE Bicd2 p-S817 (z= 2) 100.0 84.5 62.9 65.0 
BIN1_MOUSE Bin1 p-S296 (z= 2) 70.9 100.0 58.6 90.8 
BIN1_MOUSE Bin1 p-S298 (z= 3) 92.0 100.0 83.2 92.8 
BIN1_MOUSE Bin1 p-S324 (z= 2) 100.0 72.7 74.9 60.5 
BIN1_MOUSE Bin1 p-T328 (z= 3) 87.5 93.8 100.0 69.1 
BLM_MOUSE Blm p-T1311 (z= 3) 100.0 85.8 80.4 82.9 
BNI3L_MOUSE Bnip3l p-S165 (z= 2) + Oxi 67.2 100.0 8.8 53.4 
BNIP2_MOUSE Bnip2 p-S114 (z= 2) 77.6 94.4 100.0 85.7 
BORG5_MOUSE Cdc42ep1 p-S113 (z= 2) 54.5 100.0 99.9 58.4 
BORG5_MOUSE Cdc42ep1 p-S121 (z= 2) 72.9 100.0 28.4 38.4 
BORG5_MOUSE Cdc42ep1 p-S19 (z= 4) 65.3 100.0 80.9 59.6 
BORG5_MOUSE Cdc42ep1 p-S207 (z= 2) 36.1 85.7 100.0 86.4 
BORG5_MOUSE Cdc42ep1 p-S207 (z= 2) 93.0 97.9 100.0 94.4 
BORG5_MOUSE Cdc42ep1 p-S207 p-S210 (z= 2) 31.7 78.6 54.0 100.0 
BORG5_MOUSE Cdc42ep1 p-S339 (z= 2) 30.0 100.0 39.2 71.8 
BORG5_MOUSE Cdc42ep1 p-S368 p-S371 (z= 3) 0.0 6.1 0.0 100.0 
BRD2_MOUSE Brd2 p-S297 p-S300 (z= 3) 91.5 79.0 94.4 100.0 
BRD3_MOUSE Brd3 p-S262 (z= 2) 75.4 100.0 65.0 90.7 
BRD8_MOUSE Brd8 p-S617 (z= 2) 92.5 52.8 3.6 100.0 
BRE1A_MOUSE Rnf20 p-S138 (z= 2) 100.0 80.9 79.2 82.0 
BRWD3_MOUSE Brwd3 p-T1014 (z= 2) + Oxi 89.8 100.0 48.4 81.4 
BTBD3_MOUSE Btbd3 p-S44 p-S47 p-S49 (z= 3) 62.2 38.6 100.0 68.9 
BUD13_MOUSE Bud13 p-S420 p-S423 (z= 3) 56.8 3.9 100.0 6.4 
BUD13_MOUSE Bud13 p-T131 p-S135 (z= 2) 100.0 35.9 95.3 80.8 
BUD13_MOUSE Bud13 p-T144 p-S148 (z= 2) 93.5 16.0 100.0 81.9 
BUD13_MOUSE Bud13 p-T196 p-S200 (z= 3) 100.0 77.0 80.8 84.2 
BUD13_MOUSE Bud13 p-T196 p-S200 (z= 4) 100.0 68.8 72.4 62.1 
BUD13_MOUSE Bud13 p-T222 p-S226 (z= 3) 100.0 40.9 56.8 84.7 
BYST_MOUSE Bysl p-S97 (z= 2) 81.5 100.0 47.8 95.4 
BYST_MOUSE Bysl p-S97 (z= 3) 100.0 91.8 99.5 88.7 
BZW1_MOUSE Bzw1 p-S411 p-S413 (z= 2) 61.6 100.0 56.4 0.0 
C1TC_MOUSE Mthfd1 p-S549 (z= 2) 100.0 74.9 63.5 67.9 
CA052_MOUSE Eps8l2 p-S156 (z= 2) 82.0 100.0 42.0 46.7 
CA112_MOUSE CA112 p-S725 p-T735 (z= 4) 100.0 79.8 61.2 74.8 
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CA2D4_MOUSE Cacna2d4 p-S804 p-S814 p-T815 (z= 4) + Oxi 100.0 35.6 64.5 37.7 
CALX_MOUSE Canx p-S553 p-S563 (z= 3) 27.6 100.0 30.6 47.3 
CALX_MOUSE Canx p-S553 p-S563 (z= 3) 56.9 100.0 93.6 95.6 
CALX_MOUSE Canx p-S582 (z= 2) 54.3 100.0 83.4 57.1 
CALX_MOUSE Canx p-S582 (z= 3) 58.8 100.0 68.4 62.6 
CAMP1_MOUSE Camsap1 p-S1069 (z= 3) 80.8 100.0 69.6 76.2 
CAMP1_MOUSE Camsap1 p-S1133 (z= 2) 94.3 100.0 60.8 94.5 
CAMP1_MOUSE Camsap1 p-T559 (z= 2) 96.6 100.0 88.8 97.7 
CAMP2_MOUSE Camsap2 p-S573 (z= 2) 100.0 72.8 51.5 80.9 
CAPG_MOUSE Capg p-S341 (z= 3) 82.9 65.6 100.0 55.1 
CASC3_MOUSE Casc3 p-S263 (z= 3) 100.0 93.7 87.4 90.5 
CASP8_MOUSE Casp8 p-S188 (z= 2) 58.3 100.0 94.8 62.1 
CASP8_MOUSE Casp8 p-S188 (z= 2) + Oxi 100.0 65.0 78.7 51.7 
CB071_MOUSE Rpap3 p-S653 (z= 2) 82.9 96.2 89.3 100.0 
CBX3_MOUSE Cbx3 p-S93 p-S95 (z= 3) 100.0 69.4 65.0 60.0 
CBX3_MOUSE Cbx3 p-S93 p-S95 p-S99 (z= 2) 100.0 92.7 33.4 37.5 
CBX3_MOUSE Cbx3 p-S93 p-S97 (z= 2) 100.0 98.3 84.7 78.6 
CBX3_MOUSE Cbx3 p-S95 (z= 2) 39.4 32.6 100.0 71.4 
CBX5_MOUSE Cbx5 p-S11 p-S12 p-S13 (z= 2) 52.8 48.6 100.0 92.1 
CBX5_MOUSE Cbx5 p-S93 (z= 2) 52.7 100.0 74.5 75.8 
CC020_MOUSE Srrm2 p-T103 p-T109 p-Y114 (z= 4) 87.3 68.9 100.0 67.9 
CCD12_MOUSE Ccdc12 p-S165 (z= 2) 77.0 78.5 100.0 82.1 
CCD25_MOUSE Ccdc25 p-S204 (z= 2) 79.4 69.0 90.3 100.0 
CCD43_MOUSE Ccdc43 p-T137 (z= 4) 96.1 87.2 75.9 100.0 
CCD86_MOUSE Ccdc86 p-S18 (z= 3) 81.8 100.0 85.6 61.6 
CCD86_MOUSE Ccdc86 p-S18 (z= 3) 100.0 96.7 56.7 71.3 
CCD94_MOUSE CCD94 p-S211 p-S213 (z= 2) 70.9 34.1 100.0 70.7 
CCG8_MOUSE Cacng8 p-S290 p-S301 p-Y307 p-Y337 (z= 4) 80.3 100.0 85.2 27.0 
CCKAR_MOUSE Cckar p-S265 p-S266 (z= 3) 90.3 22.3 100.0 90.5 
CCNK_MOUSE Ccnk p-S325 p-S329 (z= 2) 85.1 50.2 71.4 100.0 
CCNK_MOUSE Ccnk p-S341 (z= 2) 98.8 87.4 100.0 67.7 
CCNL1_MOUSE Ccnl1 p-S341 p-S344 p-S347 (z= 3) 82.2 83.1 100.0 76.9 
CCNL1_MOUSE Ccnl1 p-S344 p-S347 (z= 3) 4.8 77.8 2.6 100.0 
CCNL1_MOUSE Ccnl1 p-S358 (z= 2) 77.0 100.0 95.2 75.6 
CD11B_MOUSE Cdk11b p-S270 (z= 2) 59.7 75.4 100.0 76.6 
CD11B_MOUSE Cdk11b p-S47 (z= 2) 73.6 100.0 95.3 70.3 
CD11B_MOUSE Cdk11b p-T740 p-S741 (z= 3) 61.5 85.1 97.0 100.0 
CD226_MOUSE Cd226 p-Y188 p-S190 p-T196 (z= 3) 84.9 100.0 78.4 71.4 
CD2AP_MOUSE Cd2ap p-S404 (z= 2) 100.0 58.6 82.4 55.3 
CD2AP_MOUSE Cd2ap p-S458 (z= 2) 100.0 52.6 52.5 67.5 
CDCA3_MOUSE Cdca3 p-S67 (z= 2) 69.2 86.5 100.0 82.3 
CDK12_MOUSE Cdk12 p-S382 p-S384 (z= 3) 69.8 100.0 86.7 67.1 
CDK13_MOUSE Cdk13 p-S384 (z= 2) 70.8 91.0 100.0 99.3 
CDK13_MOUSE Cdk13 p-T1245 (z= 3) 100.0 86.5 68.5 66.7 
CDK16_MOUSE CDK16 p-S119 (z= 2) 83.4 100.0 95.2 98.2 
CDK17_MOUSE Cdk17 p-S180 (z= 2) 72.3 92.9 81.4 100.0 
CDK18_MOUSE Cdk18 p-S111 (z= 2) 49.9 96.5 90.3 100.0 
CDK3_MOUSE Cdk3 p-T14 p-Y15 (z= 2) 67.0 94.8 61.0 100.0 
CDK3_MOUSE Cdk3 p-Y15 (z= 2) 97.2 100.0 96.7 92.3 
CDK4_MOUSE Cdk4 p-S300 (z= 2) 100.0 75.2 90.0 46.7 
CDN1A_MOUSE Cdkn1a p-S81 (z= 2) 80.8 100.0 66.9 82.3 
CE104_MOUSE CE104 p-S327 (z= 2) 100.0 72.7 57.2 67.1 
CE170_MOUSE Cep170 p-S1102 (z= 2) 89.0 100.0 56.8 79.6 
CE170_MOUSE Cep170 p-S1184 (z= 2) 100.0 71.1 59.3 58.1 
CE170_MOUSE Cep170 p-S829 (z= 3) 68.0 100.0 33.6 31.7 
CE170_MOUSE Cep170 p-S829 (z= 3) 72.2 100.0 69.5 64.9 
CENPC_MOUSE Cenpc1 p-S158 (z= 3) 100.0 77.6 52.0 65.8 
CEP55_MOUSE Cep55 p-S423 p-S426 (z= 3) 100.0 55.3 66.1 72.9 
CEP55_MOUSE Cep55 p-S428 (z= 2) 65.2 90.1 93.6 100.0 
CEP55_MOUSE Cep55 p-T422 p-S426 (z= 3) 70.4 85.2 79.1 100.0 
CF132_MOUSE Dync1li1 p-S1026 (z= 2) 0.0 0.0 100.0 0.0 
CF132_MOUSE Frmd4a p-S1131 (z= 2) 61.6 64.4 100.0 36.4 
CF132_MOUSE SMCE1 p-S368 (z= 3) 100.0 85.8 78.3 78.6 
CGNL1_MOUSE Cgnl1 p-S199 p-S203 (z= 2) 100.0 80.6 68.1 92.1 
CGNL1_MOUSE Cgnl1 p-S252 (z= 2) 75.3 100.0 73.5 69.8 
CGNL1_MOUSE Cgnl1 p-S284 (z= 2) 58.9 59.7 100.0 60.1 
CGNL1_MOUSE Cgnl1 p-S284 (z= 3) 77.9 100.0 92.0 88.0 
CGNL1_MOUSE Cgnl1 p-S416 (z= 3) 82.9 100.0 73.7 52.7 
CGNL1_MOUSE Cgnl1 p-S602 (z= 3) 70.2 100.0 39.6 55.0 
CGNL1_MOUSE Cgnl1 p-Y197 p-S203 (z= 2) 63.4 22.2 100.0 54.1 
CH10_MOUSE Hspe1 p-T27 (z= 3) 100.0 73.9 79.3 64.1 
CHAP1_MOUSE Champ1 p-S416 (z= 3) 84.0 100.0 90.3 90.4 
CHAP1_MOUSE Champ1 p-S416 p-S421 p-S425 (z= 3) 78.1 82.3 95.0 100.0 
CHAP1_MOUSE Champ1 p-S603 (z= 2) 72.1 89.9 100.0 57.4 
CHERP_MOUSE Cherp p-S822 p-S824 p-S826 (z= 3) 80.9 82.4 100.0 100.0 
CHERP_MOUSE Cherp p-S824 p-S826 p-T828 (z= 3) 77.6 85.0 100.0 98.8 
CHIP_MOUSE Stub1 p-T15 (z= 2) 100.0 89.6 85.5 71.4 
CHIP_MOUSE Stub1 p-T15 (z= 3) 100.0 93.4 72.6 58.4 
CHM2B_MOUSE Chmp2b p-S199 (z= 2) 100.0 71.0 53.9 54.1 
CHRC1_MOUSE Chrac1 p-S122 (z= 2) 100.0 80.3 85.4 84.9 
CHRC1_MOUSE Chrac1 p-S122 (z= 3) 100.0 97.6 100.0 91.1 
CHSP1_MOUSE Carhsp1 p-S31 (z= 2) 76.4 85.2 100.0 74.4 
CHSP1_MOUSE Carhsp1 p-S31 p-S33 (z= 2) 53.5 45.6 100.0 48.5 
CHSP1_MOUSE Carhsp1 p-S31 p-S33 (z= 3) 91.2 81.8 100.0 94.6 
CHSP1_MOUSE Carhsp1 p-S31 p-S33 p-S42 (z= 3) 98.1 85.9 92.0 100.0 
CHSP1_MOUSE Carhsp1 p-S42 (z= 2) 66.7 94.7 92.8 100.0 
CHSP1_MOUSE Carhsp1 p-S42 (z= 3) 100.0 95.8 95.3 88.5 
CHSP1_MOUSE Carhsp1 p-S53 (z= 2) 85.0 100.0 37.7 36.4 
CI078_MOUSE PPDPF p-S261 (z= 3) 92.8 81.1 100.0 83.9 
CIC_MOUSE Cic p-S1080 (z= 2) 74.8 100.0 76.0 64.2 
CIC_MOUSE Cic p-S1403 (z= 2) 63.6 92.3 100.0 49.4 
CIC_MOUSE Cic p-S2280 p-S2284 (z= 3) 89.8 83.8 67.2 100.0 
CING_MOUSE Cgn p-T283 (z= 2) 100.0 44.9 44.0 39.8 
CJ088_MOUSE Gtf2b p-S423 (z= 2) 93.4 58.4 100.0 84.4 
CLAP1_MOUSE Clasp1 p-S1088 (z= 2) 96.5 100.0 48.5 38.7 
CLAP1_MOUSE Clasp1 p-S1193 (z= 2) 100.0 29.5 59.4 82.1 
CLAP1_MOUSE Clasp1 p-S1220 (z= 2) 100.0 62.1 28.1 36.6 
CLASR_MOUSE Clasrp p-S541 (z= 3) 100.0 97.6 77.9 88.7 
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CLPX_MOUSE Clpx p-S97 (z= 3) 100.0 91.6 75.1 54.2 
CLSPN_MOUSE Clspn p-S787 (z= 2) 97.1 100.0 97.1 75.9 
CND1_MOUSE Ncapd2 p-S1320 p-S1323 (z= 3) 86.1 81.2 73.3 100.0 
CND1_MOUSE Ncapd2 p-T1319 (z= 3) 100.0 71.3 76.7 79.4 
CND2_MOUSE Ncaph p-S25 (z= 2) 100.0 41.0 64.7 98.4 
CND2_MOUSE Ncaph p-S83 (z= 3) 43.4 89.1 26.5 100.0 
CNOT2_MOUSE Cnot2 p-S165 (z= 2) 72.1 100.0 97.8 78.8 
CO2A1_MOUSE Col2a1 p-S391 (z= 3) 51.4 100.0 15.3 67.4 
COBL1_MOUSE Cobll1 p-S1214 (z= 2) 75.1 93.3 87.1 100.0 
COBL1_MOUSE Cobll1 p-S546 p-T550 (z= 3) 74.5 87.5 89.3 100.0 
COBL1_MOUSE Cobll1 p-T1091 (z= 3) 100.0 77.3 80.3 73.2 
COKA1_MOUSE Col20a1 p-Y731 p-S734 p-S737 (z= 2) 80.5 36.7 100.0 72.2 
COMT_MOUSE Comt p-S261 (z= 2) 100.0 67.4 93.4 86.6 
COPD_MOUSE Arcn1 p-Y58 (z= 3) + Oxi 72.7 100.0 71.7 89.2 
CP088_MOUSE Tsg118 p-S57 (z= 2) 60.5 86.3 100.0 89.0 
CP088_MOUSE Tsg118 p-S57 (z= 3) 76.7 82.5 100.0 76.4 
CP135_MOUSE Cep135 p-S441 (z= 2) 100.0 0.1 25.0 0.1 
CPSF2_MOUSE Cpsf2 p-S419 p-S420 p-S423 (z= 3) 76.0 72.7 86.8 100.0 
CQ085_MOUSE Iqch p-S30 (z= 3) 73.1 88.2 100.0 69.7 
CR025_MOUSE Sorbs1 p-S66 p-S67 (z= 3) 98.0 100.0 94.3 97.1 
CRKL_MOUSE Crkl p-Y207 (z= 4) 6.5 66.1 3.7 100.0 
CRTC2_MOUSE Crtc2 p-S70 (z= 4) 43.3 100.0 63.6 57.7 
CS021_MOUSE Gjd3 p-S346 (z= 2) 100.0 27.6 39.6 30.2 
CS021_MOUSE Sdad1 p-S364 (z= 2) 100.0 50.3 59.5 58.9 
CS044_MOUSE Atn1 p-S228 (z= 3) 100.0 68.3 95.1 73.4 
CSTF3_MOUSE Cstf3 p-S691 (z= 3) 100.0 41.9 30.1 12.0 
CSTF3_MOUSE CSTF3 p-S691 (z= 4) 100.0 39.9 29.1 11.7 
CT2NL_MOUSE Cttnbp2nl p-S522 (z= 3) 100.0 98.0 90.2 90.1 
CT2NL_MOUSE Cttnbp2nl p-S548 (z= 2) 24.4 40.0 100.0 9.0 
CT2NL_MOUSE Cttnbp2nl p-S559 p-S567 (z= 3) 82.8 83.0 100.0 71.7 
CT2NL_MOUSE Cttnbp2nl p-S567 (z= 3) 100.0 73.9 62.9 40.1 
CTBP2_MOUSE Ctbp2 p-S428 (z= 4) 49.8 100.0 64.4 70.2 
CTF18_MOUSE CTF18 p-S70 (z= 4) 87.4 75.3 78.5 100.0 
CTGE5_MOUSE Ctage5 p-S514 p-T517 (z= 3) 56.9 100.0 25.4 47.1 
CTNA1_MOUSE Ctnna1 p-S641 (z= 2) 94.7 90.7 100.0 89.1 
CTNA1_MOUSE Ctnna1 p-S641 (z= 3) 87.4 79.2 95.8 100.0 
CTNA1_MOUSE Ctnna1 p-S652 p-T654 (z= 2) 75.1 100.0 38.3 76.6 
CTNA1_MOUSE Ctnna1 p-S652 p-T654 p-S655 (z= 3) 100.0 75.1 57.5 95.5 
CTNB1_MOUSE Ctnnb1 p-S191 (z= 3) 100.0 56.3 50.6 25.8 
CTND1_MOUSE Ctnnd1 p-S268 (z= 2) 100.0 73.7 49.2 37.1 
CTND1_MOUSE Ctnnd1 p-S268 p-S269 (z= 2) 97.8 100.0 66.4 95.4 
CTND1_MOUSE Ctnnd1 p-S346 p-S349 p-S352 (z= 2) 99.2 76.2 80.8 100.0 
CTND1_MOUSE Ctnnd1 p-S349 (z= 2) 100.0 75.7 72.2 73.9 
CTND1_MOUSE Ctnnd1 p-S349 (z= 3) 100.0 85.0 78.2 85.6 
CTND1_MOUSE Ctnnd1 p-S349 p-S352 (z= 2) 79.9 77.2 70.8 100.0 
CTND1_MOUSE Ctnnd1 p-S349 p-S352 (z= 3) 52.8 62.5 62.5 100.0 
CTND1_MOUSE Ctnnd1 p-S53 (z= 3) 80.1 75.6 79.8 100.0 
CTND1_MOUSE Ctnnd1 p-S920 (z= 2) 68.1 75.8 62.9 100.0 
CTR9_MOUSE Ctr9 p-T925 (z= 2) 71.6 76.6 100.0 63.9 
CTR9_MOUSE Ctr9 p-T925 (z= 3) 82.2 91.2 79.8 100.0 
CUL4B_MOUSE Cul4b p-S149 (z= 3) 99.0 94.7 100.0 67.0 
CWC15_MOUSE Cwc15 p-T110 p-S121 (z= 3) 85.6 100.0 85.9 1.3 
CWC15_MOUSE Cwc15 p-T110 p-S121 (z= 4) 73.2 59.0 45.2 100.0 
CWC22_MOUSE Cwc22 p-S831 (z= 2) 60.6 89.3 100.0 56.9 
CX023_MOUSE Lama3 p-S78 p-S80 (z= 3) 91.3 95.7 100.0 89.4 
CX023_MOUSE Srrm1 p-S410 (z= 2) 100.0 53.8 84.6 93.0 
CXAR_MOUSE Cxadr p-S332 (z= 2) 55.4 100.0 53.6 84.3 
CXAR_MOUSE Cxadr p-S332 (z= 3) 100.0 80.3 76.9 78.5 
CYTSB_MOUSE Specc1 p-S133 (z= 2) 43.3 100.0 41.5 28.7 
CYTSB_MOUSE Specc1 p-S847 (z= 2) 100.0 91.6 92.9 99.3 
CYTSB_MOUSE Specc1 p-T357 p-S359 (z= 3) 85.4 81.0 76.8 100.0 
DAB2_MOUSE Dab2 p-S401 (z= 2) 28.0 100.0 78.9 90.8 
DAP1_MOUSE Dap p-S51 (z= 3) 81.2 67.6 68.9 100.0 
DBNL_MOUSE Dbnl p-S291 (z= 2) 78.2 100.0 88.5 75.7 
DBPA_MOUSE Csda p-S328 (z= 2) 78.1 95.3 100.0 99.5 
DBPA_MOUSE Csda p-S52 (z= 3) 100.0 57.4 75.1 52.4 
DBPA_MOUSE Csda p-S52 p-S66 (z= 4) 64.0 76.9 86.1 100.0 
DC1I2_MOUSE Dync1i2 p-S84 (z= 3) 45.3 89.8 78.9 100.0 
DC1L1_MOUSE Dync1li1 p-S207 (z= 3) 98.5 98.8 100.0 98.8 
DC1L1_MOUSE Dync1li1 p-S405 (z= 2) 62.5 0.0 100.0 9.5 
DC1L1_MOUSE Dync1li1 p-S421 (z= 2) 100.0 93.3 81.4 69.1 
DC1L1_MOUSE Dync1li1 p-S516 (z= 2) 72.4 75.6 100.0 94.5 
DC1L1_MOUSE Dync1li1 p-T513 p-T515 (z= 2) 69.9 100.0 70.1 78.6 
DCLK3_MOUSE Dclk3 p-S221 p-S229 p-S236 (z= 3) 94.1 90.8 89.9 100.0 
DCP1A_MOUSE Dcp1a p-S372 (z= 3) 100.0 87.7 83.8 67.1 
DDX10_MOUSE Ddx10 p-T587 (z= 3) 100.0 80.9 84.3 82.9 
DDX20_MOUSE Ddx20 p-S569 (z= 2) 62.0 14.7 100.0 88.2 
DDX21_MOUSE Ddx21 p-S118 (z= 2) 100.0 96.0 94.3 89.5 
DDX21_MOUSE Ddx21 p-S118 (z= 2) + Oxi 100.0 70.1 50.3 53.1 
DDX21_MOUSE Ddx21 p-S118 (z= 3) 100.0 20.7 22.2 22.9 
DDX21_MOUSE Ddx21 p-S144 (z= 2) 51.6 61.5 100.0 44.7 
DDX21_MOUSE Ddx21 p-S211 (z= 3) 100.0 49.2 60.0 38.2 
DDX21_MOUSE Ddx21 p-S218 (z= 2) 100.0 47.0 92.8 53.9 
DDX21_MOUSE Ddx21 p-S243 (z= 3) 91.6 100.0 98.1 70.9 
DDX21_MOUSE Ddx21 p-S244 p-S245 (z= 3) 87.1 100.0 76.2 77.1 
DDX21_MOUSE Ddx21 p-S245 p-T247 (z= 2) 100.0 81.2 54.9 75.6 
DDX24_MOUSE Ddx24 p-S170 (z= 2) 100.0 84.5 81.5 78.2 
DDX24_MOUSE Ddx24 p-S288 (z= 3) 97.9 100.0 98.7 81.0 
DDX3L_MOUSE D1Pas1 p-S592 (z= 2) 95.6 97.8 74.9 100.0 
DDX42_MOUSE Ddx42 p-S104 p-S111 (z= 3) 12.2 100.0 70.8 7.1 
DDX42_MOUSE Ddx42 p-S109 p-S111 (z= 3) 62.5 86.6 61.0 100.0 
DDX42_MOUSE Ddx42 p-S185 (z= 3) 87.7 77.7 85.0 100.0 
DDX46_MOUSE Ddx46 p-S804 (z= 3) 11.9 0.0 100.0 0.0 
DDX54_MOUSE Ddx54 p-S74 (z= 2) 95.0 89.6 96.8 100.0 
DDX54_MOUSE Ddx54 p-S74 (z= 3) 76.6 74.6 82.4 100.0 
DEK_MOUSE Dek p-S306 p-S308 p-S311 (z= 2) 34.1 1.2 100.0 31.8 
DEK_MOUSE Dek p-S306 p-S308 p-S311 (z= 2) 100.0 55.0 93.8 90.3 
DEK_MOUSE Dek p-S306 p-S308 p-S311 (z= 3) 100.0 62.5 96.0 86.3 
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DEK_MOUSE Dek p-S33 (z= 3) 65.0 99.6 74.8 100.0 
DEN5A_MOUSE Dennd5a p-S13 (z= 3) 73.9 100.0 38.8 72.6 
DENR_MOUSE Denr p-S73 (z= 3) 95.0 100.0 99.0 95.2 
DESP_MOUSE Dsp p-S2620 (z= 3) 79.0 100.0 61.2 9.8 
DESP_MOUSE Dsp p-S2622 (z= 2) 91.5 53.6 52.8 100.0 
DFFB_MOUSE Dffb p-T270 p-T274 (z= 3) 54.6 95.8 86.3 100.0 
DGCR8_MOUSE Dgcr8 p-S271 p-S275 (z= 3) 88.7 92.2 77.4 100.0 
DGCR8_MOUSE Dgcr8 p-S377 (z= 3) 81.2 100.0 87.3 76.9 
DGCR8_MOUSE Dgcr8 p-Y267 p-S275 (z= 3) 93.8 87.8 100.0 85.5 
DHSB_MOUSE DHSB p-S124 (z= 2) 100.0 48.9 53.6 60.0 
DKC1_MOUSE Dkc1 p-S451 p-S453 p-S455 (z= 3) 100.0 81.0 93.9 98.3 
DKC1_MOUSE Dkc1 p-S451 p-S455 (z= 3) 100.0 79.6 83.0 89.9 
DKC1_MOUSE Dkc1 p-S481 (z= 2) 100.0 77.3 57.5 52.3 
DLGP5_MOUSE Dlgap5 p-S328 (z= 2) 100.0 95.1 81.4 83.7 
DLGP5_MOUSE Dlgap5 p-T453 (z= 2) 67.8 91.3 76.1 100.0 
DMBX1_MOUSE Dmbx1 p-S227 p-S232 p-Y254 (z= 4) 100.0 80.1 71.2 83.4 
DNJC5_MOUSE Dnajc5 p-S10 (z= 2) 12.6 100.0 11.0 5.8 
DNJC5_MOUSE Dnajc5 p-S10 (z= 3) 21.5 100.0 22.0 46.9 
DNLI1_MOUSE Lig1 p-S51 (z= 2) 78.2 100.0 74.0 73.0 
DNLI1_MOUSE Lig1 p-S51 (z= 3) 100.0 87.4 47.7 71.8 
DNLI1_MOUSE Lig1 p-S907 p-S911 (z= 2) 100.0 80.1 82.9 97.1 
DNLI1_MOUSE Lig1 p-T195 (z= 3) 68.6 99.5 90.0 100.0 
DNLI1_MOUSE Lig1 p-T77 (z= 2) 100.0 74.2 71.0 57.8 
DNLI1_MOUSE Lig1 p-T77 (z= 2) 95.3 100.0 60.4 58.2 
DNLI1_MOUSE Lig1 p-T77 (z= 3) 100.0 87.1 67.4 75.6 
DNLI3_MOUSE Lig3 p-S211 (z= 2) 55.2 100.0 52.5 93.0 
DNM1L_MOUSE Dnm1l p-S622 (z= 2) 77.9 100.0 93.5 95.9 
DNMT1_MOUSE Dnmt1 p-S717 (z= 2) 64.5 100.0 67.7 76.6 
DOCK5_MOUSE Dock5 p-S1765 (z= 2) 100.0 83.6 80.7 85.4 
DOCK7_MOUSE Dock7 p-S1428 (z= 2) 100.0 28.5 96.9 69.3 
DOCK7_MOUSE Dock7 p-S452 (z= 3) 18.8 100.0 56.3 4.3 
DOCK7_MOUSE Dock7 p-S888 (z= 3) 97.0 100.0 41.8 68.3 
DOCK7_MOUSE Dock7 p-S898 (z= 2) 100.0 53.5 42.6 52.8 
DPM1_MOUSE Dpm1 p-S9 p-S13 (z= 4) 84.0 88.8 77.5 100.0 
DPOA2_MOUSE Pola2 p-S126 (z= 2) 52.4 88.5 96.6 100.0 
DPOD3_MOUSE Pold3 p-S306 (z= 2) 53.2 78.3 100.0 65.9 
DPOLA_MOUSE Pola1 p-S215 (z= 3) 82.4 98.9 100.0 68.5 
DPTOR_MOUSE Deptor p-S238 (z= 3) 100.0 99.6 73.6 74.5 
DPYL2_MOUSE Dpysl2 p-S522 (z= 2) 100.0 0.0 2.5 0.0 
DPYL2_MOUSE Dpysl2 p-T509 (z= 2) 82.2 74.0 100.0 90.0 
DREB_MOUSE Dbn1 p-S142 (z= 2) 100.0 69.7 52.4 48.7 
DREB_MOUSE Dbn1 p-S387 (z= 2) 79.5 90.3 100.0 98.9 
DTD1_MOUSE Dtd1 p-S197 (z= 2) 100.0 91.2 97.8 94.9 
DUS6_MOUSE Dusp6 p-S331 (z= 2) 65.0 0.6 100.0 74.4 
DUS6_MOUSE Dusp6 p-S331 (z= 3) 76.1 100.0 79.2 3.1 
DYH2_MOUSE Dnah2 p-S2571 (z= 2) 83.8 100.0 67.2 50.4 
DYHC1_MOUSE Dync1h1 p-S4366 (z= 2) 82.3 100.0 84.8 90.4 
DYHC1_MOUSE Dync1h1 p-S4366 (z= 3) 82.3 95.9 91.1 100.0 
DYR1A_MOUSE Dyrk1a p-Y321 (z= 2) 96.8 66.2 100.0 89.2 
E2F8_MOUSE E2f8 p-S71 (z= 2) 76.5 100.0 80.3 97.6 
E41L1_MOUSE Epb41l1 p-S782 (z= 2) 82.5 100.0 86.6 84.5 
E41L2_MOUSE Epb41l2 p-S38 (z= 3) 53.7 100.0 39.1 63.3 
E41L2_MOUSE Epb41l2 p-S38 (z= 4) 100.0 85.8 93.8 70.1 
E41L2_MOUSE Epb41l2 p-S86 (z= 2) 100.0 75.6 75.3 93.4 
E41L2_MOUSE Epb41l2 p-T35 (z= 3) 100.0 83.0 74.4 51.7 
E41L2_MOUSE Epb41l2 p-T669 (z= 3) 100.0 67.0 59.4 75.7 
EAF1_MOUSE Eaf1 p-S158 p-S165 (z= 3) 80.9 85.3 94.0 100.0 
EDC3_MOUSE Edc3 p-S131 (z= 2) 81.7 100.0 44.7 54.7 
EDC4_MOUSE Edc4 p-S727 (z= 3) 81.7 43.3 100.0 71.5 
EDC4_MOUSE Edc4 p-S727 (z= 4) 94.3 94.5 77.8 100.0 
EDC4_MOUSE Edc4 p-S733 (z= 3) 75.3 0.8 100.0 40.4 
EDC4_MOUSE Edc4 p-S745 (z= 3) 85.0 2.2 100.0 41.3 
EDC4_MOUSE Edc4 p-S895 (z= 3) 81.0 89.9 90.1 100.0 
EF1B_MOUSE Eef1b p-S106 (z= 3) 73.3 75.3 84.5 100.0 
EF1B_MOUSE Eef1b p-S106 (z= 3) 51.6 76.3 71.2 100.0 
EF1B_MOUSE Eef1b p-S106 (z= 3) 100.0 66.4 79.6 74.0 
EF1B_MOUSE Eef1b p-S106 (z= 4) 98.0 81.8 100.0 98.3 
EF1D_MOUSE Eef1d p-S119 (z= 2) 100.0 22.9 24.9 24.7 
EF1D_MOUSE Eef1d p-S133 (z= 2) 83.5 93.4 100.0 93.5 
EF1D_MOUSE Eef1d p-S133 (z= 2) + Oxi 100.0 83.4 68.8 45.9 
EF1D_MOUSE Eef1d p-S133 (z= 3) 79.9 10.4 100.0 82.7 
EF1D_MOUSE Eef1d p-S133 (z= 3) + Oxi 100.0 92.3 77.7 77.7 
EF1D_MOUSE Eef1d p-S162 (z= 3) 74.7 84.5 88.5 100.0 
EF1D_MOUSE Eef1d p-S162 (z= 3) 99.4 85.6 92.2 100.0 
EF1D_MOUSE Eef1d p-S162 (z= 4) 84.0 84.5 88.6 100.0 
EF1D_MOUSE Eef1d p-T147 p-S162 (z= 3) 100.0 76.6 86.4 86.7 
EF1D_MOUSE Eef1d p-T147 p-S162 (z= 4) 96.3 85.7 93.4 100.0 
EF1G_MOUSE Eef1g p-T46 (z= 2) 65.6 90.5 79.9 100.0 
EFHD2_MOUSE Efhd2 p-S74 (z= 2) 100.0 51.0 97.6 79.3 
EFHD2_MOUSE Efhd2 p-S74 (z= 2) 100.0 45.3 65.1 62.9 
EFHD2_MOUSE Efhd2 p-S74 (z= 3) 100.0 51.8 50.3 36.0 
EFHD2_MOUSE Efhd2 p-S76 (z= 3) 99.1 88.8 100.0 90.3 
EHD1_MOUSE Ehd1 p-T454 (z= 3) 76.0 100.0 53.8 63.8 
EI2BE_MOUSE Eif2b5 p-S540 (z= 2) 98.2 89.7 100.0 86.4 
EIF3B_MOUSE Eif3b p-S120 p-S123 (z= 2) 84.9 100.0 53.7 19.4 
EIF3B_MOUSE Eif3b p-S120 p-S123 (z= 3) 100.0 91.0 83.2 87.3 
EIF3B_MOUSE Eif3b p-S143 (z= 3) 100.0 0.2 98.3 0.4 
EIF3B_MOUSE Eif3b p-S143 p-S153 (z= 3) 40.2 100.0 16.5 48.6 
EIF3B_MOUSE Eif3b p-S75 (z= 3) 100.0 87.1 92.2 89.6 
EIF3B_MOUSE Eif3b p-S75 p-S79 (z= 2) 94.1 100.0 76.6 73.5 
EIF3B_MOUSE Eif3b p-S75 p-S79 (z= 3) 59.1 99.8 56.3 100.0 
EIF3B_MOUSE Eif3b p-S75 p-S79 (z= 4) 100.0 58.8 33.0 59.9 
EIF3B_MOUSE Eif3b p-T74 p-S75 p-S79 (z= 4) 100.0 60.6 62.4 46.9 
EIF3C_MOUSE Eif3c p-S39 (z= 2) 97.6 93.2 96.5 100.0 
EIF3C_MOUSE Eif3c p-S39 (z= 2) 100.0 87.0 87.4 88.4 
EIF3C_MOUSE Eif3c p-S39 (z= 3) 95.9 88.2 92.0 100.0 
EIF3G_MOUSE Eif3g p-S42 (z= 2) 37.0 100.0 31.0 41.4 
EIF3G_MOUSE Eif3g p-S42 (z= 3) 100.0 49.7 65.8 67.1 
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EIF3G_MOUSE Eif3g p-S42 (z= 3) 88.5 96.1 100.0 92.7 
EIF3G_MOUSE Eif3g p-T41 p-S42 (z= 3) 76.9 67.5 100.0 77.3 
EMAL4_MOUSE Eml4 p-S146 (z= 2) 100.0 56.8 81.7 63.5 
EMIL1_MOUSE Emilin1 p-S508 (z= 2) 100.0 28.5 54.9 46.4 
ENPP1_MOUSE ENPP1 p-S685 p-S690 p-Y694 (z= 4) 89.1 57.2 76.7 100.0 
ENSA_MOUSE Ensa p-S67 (z= 2) 75.6 95.5 93.7 100.0 
ENSA_MOUSE Ensa p-S67 (z= 2) + Oxi 100.0 97.6 66.1 66.3 
EPCR_MOUSE Procr p-S206 p-S214 p-T237 (z= 4) + Oxi 100.0 76.5 67.2 81.2 
EPIPL_MOUSE Eppk1 p-S1537 (z= 2) 100.0 75.8 66.8 69.3 
EPN2_MOUSE Epn2 p-S173 (z= 2) 71.3 77.6 90.7 100.0 
EPN2_MOUSE Epn2 p-S192 p-S195 (z= 2) 58.4 100.0 53.3 37.4 
EPN2_MOUSE Epn2 p-T441 (z= 3) 92.8 99.9 100.0 96.0 
EPS8_MOUSE Eps8 p-S624 (z= 3) 77.8 94.4 100.0 86.5 
EPS8_MOUSE Eps8 p-S658 (z= 2) 71.1 77.9 36.1 100.0 
ERRFI_MOUSE Errfi1 p-S251 (z= 3) 100.0 84.4 65.1 67.0 
ERRFI_MOUSE Errfi1 p-T126 p-T130 (z= 2) 56.4 78.7 78.8 100.0 
ES8L2_MOUSE Eps8l2 p-S483 (z= 3) 100.0 94.5 88.0 86.5 
ESF1_MOUSE Esf1 p-S156 (z= 2) 82.5 100.0 45.1 94.5 
ESF1_MOUSE Esf1 p-S156 (z= 3) 100.0 49.6 46.8 22.9 
ESF1_MOUSE Esf1 p-S651 (z= 3) 95.2 94.7 100.0 68.1 
ESF1_MOUSE Esf1 p-S651 p-S657 (z= 3) 85.9 70.3 100.0 79.7 
ESF1_MOUSE Esf1 p-S686 p-S688 p-S689 (z= 2) 79.9 55.3 57.1 100.0 
ESF1_MOUSE Esf1 p-T305 p-S306 p-S307 (z= 3) 100.0 57.2 36.2 20.2 
ESPL1_MOUSE Espl1 p-S1504 (z= 3) 85.4 91.4 95.6 100.0 
ETV6_MOUSE Etv6 p-S205 (z= 2) 90.2 78.1 100.0 97.9 
ETV6_MOUSE Etv6 p-S215 (z= 2) 100.0 81.7 47.5 37.3 
ETV6_MOUSE Etv6 p-Y17 p-S22 (z= 2) 91.6 62.2 100.0 95.1 
ETV6_MOUSE Etv6 p-Y17 p-S22 (z= 3) 99.5 100.0 96.6 86.0 
EZH2_MOUSE Ezh2 p-S406 p-S407 p-S408 (z= 3) 100.0 0.0 0.0 0.0 
F10A1_MOUSE St13 p-S74 p-S75 p-S78 (z= 4) 100.0 49.1 52.5 73.8 
F110A_MOUSE Fam110a p-S190 (z= 2) 100.0 77.0 65.1 59.7 
F110C_MOUSE Fam110c p-S350 (z= 2) 77.3 87.6 90.6 100.0 
F122A_MOUSE Fam122a p-S34 (z= 3) 94.3 100.0 96.3 68.4 
F122A_MOUSE Fam122a p-S73 (z= 2) 100.0 87.9 84.4 79.5 
F195B_MOUSE Fam195b p-S21 (z= 2) 96.9 100.0 96.9 96.3 
F195B_MOUSE Fam195b p-S25 p-S26 (z= 3) 100.0 61.2 51.8 72.0 
F195B_MOUSE Fam195b p-T23 (z= 3) 86.7 92.1 92.6 100.0 
F207A_MOUSE Fam207a p-S38 (z= 2) 76.8 100.0 71.6 82.8 
FA40A_MOUSE Fam40a p-S335 (z= 2) 87.0 98.1 100.0 96.3 
FA54B_MOUSE Fam54b p-S100 (z= 2) 100.0 84.8 69.3 78.3 
FA54B_MOUSE Fam54b p-S235 (z= 2) 60.4 100.0 60.7 50.9 
FA65A_MOUSE FA65A p-Y78 (z= 2) 84.2 100.0 96.9 85.7 
FA76B_MOUSE Fam76b p-S193 (z= 2) 96.9 95.2 96.9 100.0 
FA83H_MOUSE Fam83h p-S522 (z= 2) 100.0 60.8 65.9 52.4 
FA83H_MOUSE Fam83h p-S871 (z= 2) 82.8 94.0 100.0 69.6 
FA83H_MOUSE Fam83h p-S871 (z= 3) 83.1 96.2 100.0 86.5 
FA83H_MOUSE Fam83h p-S904 (z= 2) 99.0 100.0 97.3 49.0 
FA83H_MOUSE Fam83h p-S915 (z= 2) 83.5 90.8 100.0 42.2 
FA83H_MOUSE Fam83h p-S926 (z= 2) 81.3 96.7 100.0 74.8 
FA83H_MOUSE Fam83h p-S948 (z= 2) 100.0 87.4 87.3 66.5 
FA83H_MOUSE Fam83h p-S970 (z= 2) 100.0 87.2 94.0 66.8 
FAK1_MOUSE Ptk2 p-S948 (z= 2) 60.9 90.9 100.0 90.2 
FAM21_MOUSE Fam21 p-S1169 p-S1172 p-S1173 (z= 3) 96.8 48.3 100.0 63.5 
FAM21_MOUSE Fam21 p-S157 p-S159 (z= 3) 67.7 100.0 98.2 91.3 
FAM21_MOUSE Fam21 p-S533 (z= 3) 74.2 80.5 100.0 78.1 
FAM21_MOUSE Fam21 p-S613 p-S614 (z= 3) 75.8 88.4 84.3 100.0 
FAM21_MOUSE Fam21 p-S723 (z= 3) 65.1 86.6 100.0 73.7 
FAT3_MOUSE Fat3 p-S1659 (z= 4) + Oxi 73.5 88.2 78.4 100.0 
FBX15_MOUSE Fbxo15 p-S185 (z= 2) 100.0 98.2 56.2 44.9 
FCHO2_MOUSE Fcho2 p-S387 (z= 2) 77.5 100.0 99.6 73.1 
FGD6_MOUSE Fgd6 p-S557 (z= 3) 100.0 98.9 50.5 36.1 
FHOD1_MOUSE Fhod1 p-S502 (z= 2) 73.5 10.1 100.0 73.3 
FHOD1_MOUSE Fhod1 p-S524 (z= 2) 100.0 73.6 51.2 40.7 
FHOD1_MOUSE Fhod1 p-S524 p-S527 (z= 2) 88.0 72.2 100.0 97.9 
FIL1L_MOUSE Filip1l p-S789 (z= 2) 94.7 94.0 100.0 94.4 
FIP1_MOUSE Fip1l1 p-S235 (z= 2) 96.8 98.5 86.2 100.0 
FIP1_MOUSE Fip1l1 p-S280 (z= 2) 40.9 84.9 100.0 19.7 
FIP1_MOUSE Fip1l1 p-S479 (z= 2) 99.8 97.8 100.0 82.8 
FIP1_MOUSE Fip1l1 p-S479 (z= 3) 77.2 94.2 100.0 69.0 
FIP1_MOUSE Fip1l1 p-S479 p-S487 (z= 3) 100.0 74.9 80.7 71.2 
FIP1_MOUSE Fip1l1 p-S483 p-S487 (z= 2) 71.2 89.7 53.0 100.0 
FIP1_MOUSE Fip1l1 p-T481 (z= 3) 100.0 90.6 72.8 44.1 
FLNA_MOUSE Flna p-S1084 (z= 2) 100.0 82.5 26.4 39.0 
FLNA_MOUSE Flna p-S1459 (z= 2) 91.3 100.0 63.0 71.4 
FLNA_MOUSE Flna p-S2152 (z= 3) 8.7 100.0 66.2 80.5 
FLNA_MOUSE Flna p-S2327 (z= 3) 99.1 99.2 100.0 85.6 
FLNA_MOUSE Flna p-S968 (z= 2) 73.6 85.3 0.1 100.0 
FLNC_MOUSE Flnc p-S2234 (z= 2) 64.1 100.0 60.8 99.9 
FMNL_MOUSE Fmnl1 p-S184 (z= 2) 100.0 94.8 88.2 91.0 
FNBP4_MOUSE Fnbp4 p-S19 (z= 2) 100.0 86.9 82.7 90.5 
FNBP4_MOUSE Fnbp4 p-S19 (z= 3) 79.3 69.7 69.9 100.0 
FOSL2_MOUSE Fosl2 p-S200 (z= 2) 100.0 77.4 75.4 79.0 
FOXA1_MOUSE Foxa1 p-S283 (z= 2) 93.7 100.0 57.6 44.0 
FOXK1_MOUSE Foxk1 p-S402 p-S406 (z= 2) 91.1 100.0 91.5 80.8 
FOXK2_MOUSE Foxk2 p-S389 (z= 2) 71.8 100.0 73.4 77.5 
FOXP2_MOUSE Foxp2 p-S5 (z= 4) + Oxi 94.0 100.0 94.0 80.3 
FRK_MOUSE Frk p-T407 (z= 2) 64.3 52.4 100.0 61.9 
FRM4A_MOUSE Frmd4a p-S782 (z= 2) 80.9 89.2 79.1 100.0 
FRM4A_MOUSE Frmd4a p-T511 (z= 2) 95.7 100.0 83.4 66.3 
FUBP2_MOUSE Khsrp p-S182 (z= 2) 55.4 56.2 100.0 66.5 
FXR1_MOUSE Fxr1 p-S641 (z= 3) 100.0 88.9 84.4 79.2 
FXR2_MOUSE Fxr2 p-S602 (z= 3) 82.2 82.7 84.6 100.0 
FXR2_MOUSE Fxr2 p-S602 p-S604 (z= 3) 88.8 89.6 100.0 95.4 
G3BP1_MOUSE G3bp1 p-S149 (z= 2) 97.6 65.6 95.2 100.0 
G3BP1_MOUSE G3bp1 p-S149 (z= 3) 89.3 85.1 100.0 86.5 
G3BP1_MOUSE G3bp1 p-S231 (z= 2) 97.3 97.5 80.1 100.0 
G3BP1_MOUSE G3bp1 p-S231 (z= 3) 79.8 80.2 79.5 100.0 
G3BP2_MOUSE G3bp2 p-T227 (z= 2) 100.0 91.4 81.5 71.7 
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GAPD1_MOUSE Gapvd1 p-S452 p-S453 p-S454 (z= 3) + Oxi 100.0 59.9 49.0 39.5 
GAPD1_MOUSE Gapvd1 p-S761 p-T762 (z= 4) 78.0 80.1 76.6 100.0 
GFPT1_MOUSE Gfpt1 p-T260 (z= 2) 82.3 89.7 94.9 100.0 
GIT1_MOUSE Git1 p-S370 (z= 2) 100.0 87.3 88.1 93.4 
GIT1_MOUSE Git1 p-S394 p-S397 (z= 3) 100.0 85.2 92.4 87.9 
GIT1_MOUSE Git1 p-S601 p-Y607 (z= 3) 80.9 98.4 100.0 82.5 
GMIP_MOUSE Gmip p-S436 p-S440 (z= 2) 52.7 100.0 37.6 35.9 
GNL3_MOUSE Gnl3 p-S505 (z= 2) 75.0 100.0 46.3 43.0 
GNL3_MOUSE Gnl3 p-S505 (z= 3) 61.1 100.0 42.2 68.9 
GNL3_MOUSE Gnl3 p-S95 (z= 2) 76.7 85.1 100.0 63.7 
GNL3_MOUSE Gnl3 p-S95 (z= 3) 56.0 100.0 41.0 57.1 
GOG7B_MOUSE GOLGA7B p-S142 p-S157 p-S158 (z= 3) 36.5 59.0 100.0 76.6 
GOGA1_MOUSE Golga1 p-S41 p-S47 p-S50 (z= 4) + Oxi 22.4 100.0 30.7 12.5 
GOGA4_MOUSE Golga4 p-S93 (z= 2) 100.0 79.6 83.0 59.5 
GOLP3_MOUSE Golph3 p-S35 (z= 2) 100.0 88.2 33.7 86.0 
GPN1_MOUSE Gpn1 p-S314 (z= 2) 56.0 100.0 91.2 81.9 
GPN1_MOUSE Gpn1 p-S338 (z= 2) 100.0 89.5 71.4 76.4 
GPN1_MOUSE Gpn1 p-S338 (z= 3) 80.1 44.6 100.0 81.7 
GPR98_MOUSE Gpr98 p-S133 p-T135 p-S155 (z= 3) 19.0 100.0 58.4 79.1 
GPTC4_MOUSE Gpatch4 p-S130 (z= 4) 100.0 75.7 76.7 50.5 
GPTC4_MOUSE Gpatch4 p-S258 (z= 2) 57.0 100.0 60.2 50.0 
GPTC4_MOUSE Gpatch4 p-S258 (z= 2) 100.0 90.5 59.6 15.0 
GPTC4_MOUSE Gpatch4 p-S258 (z= 3) 100.0 55.3 88.8 89.1 
GRAA_MOUSE Gzma p-S5 (z= 2) 100.0 75.6 50.2 86.0 
GSK3A_MOUSE Gsk3a p-Y279 (z= 2) 98.1 85.5 81.7 100.0 
GTPB1_MOUSE Gtpbp1 p-S6 p-S25 (z= 3) + Oxi 100.0 61.0 56.5 62.7 
GTPB1_MOUSE Gtpbp1 p-S8 p-S25 (z= 3) 82.2 82.6 83.2 100.0 
GUAA_MOUSE Gmps p-T331 (z= 2) 100.0 71.1 95.6 83.4 
H15_MOUSE Hist1h1b p-S18 (z= 2) 69.0 81.0 45.3 100.0 
H15_MOUSE Hist1h1b p-T135 (z= 2) 29.3 100.0 24.2 23.9 
HAP28_MOUSE Pdap1 p-S60 p-S63 (z= 2) 75.8 100.0 39.4 45.0 
HAP28_MOUSE Pdap1 p-S60 p-S63 (z= 2) 79.2 24.9 100.0 86.4 
HAP28_MOUSE Pdap1 p-S60 p-S63 (z= 3) 100.0 42.6 89.3 84.5 
HAVR1_MOUSE HAVR1 p-S270 p-S279 (z= 3) 100.0 81.9 88.9 86.4 
HCDH_MOUSE Hadh p-S13 (z= 3) + Oxi 100.0 87.1 43.5 35.8 
HCN3_MOUSE HCN3 p-S648 (z= 3) 70.9 85.3 89.7 100.0 
HDAC1_MOUSE Hdac1 p-S393 (z= 3) 100.0 99.2 79.8 78.8 
HDAC1_MOUSE Hdac1 p-S393 (z= 3) + Oxi 100.0 67.0 66.8 82.9 
HDAC1_MOUSE Hdac1 p-S393 (z= 4) 95.7 100.0 95.5 98.2 
HDAC1_MOUSE Hdac1 p-S393 (z= 4) + Oxi 100.0 71.8 61.4 97.5 
HDAC1_MOUSE Hdac1 p-S393 (z= 4) + Oxi 100.0 55.5 51.1 70.8 
HDAC1_MOUSE Hdac1 p-S421 p-S423 (z= 2) 58.9 100.0 33.5 76.4 
HDAC1_MOUSE Hdac1 p-S421 p-S423 (z= 2) 100.0 90.8 55.0 68.0 
HDAC1_MOUSE Hdac1 p-S421 p-S423 (z= 3) 88.6 59.8 100.0 87.0 
HDAC2_MOUSE Hdac2 p-S394 (z= 4) 100.0 85.3 92.2 65.4 
HDAC2_MOUSE Hdac2 p-S394 (z= 4) + Oxi 84.7 77.4 78.7 100.0 
HDAC2_MOUSE Hdac2 p-S394 (z= 4) + Oxi 100.0 56.9 51.8 62.4 
HDAC2_MOUSE Hdac2 p-S422 p-S424 (z= 3) 81.4 100.0 99.3 82.9 
HDAC7_MOUSE Hdac7 p-S204 (z= 2) 100.0 78.2 64.5 24.5 
HDGF_MOUSE Hdgf p-S132 p-S133 (z= 2) 50.6 81.8 89.2 100.0 
HDGF_MOUSE Hdgf p-S132 p-S133 (z= 2) 81.3 94.7 91.2 100.0 
HDGF_MOUSE Hdgf p-S132 p-S133 (z= 3) 74.9 100.0 96.6 68.1 
HDGF_MOUSE Hdgf p-S133 (z= 3) 74.4 100.0 83.6 97.6 
HDGF_MOUSE Hdgf p-S165 (z= 2) 65.3 100.0 73.9 76.0 
HDGF_MOUSE Hdgf p-S165 (z= 2) 100.0 63.5 84.4 47.6 
HDGF_MOUSE Hdgf p-S165 (z= 2) 86.8 100.0 99.5 72.8 
HDGF_MOUSE Hdgf p-S165 (z= 3) 93.6 100.0 98.6 69.4 
HDGF_MOUSE Hdgf p-S165 (z= 3) 100.0 82.4 80.9 56.9 
HDGF_MOUSE Hdgf p-T200 (z= 3) 77.0 83.8 99.6 100.0 
HDGR2_MOUSE Hdgfrp2 p-S366 p-S367 (z= 2) 92.2 52.6 85.1 100.0 
HDGR2_MOUSE Hdgfrp2 p-S366 p-S367 (z= 2) 78.4 54.1 100.0 87.4 
HDGR2_MOUSE Hdgfrp2 p-S366 p-S367 (z= 2) 100.0 84.9 91.6 96.9 
HDGR2_MOUSE Hdgfrp2 p-S366 p-S367 (z= 3) 100.0 72.1 45.7 61.0 
HDGR2_MOUSE Hdgfrp2 p-S450 (z= 2) 27.7 100.0 44.9 83.0 
HDGR2_MOUSE Hdgfrp2 p-S450 (z= 3) 65.4 100.0 29.5 48.5 
HDGR2_MOUSE Hdgfrp2 p-S659 (z= 2) 100.0 61.3 42.7 20.8 
HEBP1_MOUSE Hebp1 p-T158 p-Y162 (z= 4) + Oxi 65.3 76.5 100.0 95.7 
HECD1_MOUSE Hectd1 p-S358 (z= 2) 82.8 100.0 57.7 28.2 
HELB_MOUSE Helb p-S1015 (z= 3) 100.0 92.9 82.2 55.6 
HELB_MOUSE HELB p-S1068 (z= 3) 98.0 83.9 100.0 98.8 
HEXI1_MOUSE Hexim1 p-S114 (z= 4) 75.7 46.0 100.0 95.6 
HIRP3_MOUSE Hirip3 p-S134 p-T135 (z= 2) 80.0 100.0 66.1 67.5 
HIRP3_MOUSE Hirip3 p-S152 p-S153 (z= 2) 39.9 70.2 45.9 100.0 
HIRP3_MOUSE Hirip3 p-S163 p-T167 (z= 2) 84.7 100.0 98.4 79.3 
HIRP3_MOUSE Hirip3 p-S163 p-T167 (z= 3) 73.3 100.0 76.5 61.2 
HIRP3_MOUSE Hirip3 p-S205 p-S207 p-S208 (z= 2) 50.4 83.3 66.3 100.0 
HIRP3_MOUSE Hirip3 p-S575 (z= 2) 80.9 90.0 83.0 100.0 
HJURP_MOUSE Hjurp p-S388 (z= 2) 68.0 80.3 68.3 100.0 
HM20A_MOUSE Hmg20a p-S104 (z= 2) 68.2 45.6 100.0 28.1 
HMGA1_MOUSE Hmga1 p-S102 p-S103 (z= 2) 0.0 0.0 100.0 0.3 
HMGA1_MOUSE Hmga1 p-S102 p-S103 (z= 2) 100.0 68.2 71.2 63.2 
HMGA1_MOUSE Hmga1 p-S102 p-S103 (z= 3) 100.0 73.5 81.4 75.3 
HMGA1_MOUSE Hmga1 p-S103 (z= 3) 100.0 64.8 67.6 69.0 
HMGA1_MOUSE Hmga1 p-S36 p-T53 (z= 3) 100.0 72.2 97.1 95.1 
HMGA1_MOUSE Hmga1 p-S99 p-S102 p-S103 (z= 2) 83.5 100.0 39.7 42.9 
HMGA1_MOUSE Hmga1 p-S99 p-S102 p-S103 (z= 2) 73.1 73.1 64.1 100.0 
HMGA1_MOUSE Hmga1 p-S99 p-S102 p-S103 (z= 3) 100.0 98.2 87.8 89.0 
HMGA1_MOUSE Hmga1 p-T53 (z= 3) 100.0 70.0 80.5 67.3 
HMGA2_MOUSE Hmga2 p-S44 (z= 2) 67.3 100.0 80.0 60.8 
HMGA2_MOUSE Hmga2 p-T99 p-S104 (z= 2) 37.9 100.0 39.7 33.1 
HMGN1_MOUSE Hmgn1 p-S84 p-S87 (z= 3) 79.8 96.9 100.0 92.9 
HMGN1_MOUSE Hmgn1 p-S84 p-S87 (z= 4) 76.6 78.4 54.7 100.0 
HMGN1_MOUSE Hmgn1 p-S87 (z= 3) 91.6 100.0 88.9 96.6 
HMGN1_MOUSE Hmgn1 p-S87 (z= 3) 100.0 92.2 71.5 55.1 
HMGN1_MOUSE Hmgn1 p-S87 (z= 4) 89.3 93.9 100.0 73.7 
HMGN1_MOUSE Hmgn1 p-T70 p-T71 (z= 3) 68.2 100.0 36.8 65.8 
HN1_MOUSE Hn1 p-S88 (z= 2) 46.3 89.6 81.5 100.0 
HN1_MOUSE Hn1 p-T54 (z= 2) 100.0 83.3 89.2 69.0 
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HN1L_MOUSE Hn1l p-S97 (z= 3) 100.0 92.8 90.9 78.8 
HNRH1_MOUSE Hnrnph1 p-S104 (z= 2) 100.0 73.7 82.4 71.0 
HNRH1_MOUSE Hnrnph1 p-T107 (z= 3) 99.3 100.0 95.4 87.7 
HNRL2_MOUSE Hnrnpul2 p-S159 (z= 2) 84.3 77.8 74.4 100.0 
HNRL2_MOUSE Hnrnpul2 p-S226 (z= 4) 100.0 28.4 30.4 4.2 
HNRPC_MOUSE Hnrnpc p-S232 (z= 2) 73.9 93.1 84.5 100.0 
HNRPC_MOUSE Hnrnpc p-S232 (z= 2) 66.3 88.1 100.0 71.6 
HNRPC_MOUSE Hnrnpc p-S268 (z= 3) 53.5 71.8 100.0 93.4 
HNRPC_MOUSE Hnrnpc p-S268 (z= 3) + Oxi 47.8 61.0 46.0 100.0 
HNRPC_MOUSE Hnrnpc p-S268 (z= 3) + Oxi 69.0 71.4 87.6 100.0 
HNRPC_MOUSE Hnrnpc p-S268 (z= 4) 55.5 100.0 97.8 99.6 
HNRPC_MOUSE Hnrnpc p-S268 (z= 4) + Oxi 83.4 96.2 79.2 100.0 
HNRPC_MOUSE Hnrnpc p-S306 (z= 2) 63.7 100.0 67.7 97.4 
HNRPC_MOUSE Hnrnpc p-S306 (z= 3) 42.5 100.0 55.6 85.8 
HNRPD_MOUSE Hnrnpd p-S83 (z= 3) 72.6 90.5 100.0 83.5 
HNRPK_MOUSE Hnrnpk p-S116 (z= 3) 61.7 56.5 78.1 100.0 
HNRPK_MOUSE Hnrnpk p-S116 (z= 4) 39.6 100.0 52.6 38.5 
HNRPK_MOUSE Hnrnpk p-S116 (z= 4) 0.1 0.1 0.1 100.0 
HNRPK_MOUSE Hnrnpk p-S216 (z= 2) 85.1 97.6 94.5 100.0 
HNRPK_MOUSE Hnrnpk p-S216 (z= 3) 100.0 87.0 82.1 95.3 
HNRPK_MOUSE Hnrnpk p-S284 (z= 2) 74.8 68.0 100.0 84.2 
HNRPK_MOUSE Hnrnpk p-S284 (z= 2) 94.7 100.0 93.5 77.0 
HNRPK_MOUSE Hnrnpk p-S284 (z= 2) + Oxi 100.0 60.6 71.3 40.6 
HNRPK_MOUSE Hnrnpk p-S379 (z= 2) 57.9 88.3 100.0 87.3 
HNRPU_MOUSE Hnrnpu p-S247 (z= 4) 100.0 40.0 37.2 14.5 
HPBP1_MOUSE Hspbp1 p-T351 (z= 2) 75.7 88.7 84.6 100.0 
HS105_MOUSE Hsph1 p-S810 (z= 2) 100.0 54.3 55.9 26.7 
HS90A_MOUSE Hsp90aa1 p-S252 (z= 2) 49.0 100.0 86.6 81.6 
HS90A_MOUSE Hsp90aa1 p-S263 (z= 2) 50.4 92.1 100.0 97.5 
HS90A_MOUSE Hsp90aa1 p-S263 (z= 3) 54.4 97.9 90.2 100.0 
HS90A_MOUSE Hsp90aa1 p-S263 (z= 3) 58.6 94.4 100.0 85.9 
HS90A_MOUSE Hsp90aa1 p-S263 (z= 3) 49.9 100.0 86.2 71.2 
HS90A_MOUSE Hsp90aa1 p-S263 (z= 4) 54.6 100.0 97.8 97.6 
HS90B_MOUSE Hsp90ab1 p-S255 (z= 2) 77.7 100.0 62.7 33.7 
HS90B_MOUSE Hsp90ab1 p-S255 (z= 2) 67.3 100.0 97.7 88.8 
HS90B_MOUSE Hsp90ab1 p-S255 (z= 2) 37.1 100.0 43.6 81.0 
HS90B_MOUSE Hsp90ab1 p-S255 (z= 3) 58.5 88.3 87.9 100.0 
HS90B_MOUSE Hsp90ab1 p-S255 (z= 3) 75.5 100.0 95.4 82.6 
HS90B_MOUSE Hsp90ab1 p-S255 (z= 4) 72.9 99.6 100.0 88.7 
HSF1_MOUSE Hsf1 p-S314 (z= 3) 71.5 8.7 100.0 80.4 
HSF1_MOUSE Hsf1 p-S314 p-S319 (z= 3) 45.7 100.0 18.9 35.5 
HSPB8_MOUSE Hspb8 p-S87 (z= 2) 62.9 85.1 92.1 100.0 
HSPB8_MOUSE Hspb8 p-S87 (z= 3) 100.0 86.9 90.3 82.9 
HTSF1_MOUSE Htatsf1 p-S705 (z= 3) 72.3 95.1 82.9 100.0 
HTSF1_MOUSE Htatsf1 p-S724 (z= 2) 93.2 74.4 100.0 82.1 
HUWE1_MOUSE Huwe1 p-S1907 (z= 2) 100.0 75.4 93.9 88.5 
HYDIN_MOUSE Hydin p-T2739 p-Y2740 (z= 2) 22.7 92.1 43.7 100.0 
I2BP1_MOUSE Irf2bp1 p-S453 (z= 3) 60.8 100.0 50.5 58.8 
I2BP2_MOUSE Irf2bp2 p-S169 (z= 2) 100.0 66.9 52.6 63.5 
I2BP2_MOUSE Irf2bp2 p-S169 (z= 3) 100.0 77.4 79.5 75.2 
I2BP2_MOUSE Irf2bp2 p-S71 (z= 2) 81.6 100.0 71.2 80.7 
I2BPL_MOUSE Irf2bpl p-S195 (z= 4) 98.8 78.5 91.1 100.0 
I2BPL_MOUSE Irf2bpl p-S526 (z= 2) 86.3 99.8 100.0 63.1 
I2BPL_MOUSE Irf2bpl p-S636 p-S638 (z= 2) 50.3 100.0 65.8 80.6 
I2BPL_MOUSE Irf2bpl p-S636 p-S638 p-S641 (z= 2) 65.8 100.0 30.2 67.7 
I2BPL_MOUSE Irf2bpl p-S638 (z= 2) 88.9 77.4 100.0 95.4 
IASPP_MOUSE Ppp1r13l p-S485 (z= 3) 100.0 2.4 95.0 1.9 
ICAL_MOUSE Cast p-S219 (z= 3) 75.4 100.0 95.5 83.5 
ICAL_MOUSE Cast p-S444 (z= 2) 100.0 50.7 92.3 71.7 
ICAL_MOUSE Cast p-T321 (z= 3) 60.1 100.0 72.6 81.6 
ICAL_MOUSE Cast p-T479 (z= 2) 82.1 82.4 100.0 87.1 
IF2B1_MOUSE Igf2bp1 p-S181 (z= 2) 89.4 100.0 57.8 40.3 
IF2B1_MOUSE Igf2bp1 p-S181 (z= 2) 100.0 72.4 97.8 49.5 
IF2P_MOUSE Eif5b p-S114 (z= 2) 100.0 80.7 76.0 82.2 
IF2P_MOUSE Eif5b p-S137 (z= 3) 100.0 85.9 70.1 68.9 
IF2P_MOUSE Eif5b p-S137 (z= 3) 68.3 100.0 59.0 81.0 
IF2P_MOUSE Eif5b p-S137 p-S139 (z= 3) 100.0 90.8 81.1 77.2 
IF2P_MOUSE Eif5b p-S139 (z= 4) 100.0 60.2 50.8 38.0 
IF2P_MOUSE Eif5b p-S165 (z= 2) 100.0 72.1 56.5 63.0 
IF2P_MOUSE Eif5b p-S183 p-S184 p-S187 (z= 3) 90.2 79.7 73.6 100.0 
IF2P_MOUSE Eif5b p-S215 (z= 2) 100.0 14.7 18.7 22.9 
IF2P_MOUSE Eif5b p-S215 (z= 2) 77.6 79.5 100.0 95.2 
IF4B_MOUSE Eif4b p-S424 p-S425 (z= 2) 61.2 100.0 27.7 37.6 
IF4B_MOUSE Eif4b p-S424 p-S425 (z= 2) 37.1 61.0 46.6 100.0 
IF4B_MOUSE Eif4b p-S424 p-S425 (z= 3) 58.7 57.5 100.0 99.7 
IF4B_MOUSE Eif4b p-S498 (z= 2) 69.6 100.0 41.6 41.2 
IF4B_MOUSE Eif4b p-S93 (z= 3) 5.7 100.0 56.4 5.2 
IF4B_MOUSE Eif4b p-T427 (z= 2) 74.2 100.0 68.7 47.6 
IF4B_MOUSE Eif4b p-T461 (z= 4) 96.9 100.0 87.0 99.3 
IF4B_MOUSE Eif4b p-T500 p-S504 (z= 2) 88.9 0.0 100.0 79.3 
IF4G1_MOUSE Eif4g1 p-S1096 (z= 3) 100.0 51.4 58.3 50.2 
IF4G1_MOUSE Eif4g1 p-S1187 p-S1189 (z= 2) 81.0 79.3 100.0 71.0 
IF4G1_MOUSE Eif4g1 p-S1189 (z= 2) 100.0 57.5 73.5 48.2 
IF4G1_MOUSE Eif4g1 p-S1201 (z= 3) 100.0 49.5 45.8 15.8 
IF4G1_MOUSE Eif4g1 p-S1211 (z= 2) 100.0 55.8 51.6 60.7 
IF4G1_MOUSE Eif4g1 p-S1597 (z= 2) 100.0 56.9 94.6 76.6 
IF4G1_MOUSE Eif4g1 p-T1213 (z= 2) 89.4 54.4 100.0 54.8 
IF4G2_MOUSE Eif4g2 p-S394 (z= 2) 71.3 34.3 100.0 98.2 
IF4G2_MOUSE Eif4g2 p-S394 (z= 4) 100.0 80.5 89.4 8.4 
IFIH1_MOUSE Ifih1 p-S289 (z= 2) 100.0 98.3 76.1 98.2 
IFIH1_MOUSE Ifih1 p-S645 p-S648 (z= 3) 59.9 79.6 89.7 100.0 
IGEB_MOUSE Iap p-S178 (z= 2) 67.9 90.6 59.4 100.0 
ILF3_MOUSE Ilf3 p-S382 (z= 3) 78.1 83.3 100.0 58.3 
ILF3_MOUSE Ilf3 p-S477 p-S482 (z= 4) 58.3 1.8 100.0 24.8 
ILF3_MOUSE Ilf3 p-S482 (z= 4) 58.5 100.0 93.2 77.7 
ILFT1_MOUSE Ifltd1 p-T112 p-S113 (z= 3) 100.0 48.3 66.3 48.9 
IMA2_MOUSE Kpna2 p-S62 (z= 2) 71.6 74.5 76.4 100.0 
IMA3_MOUSE Kpna3 p-S60 (z= 2) 68.1 75.7 86.9 100.0 
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IMA3_MOUSE Kpna3 p-T72 (z= 4) 100.0 18.4 39.7 1.5 
IMDH2_MOUSE Impdh2 p-S444 (z= 3) 65.8 100.0 69.3 64.3 
INCE_MOUSE Incenp p-S259 p-S273 (z= 3) 83.2 100.0 47.9 84.1 
INO1_MOUSE Isyna1 p-S524 (z= 4) 99.2 100.0 66.9 39.9 
IPP2_MOUSE Ppp1r2 p-S122 p-S123 (z= 2) 100.0 67.4 82.7 79.7 
IPP2_MOUSE Ppp1r2 p-S122 p-S123 (z= 2) 46.3 100.0 47.9 56.5 
IPP2_MOUSE Ppp1r2 p-S122 p-S123 (z= 3) 100.0 11.4 9.6 16.6 
IPP2_MOUSE Ppp1r2 p-S122 p-S123 (z= 3) 100.0 89.0 44.2 84.8 
IPP2_MOUSE Ppp1r2 p-S88 (z= 3) 73.7 100.0 86.3 79.3 
IPP2_MOUSE Ppp1r2 p-S88 (z= 3) + Oxi 100.0 78.1 78.2 63.2 
IPP2_MOUSE Ppp1r2 p-S90 (z= 4) 82.6 93.6 100.0 83.2 
IRS2_MOUSE Irs2 p-S1089 (z= 2) 60.3 100.0 70.4 58.4 
IRS2_MOUSE Irs2 p-S678 (z= 2) 62.2 83.4 93.9 100.0 
IRX2_MOUSE Irx2 p-S2 p-Y9 p-S14 p-Y18 (z= 4) + Oxi 100.0 51.0 48.3 25.6 
ITSN1_MOUSE Itsn1 p-S335 (z= 2) 53.2 100.0 71.8 59.7 
IWS1_MOUSE Iws1 p-S183 (z= 2) 100.0 95.1 70.4 83.0 
IWS1_MOUSE Iws1 p-S183 p-S185 (z= 2) 71.9 66.3 100.0 68.9 
IWS1_MOUSE Iws1 p-S183 p-S185 (z= 3) 77.6 77.6 100.0 93.1 
IWS1_MOUSE Iws1 p-S198 p-S200 p-S209 (z= 4) 41.7 13.7 100.0 57.0 
IWS1_MOUSE Iws1 p-S343 p-S345 (z= 2) 100.0 44.3 91.7 81.0 
IWS1_MOUSE Iws1 p-S343 p-S345 (z= 2) 100.0 73.7 63.8 69.2 
IWS1_MOUSE Iws1 p-S343 p-S345 (z= 2) 94.7 100.0 83.4 73.9 
IWS1_MOUSE Iws1 p-S366 (z= 2) 100.0 78.6 89.2 86.3 
IWS1_MOUSE Iws1 p-S366 p-S368 (z= 2) 100.0 84.6 73.3 100.0 
IWS1_MOUSE Iws1 p-T672 (z= 2) 61.0 100.0 37.5 33.7 
JIP3_MOUSE JIP3 p-S330 p-T358 (z= 3) + Oxi 46.6 100.0 62.8 87.7 
JIP4_MOUSE Spag9 p-S730 p-S733 (z= 3) 100.0 60.9 73.7 65.7 
JIP4_MOUSE Spag9 p-S732 p-S733 (z= 2) 66.9 84.8 83.4 100.0 
JUNB_MOUSE Junb p-S248 p-T252 p-S256 (z= 3) 86.5 74.4 100.0 73.0 
JUNB_MOUSE Junb p-T252 p-S256 (z= 2) 59.3 87.1 73.0 100.0 
JUNB_MOUSE Junb p-T252 p-S256 (z= 3) 64.9 86.3 62.1 100.0 
JUND_MOUSE Jund p-S100 (z= 2) 68.2 100.0 85.2 78.6 
JUND_MOUSE Jund p-S249 p-S253 (z= 3) 82.5 66.3 91.1 100.0 
JUND_MOUSE Jund p-S249 p-S253 (z= 4) 99.6 100.0 91.2 91.3 
K0284_MOUSE Kiaa0284 p-S1122 (z= 2) 100.0 68.7 67.3 70.2 
K0284_MOUSE Kiaa0284 p-S843 (z= 3) 100.0 46.9 52.7 36.4 
K1143_MOUSE Map4 p-S50 (z= 4) 100.0 65.1 68.6 41.2 
K1430_MOUSE Kiaa1430 p-S121 (z= 2) 100.0 71.9 87.7 40.4 
K1522_MOUSE Kiaa1522 p-S543 (z= 3) 100.0 47.7 32.9 5.2 
K1522_MOUSE Kiaa1522 p-S909 (z= 3) 70.0 96.3 100.0 97.7 
K1704_MOUSE Kiaa1704 p-S146 (z= 3) 100.0 97.9 72.8 75.4 
K1C18_MOUSE Krt18 p-S35 (z= 2) 96.8 97.4 69.9 100.0 
K1C18_MOUSE Krt18 p-S7 (z= 2) 75.4 100.0 76.1 89.8 
K22E_MOUSE Krt2 p-S563 p-T564 p-S571 (z= 3) 66.5 82.9 83.5 100.0 
K2C7_MOUSE Krt7 p-S32 (z= 3) 43.3 72.6 71.3 100.0 
K2C8_MOUSE Krt8 p-S24 (z= 2) 100.0 93.0 43.7 53.5 
K2C8_MOUSE Krt8 p-S37 (z= 2) 99.7 100.0 55.0 51.5 
K2C8_MOUSE Krt8 p-S47 (z= 2) 16.3 1.2 100.0 23.6 
K2C8_MOUSE Krt8 p-T54 (z= 4) 25.0 52.2 100.0 0.0 
K6PL_MOUSE Pfkl p-S775 (z= 2) 47.5 100.0 72.5 99.4 
KANK3_MOUSE Kank3 p-S163 p-S167 p-S176 (z= 3) 88.1 79.6 100.0 96.9 
KANK3_MOUSE Kank3 p-S166 p-S167 (z= 3) 100.0 73.1 74.0 79.2 
KANK3_MOUSE Kank3 p-S167 (z= 3) 81.5 95.6 98.7 100.0 
KAP0_MOUSE Prkar1a p-S83 (z= 2) 100.0 80.2 80.7 81.8 
KAP2_MOUSE Prkar2a p-S96 (z= 3) 100.0 80.7 76.8 78.8 
KAP3_MOUSE Prkar2b p-S112 (z= 3) 100.0 66.5 56.1 31.5 
KAP3_MOUSE Prkar2b p-S83 p-S85 (z= 3) 99.9 85.7 100.0 83.0 
KAPCA_MOUSE Prkaca p-T198 (z= 2) 45.9 1.4 100.0 47.6 
KC1D_MOUSE Csnk1d p-S382 (z= 2) 91.5 56.6 100.0 67.9 
KC1E_MOUSE Csnk1e p-S363 (z= 2) 100.0 58.7 28.3 74.0 
KCNQ4_MOUSE Kcnq4 p-S411 (z= 3) 100.0 97.8 80.5 75.2 
KIF15_MOUSE Kif15 p-S568 (z= 2) 76.8 100.0 69.1 91.5 
KIF1A_MOUSE Kif1a p-S1490 p-T1492 p-S1498 (z= 4) + Oxi 54.8 100.0 44.8 61.8 
KIF1C_MOUSE KIF1C p-S1020 (z= 2) 94.1 25.3 100.0 34.7 
KIFC2_MOUSE Kifc2 p-S342 (z= 2) + Oxi 100.0 87.5 72.1 65.3 
KITH_MOUSE Tk1 p-Y61 p-S62 p-S66 p-T67 (z= 3) 86.3 47.4 81.5 100.0 
KKCC1_MOUSE Camkk1 p-S74 p-T93 p-S97 (z= 4) 31.9 41.4 58.0 100.0 
KLC1_MOUSE Klc1 p-S520 (z= 2) 90.8 100.0 94.8 87.4 
KLC3_MOUSE Klc3 p-S467 (z= 2) 96.2 87.5 100.0 75.8 
KLC3_MOUSE Klc3 p-S501 (z= 2) 100.0 84.2 76.7 75.5 
KLF1_MOUSE Klf1 p-S347 (z= 3) + Oxi 100.0 51.9 70.3 49.2 
KPCD_MOUSE Prkcd p-S643 (z= 3) 5.2 60.8 4.5 100.0 
KPRB_MOUSE Prpsap2 p-S227 (z= 4) 100.0 65.3 44.1 38.3 
KRI1_MOUSE Kri1 p-S148 (z= 2) 86.3 100.0 77.5 82.6 
KRI1_MOUSE Kri1 p-S148 (z= 3) 88.7 100.0 97.6 96.0 
KS6A1_MOUSE Rps6ka1 p-S721 (z= 2) 94.2 85.6 94.7 100.0 
KS6A3_MOUSE Rps6ka3 p-S715 (z= 2) 100.0 82.3 71.0 81.5 
KS6B1_MOUSE KS6B1 p-S441 (z= 2) 100.0 83.5 74.9 56.4 
LAD1_MOUSE Lad1 p-S336 (z= 2) 100.0 84.1 84.5 77.6 
LAD1_MOUSE Lad1 p-S367 (z= 3) 71.7 84.2 91.8 100.0 
LAD1_MOUSE Lad1 p-S367 (z= 3) 100.0 81.0 86.4 90.5 
LAD1_MOUSE Lad1 p-S62 (z= 4) 10.3 100.0 85.6 68.7 
LAD1_MOUSE Lad1 p-S62 (z= 4) 63.3 100.0 84.2 62.2 
LAD1_MOUSE Lad1 p-S62 p-S72 (z= 4) 100.0 86.5 75.8 71.9 
LAD1_MOUSE Lad1 p-T522 (z= 2) 73.8 76.5 82.2 100.0 
LAP2A_MOUSE Tmpo p-S308 (z= 2) 100.0 72.1 87.5 76.5 
LAP2A_MOUSE Tmpo p-S422 (z= 2) 90.4 82.8 88.9 100.0 
LAP2A_MOUSE Tmpo p-T74 (z= 3) 87.5 94.1 75.3 100.0 
LAP2B_MOUSE Tmpo p-S158 (z= 2) 78.5 100.0 50.0 56.5 
LAP2B_MOUSE Tmpo p-S179 (z= 3) 100.0 90.3 58.8 66.0 
LAP2B_MOUSE Tmpo p-S179 p-S183 (z= 3) 100.0 57.2 67.5 89.9 
LAP2B_MOUSE Tmpo p-S179 p-S183 (z= 3) 78.3 100.0 43.1 61.6 
LAP2B_MOUSE Tmpo p-S179 p-Y182 (z= 3) 87.5 100.0 73.9 78.6 
LAP2B_MOUSE Tmpo p-S183 (z= 3) 96.2 100.0 60.5 84.3 
LAP2B_MOUSE Tmpo p-S66 p-S67 (z= 3) 89.0 86.5 100.0 99.8 
LAP2B_MOUSE Tmpo p-T207 (z= 2) 95.5 100.0 41.5 16.2 
LAP2B_MOUSE Tmpo p-Y182 p-S183 (z= 3) 100.0 88.4 45.0 71.9 
LAR4B_MOUSE LAR4B p-S603 (z= 3) 90.9 94.4 100.0 90.2 
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LAR4B_MOUSE Larp4b p-S721 (z= 2) 100.0 70.0 73.2 52.4 
LAR4B_MOUSE Larp4b p-S739 (z= 2) 33.0 43.9 100.0 2.3 
LARP1_MOUSE Larp1 p-S299 p-S302 (z= 3) 100.0 68.2 63.3 64.3 
LARP1_MOUSE Larp1 p-S494 p-S498 (z= 2) 88.0 84.6 58.2 100.0 
LARP1_MOUSE Larp1 p-S498 (z= 2) 81.3 100.0 51.3 34.9 
LARP1_MOUSE Larp1 p-S525 (z= 2) 56.2 100.0 25.0 53.8 
LARP1_MOUSE Larp1 p-S68 (z= 3) 79.5 100.0 92.3 78.3 
LARP1_MOUSE Larp1 p-S68 (z= 4) 100.0 59.5 56.5 21.9 
LARP1_MOUSE Larp1 p-S743 p-S751 (z= 2) 50.5 77.5 39.9 100.0 
LARP1_MOUSE Larp1 p-S751 (z= 2) 100.0 84.1 85.1 87.1 
LARP1_MOUSE Larp1 p-S81 (z= 4) 100.0 16.1 14.2 19.6 
LARP1_MOUSE Larp1 p-T297 (z= 3) 100.0 58.5 64.5 39.6 
LARP1_MOUSE Larp1 p-T503 (z= 2) 100.0 92.6 78.8 61.8 
LARP1_MOUSE Larp1 p-T503 (z= 3) 100.0 69.6 70.0 63.2 
LARP4_MOUSE Larp4 p-S578 (z= 4) 62.4 100.0 90.0 94.8 
LARP4_MOUSE Larp4 p-T583 (z= 3) 70.7 98.6 100.0 95.7 
LARP7_MOUSE Larp7 p-S253 p-S256 (z= 2) 89.4 55.9 49.6 100.0 
LARP7_MOUSE Larp7 p-S253 p-S256 (z= 2) 69.6 0.0 100.0 0.0 
LARP7_MOUSE Larp7 p-S253 p-S256 (z= 3) 100.0 75.5 93.3 96.8 
LARP7_MOUSE Larp7 p-S253 p-S256 (z= 3) 70.2 100.0 61.8 74.8 
LASP1_MOUSE Lasp1 p-T104 (z= 2) 100.0 71.3 70.2 69.1 
LATS1_MOUSE Lats1 p-S463 (z= 2) 75.0 97.7 100.0 91.0 
LC7L2_MOUSE Luc7l2 p-S281 p-S283 p-S285 (z= 2) 100.0 60.4 32.5 87.7 
LEG1_MOUSE Lgals1 p-S30 (z= 2) 48.9 100.0 60.5 61.7 
LEGLA_MOUSE Lgalsla p-S25 (z= 3) 79.5 90.9 100.0 68.4 
LEO1_MOUSE Leo1 p-S631 (z= 3) 100.0 63.0 93.3 72.1 
LEO1_MOUSE Leo1 p-S659 (z= 2) 79.4 100.0 95.7 72.6 
LGMN_MOUSE Lgmn p-S218 p-Y222 p-Y222 p-Y230 (z= 3) 0.1 0.1 0.1 100.0 
LIMA1_MOUSE Lima1 p-S488 (z= 3) 100.0 77.7 84.5 48.3 
LIMA1_MOUSE Lima1 p-S488 (z= 4) 100.0 67.7 95.8 70.2 
LIMA1_MOUSE Lima1 p-S607 (z= 2) 78.8 100.0 53.7 27.5 
LIPB1_MOUSE Ppfibp1 p-S37 (z= 3) 80.9 63.5 94.0 100.0 
LIPB1_MOUSE Ppfibp1 p-S435 (z= 2) 100.0 84.8 83.3 80.7 
LIPB1_MOUSE Ppfibp1 p-S500 (z= 3) 100.0 84.5 51.0 68.7 
LMNA_MOUSE Lmna p-S390 (z= 2) 100.0 73.8 79.0 61.6 
LMNA_MOUSE Lmna p-S390 p-S395 (z= 2) 100.0 99.6 55.8 57.1 
LMNA_MOUSE Lmna p-S392 (z= 2) 46.1 100.0 56.0 45.8 
LMNA_MOUSE Lmna p-S404 (z= 2) 74.8 100.0 77.8 74.8 
LMNA_MOUSE Lmna p-T19 p-S22 (z= 2) 42.2 100.0 40.3 33.8 
LMNA_MOUSE Lmna p-T24 (z= 2) 82.9 100.0 78.3 77.3 
LMNB1_MOUSE Lmnb1 p-T21 (z= 2) 90.6 100.0 97.2 61.9 
LMNB2_MOUSE Lmnb2 p-S385 (z= 2) 100.0 79.0 56.1 58.2 
LRBA_MOUSE Lrba p-S979 (z= 3) 98.6 100.0 75.1 55.9 
LRRF1_MOUSE Lrrfip1 p-S302 (z= 3) 97.1 99.0 91.1 100.0 
LRRF1_MOUSE Lrrfip1 p-S547 (z= 2) 100.0 51.8 60.4 22.6 
LRRF1_MOUSE Lrrfip1 p-S547 (z= 3) 100.0 74.9 44.0 66.6 
LRRF1_MOUSE Lrrfip1 p-S83 (z= 2) 96.9 100.0 90.1 80.0 
LRRF2_MOUSE Lrrfip2 p-S111 (z= 2) 88.3 100.0 97.1 66.0 
LS14A_MOUSE Lsm14a p-S182 p-S183 (z= 4) 93.7 73.0 100.0 98.5 
LS14A_MOUSE Lsm14a p-S183 (z= 3) 78.0 97.2 100.0 88.0 
LS14A_MOUSE Lsm14a p-S192 (z= 3) 38.8 57.2 53.0 100.0 
LUZP1_MOUSE Luzp1 p-S660 (z= 2) 99.8 80.2 100.0 97.0 
M3K1_MOUSE Map3k1 p-S411 p-S413 p-T415 (z= 4) + Oxi 100.0 69.2 0.0 0.0 
M3K7_MOUSE Map3k7 p-S431 p-S432 p-S434 (z= 4) 30.1 80.0 50.8 100.0 
M4K5_MOUSE Map4k5 p-T333 (z= 3) 92.0 100.0 63.5 70.6 
MA7D1_MOUSE Map7d1 p-S315 (z= 2) 36.5 2.5 35.7 100.0 
MA7D1_MOUSE Map7d1 p-S401 (z= 2) 55.5 63.9 100.0 65.3 
MA7D1_MOUSE Map7d1 p-S401 (z= 3) 100.0 69.8 59.3 35.8 
MA7D3_MOUSE Map7d3 p-S49 (z= 3) 100.0 57.7 62.0 45.1 
MAP1B_MOUSE Map1b p-S1260 (z= 2) 69.2 100.0 71.2 92.4 
MAP1B_MOUSE Map1b p-S1293 p-S1307 (z= 3) 56.3 92.3 57.3 100.0 
MAP1B_MOUSE Map1b p-S1307 (z= 3) 95.7 100.0 69.7 99.6 
MAP1B_MOUSE Map1b p-S1373 (z= 2) 63.3 88.9 92.6 100.0 
MAP1B_MOUSE Map1b p-S1391 p-S1395 (z= 3) 35.3 100.0 35.1 65.0 
MAP1B_MOUSE Map1b p-S1395 (z= 3) 83.6 100.0 83.7 85.6 
MAP1B_MOUSE Map1b p-S1438 (z= 3) 100.0 93.6 78.6 55.3 
MAP1B_MOUSE Map1b p-S1438 (z= 4) 100.0 87.6 95.8 82.9 
MAP1B_MOUSE Map1b p-S1775 (z= 2) 63.7 100.0 55.4 58.4 
MAP1B_MOUSE Map1b p-S1775 p-S1778 p-S1781 (z= 3) 63.5 80.9 84.7 100.0 
MAP1B_MOUSE Map1b p-S1789 p-S1793 (z= 2) 79.0 76.6 63.3 100.0 
MAP1B_MOUSE Map1b p-S1793 (z= 2) 100.0 87.4 98.1 84.9 
MAP1B_MOUSE Map1b p-S1813 (z= 3) 100.0 96.0 98.4 98.8 
MAP1B_MOUSE Map1b p-S2030 (z= 2) 51.0 88.9 64.2 100.0 
MAP1B_MOUSE Map1b p-S2094 (z= 3) 82.5 99.2 58.6 100.0 
MAP1B_MOUSE Map1b p-S609 (z= 3) 96.3 100.0 88.4 79.8 
MAP1B_MOUSE Map1b p-S828 p-S829 (z= 3) 41.8 100.0 30.9 57.9 
MAP1B_MOUSE Map1b p-T1499 (z= 3) 49.9 93.5 61.4 100.0 
MAP1S_MOUSE Map1s p-S462 (z= 2) 90.2 97.8 72.7 100.0 
MAP1S_MOUSE Map1s p-S658 p-S660 (z= 3) 100.0 83.9 67.9 47.2 
MAP1S_MOUSE Map1s p-S724 (z= 4) 100.0 66.0 77.6 68.1 
MAP1S_MOUSE Map1s p-T659 (z= 3) 100.0 96.3 87.9 75.8 
MAP4_MOUSE Map4 p-S1046 (z= 2) 100.0 54.4 67.1 57.2 
MAP4_MOUSE Map4 p-S1046 (z= 3) 100.0 57.7 73.0 67.9 
MAP4_MOUSE Map4 p-S254 (z= 3) 81.4 99.9 100.0 96.7 
MAP4_MOUSE Map4 p-S345 (z= 3) 68.4 100.0 98.9 69.0 
MAP4_MOUSE Map4 p-S475 (z= 2) 65.4 97.0 96.8 100.0 
MAP4_MOUSE Map4 p-S475 (z= 2) + Oxi 87.8 86.4 81.4 100.0 
MAP4_MOUSE Map4 p-S475 (z= 3) 100.0 72.1 75.3 80.5 
MAP4_MOUSE Map4 p-S517 (z= 2) 40.5 100.0 41.2 62.9 
MAP4_MOUSE Map4 p-S517 (z= 2) + Oxi 100.0 76.3 95.8 81.0 
MAP4_MOUSE Map4 p-S517 (z= 3) 100.0 71.0 72.3 57.2 
MAP4_MOUSE Map4 p-S667 (z= 3) 81.2 100.0 77.7 80.5 
MAP4_MOUSE Map4 p-S760 (z= 3) 85.8 100.0 98.0 77.8 
MAP4_MOUSE Map4 p-S785 (z= 2) 100.0 86.3 79.4 90.8 
MAP4_MOUSE Map4 p-S798 (z= 2) 79.1 100.0 59.8 75.2 
MAP4_MOUSE Map4 p-S914 (z= 2) 100.0 54.3 57.8 42.5 
MAP4_MOUSE Map4 p-T847 (z= 2) 96.5 100.0 90.5 79.8 
MAP6_MOUSE Map6 p-T774 p-T779 (z= 3) 81.9 100.0 61.7 32.1 
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MARCS_MOUSE Marcks p-S141 (z= 2) 85.8 100.0 69.8 55.7 
MARCS_MOUSE Marcks p-S163 (z= 2) 16.4 87.6 85.7 100.0 
MARCS_MOUSE Marcks p-S163 (z= 2) 45.8 100.0 89.6 94.1 
MARK2_MOUSE Mark2 p-S453 (z= 2) 100.0 99.7 79.2 92.9 
MARK2_MOUSE Mark2 p-S480 (z= 2) 100.0 73.7 73.6 48.4 
MARK2_MOUSE MARK2 p-S483 (z= 3) 100.0 93.4 75.9 60.1 
MATR3_MOUSE Matr3 p-S188 (z= 2) 26.7 62.7 100.0 78.2 
MATR3_MOUSE Matr3 p-S188 (z= 4) 44.9 34.2 59.9 100.0 
MBB1A_MOUSE Mybbp1a p-S1164 (z= 2) 89.2 86.6 100.0 96.5 
MBB1A_MOUSE Mybbp1a p-S1164 (z= 2) 100.0 97.3 74.7 82.4 
MBB1A_MOUSE Mybbp1a p-S1187 (z= 3) 65.9 100.0 49.2 78.0 
MBB1A_MOUSE Mybbp1a p-S1248 (z= 3) 100.0 29.6 26.3 28.3 
MBB1A_MOUSE Mybbp1a p-S1253 (z= 2) 73.7 100.0 42.4 54.4 
MBB1A_MOUSE Mybbp1a p-S1253 p-S1255 (z= 3) 100.0 75.1 32.0 45.1 
MBB1A_MOUSE Mybbp1a p-S1280 (z= 2) 79.2 100.0 96.8 67.1 
MBB1A_MOUSE Mybbp1a p-S6 (z= 3) 66.0 100.0 78.0 81.6 
MBB1A_MOUSE Mybbp1a p-T1251 p-T1256 (z= 2) 45.6 100.0 44.2 74.5 
MCAF1_MOUSE Atf7ip p-S593 (z= 2) 100.0 86.9 56.3 28.1 
MCES_MOUSE Rnmt p-S100 (z= 2) 72.0 51.2 82.8 100.0 
MCES_MOUSE Rnmt p-S15 (z= 2) 100.0 46.9 88.8 77.9 
MCM2_MOUSE Mcm2 p-S139 (z= 2) 100.0 93.6 92.7 93.9 
MCM2_MOUSE Mcm2 p-S139 (z= 3) 100.0 77.1 76.5 57.1 
MCM2_MOUSE Mcm2 p-S139 p-S140 (z= 2) 100.0 82.7 94.1 99.7 
MCM2_MOUSE Mcm2 p-S139 p-S140 (z= 3) 100.0 67.3 77.6 80.0 
MCM2_MOUSE Mcm2 p-S139 p-S140 (z= 3) 81.0 80.0 100.0 89.2 
MCM2_MOUSE Mcm2 p-S140 (z= 3) 91.5 100.0 89.1 77.8 
MCM2_MOUSE Mcm2 p-S21 p-S26 (z= 2) 83.7 99.4 100.0 90.0 
MCM2_MOUSE Mcm2 p-S26 (z= 2) 100.0 82.1 92.6 75.7 
MCM2_MOUSE Mcm2 p-S26 p-S27 (z= 2) 78.0 100.0 45.7 75.0 
MCM2_MOUSE Mcm2 p-S27 (z= 2) 84.6 100.0 84.8 75.4 
MCM2_MOUSE Mcm2 p-S40 p-S41 (z= 2) 57.4 2.1 100.0 48.2 
MCM2_MOUSE Mcm2 p-S41 (z= 2) 82.5 96.3 100.0 74.9 
MCM2_MOUSE Mcm2 p-S41 (z= 4) 100.0 58.7 57.2 9.7 
MCM3_MOUSE Mcm3 p-S668 p-S672 (z= 3) 98.3 100.0 74.9 89.3 
MCM3_MOUSE Mcm3 p-S672 (z= 3) 91.1 91.2 64.2 100.0 
MCM3_MOUSE Mcm3 p-S672 (z= 3) 100.0 91.2 87.9 99.2 
MCM3_MOUSE Mcm3 p-S672 (z= 3) 100.0 81.8 72.5 73.9 
MCM3_MOUSE Mcm3 p-T719 (z= 3) 86.5 93.6 100.0 84.0 
MCM4_MOUSE Mcm4 p-S119 (z= 2) 84.7 100.0 94.0 72.2 
MCM4_MOUSE Mcm4 p-S31 (z= 2) 100.0 0.0 0.0 37.1 
MCM4_MOUSE Mcm4 p-S53 (z= 4) 90.3 4.5 100.0 0.0 
MCM6_MOUSE Mcm6 p-S704 (z= 3) 71.5 85.2 100.0 68.7 
MCPT2_MOUSE Mcpt2 p-S217 p-Y219 p-T228 (z= 4) 74.4 100.0 82.2 80.8 
MD1L1_MOUSE Mad1l1 p-T9 p-S13 (z= 4) 38.9 10.0 100.0 32.1 
MDC1_MOUSE Mdc1 p-S168 (z= 2) 100.0 69.2 73.0 67.5 
MED1_MOUSE Med1 p-S1078 p-S1079 p-Y1083 (z= 4) + Oxi 88.3 39.3 100.0 90.5 
MED24_MOUSE Med24 p-S871 (z= 2) 100.0 79.7 82.6 93.2 
MELK_MOUSE Melk p-S497 (z= 2) 50.3 100.0 49.4 91.9 
MELK_MOUSE Melk p-S521 (z= 2) 100.0 78.9 81.1 96.3 
MELT_MOUSE Veph1 p-S783 (z= 2) 81.5 63.9 100.0 87.3 
MEPCE_MOUSE Mepce p-T188 p-S191 (z= 2) 88.7 53.6 100.0 70.5 
METL6_MOUSE Mettl6 p-T276 p-S281 (z= 3) 58.2 0.0 100.0 0.0 
MFAP1_MOUSE Mfap1 p-S116 p-S118 (z= 2) 2.3 71.7 100.0 95.8 
MFAP1_MOUSE Mfap1 p-S116 p-S118 (z= 3) 96.6 76.0 94.7 100.0 
MFAP1_MOUSE Mfap1 p-S132 p-S133 (z= 2) 74.1 86.4 95.0 100.0 
MFAP1_MOUSE Mfap1 p-S132 p-S133 (z= 3) 82.8 76.6 86.5 100.0 
MFAP1_MOUSE Mfap1 p-S132 p-S133 (z= 3) 100.0 78.0 79.7 83.8 
MFAP1_MOUSE Mfap1 p-S52 p-S53 (z= 3) 88.3 70.9 100.0 78.2 
MFAP1_MOUSE Mfap1 p-S52 p-S53 (z= 3) 100.0 78.0 76.1 58.0 
MFAP1_MOUSE Mfap1 p-T267 (z= 2) 86.5 89.6 100.0 72.2 
MFAP1_MOUSE Mfap1 p-T267 (z= 3) 87.2 52.1 100.0 99.9 
MIA3_MOUSE Mia3 p-S1766 (z= 2) 77.9 100.0 53.8 30.6 
MILK1_MOUSE Micall1 p-S496 (z= 3) 100.0 64.1 76.1 87.7 
MK01_MOUSE Mapk1 p-T183 p-Y185 (z= 3) 70.3 92.3 88.7 100.0 
MK03_MOUSE Mapk3 p-T203 p-Y205 (z= 3) 70.2 91.3 76.7 100.0 
MKL1_MOUSE Mkl1 p-T488 p-S492 (z= 2) 100.0 45.1 61.2 56.1 
MLF2_MOUSE Mlf2 p-S237 (z= 2) 100.0 5.0 93.3 75.2 
MLL2_MOUSE Mll2 p-S4789 (z= 2) 100.0 81.2 67.5 95.8 
MOR2A_MOUSE MOR2A p-S977 (z= 2) 100.0 58.6 85.4 44.5 
MOR2A_MOUSE Morc2a p-S614 (z= 2) 100.0 98.4 88.0 88.6 
MOV10_MOUSE Mov10 p-S967 (z= 3) 26.1 100.0 32.2 0.4 
MPP10_MOUSE Mphosph10 p-S164 p-S168 p-S172 (z= 3) 89.0 93.6 100.0 74.2 
MPRI_MOUSE Igf2r p-S2471 (z= 2) 68.7 100.0 42.0 45.1 
MPRIP_MOUSE Mprip p-S992 (z= 3) 100.0 73.4 81.4 44.2 
MRE11_MOUSE Mre11a p-S686 (z= 2) 90.5 88.7 100.0 94.2 
MRE11_MOUSE Mre11a p-S686 (z= 3) 95.7 79.9 100.0 100.0 
MRP_MOUSE Marcksl1 p-S104 (z= 2) 79.4 100.0 77.4 80.8 
MRP_MOUSE Marcksl1 p-S22 (z= 2) 70.3 74.9 85.3 100.0 
MRP_MOUSE Marcksl1 p-T148 (z= 2) 64.6 100.0 42.3 61.3 
MRP_MOUSE Marcksl1 p-T85 (z= 2) 95.9 100.0 77.5 89.4 
MRP_MOUSE Marcksl1 p-T85 (z= 3) 75.6 100.0 61.7 34.9 
MSH6_MOUSE Msh6 p-S252 p-S254 p-S261 (z= 3) 100.0 78.2 87.2 97.4 
MSH6_MOUSE Msh6 p-S63 (z= 2) 52.7 100.0 36.6 69.9 
MTA1_MOUSE Mta1 p-S449 (z= 2) 100.0 84.6 51.3 54.3 
MTA1_MOUSE Mta1 p-S449 (z= 3) 100.0 98.4 69.9 87.1 
MTA1_MOUSE Mta1 p-S576 (z= 2) 86.1 82.0 88.2 100.0 
MTA3_MOUSE Mta3 p-S516 (z= 2) 100.0 70.9 89.7 73.7 
MTMR2_MOUSE Mtmr2 p-S6 (z= 2) 96.7 100.0 84.9 98.0 
MTR1_MOUSE Ftsjd2 p-S28 p-S30 (z= 3) 81.3 93.8 100.0 98.5 
MTR1B_MOUSE MTR1B p-T342 (z= 3) 83.2 100.0 48.4 97.0 
MY18A_MOUSE Myo18a p-S140 (z= 2) 100.0 94.9 87.2 59.0 
MY18A_MOUSE Myo18a p-S1966 p-S1970 (z= 3) 100.0 79.1 84.9 88.8 
MY18A_MOUSE Myo18a p-S2037 p-T2041 (z= 2) 67.5 100.0 85.7 73.2 
MYBB_MOUSE Mybl2 p-S505 p-T522 p-T524 (z= 3) + Oxi 80.1 53.6 100.0 74.1 
MYC_MOUSE Myc p-T58 p-S62 (z= 3) 93.1 83.5 100.0 69.9 
MYH10_MOUSE Myh10 p-S1956 (z= 2) 63.2 63.7 100.0 83.4 
MYH9_MOUSE Myh9 p-S1943 (z= 2) 43.7 30.0 100.0 48.1 
MYH9_MOUSE Myh9 p-S1943 (z= 2) 81.6 93.7 87.1 100.0 
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MYH9_MOUSE Myh9 p-S1943 (z= 2) 93.0 93.4 100.0 65.9 
MYH9_MOUSE Myh9 p-S1943 (z= 2) 61.3 100.0 86.6 67.7 
MYH9_MOUSE Myh9 p-S1943 (z= 3) 76.0 100.0 78.1 84.5 
MYH9_MOUSE Myh9 p-T1939 (z= 3) 0.2 2.1 100.0 11.6 
MYH9_MOUSE Myh9 p-T1939 p-S1943 (z= 3) 57.7 92.4 65.4 100.0 
MYL9_MOUSE Myl9 p-S20 (z= 2) 28.9 91.3 64.3 100.0 
MYL9_MOUSE Myl9 p-S20 (z= 3) + Oxi 16.3 33.6 70.2 100.0 
MYL9_MOUSE Myl9 p-T19 p-S20 (z= 2) 11.8 43.8 100.0 89.2 
MYL9_MOUSE Myl9 p-T19 p-S20 (z= 3) 28.7 45.7 100.0 88.6 
MYO9B_MOUSE Myo9b p-S1220 (z= 3) 100.0 87.6 80.0 94.7 
MYO9B_MOUSE Myo9b p-S1264 (z= 3) 88.1 91.9 82.3 100.0 
MYPT1_MOUSE Ppp1r12a p-S417 (z= 3) 100.0 71.3 81.9 60.6 
MYPT1_MOUSE Ppp1r12a p-T419 (z= 3) 80.6 100.0 82.1 90.7 
NACAM_MOUSE Naca p-S2138 (z= 3) 100.0 86.3 91.4 90.8 
NADK_MOUSE Nadk p-S48 (z= 2) 100.0 44.9 66.4 28.7 
NASP_MOUSE Nasp p-S712 (z= 2) 36.4 100.0 0.0 0.0 
NBEL2_MOUSE Nbeal2 p-T929 p-S940 (z= 4) 97.8 88.8 90.1 100.0 
NBN_MOUSE Nbn p-S398 (z= 2) 100.0 77.2 54.1 73.0 
NCBP1_MOUSE Ncbp1 p-S22 (z= 3) 74.6 100.0 90.2 84.9 
NCOA5_MOUSE Ncoa5 p-S29 p-S34 (z= 2) 89.5 100.0 99.1 73.0 
NCOA5_MOUSE Ncoa5 p-S29 p-S34 (z= 3) 100.0 65.2 72.3 56.2 
NCOAT_MOUSE Mgea5 p-S364 (z= 3) 63.3 67.4 100.0 80.8 
NCOR1_MOUSE Ncor1 p-S2165 (z= 3) 83.0 84.4 100.0 66.7 
NCOR1_MOUSE Ncor1 p-S2198 (z= 2) 100.0 77.2 59.4 98.3 
NDRG1_MOUSE Ndrg1 p-S332 p-S333 (z= 2) 76.4 56.3 71.1 100.0 
NDRG1_MOUSE Ndrg1 p-S333 p-T335 p-S336 (z= 2) 60.8 76.9 48.6 100.0 
NDRG1_MOUSE Ndrg1 p-T328 (z= 2) 78.3 100.0 43.7 55.2 
NDRG1_MOUSE Ndrg1 p-T328 p-S330 (z= 2) 70.3 100.0 24.7 79.7 
NDRG1_MOUSE Ndrg1 p-T366 (z= 2) 47.2 82.7 9.2 100.0 
NED4L_MOUSE Nedd4l p-S475 (z= 2) 80.2 95.5 70.7 100.0 
NEDD4_MOUSE Nedd4 p-S281 (z= 3) + Oxi 100.0 63.1 54.7 70.9 
NEDD4_MOUSE Nedd4 p-T287 (z= 3) 83.7 86.6 84.7 100.0 
NEK3_MOUSE Nek3 p-T477 (z= 3) 100.0 88.5 94.0 85.0 
NELFB_MOUSE Cobra1 p-S557 (z= 3) 44.9 1.0 100.0 21.1 
NEST_MOUSE Nes p-S1127 (z= 4) 100.0 66.9 56.9 14.5 
NEST_MOUSE Nes p-S1481 (z= 4) 87.1 95.1 76.4 100.0 
NEST_MOUSE Nes p-S1541 (z= 3) 35.1 100.0 70.3 68.9 
NEST_MOUSE Nes p-S169 (z= 3) 100.0 59.0 46.9 12.8 
NEST_MOUSE Nes p-S169 (z= 4) 60.0 100.0 62.9 26.0 
NEST_MOUSE Nes p-S1837 (z= 2) 83.9 100.0 86.1 83.1 
NEST_MOUSE Nes p-S1837 (z= 3) 84.3 100.0 94.0 94.7 
NEST_MOUSE Nes p-S353 (z= 4) 5.0 100.0 85.5 2.3 
NEST_MOUSE Nes p-S623 (z= 3) 54.7 100.0 78.3 78.2 
NEST_MOUSE Nes p-S623 (z= 3) + Oxi 20.6 100.0 80.5 8.0 
NEST_MOUSE Nes p-S688 (z= 2) 70.2 100.0 79.5 93.7 
NEST_MOUSE Nes p-S688 (z= 3) 67.1 100.0 90.5 88.7 
NEST_MOUSE Nes p-S731 (z= 2) 80.2 59.5 100.0 81.4 
NEST_MOUSE Nes p-S894 (z= 2) 100.0 69.5 58.5 55.5 
NEST_MOUSE Nes p-S894 (z= 3) 100.0 80.3 73.3 91.2 
NEST_MOUSE Nes p-S963 (z= 3) 87.4 98.3 100.0 95.7 
NF2IP_MOUSE Nfatc2ip p-S79 p-S81 p-S83 (z= 3) 70.8 57.1 100.0 71.7 
NFAC2_MOUSE Nfatc2 p-S136 (z= 3) 94.2 100.0 82.4 78.8 
NFH_MOUSE Nefh p-S70 p-S71 p-S79 (z= 4) 80.2 83.6 73.8 100.0 
NFIB_MOUSE Nfib p-S328 (z= 3) 100.0 90.6 92.5 82.6 
NFIL3_MOUSE Nfil3 p-S301 (z= 3) 100.0 81.4 37.9 68.2 
NFIX_MOUSE Nfix p-S284 (z= 2) 77.2 79.2 97.7 100.0 
NFIX_MOUSE Nfix p-S301 (z= 3) 88.4 94.0 91.5 100.0 
NFKB2_MOUSE Nfkb2 p-T425 (z= 3) 100.0 80.3 77.2 76.0 
NHRF1_MOUSE Slc9a3r1 p-S285 (z= 2) 100.0 96.1 92.1 62.8 
NHRF1_MOUSE Slc9a3r1 p-S285 (z= 2) 64.9 100.0 50.4 67.5 
NIBL1_MOUSE Fam129b p-S574 (z= 4) 68.4 100.0 58.3 21.1 
NIBL1_MOUSE Fam129b p-S669 p-S670 p-S695 (z= 4) 71.4 72.5 100.0 66.1 
NIPA_MOUSE Zc3hc1 p-S343 (z= 3) 58.1 100.0 77.4 66.4 
NIPA_MOUSE Zc3hc1 p-S394 (z= 3) + Oxi 100.0 90.1 79.0 71.7 
NKAP_MOUSE Nkap p-S147 (z= 2) 62.6 79.4 100.0 80.7 
NKPD1_MOUSE Nkpd1 p-T408 p-T412 (z= 3) 93.4 97.6 100.0 91.3 
NKTR_MOUSE Nktr p-S1148 (z= 3) 52.4 92.5 100.0 94.0 
NMT1_MOUSE Nmt1 p-S47 (z= 2) 57.2 100.0 51.4 66.8 
NOC2L_MOUSE Noc2l p-S673 p-S674 (z= 2) 4.6 1.8 2.3 100.0 
NOC2L_MOUSE Noc2l p-S673 p-S674 (z= 3) 100.0 59.1 41.8 7.0 
NOC2L_MOUSE Noc2l p-S673 p-S674 p-T680 (z= 2) 58.1 40.6 100.0 62.7 
NODAL_MOUSE Nodal p-S175 (z= 2) 77.9 48.8 1.6 100.0 
NOG1_MOUSE Gtpbp4 p-S468 p-S470 p-S472 (z= 2) 66.1 100.0 92.7 69.4 
NOL7_MOUSE Nol7 p-S129 (z= 3) 92.6 100.0 62.1 79.1 
NOL8_MOUSE Nol8 p-S1064 p-S1065 p-S1077 (z= 4) 94.5 81.9 100.0 91.1 
NOL8_MOUSE Nol8 p-S300 p-S306 (z= 2) 46.3 100.0 42.8 60.6 
NOP14_MOUSE Nop14 p-S96 (z= 2) 82.1 100.0 44.1 54.9 
NOP56_MOUSE Nop56 p-S513 (z= 2) 73.5 100.0 43.4 55.3 
NOP56_MOUSE Nop56 p-S513 (z= 2) 21.4 100.0 55.2 69.8 
NOP56_MOUSE Nop56 p-S513 (z= 3) 31.4 78.1 100.0 77.2 
NOP56_MOUSE Nop56 p-S513 (z= 3) 100.0 94.8 77.2 73.0 
NOP56_MOUSE Nop56 p-S513 (z= 3) 100.0 75.9 58.5 57.3 
NOP56_MOUSE Nop56 p-S513 (z= 3) 100.0 26.4 17.2 14.8 
NOP56_MOUSE Nop56 p-S513 (z= 3) + Oxi 78.8 83.1 100.0 87.0 
NOP56_MOUSE Nop56 p-S513 (z= 3) + Oxi 100.0 78.4 69.9 78.5 
NOP56_MOUSE Nop56 p-S528 p-T545 p-T546 (z= 3) 100.0 91.9 91.3 84.1 
NOP56_MOUSE Nop56 p-S529 p-S543 (z= 3) 100.0 49.3 65.4 66.7 
NOP56_MOUSE Nop56 p-S529 p-S543 (z= 3) 87.1 100.0 74.1 84.2 
NOP56_MOUSE Nop56 p-S536 (z= 2) 100.0 67.2 65.9 73.9 
NOP56_MOUSE Nop56 p-S536 (z= 2) 51.9 100.0 69.5 77.9 
NOP56_MOUSE Nop56 p-S536 (z= 3) 100.0 48.8 64.8 41.9 
NOP56_MOUSE Nop56 p-S536 (z= 3) 91.5 100.0 95.6 65.3 
NOP56_MOUSE Nop56 p-S536 p-S543 (z= 2) 100.0 50.0 89.6 86.6 
NOP56_MOUSE Nop56 p-S536 p-S543 (z= 2) 0.0 0.0 100.0 0.0 
NOP56_MOUSE Nop56 p-S536 p-S543 p-T545 (z= 3) 75.7 64.8 95.2 100.0 
NOP56_MOUSE Nop56 p-S536 p-S543 p-T546 (z= 2) 59.6 0.0 100.0 0.0 
NOP56_MOUSE Nop56 p-S536 p-T545 (z= 3) 100.0 56.8 72.2 60.5 
NOP56_MOUSE Nop56 p-S554 (z= 2) 66.4 100.0 75.9 78.7 
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NOP58_MOUSE Nop58 p-S509 (z= 3) 100.0 22.1 44.5 0.0 
NOP58_MOUSE Nop58 p-S509 (z= 3) 100.0 91.2 91.0 73.9 
NOP58_MOUSE Nop58 p-S509 p-S521 (z= 3) 60.3 75.1 79.5 100.0 
NOP58_MOUSE Nop58 p-S509 p-S521 (z= 3) 100.0 77.9 72.0 69.9 
NOP58_MOUSE Nop58 p-S509 p-T517 (z= 3) 86.5 86.6 96.6 100.0 
NOP58_MOUSE Nop58 p-T515 p-S521 (z= 4) 100.0 86.9 81.3 86.6 
NP1L1_MOUSE Nap1l1 p-T62 (z= 2) 87.7 91.6 100.0 74.7 
NP1L4_MOUSE Nap1l4 p-S125 (z= 3) 100.0 89.7 69.6 81.2 
NP1L4_MOUSE Nap1l4 p-S125 (z= 4) 100.0 87.7 79.1 90.1 
NPM_MOUSE Npm1 p-S10 (z= 3) + Oxi 43.9 100.0 39.4 59.7 
NPM_MOUSE Npm1 p-S125 (z= 3) 71.5 93.3 83.5 100.0 
NPM_MOUSE Npm1 p-S125 (z= 4) 34.3 51.2 42.8 100.0 
NPM_MOUSE Npm1 p-S125 (z= 4) 92.1 100.0 69.6 97.1 
NPM_MOUSE Npm1 p-S125 (z= 4) + Oxi 100.0 61.5 37.5 67.5 
NPM_MOUSE Npm1 p-S139 (z= 2) 80.1 93.6 100.0 72.7 
NPM_MOUSE Npm1 p-S252 (z= 2) 74.8 70.6 100.0 69.3 
NPM_MOUSE Npm1 p-S4 (z= 4) + Oxi 79.9 38.8 100.0 79.7 
NPM_MOUSE Npm1 p-S4 p-S10 (z= 4) + Oxi 100.0 72.2 65.9 83.1 
NPM_MOUSE Npm1 p-S4 p-Y17 (z= 4) 43.5 100.0 42.9 43.1 
NPM_MOUSE Npm1 p-S70 (z= 4) 100.0 99.7 75.5 29.8 
NPM_MOUSE Npm1 p-S70 (z= 4) 23.4 100.0 0.0 11.8 
NPM_MOUSE Npm1 p-S70 (z= 4) + Oxi 46.0 100.0 32.7 91.7 
NPM_MOUSE Npm1 p-T198 (z= 2) 62.4 70.0 100.0 58.8 
NPM_MOUSE Npm1 p-T217 (z= 2) 83.6 100.0 89.2 65.0 
NRBP_MOUSE Nrbp1 p-T431 (z= 2) 96.8 100.0 58.7 81.5 
NRDC_MOUSE Nrd1 p-S85 (z= 2) 59.0 100.0 50.7 25.9 
NS1BP_MOUSE Ivns1abp p-S338 (z= 3) 66.7 100.0 95.3 6.7 
NSF1C_MOUSE Nsfl1c p-S114 (z= 2) 30.3 0.0 100.0 44.1 
NSF1C_MOUSE Nsfl1c p-S114 (z= 3) 100.0 0.0 0.0 0.0 
NSF1C_MOUSE Nsfl1c p-S140 (z= 3) 100.0 73.4 56.6 57.1 
NSRP1_MOUSE Nsrp1 p-S31 p-S33 (z= 3) 81.1 75.5 85.6 100.0 
NSUN2_MOUSE Nsun2 p-S23 (z= 2) 64.3 100.0 60.7 68.5 
NSUN2_MOUSE Nsun2 p-S723 (z= 2) 66.3 80.7 100.0 88.6 
NSUN2_MOUSE Nsun2 p-S723 (z= 3) 64.1 76.2 63.6 100.0 
NSUN2_MOUSE Nsun2 p-S723 (z= 3) 99.6 100.0 90.1 84.2 
NU160_MOUSE Nup160 p-S1123 (z= 3) 70.5 100.0 81.4 88.0 
NUCKS_MOUSE Nucks1 p-S181 (z= 2) 100.0 1.4 5.9 12.7 
NUCKS_MOUSE Nucks1 p-S181 (z= 2) 100.0 53.5 40.9 40.3 
NUCKS_MOUSE Nucks1 p-S181 (z= 2) 70.0 100.0 62.0 84.2 
NUCKS_MOUSE Nucks1 p-S181 (z= 2) 66.5 100.0 55.7 51.3 
NUCKS_MOUSE Nucks1 p-S181 (z= 3) 100.0 96.2 63.8 66.1 
NUCKS_MOUSE Nucks1 p-S19 (z= 2) 37.4 27.8 94.1 100.0 
NUCKS_MOUSE Nucks1 p-S19 (z= 2) 68.0 82.5 81.1 100.0 
NUCKS_MOUSE Nucks1 p-S19 (z= 3) 33.9 64.0 59.2 100.0 
NUCKS_MOUSE Nucks1 p-S19 (z= 3) 65.8 79.2 81.6 100.0 
NUCKS_MOUSE Nucks1 p-S19 (z= 3) 100.0 63.8 73.7 80.3 
NUCKS_MOUSE Nucks1 p-S214 (z= 2) 68.4 89.5 100.0 66.1 
NUCKS_MOUSE Nucks1 p-S214 (z= 3) 98.2 98.4 100.0 98.2 
NUCKS_MOUSE Nucks1 p-S214 (z= 4) 75.1 90.2 100.0 77.5 
NUCKS_MOUSE Nucks1 p-S58 (z= 2) 64.8 93.5 92.2 100.0 
NUCKS_MOUSE Nucks1 p-S58 p-S61 (z= 2) 85.2 72.6 91.8 100.0 
NUCKS_MOUSE Nucks1 p-S58 p-S61 (z= 3) 100.0 89.7 79.0 74.8 
NUCKS_MOUSE Nucks1 p-T179 p-S181 (z= 2) 70.2 41.7 65.3 100.0 
NUCKS_MOUSE Nucks1 p-T179 p-S181 (z= 2) 100.0 79.2 65.0 74.3 
NUCL_MOUSE Ncl p-S145 p-S157 (z= 3) 83.2 72.5 100.0 87.3 
NUCL_MOUSE Ncl p-S145 p-S157 (z= 4) 49.3 73.1 81.7 100.0 
NUCL_MOUSE Ncl p-S189 p-S212 (z= 3) 57.0 43.1 100.0 61.5 
NUCL_MOUSE Ncl p-S189 p-S212 (z= 3) + Oxi 93.6 74.8 68.9 100.0 
NUCL_MOUSE Ncl p-S189 p-S212 (z= 4) 61.1 51.7 67.6 100.0 
NUCL_MOUSE Ncl p-S28 p-S34 p-S40 (z= 3) 40.6 47.2 87.4 100.0 
NUCL_MOUSE Ncl p-S28 p-S34 p-S40 (z= 3) 82.6 64.5 92.2 100.0 
NUCL_MOUSE Ncl p-S28 p-S34 p-S40 (z= 3) 79.4 81.9 93.5 100.0 
NUCL_MOUSE Ncl p-S28 p-S34 p-S40 (z= 3) + Oxi 100.0 61.9 58.6 59.4 
NUCL_MOUSE Ncl p-S28 p-S34 p-S40 (z= 3) + Oxi 56.6 81.7 53.3 100.0 
NUCL_MOUSE Ncl p-S28 p-S34 p-S40 (z= 4) 44.8 47.6 100.0 64.1 
NUCL_MOUSE Ncl p-S28 p-S34 p-S40 (z= 4) 75.1 71.5 100.0 91.0 
NUCL_MOUSE Ncl p-S28 p-S34 p-S40 (z= 4) + Oxi 100.0 41.2 43.0 65.0 
NUCL_MOUSE Ncl p-S28 p-S34 p-S40 (z= 4) + Oxi 77.8 81.0 96.6 100.0 
NUCL_MOUSE Ncl p-S403 (z= 2) 73.5 77.0 100.0 82.3 
NUCL_MOUSE Ncl p-T76 (z= 2) 100.0 75.9 83.9 68.3 
NUCL_MOUSE Ncl p-T84 (z= 2) 89.2 44.2 100.0 42.1 
NUDC3_MOUSE Nudcd3 p-S218 p-S223 (z= 4) + Oxi 100.0 83.2 63.6 97.1 
NUDT5_MOUSE Nudt5 p-T7 (z= 3) 100.0 71.0 67.8 69.3 
NUFP1_MOUSE Nufip1 p-S329 p-S331 p-S333 (z= 3) 86.5 80.8 100.0 73.7 
NUFP2_MOUSE Nufip2 p-S626 (z= 2) 81.4 100.0 85.6 79.1 
NUFP2_MOUSE Nufip2 p-S626 (z= 3) 0.9 62.1 1.2 100.0 
NUFP2_MOUSE Nufip2 p-S649 (z= 2) 85.2 89.8 100.0 75.1 
NVL_MOUSE Nvl p-S190 (z= 2) 85.6 90.3 93.2 100.0 
ODP2_MOUSE Dlat p-T66 (z= 3) 68.0 100.0 83.5 79.9 
ODPA_MOUSE Pdha1 p-S232 (z= 2) 80.6 91.9 100.0 98.9 
ODPA_MOUSE Pdha1 p-S293 p-S300 (z= 3) 100.0 92.8 95.0 62.7 
ODPA_MOUSE Pdha1 p-S293 p-Y301 (z= 3) 100.0 92.8 94.9 62.5 
OGFR_MOUSE Ogfr p-S403 (z= 2) 67.1 100.0 98.6 98.3 
OSB11_MOUSE Osbpl11 p-S186 (z= 2) 100.0 80.2 78.2 82.3 
OSB11_MOUSE Osbpl11 p-S194 (z= 3) 84.1 63.0 100.0 25.5 
OSBL3_MOUSE Osbpl3 p-S271 (z= 3) 90.7 94.2 100.0 91.3 
OSTF1_MOUSE Ostf1 p-S214 (z= 2) 100.0 81.8 96.1 98.4 
OTU7A_MOUSE Otud7a p-S593 (z= 2) 100.0 66.0 70.6 49.1 
OTUD4_MOUSE Otud4 p-S1000 (z= 2) 59.8 62.4 82.8 100.0 
OTUD4_MOUSE Otud4 p-S1016 p-S1017 (z= 3) 68.3 79.2 100.0 88.6 
P3C2A_MOUSE Pik3c2a p-S261 (z= 2) 53.8 100.0 66.3 75.5 
P3C2A_MOUSE Pik3c2a p-S339 (z= 2) 82.5 99.1 76.8 100.0 
P4R3B_MOUSE Smek2 p-T358 (z= 3) + Oxi 54.0 1.2 100.0 52.3 
P66A_MOUSE Gatad2a p-S96 p-S103 p-S110 (z= 3) 76.1 79.1 68.3 100.0 
P66B_MOUSE Gatad2b p-T121 p-S123 p-S130 (z= 3) 67.4 80.1 100.0 65.2 
P66B_MOUSE Gatad2b p-T121 p-S123 p-S136 (z= 3) 95.1 81.8 96.1 100.0 
PA1_MOUSE Pa1 p-S236 (z= 2) 71.7 81.6 100.0 84.7 
PA24A_MOUSE Pla2g4a p-S437 (z= 2) 78.8 84.9 94.0 100.0 
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PACN2_MOUSE Pacsin2 p-T424 (z= 3) 71.1 65.6 100.0 70.4 
PAIRB_MOUSE Serbp1 p-S25 (z= 2) 73.7 100.0 87.0 81.2 
PAIRB_MOUSE Serbp1 p-T232 (z= 3) 100.0 77.6 72.8 74.0 
PAK1_MOUSE Pak1 p-T146 (z= 2) 70.1 100.0 72.3 90.9 
PAK1_MOUSE Pak1 p-T230 (z= 2) 100.0 68.0 80.9 74.9 
PAK2_MOUSE Pak2 p-S141 (z= 3) 100.0 91.3 83.9 73.8 
PAK4_MOUSE Pak4 p-S476 (z= 2) 50.1 100.0 45.3 14.9 
PALLD_MOUSE Palld p-S1141 p-S1143 p-S1146 (z= 3) 100.0 77.6 76.4 83.8 
PALLD_MOUSE Palld p-S901 (z= 2) 54.7 100.0 48.0 68.3 
PALLD_MOUSE Palld p-S901 (z= 3) 100.0 53.0 31.9 45.8 
PARD3_MOUSE Pard3 p-S144 (z= 3) 100.0 85.4 81.6 90.8 
PATL1_MOUSE Patl1 p-S179 (z= 2) 100.0 80.8 99.6 70.1 
PAXI_MOUSE Pxn p-S322 (z= 3) 100.0 99.9 80.7 97.3 
PAXI_MOUSE Pxn p-S83 (z= 2) 100.0 88.9 86.5 80.7 
PCBP1_MOUSE Pcbp1 p-S173 (z= 2) 75.2 100.0 39.5 10.5 
PCBP1_MOUSE Pcbp1 p-S173 (z= 2) 40.8 100.0 15.1 62.4 
PCBP1_MOUSE Pcbp1 p-S173 (z= 3) 48.1 7.8 100.0 47.0 
PCBP1_MOUSE Pcbp1 p-S189 (z= 2) 85.2 87.4 100.0 67.7 
PCBP1_MOUSE Pcbp1 p-S189 (z= 3) 90.3 82.4 100.0 74.0 
PCBP1_MOUSE Pcbp1 p-S190 (z= 3) + Oxi 100.0 80.5 81.2 91.8 
PCBP2_MOUSE Pcbp2 p-S183 (z= 3) 100.0 80.3 78.6 79.7 
PCBP2_MOUSE Pcbp2 p-T175 (z= 4) 100.0 92.2 81.8 92.7 
PCM1_MOUSE Pcm1 p-S1766 p-S1769 (z= 3) 100.0 71.8 81.0 80.4 
PCM1_MOUSE Pcm1 p-S1769 (z= 3) 81.9 71.0 100.0 92.7 
PCM1_MOUSE Pcm1 p-S65 (z= 2) 79.7 100.0 73.2 81.5 
PCM1_MOUSE Pcm1 p-S65 p-S69 (z= 2) 100.0 0.0 73.9 41.0 
PCM1_MOUSE Pcm1 p-S957 (z= 3) 100.0 74.1 81.2 66.3 
PCY1A_MOUSE Pcyt1a p-S315 (z= 2) 72.1 100.0 81.7 64.0 
PDCD4_MOUSE Pdcd4 p-S94 (z= 2) 100.0 83.2 85.7 82.3 
PDCD5_MOUSE Pdcd5 p-S119 (z= 2) 76.3 89.6 100.0 83.3 
PDCD5_MOUSE Pdcd5 p-S119 (z= 2) 88.3 100.0 96.3 82.1 
PDCD5_MOUSE Pdcd5 p-S119 (z= 2) + Oxi 100.0 68.4 55.3 59.6 
PDCL3_MOUSE Pdcl3 p-S235 p-S237 (z= 2) 100.0 23.6 30.2 13.1 
PDIA6_MOUSE Pdia6 p-S428 (z= 2) 41.5 72.9 82.9 100.0 
PDIA6_MOUSE Pdia6 p-S428 (z= 3) 100.0 39.2 59.5 81.3 
PDIP3_MOUSE Poldip3 p-S127 (z= 3) 100.0 46.0 57.3 16.6 
PDIP3_MOUSE Poldip3 p-T132 (z= 2) 89.1 85.4 79.6 100.0 
PDLI2_MOUSE Pdlim2 p-S199 p-S204 (z= 2) 100.0 69.5 97.4 88.0 
PDLI2_MOUSE Pdlim2 p-S199 p-S204 (z= 3) 100.0 90.5 89.9 81.4 
PDLI5_MOUSE Pdlim5 p-S137 (z= 3) 100.0 60.5 73.6 65.4 
PDLI5_MOUSE Pdlim5 p-S228 (z= 2) 82.7 100.0 10.4 4.3 
PDS5B_MOUSE Pds5b p-S1166 (z= 2) 63.2 100.0 44.8 84.1 
PDS5B_MOUSE Pds5b p-S1255 (z= 2) 75.7 100.0 89.6 77.0 
PDS5B_MOUSE Pds5b p-S1356 (z= 2) 94.4 100.0 66.0 44.1 
PDS5B_MOUSE Pds5b p-S1356 p-T1368 (z= 2) 30.7 100.0 43.5 34.6 
PDS5B_MOUSE Pds5b p-S1381 (z= 2) 100.0 79.2 79.5 32.7 
PDS5B_MOUSE Pds5b p-S1381 (z= 2) 100.0 63.3 42.3 51.3 
PDXD1_MOUSE Pdxdc1 p-T687 (z= 2) 100.0 95.7 99.5 91.3 
PDXD1_MOUSE Pdxdc1 p-T687 p-T691 (z= 2) 57.4 98.1 71.1 100.0 
PEA15_MOUSE Pea15 p-S116 (z= 2) 100.0 80.4 89.4 93.5 
PEAK1_MOUSE Peak1 p-S282 (z= 2) 67.6 77.2 70.6 100.0 
PEBP1_MOUSE Pebp1 p-S52 (z= 3) 77.9 100.0 97.7 68.4 
PELP1_MOUSE Pelp1 p-S7 p-S13 (z= 3) 95.1 87.0 100.0 73.2 
PERE_MOUSE Epx p-S671 p-S673 (z= 2) 37.5 98.8 54.6 100.0 
PERQ1_MOUSE Gigyf1 p-S408 (z= 2) 96.0 94.5 100.0 87.2 
PERQ2_MOUSE Gigyf2 p-S20 p-S30 (z= 2) 97.0 80.6 87.9 100.0 
PERQ2_MOUSE Gigyf2 p-S26 (z= 2) 99.5 90.5 100.0 91.2 
PERQ2_MOUSE Gigyf2 p-T383 (z= 4) 99.7 91.1 100.0 93.2 
PGAM1_MOUSE Pgam1 p-Y119 (z= 3) + Oxi 100.0 73.4 66.4 98.0 
PGK1_MOUSE Pgk1 p-S203 (z= 2) 78.2 100.0 73.3 84.8 
PGM1_MOUSE Pgm1 p-S117 (z= 3) 26.5 94.1 31.9 100.0 
PGRC1_MOUSE Pgrmc1 p-S181 (z= 2) 57.9 100.0 53.8 47.7 
PGRC1_MOUSE Pgrmc1 p-S181 (z= 3) 100.0 32.2 26.7 25.1 
PGRC1_MOUSE Pgrmc1 p-S181 (z= 3) 82.1 100.0 60.0 80.9 
PGRC2_MOUSE Pgrmc2 p-T205 (z= 4) 81.4 100.0 63.4 51.6 
PHAR4_MOUSE Phactr4 p-S118 (z= 2) 70.1 100.0 74.4 65.5 
PHIP_MOUSE Phip p-S1281 p-S1283 (z= 3) 98.2 100.0 74.2 83.1 
PHIP_MOUSE Phip p-S1783 (z= 2) 84.4 69.8 85.8 100.0 
PHLB1_MOUSE Phldb1 p-S463 (z= 2) 100.0 88.1 99.1 81.9 
PHLB2_MOUSE Phldb2 p-S465 (z= 2) 100.0 87.4 77.3 68.5 
PHLB2_MOUSE Phldb2 p-S510 (z= 3) 100.0 91.4 70.0 54.0 
PHLB2_MOUSE Phldb2 p-S976 (z= 3) 88.4 93.5 84.2 100.0 
PHLP_MOUSE Pdcl p-S293 p-S296 (z= 2) 75.6 98.7 73.9 100.0 
PHLP_MOUSE Pdcl p-S296 (z= 2) 90.7 87.6 100.0 88.0 
PHRF1_MOUSE Phrf1 p-S1201 (z= 2) 92.3 100.0 68.2 48.9 
PI4KB_MOUSE Pi4kb p-S428 (z= 2) 100.0 88.9 91.0 71.7 
PI4KB_MOUSE Pi4kb p-S428 (z= 3) 84.0 100.0 71.3 96.5 
PIGH_MOUSE Pigh p-S8 (z= 2) 87.1 100.0 65.4 85.0 
PININ_MOUSE Pnn p-S100 (z= 3) 100.0 75.3 81.8 83.6 
PININ_MOUSE Pnn p-S100 (z= 3) 100.0 78.7 69.0 46.2 
PININ_MOUSE Pnn p-S380 (z= 3) 14.8 11.2 14.3 100.0 
PININ_MOUSE Pnn p-S380 (z= 3) 100.0 19.6 46.7 19.2 
PITM1_MOUSE Pitpnm1 p-S621 (z= 2) 54.8 0.0 100.0 88.0 
PJA1_MOUSE Pja1 p-T231 (z= 3) 94.7 90.5 85.8 100.0 
PKHG3_MOUSE Plekhg3 p-S1136 p-S1141 (z= 2) 88.0 92.5 81.3 100.0 
PKHG3_MOUSE Plekhg3 p-S76 (z= 2) 83.0 99.6 95.2 100.0 
PKHO2_MOUSE Plekho2 p-S395 (z= 2) 100.0 47.3 53.6 57.8 
PKN2_MOUSE Pkn2 p-S582 (z= 2) 85.6 74.3 100.0 93.4 
PKN3_MOUSE Pkn3 p-S292 p-S302 p-T308 (z= 4) + Oxi 75.9 15.9 100.0 79.4 
PLEC_MOUSE Plec p-S1443 (z= 2) 55.5 100.0 55.8 80.3 
PLEC_MOUSE Plec p-S1729 (z= 2) 60.0 100.0 82.0 68.9 
PLEC_MOUSE Plec p-S4393 (z= 2) 81.1 78.1 82.0 100.0 
PLEC_MOUSE Plec p-S4393 p-S4396 (z= 2) 69.3 100.0 86.7 89.8 
PLEC_MOUSE Plec p-S4413 (z= 3) 74.8 57.9 81.8 100.0 
PLEC_MOUSE Plec p-S4633 (z= 2) 100.0 47.4 79.2 51.5 
PLEC_MOUSE Plec p-T4037 (z= 2) 100.0 56.9 55.3 79.3 
PLEC_MOUSE Plec p-T731 (z= 2) 50.4 100.0 58.6 71.2 
PLTP_MOUSE Pltp p-T330 (z= 3) 100.0 93.1 76.9 50.1 
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PMF1_MOUSE Pmf1 p-S18 (z= 3) 100.0 91.1 82.3 96.5 
PML_MOUSE Pml p-S528 (z= 3) 100.0 71.3 76.3 64.7 
PNISR_MOUSE Pnisr p-S211 (z= 2) 52.1 100.0 81.7 97.7 
PNISR_MOUSE Pnisr p-S211 (z= 3) 100.0 69.3 67.2 67.4 
PP1R7_MOUSE Ppp1r7 p-S24 p-S27 (z= 2) 100.0 68.7 25.7 57.1 
PP1RA_MOUSE Ppp1r10 p-S313 (z= 2) 69.0 100.0 99.6 78.0 
PP1RA_MOUSE Ppp1r10 p-T315 (z= 3) 82.1 99.6 100.0 66.3 
PP6R3_MOUSE Ppp6r3 p-S588 (z= 2) 87.1 80.4 88.6 100.0 
PPHLN_MOUSE Pphln1 p-S219 (z= 2) 78.3 100.0 44.9 26.8 
PPIA_MOUSE Ppia p-T5 (z= 3) 32.5 100.0 14.0 61.0 
PPIG_MOUSE Ppig p-S354 p-T356 (z= 2) 91.7 100.0 80.6 97.3 
PPIG_MOUSE Ppig p-S411 p-S413 (z= 2) 21.9 79.7 100.0 13.1 
PPIL4_MOUSE PPIL4 p-S178 (z= 4) 100.0 94.0 60.9 8.4 
PPM1G_MOUSE Ppm1g p-T212 p-S215 p-S216 (z= 4) 90.4 85.6 81.2 100.0 
PPR18_MOUSE Ppp1r18 p-S146 (z= 2) 80.1 78.1 100.0 44.2 
PPR18_MOUSE Ppp1r18 p-S212 (z= 2) 54.3 44.1 100.0 55.8 
PR38A_MOUSE Prpf38a p-S193 p-S194 (z= 3) 58.5 73.2 89.1 100.0 
PR38A_MOUSE Prpf38a p-S193 p-S194 p-S209 (z= 4) 100.0 46.3 45.9 47.3 
PR38A_MOUSE Prpf38a p-S226 (z= 2) 100.0 79.5 89.2 56.5 
PR40A_MOUSE Prpf40a p-T928 p-S929 p-S931 (z= 3) 68.2 82.4 93.4 100.0 
PRC2A_MOUSE Prrc2a p-S1083 p-S1087 p-S1090 (z= 3) 79.3 0.5 100.0 74.7 
PRC2A_MOUSE Prrc2a p-S1217 (z= 2) 90.7 100.0 93.8 94.5 
PRC2A_MOUSE Prrc2a p-S808 (z= 3) 58.9 100.0 54.0 88.8 
PRC2C_MOUSE Prrc2c p-S1514 (z= 2) 77.2 100.0 38.4 33.9 
PRC2C_MOUSE Prrc2c p-S851 (z= 2) 100.0 74.7 29.3 52.9 
PRDBP_MOUSE Prkcdbp p-S165 p-S166 (z= 3) 85.9 75.7 100.0 93.6 
PRP4B_MOUSE Prpf4b p-S278 (z= 3) 100.0 87.0 83.6 51.1 
PRP4B_MOUSE Prpf4b p-S292 p-S294 (z= 2) 76.4 100.0 74.2 81.7 
PRP4B_MOUSE Prpf4b p-S366 p-S368 (z= 2) 86.6 100.0 87.3 97.5 
PRP4B_MOUSE Prpf4b p-S410 p-S411 (z= 2) 70.7 61.9 100.0 43.9 
PRP4B_MOUSE Prpf4b p-S411 (z= 2) 62.9 37.0 100.0 37.2 
PRP4B_MOUSE Prpf4b p-Y849 (z= 3) 96.2 88.3 94.6 100.0 
PSA3_MOUSE Psma3 p-S250 (z= 2) 79.8 100.0 77.0 97.3 
PSA3_MOUSE Psma3 p-S250 (z= 2) + Oxi 100.0 37.6 82.9 77.8 
PSA5_MOUSE Psma5 p-S56 (z= 2) 73.8 100.0 87.6 91.4 
PSIP1_MOUSE Psip1 p-S106 (z= 2) 46.7 100.0 43.5 56.3 
PSIP1_MOUSE Psip1 p-S270 p-S274 (z= 3) 100.0 65.9 54.5 44.6 
PSIP1_MOUSE Psip1 p-S272 p-S274 (z= 4) 100.0 68.4 61.2 55.1 
PSIP1_MOUSE Psip1 p-T141 (z= 2) 100.0 84.7 43.8 69.4 
PSIP1_MOUSE Psip1 p-T269 p-S272 p-S274 (z= 3) 66.5 43.7 100.0 77.0 
PSIP1_MOUSE Psip1 p-T269 p-S274 (z= 3) 51.0 100.0 32.6 47.2 
PSIP1_MOUSE Psip1 p-T269 p-S274 (z= 3) 88.2 100.0 75.3 78.4 
PSIP1_MOUSE Psip1 p-T271 p-S272 p-S274 (z= 3) 69.2 75.4 100.0 87.0 
PSIP1_MOUSE Psip1 p-T271 p-S272 p-S274 (z= 3) 100.0 74.4 61.7 69.1 
PTN12_MOUSE Ptpn12 p-S323 (z= 4) 100.0 85.4 98.7 87.6 
PTN12_MOUSE Ptpn12 p-S434 (z= 2) 69.7 74.6 78.6 100.0 
PTN12_MOUSE Ptpn12 p-S603 p-S606 p-S608 (z= 3) 65.3 70.7 100.0 67.6 
PTN21_MOUSE Ptpn21 p-S637 (z= 3) 100.0 43.6 30.1 39.9 
PTN21_MOUSE Ptpn21 p-S658 (z= 2) 83.3 100.0 60.3 95.1 
PTN22_MOUSE PTN22 p-Y440 p-S443 (z= 2) 68.0 9.1 100.0 56.6 
PTRF_MOUSE Ptrf p-S171 (z= 2) 34.5 100.0 54.0 44.7 
PTRF_MOUSE Ptrf p-S204 p-S205 (z= 4) 100.0 96.6 51.6 61.8 
PUM2_MOUSE Pum2 p-S136 (z= 2) 100.0 90.1 87.9 95.1 
PUM2_MOUSE Pum2 p-S181 (z= 2) 100.0 74.9 95.0 97.7 
PUR9_MOUSE Atic p-S554 p-T566 (z= 3) 100.0 97.1 87.3 95.9 
PURB_MOUSE Purb p-S310 (z= 2) 71.3 100.0 67.6 28.0 
PURB_MOUSE Purb p-S316 (z= 2) 100.0 48.3 29.4 51.2 
PWP1_MOUSE Pwp1 p-S49 (z= 3) 100.0 71.7 99.3 93.2 
PWP1_MOUSE Pwp1 p-S493 (z= 2) 100.0 99.9 95.2 71.0 
PWP2_MOUSE Pwp2 p-T891 p-S898 (z= 3) 81.2 80.7 100.0 68.0 
PWP2_MOUSE Pwp2 p-T891 p-S898 p-S902 (z= 3) 78.6 68.1 100.0 66.6 
PYRG1_MOUSE PYRG1 p-S562 (z= 2) 100.0 55.8 45.9 16.4 
RAB7A_MOUSE Rab7a p-S72 (z= 2) 13.6 100.0 89.7 57.0 
RAGP1_MOUSE Rangap1 p-S444 (z= 3) 70.6 1.2 100.0 63.6 
RAI14_MOUSE Rai14 p-S414 (z= 3) 56.9 57.6 100.0 65.8 
RAI3_MOUSE Gprc5a p-S344 (z= 2) 63.5 100.0 67.8 62.8 
RALY_MOUSE Raly p-S135 (z= 2) 81.2 100.0 66.7 62.1 
RALY_MOUSE Raly p-S270 p-T274 (z= 3) 100.0 47.0 97.6 96.1 
RALY_MOUSE Raly p-S294 p-S301 p-T304 (z= 3) 91.3 83.6 99.9 100.0 
RALY_MOUSE Raly p-T268 p-S270 (z= 2) 86.1 100.0 59.2 62.8 
RALY_MOUSE Raly p-T268 p-S270 p-T274 (z= 3) 100.0 68.6 74.8 96.8 
RALY_MOUSE Raly p-T274 (z= 2) 100.0 62.2 91.8 84.2 
RALY_MOUSE Raly p-T274 (z= 3) 100.0 69.4 83.9 88.3 
RALY_MOUSE Raly p-T304 (z= 3) 75.6 83.0 100.0 91.4 
RAM_MOUSE Fam103a1 p-S36 (z= 3) 100.0 90.7 93.8 99.6 
RANB3_MOUSE Ranbp3 p-S31 p-S40 (z= 3) 100.0 62.9 81.8 76.8 
RANB3_MOUSE Ranbp3 p-S32 p-S33 p-S40 (z= 3) 100.0 68.0 82.7 87.5 
RANB3_MOUSE Ranbp3 p-S40 (z= 3) 100.0 82.1 83.7 40.1 
RANB3_MOUSE Ranbp3 p-S58 (z= 2) 64.0 100.0 61.3 70.7 
RAVR1_MOUSE Raver1 p-S576 (z= 2) 73.7 92.4 89.2 100.0 
RB15B_MOUSE Rbm15b p-S107 (z= 2) 100.0 63.0 26.1 36.8 
RB40C_MOUSE Rab40c p-S224 p-S226 p-Y241 (z= 4) + Oxi 0.0 100.0 64.5 77.9 
RB40C_MOUSE Rab40c p-Y241 p-S245 p-S252 (z= 4) 58.2 83.5 74.0 100.0 
RBBP6_MOUSE Rbbp6 p-S1179 (z= 2) 84.8 100.0 82.4 73.5 
RBBP6_MOUSE Rbbp6 p-S1179 (z= 3) 100.0 60.0 64.1 48.8 
RBBP6_MOUSE Rbbp6 p-S1179 (z= 3) 68.2 100.0 75.3 66.7 
RBCC1_MOUSE Rb1cc1 p-S237 (z= 2) 100.0 4.7 1.9 5.5 
RBM10_MOUSE Rbm10 p-S723 (z= 2) 100.0 84.5 86.1 80.6 
RBM10_MOUSE Rbm10 p-S723 (z= 3) 100.0 82.7 89.4 86.0 
RBM14_MOUSE Rbm14 p-S618 (z= 2) 59.0 100.0 97.5 61.2 
RBM14_MOUSE Rbm14 p-T206 (z= 2) 94.7 84.2 100.0 83.6 
RBM14_MOUSE Rbm14 p-T206 (z= 2) 94.0 87.3 100.0 81.0 
RBM19_MOUSE Rbm19 p-S944 (z= 3) 37.6 41.8 18.4 100.0 
RBM25_MOUSE Rbm25 p-S581 (z= 3) 64.6 100.0 79.1 83.9 
RBM25_MOUSE Rbm25 p-S673 (z= 2) 63.6 100.0 56.8 45.7 
RBM25_MOUSE Rbm25 p-S675 (z= 2) 100.0 34.1 30.3 19.5 
RBM25_MOUSE Rbm25 p-S675 (z= 3) 100.0 61.3 64.8 54.3 
RBM39_MOUSE Rbm39 p-S136 (z= 2) 97.0 100.0 65.7 59.3 
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RBM39_MOUSE Rbm39 p-S136 (z= 3) 100.0 91.2 87.3 86.2 
RBM39_MOUSE Rbm39 p-S97 (z= 2) 100.0 80.3 98.6 72.8 
RBM5_MOUSE Rbm5 p-S624 (z= 2) 48.7 69.4 71.9 100.0 
RBP1_MOUSE Ralbp1 p-S29 (z= 3) 100.0 77.8 80.5 76.0 
RBP2_MOUSE Ranbp2 p-S2641 (z= 3) 70.1 100.0 86.0 83.6 
RBP2_MOUSE Ranbp2 p-S2729 (z= 4) 28.6 100.0 26.4 37.2 
REEP4_MOUSE Reep4 p-S152 (z= 2) 99.0 100.0 87.7 93.3 
REM2_MOUSE Rem2 p-S27 (z= 2) 99.4 54.1 96.7 100.0 
REM2_MOUSE Rem2 p-S27 (z= 2) 98.3 86.1 100.0 73.7 
REM2_MOUSE Rem2 p-S334 (z= 2) 63.9 100.0 89.5 97.5 
REM2_MOUSE Rem2 p-S69 (z= 2) 82.6 100.0 94.2 76.8 
REM2_MOUSE Rem2 p-S69 (z= 3) 74.4 100.0 76.7 47.0 
REPS1_MOUSE Reps1 p-S561 (z= 2) 75.8 100.0 47.1 81.7 
REQU_MOUSE Dpf2 p-S142 (z= 2) 100.0 76.6 81.4 67.4 
RERE_MOUSE Rere p-S656 (z= 2) 99.1 100.0 99.6 65.3 
RFC1_MOUSE Rfc1 p-S107 p-T109 (z= 3) 100.0 77.0 54.5 73.9 
RFIP1_MOUSE Rab11fip1 p-S358 (z= 2) 100.0 95.9 87.4 92.5 
RFIP5_MOUSE Rab11fip5 p-S307 (z= 2) 93.5 50.2 85.4 100.0 
RGAG1_MOUSE Rgag1 p-S1023 p-T1024 p-T1030 (z= 3) + Oxi 44.1 97.3 100.0 5.6 
RGPS1_MOUSE Ralgps1 p-T390 p-T393 p-S397 (z= 4) + Oxi 75.1 100.0 61.9 98.6 
RHG01_MOUSE Arhgap1 p-S51 (z= 2) 81.7 100.0 74.4 73.1 
RHG05_MOUSE Arhgap5 p-T1216 (z= 2) 88.5 65.9 77.0 100.0 
RHG12_MOUSE Arhgap12 p-T229 p-S238 (z= 3) 91.2 64.1 100.0 83.1 
RHG17_MOUSE Arhgap17 p-T562 (z= 3) 100.0 85.2 91.3 65.9 
RHG17_MOUSE Arhgap17 p-T730 p-T734 p-T736 (z= 3) 68.5 71.7 83.3 100.0 
RHG22_MOUSE Arhgap22 p-S387 (z= 2) 56.1 100.0 50.3 29.2 
RHG35_MOUSE Arhgap35 p-S1179 (z= 2) 100.0 78.8 80.2 95.2 
RIC8A_MOUSE Ric8a p-S435 p-T440 (z= 3) 45.9 73.5 70.9 100.0 
RIN2_MOUSE Rin2 p-S495 (z= 2) 0.0 88.3 83.4 100.0 
RIR2_MOUSE Rrm2 p-S20 (z= 3) 100.0 87.8 78.3 69.0 
RL12_MOUSE Rpl12 p-S38 (z= 2) 100.0 94.0 88.9 93.9 
RL14_MOUSE Rpl14 p-S139 (z= 2) 100.0 74.5 69.2 68.4 
RL18_MOUSE Rpl18 p-S130 (z= 2) 84.9 95.0 100.0 93.0 
RL4_MOUSE Rpl4 p-S295 (z= 2) 100.0 86.2 61.0 62.0 
RL4_MOUSE Rpl4 p-S295 (z= 3) 99.6 100.0 70.1 76.9 
RL6_MOUSE Rpl6 p-S21 (z= 3) 100.0 87.6 77.7 53.4 
RLA0_MOUSE Rplp0 p-S304 p-S307 (z= 2) 61.5 71.8 100.0 89.6 
RLA0_MOUSE Rplp0 p-S304 p-S307 (z= 2) + Oxi 48.8 100.0 24.7 62.0 
RLA0_MOUSE Rplp0 p-S304 p-S307 (z= 3) 100.0 56.8 55.1 95.3 
RLA0_MOUSE Rplp0 p-S304 p-S307 (z= 3) + Oxi 100.0 53.9 23.2 2.2 
RLA0_MOUSE Rplp0 p-S304 p-S307 (z= 4) 0.5 0.6 0.5 100.0 
RLA0_MOUSE Rplp0 p-T286 p-S304 (z= 4) + Oxi 91.3 77.1 75.5 100.0 
RLA1_MOUSE Rplp1 p-S101 p-S104 (z= 2) 42.9 69.3 66.9 100.0 
RLA1_MOUSE Rplp1 p-S101 p-S104 (z= 2) + Oxi 100.0 67.2 91.4 88.7 
RLA2_MOUSE Rplp2 p-S102 p-S105 (z= 2) 57.9 58.0 100.0 77.3 
RLA2_MOUSE Rplp2 p-S102 p-S105 (z= 2) 99.9 92.7 84.9 100.0 
RLA2_MOUSE Rplp2 p-S102 p-S105 (z= 2) + Oxi 69.2 78.5 94.5 100.0 
RLA2_MOUSE Rplp2 p-S102 p-S105 (z= 3) 50.5 40.8 100.0 71.9 
RLA2_MOUSE Rplp2 p-S105 (z= 2) 35.6 100.0 28.4 65.9 
RLA2_MOUSE Rplp2 p-S16 (z= 3) 100.0 73.6 70.9 86.7 
RLA2_MOUSE Rplp2 p-S17 (z= 2) 89.1 100.0 57.7 7.1 
RM32_MOUSE RM32 p-T134 (z= 2) 94.8 100.0 90.7 68.9 
RMXL1_MOUSE Rbmxl1 p-S113 p-S121 (z= 3) 72.7 64.0 100.0 80.6 
RMXL1_MOUSE Rbmxl1 p-S165 (z= 2) 100.0 71.5 66.7 42.5 
RMXL1_MOUSE Rbmxl1 p-S205 (z= 1) 100.0 75.9 92.9 78.2 
RMXL1_MOUSE Rbmxl1 p-S205 (z= 2) 93.2 100.0 78.2 91.9 
RMXL1_MOUSE Rbmxl1 p-S349 (z= 2) 88.9 100.0 99.2 85.9 
RNPS1_MOUSE Rnps1 p-S27 (z= 2) 91.0 68.0 100.0 48.2 
ROA1_MOUSE Hnrnpa1 p-S6 (z= 2) 92.6 100.0 86.5 72.3 
ROA1_MOUSE Hnrnpa1 p-S6 (z= 3) 70.8 100.0 41.5 33.0 
ROA1_MOUSE Hnrnpa1 p-S6 (z= 3) 100.0 82.8 81.7 56.1 
ROA2_MOUSE Hnrnpa2b1 p-S259 (z= 3) 86.6 79.6 83.9 100.0 
ROA3_MOUSE Hnrnpa3 p-S359 (z= 2) 100.0 60.5 89.9 85.3 
RON_MOUSE Mst1r p-S216 p-S218 (z= 2) 93.3 71.5 100.0 3.1 
RPA34_MOUSE Cd3eap p-S173 (z= 3) 100.0 90.4 93.4 90.0 
RPAP3_MOUSE Rpap3 p-S429 (z= 2) 100.0 72.2 41.7 23.2 
RPB1_MOUSE Polr2a p-S1913 (z= 2) 90.0 100.0 71.3 84.8 
RPR1B_MOUSE Rprd1b p-S166 (z= 3) 97.0 56.5 93.9 100.0 
RPRD2_MOUSE Rprd2 p-S392 (z= 2) 72.4 91.5 96.5 100.0 
RPRD2_MOUSE Rprd2 p-S749 (z= 3) 99.2 99.8 100.0 93.9 
RPTOR_MOUSE Rptor p-S863 (z= 2) 69.2 87.2 100.0 92.0 
RRMJ3_MOUSE Ftsj3 p-S335 p-S336 (z= 2) 0.0 65.1 1.3 100.0 
RRP1_MOUSE Rrp1 p-S434 (z= 2) 100.0 80.6 39.5 67.2 
RRP12_MOUSE Rrp12 p-S1081 (z= 2) 15.8 100.0 37.7 91.1 
RRP5_MOUSE Pdcd11 p-S1468 (z= 2) 26.9 100.0 66.6 75.4 
RS17_MOUSE Rps17 p-S113 (z= 2) 93.4 100.0 39.5 57.2 
RS3_MOUSE Rps3 p-T221 (z= 2) 83.1 94.8 98.2 100.0 
RS6_MOUSE Rps6 p-S235 p-S236 (z= 2) 37.4 98.7 54.5 100.0 
RS6_MOUSE Rps6 p-S235 p-S247 (z= 2) 88.1 100.0 8.6 30.5 
RS6_MOUSE Rps6 p-S236 (z= 2) 53.4 100.0 71.1 69.9 
RS6_MOUSE Rps6 p-S236 p-S240 (z= 3) 68.3 100.0 43.5 98.5 
RS6_MOUSE Rps6 p-S240 (z= 2) 100.0 48.2 35.9 19.4 
RSRC2_MOUSE Rsrc2 p-S45 (z= 2) 59.4 13.5 100.0 31.6 
RTKN_MOUSE Rtkn p-S220 (z= 2) 65.9 49.1 70.5 100.0 
RTN4_MOUSE Rtn4 p-S165 (z= 3) 55.0 100.0 37.7 36.5 
RTN4_MOUSE Rtn4 p-S768 (z= 3) 100.0 86.1 61.4 47.8 
RTN4_MOUSE Rtn4 p-S832 p-T834 (z= 3) 11.6 100.0 84.7 6.2 
RTN4_MOUSE Rtn4 p-T171 (z= 3) 100.0 58.2 56.0 14.8 
RTN4_MOUSE Rtn4 p-T98 (z= 3) 74.9 94.0 76.0 100.0 
RTP4_MOUSE Rtp4 p-S179 p-S181 (z= 3) 79.1 68.4 100.0 88.2 
RU17_MOUSE Snrnp70 p-S226 (z= 3) 100.0 93.5 96.0 71.4 
RU17_MOUSE Snrnp70 p-S408 (z= 2) 80.2 44.6 100.0 70.9 
SAFB1_MOUSE Safb p-S366 (z= 2) 62.2 63.7 100.0 81.5 
SAFB1_MOUSE Safb p-S366 (z= 2) 100.0 74.7 72.2 80.2 
SAFB1_MOUSE Safb p-S366 (z= 3) 88.0 19.2 100.0 68.2 
SAFB1_MOUSE Safb p-S366 (z= 4) 100.0 76.4 79.3 61.8 
SAFB1_MOUSE Safb p-S372 (z= 3) 100.0 70.5 70.2 51.5 
SAFB1_MOUSE Safb p-S626 (z= 2) 100.0 95.6 71.8 72.3 
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SAFB1_MOUSE Safb p-T362 (z= 2) 100.0 58.8 48.2 40.7 
SALL3_MOUSE Sall3 p-S889 p-S892 p-S893 (z= 4) 53.1 61.7 61.7 100.0 
SAMH1_MOUSE Samhd1 p-T603 (z= 3) 74.5 100.0 45.3 50.8 
SASH1_MOUSE Sash1 p-S805 (z= 2) 81.0 100.0 85.0 71.7 
SASH1_MOUSE Sash1 p-S83 (z= 3) 82.7 100.0 62.5 70.0 
SC61B_MOUSE Sec61b p-S17 (z= 2) 61.3 100.0 69.9 52.8 
SC61B_MOUSE Sec61b p-S17 (z= 3) 77.3 100.0 60.5 69.6 
SDE2_MOUSE Sde2 p-S269 (z= 2) 100.0 88.0 73.5 86.1 
SDE2_MOUSE Sde2 p-S269 (z= 3) 100.0 94.7 84.5 98.6 
SDPR_MOUSE Sdpr p-S203 p-S204 p-S218 (z= 4) 69.3 100.0 36.6 25.2 
SDPR_MOUSE Sdpr p-S284 p-S293 (z= 3) 100.0 27.9 35.9 32.8 
SDS3_MOUSE Suds3 p-S236 p-S237 (z= 3) 100.0 73.0 56.9 70.3 
SEM6A_MOUSE Sema6a p-S539 p-S549 (z= 4) 95.7 100.0 95.4 98.1 
SENP7_MOUSE Senp7 p-S12 (z= 2) 2.0 100.0 75.7 73.5 
SEPT2_MOUSE Sept2 p-S218 (z= 2) 26.0 53.1 69.3 100.0 
SEPT2_MOUSE Sept2 p-S218 (z= 2) 100.0 80.3 65.6 48.6 
SEPT2_MOUSE Sept2 p-S218 (z= 3) 47.9 80.8 72.2 100.0 
SEPT2_MOUSE Sept2 p-S218 (z= 3) 63.2 97.1 100.0 97.1 
SEPT2_MOUSE Sept2 p-S218 (z= 4) 94.8 93.2 91.3 100.0 
SEPT7_MOUSE Sept7 p-T425 (z= 2) 100.0 85.7 78.6 72.3 
SEPT9_MOUSE Sept9 p-S85 (z= 2) 100.0 74.4 61.5 36.5 
SEPT9_MOUSE Sept9 p-S89 (z= 3) 100.0 15.6 18.6 16.0 
SET_MOUSE Set p-S30 (z= 2) 81.9 66.7 77.5 100.0 
SETBP_MOUSE Setbp1 p-T541 p-S551 p-T556 (z= 4) + Oxi 48.0 0.0 100.0 0.0 
SETX_MOUSE SETX p-T364 (z= 2) 100.0 96.2 57.5 77.9 
SF01_MOUSE Sf1 p-S80 p-S82 (z= 3) 100.0 60.8 63.7 61.3 
SF01_MOUSE Sf1 p-S80 p-S89 (z= 3) 83.5 79.3 100.0 97.1 
SF01_MOUSE Sf1 p-S80 p-Y87 (z= 4) 100.0 65.8 81.2 87.6 
SF3B1_MOUSE Sf3b1 p-T125 p-T142 (z= 3) 50.9 1.5 100.0 64.6 
SF3B1_MOUSE Sf3b1 p-T223 p-T227 (z= 3) 100.0 85.5 87.5 94.9 
SF3B1_MOUSE Sf3b1 p-T326 p-T328 p-S332 (z= 3) 62.4 93.5 54.2 100.0 
SFR1_MOUSE Sfr1 p-S115 (z= 2) 100.0 88.9 78.1 60.9 
SFR1_MOUSE Sfr1 p-S67 (z= 2) 100.0 98.8 63.6 82.0 
SFR1_MOUSE Sfr1 p-S67 p-S71 (z= 2) 54.2 0.1 100.0 49.4 
SFR1_MOUSE Sfr1 p-S67 p-T70 (z= 3) 71.9 100.0 72.5 89.7 
SFR19_MOUSE Scaf1 p-S240 (z= 3) 70.2 100.0 47.9 64.1 
SFR19_MOUSE Scaf1 p-S491 p-S493 (z= 2) 72.6 74.2 100.0 87.5 
SFR19_MOUSE Scaf1 p-S676 p-S682 (z= 2) 86.2 82.5 92.9 100.0 
SGTA_MOUSE Sgta p-S303 p-S307 (z= 2) 53.0 100.0 28.2 74.7 
SGTA_MOUSE Sgta p-S309 (z= 2) 71.1 100.0 87.5 72.5 
SH2B1_MOUSE Sh2b1 p-S127 (z= 3) 94.4 96.2 93.2 100.0 
SH2B3_MOUSE Sh2b3 p-S129 (z= 3) 100.0 87.3 87.6 88.9 
SH3G1_MOUSE Sh3gl1 p-S288 (z= 2) 37.8 100.0 30.9 33.1 
SH3K1_MOUSE Sh3kbp1 p-S274 (z= 2) 81.0 66.6 56.3 100.0 
SH3K1_MOUSE Sh3kbp1 p-S631 (z= 2) 100.0 68.0 74.7 49.6 
SH3K1_MOUSE Sh3kbp1 p-S631 (z= 3) 100.0 73.8 72.6 67.7 
SI1L1_MOUSE Sipa1l1 p-S1507 (z= 2) 41.4 5.9 73.4 100.0 
SI1L1_MOUSE Sipa1l1 p-S1528 (z= 2) 100.0 84.1 94.0 91.6 
SI1L1_MOUSE Sipa1l1 p-S162 (z= 2) 94.9 87.7 94.0 100.0 
SKA3_MOUSE Ska3 p-S154 (z= 3) 77.6 76.2 69.1 100.0 
SKT_MOUSE Skt p-S361 (z= 2) 100.0 48.7 69.0 57.7 
SL9A1_MOUSE Slc9a1 p-S707 (z= 2) 94.1 100.0 60.2 95.9 
SLIRP_MOUSE Slirp p-S105 (z= 2) 100.0 78.6 55.9 47.0 
SLK_MOUSE Slk p-S189 (z= 3) 100.0 88.5 85.9 18.6 
SLTM_MOUSE Sltm p-S289 (z= 2) 100.0 93.8 70.7 68.2 
SLTM_MOUSE Sltm p-S289 (z= 3) 100.0 85.3 94.7 76.6 
SLTM_MOUSE Sltm p-S552 (z= 2) 98.7 100.0 96.9 86.0 
SLU7_MOUSE Slu7 p-S215 (z= 2) 68.8 50.3 100.0 66.2 
SMAP_MOUSE Smap p-S17 (z= 2) 99.3 86.1 100.0 98.0 
SMAP_MOUSE Smap p-S17 (z= 3) 82.5 76.3 89.8 100.0 
SMAP_MOUSE Smap p-S17 (z= 3) 100.0 76.7 81.3 82.4 
SMAP_MOUSE Smap p-S24 (z= 3) 100.0 89.9 91.3 94.0 
SMCA4_MOUSE Smarca4 p-S1419 (z= 3) 100.0 94.4 93.3 83.3 
SMCA5_MOUSE Smarca5 p-S65 (z= 3) 41.8 78.4 54.5 100.0 
SMCA5_MOUSE Smarca5 p-S65 (z= 4) 70.5 100.0 89.4 95.4 
SMGC_MOUSE Muc19 p-S583 p-S600 (z= 4) + Oxi 82.2 80.7 75.9 100.0 
SMN_MOUSE Smn1 p-S25 (z= 2) 94.7 74.5 100.0 89.0 
SMN_MOUSE Smn1 p-S25 p-S28 (z= 2) 100.0 75.7 74.7 60.4 
SMRC1_MOUSE Smarcc1 p-S327 p-S329 (z= 2) 100.0 72.5 54.9 50.3 
SMRC1_MOUSE Smarcc1 p-S327 p-S329 (z= 3) 94.5 18.2 100.0 93.1 
SMRC1_MOUSE Smarcc1 p-S327 p-T336 (z= 2) 100.0 52.1 61.7 37.0 
SMRC2_MOUSE Smarcc2 p-S302 p-S306 (z= 2) 100.0 66.8 65.3 51.4 
SMRCD_MOUSE Smarcad1 p-S124 p-S127 (z= 3) 73.1 75.6 78.5 100.0 
SMRCD_MOUSE Smarcad1 p-S144 p-S145 (z= 3) 100.0 91.2 86.8 65.6 
SMTN_MOUSE Smtn p-S304 (z= 2) 100.0 93.4 94.1 83.2 
SMTN_MOUSE Smtn p-T440 (z= 3) 76.1 100.0 89.8 85.5 
SN_MOUSE Siglec1 p-S1331 p-S1335 p-Y1340 (z= 4) 2.1 0.0 1.6 100.0 
SNAG_MOUSE SNAG p-Y19 (z= 2) 49.0 100.0 86.7 97.0 
SNIP1_MOUSE Snip1 p-S18 (z= 3) 100.0 99.5 50.8 42.7 
SNP23_MOUSE Snap23 p-S110 (z= 2) 52.6 100.0 38.3 42.7 
SNR27_MOUSE Snrnp27 p-S59 p-S61 p-S63 (z= 3) 87.1 6.7 100.0 21.6 
SNTB2_MOUSE Sntb2 p-S75 (z= 2) 65.2 87.1 100.0 78.7 
SNTB2_MOUSE Sntb2 p-S88 (z= 3) 70.7 87.1 100.0 79.9 
SNTB2_MOUSE Sntb2 p-S90 (z= 2) 79.5 100.0 73.3 92.8 
SNW1_MOUSE Snw1 p-S224 p-S232 (z= 2) 89.0 66.1 89.5 100.0 
SNW1_MOUSE Snw1 p-S224 p-S232 (z= 2) 71.1 56.0 100.0 30.3 
SNW1_MOUSE Snw1 p-S224 p-S234 (z= 3) 82.2 57.0 100.0 92.0 
SNW1_MOUSE Snw1 p-S224 p-S234 (z= 3) 83.9 100.0 94.2 80.9 
SON_MOUSE Son p-S2027 p-S2029 p-S2031 (z= 3) 100.0 78.8 84.7 76.8 
SOX6_MOUSE Sox6 p-S527 p-S534 p-T538 (z= 4) + Oxi 4.7 100.0 58.0 74.7 
SPA3A_MOUSE Serpina3a p-Y400 (z= 4) + Oxi 100.0 96.2 87.7 84.6 
SPAG5_MOUSE Spag5 p-S229 (z= 3) 73.7 100.0 84.8 58.8 
SPD2B_MOUSE Sh3pxd2b p-S291 (z= 3) 83.6 95.1 92.9 100.0 
SPDLY_MOUSE Ccdc99 p-S558 (z= 3) 91.0 93.9 100.0 94.2 
SPF45_MOUSE Rbm17 p-S155 (z= 2) 85.4 100.0 92.0 70.6 
SPF45_MOUSE Rbm17 p-S155 (z= 3) 77.7 100.0 93.8 88.4 
SPF45_MOUSE Rbm17 p-S222 (z= 3) 65.0 83.0 93.3 100.0 
SPT5H_MOUSE Supt5h p-S664 (z= 2) 96.3 96.7 100.0 85.4 
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SPT5H_MOUSE Supt5h p-T1028 (z= 3) 100.0 59.9 60.5 47.2 
SPTB2_MOUSE Sptbn1 p-S2102 (z= 2) 72.1 100.0 78.1 92.4 
SPTB2_MOUSE Sptbn1 p-S2102 (z= 3) 85.0 99.3 100.0 95.0 
SPTB2_MOUSE Sptbn1 p-S2163 p-S2164 p-S2168 (z= 2) 100.0 59.9 57.3 81.1 
SPTB2_MOUSE Sptbn1 p-S2163 p-S2164 p-S2168 (z= 3) 97.1 100.0 76.2 82.6 
SQSTM_MOUSE Sqstm1 p-S345 (z= 3) 72.7 92.1 100.0 69.3 
SRBS2_MOUSE Sorbs2 p-S27 (z= 2) 100.0 70.9 72.5 70.8 
SRBS2_MOUSE Sorbs2 p-S339 (z= 2) 62.8 87.8 100.0 76.8 
SRBS2_MOUSE Sorbs2 p-S339 (z= 3) 90.5 90.7 100.0 71.7 
SRBS2_MOUSE Sorbs2 p-S382 (z= 2) 100.0 81.5 52.8 89.5 
SRC8_MOUSE Cttn p-T401 p-S405 p-S417 (z= 4) 54.4 75.6 87.2 100.0 
SRC8_MOUSE Cttn p-T401 p-S405 p-S417 (z= 4) 100.0 87.1 99.2 93.3 
SRC8_MOUSE Cttn p-T401 p-S405 p-Y421 (z= 3) 59.3 82.9 94.4 100.0 
SRC8_MOUSE Cttn p-T401 p-S405 p-Y421 (z= 4) 100.0 86.3 96.4 98.3 
SRC8_MOUSE Cttn p-T401 p-S407 p-S417 (z= 3) 59.3 82.9 94.4 100.0 
SRC8_MOUSE Cttn p-T401 p-S417 (z= 4) 68.1 80.9 95.2 100.0 
SRC8_MOUSE Cttn p-T401 p-S418 (z= 3) 71.1 84.8 100.0 94.6 
SRC8_MOUSE Cttn p-T401 p-S418 (z= 4) 100.0 76.0 79.7 73.2 
SRC8_MOUSE Cttn p-T401 p-Y421 (z= 4) 68.3 81.3 94.8 100.0 
SREK1_MOUSE Srek1 p-S377 (z= 2) 100.0 45.5 98.3 92.5 
SREK1_MOUSE Srek1 p-S465 (z= 2) 80.4 36.2 100.0 35.1 
SRF_MOUSE Srf p-S220 (z= 3) 100.0 71.0 85.2 63.6 
SRPK1_MOUSE Srpk1 p-S51 (z= 3) 85.4 82.1 100.0 91.8 
SRPR_MOUSE Srpr p-S295 p-S296 p-S297 (z= 3) 92.3 99.5 90.1 100.0 
SRRM1_MOUSE Srrm1 p-S220 (z= 3) 100.0 99.0 76.5 82.2 
SRRM1_MOUSE Srrm1 p-S260 (z= 3) 100.0 59.9 70.3 54.0 
SRRM1_MOUSE Srrm1 p-S260 (z= 3) 67.0 100.0 80.0 63.6 
SRRM1_MOUSE Srrm1 p-S265 (z= 4) 100.0 78.6 76.3 50.0 
SRRM1_MOUSE Srrm1 p-S387 p-S389 p-S391 (z= 2) 57.5 100.0 47.3 53.0 
SRRM1_MOUSE Srrm1 p-S387 p-S391 (z= 2) 100.0 95.3 79.2 89.5 
SRRM1_MOUSE Srrm1 p-S389 p-S391 (z= 3) 100.0 87.1 67.7 95.8 
SRRM1_MOUSE Srrm1 p-S400 p-T404 (z= 2) 87.4 72.9 100.0 76.3 
SRRM1_MOUSE Srrm1 p-S401 p-T404 (z= 3) 89.2 78.2 100.0 79.5 
SRRM1_MOUSE Srrm1 p-S427 p-S429 (z= 2) 100.0 87.2 75.2 98.9 
SRRM1_MOUSE Srrm1 p-S429 (z= 2) 87.3 100.0 60.3 72.3 
SRRM1_MOUSE Srrm1 p-S448 (z= 2) 100.0 62.2 68.5 41.8 
SRRM1_MOUSE Srrm1 p-S448 (z= 3) 100.0 61.6 70.7 45.5 
SRRM1_MOUSE Srrm1 p-S461 p-S463 (z= 2) 99.8 92.5 100.0 97.9 
SRRM1_MOUSE Srrm1 p-S461 p-S463 (z= 3) 97.1 85.7 89.1 100.0 
SRRM1_MOUSE Srrm1 p-S469 (z= 3) 100.0 88.7 79.0 57.6 
SRRM1_MOUSE Srrm1 p-S522 p-S524 p-S526 (z= 3) 80.8 0.0 100.0 16.0 
SRRM1_MOUSE Srrm1 p-S561 p-S563 (z= 2) 100.0 98.2 56.2 44.9 
SRRM1_MOUSE Srrm1 p-S561 p-S563 (z= 3) 61.3 89.8 71.5 100.0 
SRRM1_MOUSE Srrm1 p-S572 p-S574 (z= 2) 67.3 3.7 100.0 51.5 
SRRM1_MOUSE Srrm1 p-S572 p-S574 (z= 3) 100.0 68.0 90.2 89.0 
SRRM1_MOUSE Srrm1 p-S572 p-S574 (z= 3) 100.0 94.6 99.1 92.5 
SRRM1_MOUSE Srrm1 p-S572 p-S574 (z= 4) 98.9 69.4 100.0 88.4 
SRRM1_MOUSE Srrm1 p-S616 (z= 2) 100.0 89.0 81.1 78.0 
SRRM1_MOUSE Srrm1 p-S624 p-S626 (z= 2) 59.9 100.0 45.3 37.8 
SRRM1_MOUSE Srrm1 p-S635 (z= 3) 100.0 97.4 90.7 81.3 
SRRM1_MOUSE Srrm1 p-S645 p-S647 (z= 2) 77.0 60.2 97.4 100.0 
SRRM1_MOUSE Srrm1 p-S645 p-S647 (z= 2) 100.0 75.0 64.7 68.6 
SRRM1_MOUSE Srrm1 p-S645 p-S647 (z= 3) 70.9 55.9 100.0 82.0 
SRRM1_MOUSE Srrm1 p-S655 p-S657 (z= 3) 52.4 64.3 100.0 49.1 
SRRM1_MOUSE Srrm1 p-S664 (z= 2) 76.6 100.0 45.3 43.1 
SRRM1_MOUSE Srrm1 p-S713 (z= 2) 76.1 37.0 100.0 67.8 
SRRM1_MOUSE Srrm1 p-S713 (z= 3) 100.0 44.1 48.3 18.8 
SRRM1_MOUSE Srrm1 p-S723 p-S725 (z= 2) 100.0 7.4 96.2 38.0 
SRRM1_MOUSE Srrm1 p-S723 p-S725 p-S731 (z= 3) 90.8 66.0 49.8 100.0 
SRRM1_MOUSE Srrm1 p-S723 p-S725 p-S731 (z= 3) 100.0 63.6 91.1 86.4 
SRRM1_MOUSE Srrm1 p-S723 p-S725 p-S731 (z= 3) 100.0 55.6 65.4 65.4 
SRRM1_MOUSE Srrm1 p-S743 p-T745 (z= 3) 100.0 67.3 65.4 65.3 
SRRM1_MOUSE Srrm1 p-S779 (z= 2) 83.6 59.3 100.0 33.1 
SRRM1_MOUSE Srrm1 p-S779 p-S781 (z= 2) 63.2 68.9 100.0 0.0 
SRRM1_MOUSE Srrm1 p-S810 p-S814 p-S822 (z= 3) 67.2 82.9 100.0 84.9 
SRRM1_MOUSE Srrm1 p-S810 p-S816 (z= 3) 75.4 65.3 83.7 100.0 
SRRM1_MOUSE Srrm1 p-S810 p-S816 (z= 3) 98.1 81.1 100.0 80.3 
SRRM1_MOUSE Srrm1 p-S810 p-T819 p-S822 (z= 3) 85.4 75.4 99.5 100.0 
SRRM1_MOUSE Srrm1 p-S832 p-T834 p-S838 (z= 3) 90.6 61.6 44.9 100.0 
SRRM1_MOUSE Srrm1 p-S915 (z= 2) 100.0 79.7 80.1 80.0 
SRRM1_MOUSE Srrm1 p-T600 p-S602 (z= 2) 100.0 69.5 79.5 93.4 
SRRM1_MOUSE Srrm1 p-T600 p-S602 (z= 3) 100.0 78.5 73.7 53.4 
SRRM1_MOUSE Srrm1 p-T633 (z= 2) 100.0 28.0 39.2 1.8 
SRRM1_MOUSE Srrm1 p-T633 p-S635 (z= 2) 49.8 100.0 35.8 77.8 
SRRM1_MOUSE Srrm1 p-T913 (z= 3) 100.0 90.7 94.2 98.3 
SRRM1_MOUSE Srrm1 p-T913 p-S915 (z= 2) 100.0 79.2 84.1 84.6 
SRRM1_MOUSE Srrm1 p-T913 p-S915 (z= 3) 95.1 86.8 100.0 85.7 
SRRM1_MOUSE Srrm1 p-Y623 p-S624 (z= 3) 61.5 100.0 43.1 65.8 
SRRM2_MOUSE Srrm2 p-S1067 (z= 2) 69.1 98.6 100.0 87.7 
SRRM2_MOUSE Srrm2 p-S1068 p-T1074 (z= 2) 100.0 64.6 68.3 59.8 
SRRM2_MOUSE Srrm2 p-S1097 (z= 2) 100.0 27.1 41.4 12.6 
SRRM2_MOUSE Srrm2 p-S1097 (z= 2) 100.0 98.7 57.8 83.3 
SRRM2_MOUSE Srrm2 p-S1097 (z= 3) 100.0 56.7 69.5 48.4 
SRRM2_MOUSE Srrm2 p-S1151 (z= 3) 100.0 84.6 77.8 53.0 
SRRM2_MOUSE Srrm2 p-S1179 (z= 2) 82.4 64.7 100.0 50.7 
SRRM2_MOUSE Srrm2 p-S1214 (z= 3) 43.6 83.8 97.9 100.0 
SRRM2_MOUSE Srrm2 p-S1214 (z= 4) 76.9 100.0 78.7 80.0 
SRRM2_MOUSE Srrm2 p-S1216 (z= 3) 100.0 97.5 86.2 85.2 
SRRM2_MOUSE Srrm2 p-S1229 p-S1230 (z= 3) 67.6 85.9 100.0 67.2 
SRRM2_MOUSE Srrm2 p-S1229 p-S1230 (z= 3) + Oxi 79.7 74.9 84.3 100.0 
SRRM2_MOUSE Srrm2 p-S1229 p-S1230 (z= 4) 64.2 77.9 100.0 61.8 
SRRM2_MOUSE Srrm2 p-S1269 (z= 2) 95.7 83.3 100.0 78.2 
SRRM2_MOUSE Srrm2 p-S1269 (z= 3) 88.2 79.5 100.0 89.5 
SRRM2_MOUSE Srrm2 p-S1334 p-S1335 (z= 3) 100.0 27.8 46.7 36.8 
SRRM2_MOUSE Srrm2 p-S1338 (z= 3) 76.4 100.0 99.6 81.9 
SRRM2_MOUSE Srrm2 p-S1338 p-S1339 (z= 2) 89.4 100.0 71.3 86.1 
SRRM2_MOUSE Srrm2 p-S1338 p-S1339 p-S1343 (z= 2) 81.2 100.0 83.9 81.8 
SRRM2_MOUSE Srrm2 p-S1340 (z= 2) 100.0 58.8 92.9 69.2 
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SRRM2_MOUSE Srrm2 p-S1360 (z= 2) 62.1 100.0 38.0 57.0 
SRRM2_MOUSE Srrm2 p-S1360 p-S1372 (z= 3) 100.0 52.5 51.5 47.5 
SRRM2_MOUSE Srrm2 p-S1400 (z= 2) 100.0 66.0 92.1 57.7 
SRRM2_MOUSE Srrm2 p-S1434 p-S1438 p-S1439 (z= 2) 22.6 100.0 38.8 42.1 
SRRM2_MOUSE Srrm2 p-S1438 p-S1439 (z= 2) 100.0 62.3 10.4 0.0 
SRRM2_MOUSE Srrm2 p-S1453 p-S1455 p-S1458 (z= 2) 35.7 88.2 100.0 75.5 
SRRM2_MOUSE Srrm2 p-S1453 p-S1457 p-S1458 (z= 3) 80.3 50.7 100.0 20.5 
SRRM2_MOUSE Srrm2 p-S1535 p-S1537 p-S1538 (z= 2) 82.0 0.0 100.0 84.2 
SRRM2_MOUSE Srrm2 p-S1572 p-T1574 p-S1576 (z= 2) 74.1 58.7 100.0 99.0 
SRRM2_MOUSE Srrm2 p-S1572 p-T1574 p-S1576 (z= 3) 79.2 43.2 92.0 100.0 
SRRM2_MOUSE Srrm2 p-S1646 p-S1650 (z= 3) 100.0 82.6 98.0 76.6 
SRRM2_MOUSE Srrm2 p-S1703 p-S1705 p-S1706 (z= 3) 100.0 64.2 20.6 81.1 
SRRM2_MOUSE Srrm2 p-S1798 p-T1800 (z= 2) 64.7 65.6 100.0 75.4 
SRRM2_MOUSE Srrm2 p-S1798 p-T1800 (z= 3) 100.0 66.5 66.9 48.1 
SRRM2_MOUSE Srrm2 p-S1820 p-S1822 p-S1825 (z= 3) 100.0 61.3 87.2 64.2 
SRRM2_MOUSE Srrm2 p-S1834 p-T1836 (z= 2) 44.7 1.1 100.0 81.0 
SRRM2_MOUSE Srrm2 p-S1846 p-S1849 (z= 2) 27.7 100.0 21.7 79.3 
SRRM2_MOUSE Srrm2 p-S1849 (z= 2) 99.9 45.8 100.0 61.2 
SRRM2_MOUSE Srrm2 p-S1864 p-S1866 p-S1869 (z= 3) 100.0 58.2 49.8 64.1 
SRRM2_MOUSE Srrm2 p-S1866 p-S1869 (z= 2) 73.4 7.6 100.0 9.7 
SRRM2_MOUSE Srrm2 p-S1876 p-S1878 p-T1880 (z= 2) 74.9 66.3 59.1 100.0 
SRRM2_MOUSE Srrm2 p-S1876 p-S1878 p-T1880 (z= 3) 64.0 100.0 41.1 51.2 
SRRM2_MOUSE Srrm2 p-S1878 p-T1880 (z= 2) 71.3 50.7 100.0 71.5 
SRRM2_MOUSE Srrm2 p-S1924 p-S1927 (z= 2) 91.9 63.5 37.2 100.0 
SRRM2_MOUSE Srrm2 p-S1972 p-T1974 (z= 2) 84.6 100.0 70.3 83.8 
SRRM2_MOUSE Srrm2 p-S1982 p-S1984 p-T1986 (z= 3) 100.0 70.7 91.4 87.6 
SRRM2_MOUSE Srrm2 p-S1984 p-T1986 (z= 2) 100.0 78.0 69.0 80.2 
SRRM2_MOUSE Srrm2 p-S1996 p-S1998 (z= 2) 86.3 100.0 47.1 48.8 
SRRM2_MOUSE Srrm2 p-S2019 p-T2021 p-S2023 (z= 2) 82.7 49.2 89.0 100.0 
SRRM2_MOUSE Srrm2 p-S2019 p-T2021 p-S2023 (z= 3) 66.1 47.7 100.0 88.4 
SRRM2_MOUSE Srrm2 p-S2052 p-S2054 p-T2056 (z= 2) 88.1 74.6 99.5 100.0 
SRRM2_MOUSE Srrm2 p-S2052 p-S2054 p-T2056 (z= 3) 90.6 100.0 73.9 99.8 
SRRM2_MOUSE Srrm2 p-S2052 p-T2056 (z= 3) 100.0 75.6 81.4 70.7 
SRRM2_MOUSE Srrm2 p-S2070 (z= 3) + Oxi 100.0 63.7 59.2 74.7 
SRRM2_MOUSE Srrm2 p-S2073 (z= 3) 94.3 76.9 100.0 71.5 
SRRM2_MOUSE Srrm2 p-S2073 p-S2075 (z= 2) 100.0 69.5 80.9 69.9 
SRRM2_MOUSE Srrm2 p-S2084 (z= 2) 82.9 94.6 98.3 100.0 
SRRM2_MOUSE Srrm2 p-S2084 (z= 2) 98.1 52.4 100.0 33.7 
SRRM2_MOUSE Srrm2 p-S2084 (z= 2) + Oxi 100.0 64.5 58.5 59.9 
SRRM2_MOUSE Srrm2 p-S2224 (z= 2) 19.1 0.0 100.0 43.0 
SRRM2_MOUSE Srrm2 p-S2224 (z= 3) 94.3 86.1 100.0 94.1 
SRRM2_MOUSE Srrm2 p-S2335 (z= 2) 88.4 77.8 100.0 80.6 
SRRM2_MOUSE Srrm2 p-S2351 (z= 2) 100.0 92.4 99.6 76.8 
SRRM2_MOUSE Srrm2 p-S2351 (z= 2) + Oxi 100.0 79.6 58.9 56.1 
SRRM2_MOUSE Srrm2 p-S2360 p-T2362 (z= 2) 53.9 100.0 33.7 53.0 
SRRM2_MOUSE Srrm2 p-S2404 (z= 2) 83.4 100.0 69.0 87.8 
SRRM2_MOUSE Srrm2 p-S2404 (z= 4) 100.0 97.6 69.4 61.3 
SRRM2_MOUSE Srrm2 p-S2404 (z= 4) + Oxi 100.0 83.9 55.9 79.3 
SRRM2_MOUSE Srrm2 p-S2535 (z= 2) 100.0 96.2 51.1 36.2 
SRRM2_MOUSE Srrm2 p-S2642 (z= 3) 86.2 100.0 95.4 60.4 
SRRM2_MOUSE Srrm2 p-S2644 p-S2646 p-S2648 (z= 2) 93.0 59.5 73.9 100.0 
SRRM2_MOUSE Srrm2 p-S2648 (z= 2) 100.0 58.6 84.8 68.0 
SRRM2_MOUSE Srrm2 p-S2656 (z= 2) 95.3 95.3 93.3 100.0 
SRRM2_MOUSE Srrm2 p-S2656 p-S2660 (z= 2) 86.1 57.8 0.0 100.0 
SRRM2_MOUSE Srrm2 p-S351 (z= 3) 100.0 97.1 68.1 57.3 
SRRM2_MOUSE Srrm2 p-S433 p-S434 p-S435 (z= 2) 91.4 100.0 62.7 28.6 
SRRM2_MOUSE Srrm2 p-S433 p-S434 p-S435 (z= 3) 50.8 0.0 100.0 36.9 
SRRM2_MOUSE Srrm2 p-S433 p-S434 p-S435 (z= 3) 100.0 64.0 84.6 79.2 
SRRM2_MOUSE Srrm2 p-S433 p-S434 p-S447 (z= 2) 100.0 66.7 76.5 75.1 
SRRM2_MOUSE Srrm2 p-S433 p-S435 (z= 3) 100.0 96.3 82.9 89.9 
SRRM2_MOUSE Srrm2 p-S453 p-S454 (z= 2) 72.6 41.6 100.0 56.3 
SRRM2_MOUSE Srrm2 p-S757 p-S759 p-S761 (z= 2) 95.4 0.0 73.6 100.0 
SRRM2_MOUSE Srrm2 p-S759 p-S761 p-S762 (z= 2) 100.0 40.4 47.1 92.6 
SRRM2_MOUSE Srrm2 p-S773 p-S775 p-S778 (z= 2) 93.1 63.9 100.0 91.7 
SRRM2_MOUSE Srrm2 p-S876 p-S882 (z= 2) 82.5 58.1 91.2 100.0 
SRRM2_MOUSE Srrm2 p-S982 (z= 3) 100.0 98.7 99.4 99.4 
SRRM2_MOUSE Srrm2 p-T1032 (z= 3) 87.1 75.7 100.0 58.2 
SRRM2_MOUSE Srrm2 p-T1153 (z= 2) 100.0 73.4 67.2 54.4 
SRRM2_MOUSE Srrm2 p-T1390 (z= 3) 100.0 67.7 59.3 16.5 
SRRM2_MOUSE Srrm2 p-T2689 p-S2691 (z= 2) 51.4 50.4 100.0 7.8 
SRRM2_MOUSE Srrm2 p-T2689 p-S2691 (z= 3) 100.0 61.8 78.1 70.5 
SRRM2_MOUSE Srrm2 p-T288 p-T328 (z= 4) 100.0 86.6 96.1 97.0 
SRRM2_MOUSE Srrm2 p-T823 (z= 3) 73.9 96.5 100.0 58.3 
SRRM2_MOUSE Srrm2 p-T823 p-T831 (z= 3) 70.5 88.0 66.8 100.0 
SRRM2_MOUSE Srrm2 p-T823 p-T841 (z= 3) + Oxi 95.0 100.0 39.5 64.0 
SRRM2_MOUSE Srrm2 p-T955 (z= 2) 55.2 100.0 94.7 86.2 
SRRM2_MOUSE Srrm2 p-T955 (z= 2) + Oxi 90.6 100.0 23.6 80.4 
SRRM2_MOUSE Srrm2 p-T973 (z= 2) 67.0 90.6 100.0 88.1 
SRRM2_MOUSE Srrm2 p-T973 p-S982 (z= 3) + Oxi 100.0 34.5 13.6 38.0 
SRRM2_MOUSE Srrm2 p-T973 p-S984 (z= 3) 97.8 91.5 100.0 85.7 
SRRT_MOUSE Srrt p-S492 (z= 2) 100.0 65.2 62.0 50.0 
SRRT_MOUSE Srrt p-S492 (z= 3) 83.5 69.9 100.0 73.5 
SRRT_MOUSE Srrt p-S74 (z= 2) 95.4 100.0 99.4 61.6 
SRRT_MOUSE Srrt p-S74 (z= 3) 85.0 100.0 95.2 66.3 
SRRT_MOUSE Srrt p-T543 (z= 3) 82.7 62.2 93.2 100.0 
SRSF1_MOUSE Srsf1 p-S199 p-S201 (z= 3) 90.1 100.0 51.0 81.4 
SRSF1_MOUSE Srsf1 p-S199 p-S201 p-S205 (z= 2) 53.2 44.4 68.6 100.0 
SRSF1_MOUSE Srsf1 p-S223 p-S225 p-S227 (z= 2) 84.9 70.1 79.5 100.0 
SRSF2_MOUSE Srsf2 p-S187 p-S189 p-S191 (z= 3) 66.3 38.5 100.0 75.8 
SRSF2_MOUSE Srsf2 p-S189 p-S191 (z= 2) 46.2 100.0 50.2 42.8 
SRSF2_MOUSE Srsf2 p-S206 p-S208 p-S212 (z= 2) 41.7 100.0 37.9 33.4 
SRSF2_MOUSE Srsf2 p-S206 p-S208 p-S212 (z= 2) 0.0 0.0 100.0 0.0 
SRSF2_MOUSE Srsf2 p-S26 (z= 2) 69.5 62.6 100.0 57.5 
SRSF2_MOUSE Srsf2 p-S26 (z= 3) 94.4 100.0 79.2 67.5 
SRSF2_MOUSE Srsf2 p-T25 (z= 2) 99.2 98.7 100.0 74.7 
SRSF3_MOUSE Srsf3 p-S108 (z= 2) 100.0 54.3 44.6 18.8 
SRSF3_MOUSE Srsf3 p-S108 (z= 2) 75.2 32.2 100.0 34.9 
SRSF7_MOUSE Srsf7 p-S202 p-S204 (z= 2) 73.9 53.6 100.0 65.6 
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SRSF7_MOUSE Srsf7 p-S208 p-S210 (z= 2) 100.0 71.5 88.3 68.8 
SRSF7_MOUSE Srsf7 p-S208 p-S210 p-S212 (z= 2) 99.2 64.2 51.2 100.0 
SRSF7_MOUSE Srsf7 p-S210 (z= 2) 70.9 70.3 100.0 82.6 
SRSF7_MOUSE Srsf7 p-S210 p-S212 (z= 2) 86.1 26.4 100.0 86.5 
SRSF7_MOUSE Srsf7 p-S262 (z= 2) 66.7 100.0 78.8 51.9 
SSF1_MOUSE Ppan p-S362 (z= 3) 97.4 78.2 91.2 100.0 
SSF1_MOUSE Ppan p-T233 p-S240 (z= 3) 71.0 100.0 30.8 38.4 
SSFA2_MOUSE Ssfa2 p-S738 (z= 2) 100.0 86.3 97.5 70.5 
SSFA2_MOUSE SSFA2 p-T245 p-T246 p-Y255 (z= 4) 100.0 50.9 64.3 45.3 
SSH3_MOUSE Ssh3 p-S639 (z= 2) 100.0 82.3 65.3 89.0 
SSRA_MOUSE Ssr1 p-T260 (z= 3) 87.0 100.0 2.4 14.0 
SSRP1_MOUSE Ssrp1 p-S444 (z= 3) 87.1 78.7 81.6 100.0 
STALP_MOUSE Stambpl1 p-S242 (z= 2) 84.9 82.8 95.2 100.0 
STIP1_MOUSE Stip1 p-S481 (z= 2) 100.0 59.7 72.7 48.8 
STK10_MOUSE Stk10 p-S952 (z= 3) 85.9 100.0 67.9 76.3 
STK3_MOUSE Stk3 p-S316 (z= 3) 86.7 85.2 94.6 100.0 
STK4_MOUSE Stk4 p-S320 (z= 2) 84.6 86.3 100.0 90.5 
STMN1_MOUSE Stmn1 p-S16 (z= 3) 100.0 85.5 60.8 53.9 
STMN1_MOUSE Stmn1 p-S25 (z= 2) 100.0 38.2 63.9 44.0 
STMN1_MOUSE Stmn1 p-S25 (z= 3) 41.5 100.0 89.7 90.2 
STMN1_MOUSE Stmn1 p-S38 (z= 2) 77.6 100.0 94.8 92.1 
STMN1_MOUSE Stmn1 p-S38 (z= 2) 50.0 100.0 91.7 69.7 
STRN3_MOUSE Strn3 p-S257 (z= 3) 40.2 100.0 14.8 29.0 
STRN3_MOUSE Strn3 p-S257 (z= 3) + Oxi 22.1 100.0 52.8 9.4 
STX4_MOUSE Stx4 p-S15 (z= 2) 68.5 100.0 60.2 68.2 
SURF6_MOUSE Surf6 p-S97 (z= 2) 100.0 37.0 42.3 35.3 
SVIL_MOUSE Svil p-S227 (z= 2) 100.0 73.1 77.8 70.6 
SVIL_MOUSE Svil p-S227 (z= 3) 100.0 78.2 90.4 86.8 
SVIL_MOUSE Svil p-S50 (z= 3) 79.9 100.0 71.5 67.2 
SVIL_MOUSE Svil p-S960 (z= 3) 66.6 100.0 99.7 83.7 
SYHM_MOUSE Hars2 p-S66 (z= 2) 100.0 63.9 62.3 85.4 
SYMC_MOUSE Mars p-S827 (z= 3) 85.1 100.0 78.3 77.0 
SYMC_MOUSE Mars p-S827 (z= 4) 100.0 86.0 67.0 98.4 
SYT7_MOUSE Syt7 p-T98 p-T100 p-S102 (z= 4) + Oxi 93.8 81.2 86.7 100.0 
SYTC_MOUSE Tars p-S8 (z= 3) 100.0 24.2 28.0 6.5 
SZRD1_MOUSE Szrd1 p-S107 (z= 3) 100.0 99.1 95.4 81.6 
T2FA_MOUSE Gtf2f1 p-S217 p-S218 p-S221 (z= 3) 72.4 62.8 100.0 71.3 
T2FA_MOUSE Gtf2f1 p-S305 p-S307 p-S308 (z= 3) 89.8 75.4 60.9 100.0 
T2FA_MOUSE Gtf2f1 p-S385 p-T389 (z= 2) 59.6 100.0 55.3 72.0 
TACC2_MOUSE Tacc2 p-S510 p-S514 (z= 3) 55.2 100.0 49.0 84.7 
TARA_MOUSE Triobp p-S1604 (z= 3) 100.0 68.3 45.1 60.7 
TB182_MOUSE Tnks1bp1 p-S1063 (z= 2) 68.5 50.3 100.0 83.5 
TB182_MOUSE Tnks1bp1 p-S1063 (z= 3) + Oxi 100.0 76.5 50.8 81.9 
TB182_MOUSE Tnks1bp1 p-S1131 (z= 2) 93.2 58.1 100.0 89.8 
TB182_MOUSE Tnks1bp1 p-S1133 (z= 2) 80.7 80.6 100.0 67.8 
TB182_MOUSE Tnks1bp1 p-S1373 p-S1375 (z= 2) 88.1 84.7 94.1 100.0 
TB182_MOUSE Tnks1bp1 p-S1375 (z= 2) 82.5 98.6 97.8 100.0 
TB182_MOUSE Tnks1bp1 p-S1437 (z= 2) 70.8 100.0 90.1 89.3 
TB182_MOUSE Tnks1bp1 p-S1611 p-S1612 (z= 2) 33.2 0.0 100.0 44.8 
TB182_MOUSE Tnks1bp1 p-S1611 p-S1612 (z= 2) 100.0 86.4 70.5 78.7 
TB182_MOUSE Tnks1bp1 p-S1657 (z= 2) 88.3 100.0 83.2 96.9 
TB182_MOUSE Tnks1bp1 p-S298 (z= 2) 100.0 78.3 85.2 80.1 
TB182_MOUSE Tnks1bp1 p-S568 (z= 2) 59.4 100.0 84.3 71.5 
TB182_MOUSE Tnks1bp1 p-S568 (z= 3) 58.0 97.1 100.0 71.9 
TB182_MOUSE Tnks1bp1 p-S602 (z= 3) 100.0 92.2 96.0 85.9 
TB182_MOUSE Tnks1bp1 p-S692 (z= 2) 53.6 100.0 41.3 64.6 
TB182_MOUSE Tnks1bp1 p-S763 (z= 2) 100.0 65.0 50.0 56.8 
TB182_MOUSE Tnks1bp1 p-S763 (z= 2) 40.1 100.0 67.4 71.1 
TB182_MOUSE Tnks1bp1 p-T1065 (z= 3) 72.5 43.0 100.0 78.4 
TB182_MOUSE Tnks1bp1 p-T533 (z= 2) 97.7 100.0 75.0 60.3 
TB182_MOUSE Tnks1bp1 p-T533 p-S539 (z= 2) 42.2 100.0 53.7 79.5 
TBC15_MOUSE Tbc1d15 p-S623 (z= 4) 11.1 17.6 100.0 4.6 
TBCB_MOUSE Tbcb p-S110 (z= 2) 55.7 100.0 89.4 90.9 
TBCD1_MOUSE Tbc1d1 p-S231 (z= 2) 75.2 39.1 100.0 77.6 
TCEA1_MOUSE Tcea1 p-S100 (z= 2) 74.8 99.1 94.2 100.0 
TCEA1_MOUSE Tcea1 p-S100 (z= 3) 100.0 86.9 81.2 57.1 
TCEA1_MOUSE Tcea1 p-S97 (z= 2) 100.0 75.8 59.4 46.9 
TCOF_MOUSE Tcof1 p-S1128 (z= 2) 62.1 100.0 87.3 91.2 
TCOF_MOUSE Tcof1 p-S1191 (z= 2) 100.0 90.7 66.2 67.4 
TCOF_MOUSE Tcof1 p-S1216 (z= 2) 81.5 100.0 74.9 61.5 
TCOF_MOUSE Tcof1 p-S1216 (z= 2) + Oxi 100.0 18.8 32.7 1.5 
TCOF_MOUSE Tcof1 p-S1224 (z= 3) 96.5 100.0 93.9 80.1 
TCOF_MOUSE Tcof1 p-S1242 (z= 2) 95.9 85.6 100.0 69.9 
TCOF_MOUSE Tcof1 p-S151 (z= 3) 100.0 75.5 77.3 61.3 
TCOF_MOUSE Tcof1 p-S154 (z= 2) 100.0 55.4 60.4 44.5 
TCOF_MOUSE Tcof1 p-S169 (z= 3) 100.0 61.5 74.5 58.8 
TCOF_MOUSE Tcof1 p-S413 p-S414 p-S417 (z= 3) 91.0 100.0 62.2 66.0 
TCOF_MOUSE Tcof1 p-S413 p-S414 p-S417 (z= 4) 96.1 98.9 100.0 82.0 
TCOF_MOUSE Tcof1 p-S593 (z= 2) 100.0 85.1 72.8 83.8 
TCOF_MOUSE Tcof1 p-S794 (z= 2) 62.4 100.0 74.4 33.6 
TCOF_MOUSE Tcof1 p-S794 (z= 3) 87.4 43.8 100.0 45.7 
TCOF_MOUSE Tcof1 p-S83 p-S84 p-S85 (z= 3) 65.2 36.1 100.0 62.2 
TCOF_MOUSE Tcof1 p-T171 (z= 3) 97.6 92.2 96.0 100.0 
TE2IP_MOUSE Terf2ip p-S200 (z= 2) 100.0 86.3 83.4 92.9 
TEBP_MOUSE Ptges3 p-S113 (z= 2) 68.4 82.7 100.0 99.9 
TEBP_MOUSE Ptges3 p-S113 (z= 2) + Oxi 90.6 83.1 87.2 100.0 
TEBP_MOUSE Ptges3 p-S113 (z= 3) 63.5 96.3 100.0 99.1 
TEBP_MOUSE Ptges3 p-S148 (z= 3) 72.7 76.1 100.0 81.1 
TEBP_MOUSE Ptges3 p-S148 p-S151 (z= 3) 73.4 54.3 100.0 86.9 
TEBP_MOUSE Ptges3 p-S148 p-S151 (z= 3) + Oxi 57.3 100.0 42.9 92.3 
TEBP_MOUSE Ptges3 p-S148 p-S151 (z= 3) + Oxi 76.7 83.3 47.1 100.0 
TENS3_MOUSE Tns3 p-S1436 (z= 2) + Oxi 100.0 17.7 61.7 0.0 
TENS3_MOUSE Tns3 p-Y773 (z= 3) 75.5 90.3 89.8 100.0 
TF3B_MOUSE Brf1 p-S586 p-T587 (z= 3) 81.4 100.0 61.3 31.4 
TFDP1_MOUSE Tfdp1 p-S23 (z= 2) 54.1 83.2 82.9 100.0 
TFE3_MOUSE Tfe3 p-S553 (z= 2) 100.0 94.0 97.4 91.0 
TFP11_MOUSE Tfip11 p-S96 p-S99 (z= 3) 100.0 86.3 81.6 67.2 
TFPT_MOUSE Tfpt p-S180 (z= 2) 100.0 96.7 57.6 53.4 
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TGFR2_MOUSE Tgfbr2 p-S377 (z= 2) 70.0 100.0 66.7 79.8 
THUM1_MOUSE Thumpd1 p-S86 p-S88 (z= 3) 80.7 100.0 42.3 71.8 
THUM1_MOUSE Thumpd1 p-S86 p-S88 (z= 4) 84.7 100.0 91.5 75.9 
TIAM1_MOUSE Tiam1 p-S231 (z= 2) 100.0 23.6 84.1 33.1 
TIF1B_MOUSE Trim28 p-S471 (z= 3) 76.8 98.8 100.0 98.3 
TIF1B_MOUSE Trim28 p-S473 (z= 2) 68.8 100.0 58.2 61.6 
TIF1B_MOUSE Trim28 p-S51 (z= 4) 89.6 100.0 62.6 80.8 
TIF1B_MOUSE Trim28 p-S601 (z= 3) 100.0 82.7 83.9 82.4 
TIF1B_MOUSE Trim28 p-T599 (z= 4) 86.3 100.0 90.5 86.4 
TIM_MOUSE Timeless p-S1165 (z= 2) 100.0 84.7 68.5 86.8 
TISB_MOUSE Zfp36l1 p-S334 (z= 2) 66.2 100.0 75.1 96.7 
TISD_MOUSE Zfp36l2 p-S98 (z= 2) 100.0 66.9 65.8 53.6 
TJAP1_MOUSE Tjap1 p-S527 (z= 2) 89.9 91.9 93.0 100.0 
TLE3_MOUSE Tle3 p-S286 (z= 2) 90.4 75.6 100.0 85.1 
TLN1_MOUSE Tln1 p-S1328 (z= 2) 89.6 93.8 100.0 74.0 
TM10A_MOUSE Trmt10a p-S22 (z= 2) 73.9 11.4 100.0 67.9 
TM10A_MOUSE Trmt10a p-S22 (z= 2) 35.8 100.0 84.3 70.8 
TM10A_MOUSE Trmt10a p-S22 (z= 3) 74.3 13.8 100.0 73.8 
TM87A_MOUSE Tmem87a p-S540 (z= 3) 52.5 96.1 95.3 100.0 
TMM47_MOUSE Tmem47 p-S3 (z= 3) + Oxi 90.8 96.6 67.4 100.0 
TNAP3_MOUSE Tnfaip3 p-S571 (z= 2) 100.0 0.0 0.0 0.0 
TOM1_MOUSE Tom1 p-S462 (z= 3) 73.0 74.0 100.0 53.9 
TOM34_MOUSE Tomm34 p-S186 (z= 2) 100.0 91.9 51.0 37.1 
TOM70_MOUSE Tomm70a p-S94 (z= 3) 96.5 100.0 76.9 86.7 
TOP2A_MOUSE Top2a p-S1328 p-S1333 p-T1350 (z= 3) 2.4 2.6 2.7 100.0 
TOP2A_MOUSE Top2a p-S28 (z= 2) 62.7 100.0 68.4 63.6 
TOP2B_MOUSE Top2b p-S1568 (z= 3) 29.4 98.0 14.4 100.0 
TOX4_MOUSE Tox4 p-S178 p-S182 (z= 3) 52.1 87.2 62.5 100.0 
TP53B_MOUSE Tp53bp1 p-S1090 (z= 3) 85.2 97.7 100.0 96.5 
TP53B_MOUSE Tp53bp1 p-S1103 (z= 3) 83.1 100.0 64.9 55.9 
TP53B_MOUSE Tp53bp1 p-S1347 (z= 2) 90.7 100.0 89.8 61.0 
TP53B_MOUSE Tp53bp1 p-S262 (z= 2) 100.0 62.5 58.7 45.5 
TP53B_MOUSE Tp53bp1 p-S262 (z= 3) 90.5 99.0 100.0 68.3 
TP53B_MOUSE Tp53bp1 p-S376 (z= 2) 80.8 93.0 94.9 100.0 
TP53B_MOUSE Tp53bp1 p-S527 (z= 2) + Oxi 100.0 10.6 0.0 11.2 
TPD54_MOUSE Tpd52l2 p-S180 (z= 2) 100.0 42.8 39.1 52.2 
TPD54_MOUSE Tpd52l2 p-S180 (z= 3) 100.0 48.5 55.4 73.9 
TPX2_MOUSE Tpx2 p-S486 (z= 2) 67.2 94.3 82.4 100.0 
TPX2_MOUSE Tpx2 p-S737 (z= 2) 93.3 92.3 78.1 100.0 
TR150_MOUSE Thrap3 p-S243 (z= 2) 100.0 91.8 84.8 80.1 
TR150_MOUSE Thrap3 p-S248 p-S253 (z= 2) 100.0 74.7 77.8 79.2 
TR150_MOUSE Thrap3 p-S379 (z= 2) 67.6 100.0 43.3 39.0 
TR150_MOUSE Thrap3 p-S572 (z= 3) 74.0 100.0 93.8 53.6 
TR150_MOUSE Thrap3 p-S669 (z= 3) 100.0 31.3 38.4 7.5 
TR150_MOUSE Thrap3 p-S679 (z= 2) 87.8 97.4 93.0 100.0 
TR150_MOUSE Thrap3 p-S679 (z= 2) 100.0 82.2 91.5 82.8 
TR150_MOUSE Thrap3 p-S679 (z= 3) 100.0 50.6 43.9 31.8 
TRA2A_MOUSE Tra2a p-S259 p-S261 (z= 2) 100.0 81.9 81.2 94.8 
TRA2A_MOUSE Tra2a p-S259 p-S261 (z= 3) 85.1 100.0 91.0 76.8 
TRA2A_MOUSE Tra2a p-S271 p-S273 p-Y276 (z= 3) 72.7 55.5 87.4 100.0 
TRA2A_MOUSE Tra2a p-S271 p-S275 p-Y276 (z= 2) 70.4 32.5 51.5 100.0 
TRA2A_MOUSE Tra2a p-S94 p-S96 p-S98 (z= 2) 93.1 100.0 39.7 31.1 
TRA2A_MOUSE Tra2a p-S94 p-S96 p-S98 (z= 3) 59.9 100.0 52.3 35.6 
TRA2A_MOUSE Tra2a p-S96 p-S98 (z= 2) 95.3 32.5 48.5 100.0 
TRI47_MOUSE Trim47 p-S591 (z= 2) 76.1 90.0 88.7 100.0 
TRI56_MOUSE Trim56 p-S7 (z= 2) 100.0 70.7 65.2 59.7 
TRIO_MOUSE Trio p-S14 (z= 4) + Oxi 67.2 76.9 100.0 71.5 
TRIO_MOUSE Trio p-S2319 p-S2320 p-S2323 (z= 4) 100.0 75.6 74.8 79.0 
TRIPC_MOUSE Trip12 p-S312 (z= 2) 100.0 99.2 89.3 99.3 
TRPS1_MOUSE Trps1 p-S1081 p-S1085 (z= 2) 79.9 89.1 100.0 82.9 
TRPS1_MOUSE Trps1 p-S178 (z= 3) 72.6 94.6 67.7 100.0 
TRPS1_MOUSE Trps1 p-Y1080 p-S1085 (z= 2) 96.6 52.8 97.6 100.0 
TTI2_MOUSE Tti2 p-S41 p-S42 (z= 3) 57.3 100.0 73.4 61.6 
TTPAL_MOUSE Ttpal p-S196 p-S199 (z= 4) 0.3 100.0 0.2 0.4 
TXLNA_MOUSE Txlna p-S523 (z= 2) 54.8 0.0 100.0 41.7 
TYDP1_MOUSE Tdp1 p-S61 (z= 3) 96.2 1.2 100.0 76.1 
TYDP1_MOUSE TYDP1 p-S136 (z= 3) 90.3 100.0 92.1 74.8 
U3IP2_MOUSE Rrp9 p-S470 (z= 2) 100.0 89.5 92.3 81.2 
U3IP2_MOUSE Rrp9 p-S50 p-S51 p-S53 (z= 2) 70.7 0.3 100.0 46.9 
U5S1_MOUSE Eftud2 p-Y6 p-S19 (z= 3) 52.1 0.7 100.0 50.6 
UBA1_MOUSE Uba1 p-S46 (z= 2) 85.3 89.5 93.4 100.0 
UBAP2_MOUSE Ubap2 p-S634 (z= 3) 100.0 81.6 64.8 65.8 
UBAP2_MOUSE Ubap2 p-T406 (z= 4) 72.6 70.4 100.0 85.8 
UBL7_MOUSE Ubl7 p-S230 (z= 3) 97.9 55.2 86.4 100.0 
UBL7_MOUSE Ubl7 p-S230 (z= 3) + Oxi 100.0 73.4 61.7 79.0 
UBP10_MOUSE Usp10 p-S208 (z= 2) 100.0 80.2 80.6 81.8 
UBP10_MOUSE Usp10 p-S208 (z= 3) 56.5 100.0 69.0 79.4 
UBP10_MOUSE Usp10 p-T566 (z= 3) 82.2 75.8 86.0 100.0 
UBP15_MOUSE Usp15 p-S229 (z= 2) 100.0 96.1 82.6 89.3 
UBP2L_MOUSE Ubap2l p-S491 (z= 3) 100.0 70.6 74.6 91.4 
UBP2L_MOUSE Ubap2l p-S624 p-S629 (z= 3) 100.0 90.0 81.4 75.5 
UBP2L_MOUSE Ubap2l p-S628 (z= 2) 68.4 100.0 89.6 73.3 
UBP2L_MOUSE Ubap2l p-S628 (z= 3) 100.0 61.3 68.6 63.5 
UBP7_MOUSE Usp7 p-S19 (z= 3) 78.1 94.1 100.0 97.2 
UBP8_MOUSE Usp8 p-S680 (z= 3) 100.0 96.1 88.4 99.9 
UBQL1_MOUSE Ubqln1 p-Y267 p-T268 p-S289 p-S292 (z= 4) 100.0 81.1 61.6 53.1 
UBR4_MOUSE Ubr4 p-S2716 (z= 2) 100.0 84.2 96.5 79.0 
UBR5_MOUSE Ubr5 p-S133 p-S148 (z= 4) 79.6 88.9 81.3 100.0 
UBR5_MOUSE Ubr5 p-S1543 (z= 2) 100.0 83.3 50.3 73.1 
UBXN1_MOUSE Ubxn1 p-S199 (z= 3) 89.2 88.7 100.0 75.2 
UCK2_MOUSE Uck2 p-S254 (z= 2) 47.8 100.0 23.1 10.4 
UFD1_MOUSE Ufd1l p-S247 (z= 2) 78.4 100.0 77.4 67.3 
UIMC1_MOUSE Uimc1 p-S665 (z= 2) 95.2 49.9 100.0 76.1 
USO1_MOUSE Uso1 p-S940 (z= 3) 86.2 79.2 92.4 100.0 
USO1_MOUSE Uso1 p-S940 (z= 4) 100.0 70.4 72.9 93.9 
UTP15_MOUSE Utp15 p-T515 (z= 4) 100.0 92.3 93.2 99.5 
UTP15_MOUSE Utp15 p-T519 (z= 3) 100.0 76.2 85.8 84.9 
UTP18_MOUSE Utp18 p-S114 p-S115 p-S118 (z= 2) 44.5 100.0 44.5 60.9 
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UTP18_MOUSE Utp18 p-S201 p-S202 p-S206 (z= 3) 100.0 67.0 81.2 81.8 
UVSSA_MOUSE Uvssa p-S481 p-T488 (z= 4) 91.1 91.2 80.0 100.0 
VGLL4_MOUSE Vgll4 p-T52 p-S60 (z= 2) 90.1 97.3 100.0 84.1 
VIGLN_MOUSE Hdlbp p-S31 (z= 2) 100.0 77.3 95.3 97.0 
VIME_MOUSE Vim p-S419 (z= 2) 77.2 56.2 100.0 57.6 
VIME_MOUSE Vim p-S459 (z= 2) 100.0 88.9 81.1 84.0 
VIME_MOUSE Vim p-S56 (z= 2) 89.8 92.8 77.2 100.0 
VINC_MOUSE Vcl p-S290 (z= 2) 82.5 85.1 100.0 93.6 
VINC_MOUSE Vcl p-S290 (z= 3) 100.0 76.7 78.9 78.1 
VINC_MOUSE Vcl p-S346 (z= 2) 74.2 100.0 53.3 75.1 
VINC_MOUSE Vcl p-S721 (z= 2) 72.0 100.0 82.1 91.6 
VINC_MOUSE Vcl p-S820 (z= 2) 82.2 91.7 100.0 77.8 
VINC_MOUSE Vcl p-Y822 (z= 2) 62.2 91.7 100.0 75.5 
VIR_MOUSE Kiaa1429 p-S1578 (z= 2) 100.0 83.1 89.6 86.1 
WAPL_MOUSE Wapal p-S77 (z= 2) 100.0 90.1 94.6 97.7 
WAPL_MOUSE Wapal p-S77 (z= 3) 99.8 61.7 100.0 84.7 
WDHD1_MOUSE Wdhd1 p-S821 (z= 3) 100.0 78.8 75.9 74.5 
WDR26_MOUSE Wdr26 p-S101 (z= 2) 100.0 83.9 87.7 73.5 
WDR70_MOUSE Wdr70 p-S641 (z= 3) 89.2 85.8 75.0 100.0 
WNK1_MOUSE Wnk1 p-S2000 (z= 4) 100.0 2.9 2.8 0.0 
WNK1_MOUSE Wnk1 p-S378 (z= 2) 100.0 61.7 75.4 42.2 
WRIP1_MOUSE Wrnip1 p-S153 (z= 2) 88.5 100.0 90.8 69.1 
WRIP1_MOUSE Wrnip1 p-S65 (z= 2) 100.0 62.6 48.7 1.2 
XPC_MOUSE Xpc p-S875 p-S876 (z= 3) 90.6 72.5 20.6 100.0 
XRCC1_MOUSE Xrcc1 p-S445 p-T452 (z= 2) 57.3 100.0 53.0 78.4 
XRN2_MOUSE Xrn2 p-S499 p-S501 (z= 2) 47.5 0.0 100.0 40.7 
XRN2_MOUSE Xrn2 p-S499 p-S501 (z= 2) 80.3 66.3 90.7 100.0 
XRN2_MOUSE Xrn2 p-S499 p-S501 (z= 3) 100.0 90.0 92.0 99.6 
XRN2_MOUSE Xrn2 p-S499 p-S501 (z= 3) 100.0 81.1 70.2 60.7 
YAP1_MOUSE Yap1 p-S113 (z= 4) 100.0 80.4 66.5 55.4 
YAP1_MOUSE Yap1 p-S149 (z= 2) 87.5 45.9 100.0 83.6 
YAP1_MOUSE Yap1 p-S46 (z= 2) 43.4 100.0 20.9 65.9 
YAP1_MOUSE Yap1 p-T48 (z= 3) 0.0 0.0 100.0 0.0 
YAP1_MOUSE Yap1 p-T95 (z= 2) 100.0 54.5 33.8 20.1 
YAP1_MOUSE Yap1 p-T95 (z= 2) 100.0 75.4 85.2 71.4 
YAP1_MOUSE Yap1 p-T95 (z= 3) 100.0 74.7 75.2 60.8 
YBOX1_MOUSE Ybx1 p-S163 (z= 3) 70.5 100.0 44.0 58.0 
YBOX1_MOUSE Ybx1 p-S312 (z= 2) 98.0 70.4 59.8 100.0 
YD021_MOUSE Hjurp p-S553 (z= 2) 75.9 30.3 100.0 25.8 
Z280D_MOUSE Znf280d p-S901 p-S911 (z= 3) 96.1 87.6 83.4 100.0 
ZC3H4_MOUSE Zc3h4 p-S1270 p-S1276 (z= 3) 80.3 67.7 100.0 82.1 
ZC3H4_MOUSE Zc3h4 p-S1276 (z= 2) 34.0 100.0 44.5 50.7 
ZC3H4_MOUSE Zc3h4 p-T1101 p-T1119 (z= 3) 95.8 39.9 100.0 78.4 
ZC3H6_MOUSE Zc3h6 p-T100 p-S101 (z= 2) 35.8 100.0 13.5 56.0 
ZC3HE_MOUSE Zc3h14 p-S515 (z= 2) 85.2 100.0 77.5 74.8 
ZCCHV_MOUSE Zc3hav1 p-S324 (z= 2) 100.0 41.7 47.2 36.7 
ZCCHV_MOUSE Zc3hav1 p-S490 (z= 2) 48.2 87.2 100.0 95.0 
ZCH18_MOUSE Zc3h18 p-S33 (z= 3) 82.2 85.9 87.3 100.0 
ZCH18_MOUSE Zc3h18 p-S530 (z= 2) 88.2 100.0 57.6 78.2 
ZCH18_MOUSE Zc3h18 p-S863 (z= 2) 55.1 82.9 100.0 72.7 
ZCH18_MOUSE Zc3h18 p-S888 (z= 2) 99.8 92.1 100.0 78.4 
ZCH18_MOUSE Zc3h18 p-S92 (z= 3) 73.6 90.5 94.5 100.0 
ZCH24_MOUSE Zcchc24 p-S93 (z= 3) 100.0 99.1 40.7 55.3 
ZFX_MOUSE Zfx p-S269 (z= 3) 100.0 87.5 27.4 47.0 
ZN276_MOUSE Znf276 p-S21 (z= 3) 73.6 29.2 100.0 79.1 
ZN382_MOUSE Znf382 p-S30 (z= 3) + Oxi 96.2 95.2 93.7 100.0 
ZN609_MOUSE Znf609 p-S1057 (z= 2) 93.2 100.0 57.3 90.5 
ZN638_MOUSE Znf638 p-T407 p-S409 (z= 4) + Oxi 52.6 74.0 50.3 100.0 
ZN740_MOUSE Znf740 p-S19 (z= 2) 91.4 100.0 62.3 72.4 
ZO1_MOUSE Tjp1 p-S125 p-S131 (z= 3) 100.0 26.8 17.5 0.6 
ZO1_MOUSE Tjp1 p-S125 p-S131 (z= 4) 91.6 85.6 93.8 100.0 
ZO1_MOUSE Tjp1 p-S125 p-S131 (z= 4) 100.0 69.3 86.5 80.2 
ZO1_MOUSE Tjp1 p-S125 p-Y132 (z= 3) 100.0 61.3 79.4 39.3 
ZO1_MOUSE Tjp1 p-S1614 (z= 3) 96.6 95.9 88.4 100.0 
ZO1_MOUSE Tjp1 p-S175 p-S178 (z= 2) 100.0 95.7 41.8 37.7 
ZO1_MOUSE Tjp1 p-S175 p-S178 p-S179 (z= 2) 100.0 0.0 50.4 35.7 
ZO1_MOUSE Tjp1 p-S617 (z= 2) 100.0 56.3 46.9 27.6 
ZO2_MOUSE Tjp2 p-S107 (z= 3) 100.0 95.7 92.6 96.5 
ZO2_MOUSE Tjp2 p-S111 (z= 3) 62.6 85.2 83.7 100.0 
ZO2_MOUSE Tjp2 p-S111 (z= 4) 84.7 100.0 77.1 87.4 
ZO2_MOUSE Tjp2 p-S1136 (z= 2) 80.9 60.5 100.0 93.2 
ZO2_MOUSE Tjp2 p-S1136 (z= 3) 86.0 95.1 100.0 70.4 
ZO2_MOUSE Tjp2 p-S395 (z= 2) 100.0 93.7 91.7 88.2 
ZO2_MOUSE Tjp2 p-S947 (z= 2) 75.2 81.6 100.0 61.0 
ZO2_MOUSE Tjp2 p-S968 (z= 2) 84.6 100.0 91.2 85.0 
ZO2_MOUSE Tjp2 p-S968 (z= 3) 91.0 50.8 100.0 88.1 
ZRAB2_MOUSE Zranb2 p-S153 (z= 3) 19.6 37.6 100.0 34.3 
ZYX_MOUSE Zyx p-S336 (z= 2) 83.5 100.0 95.6 97.9 
 
 
